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Lay summary
Interferon induced transmembrane proteins (IFITM) 1 and 3 are molecules implicated
in cancer. They are found in several cancer types. In particular, they are manifested in
those patients that do not improve with chemotherapy treatments. Thus far, there is in-
sufficient knowledge about how IFITM1 and IFITM3 function. Therefore, the main aim of
this project is to better understand how IFITM1 and IFITM3 are able to facilitate cancer
progression.
This study proposes a new function for IFITM1 and IFITM3 in which they are impli-
cated in the production of some molecules and thereby increasing their amount inside the
cell. This process is known as protein synthesis. Moreover, this project has identified new
IFITM1 and IFITM3 associated molecules. The results show that IFITM1 and IFITM3 bind
to ISG15 and HLA-B: two molecules also highly implicated in cancer by different mecha-
nisms.
In conclusion, this work provides new cellular mechanisms for how IFITM1 and
IFITM3 molecules function. These findings may contribute to better understand IFITM1
and IFITM3 cellular functions.
iv
Abstract
Interferon induced transmembrane protein 1 (IFITM1) is an interferon (IFN) stim-
ulated protein upregulated during development of radiation resistance in cancer. It is
present in resistant tumours, generating a multi-drug resistant phenotype and escaping
from pro-apoptotic effects (Weichselbaum et al., 2008a; Yang et al., 2007). The signal trans-
duction events that are orchestrated by IFITM1/IFITM3 are not well defined. As IFITM1 is
the main isoform described as a pro-oncogene, we started studying its interactome.
To begin to elucidate its molecular mechanism of action, isogenic IFITM1 null and
IFITM1/IFITM3 double null cervical cancer cells, engineered by CRISPR/Cas9 system,
were used to define dominant pathways mediated by IFITM1/IFITM3 proteins. The re-
sults suggested a specific role for IFITM1/IFITM3 in regulating ribosomal integrity. In this
study, therefore, we explored whether IFITM1/IFITM3 were capable of facilitating pro-
tein synthesis. The localization of IFITM/IFITM3 to ribosomal translation protein fac-
tors prompted an analysis of IFNγ-dependent protein synthesis using pulse SILAC-mass
spectrometry. The IFITM1/IFITM3–IFNγ complex mediates signal transduction through
ISG15, IRF1, and HLA-B molecules. Additional experimental work consolidated the as-
sociation between IFITM1/IFITM3 and HLA-B or ISG15. Moreover, the implications of
IFITM1/IFITM3 loss of expression on RNA regulation were further investigated by RNA-
Seq and RT-qPCR.
In conclusion, the present study characterises a novel function for IFITM1/IFITM3
proteins. They are implicated in protein synthesis in IFNγ-stimulated cells, providing a
new insight into how these proteins are relevant in cancer. These data have implications
for the function of IFITM1/IFITM3 in mediating appropriate antigen presentation recog-
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Chapter 1
Introduction
1.1 Present perspectives and future directions
Cancer cells are able to hijack physiological pathways in their interest to achieve an
advantageous state over normal cells and, consequently, to increase their survival. Many
mechanisms have been proposed to explain the genesis of the cancer. Among these, ge-
nomic instability is common to all types of cancer. Despite this, the ideal of understanding
cancer as a mere genomic disease is completely outdated (Negrini et al., 2010). In fact, tu-
mours are much more than just cancer cells; they are complicated structures composed
of a wide variety of cell types, including normal cells. These normal cells form what is
known as tumour-associated stroma and play an active role in tumourigenesis and can-
cer development. In 2000, Hanahan and Weinberg combined the main cancer capabilities
into six hallmarks: sustaining proliferative signalling, evading growth suppressors, acti-
vating invasion and metastasis, enabling replicative immortality, inducing angiogenesis,
and resisting cell death (Figure 1.1) (Hanahan & Weinberg, 2000).
Cancer biology is constantly under revision and continuous research contributes to
a better framework of cancer events. A more profound understanding of cancer led to
reporting of four new complementary hallmarks that are also implicated in cancer devel-
opment. These added hallmarks are: deregulating cellular energetics, genome instability
and mutation, tumour-promoting inflammation, and avoiding immune destruction (Fig-
ure 1.2) (Hanahan & Weinberg, 2011). This thesis particularly focuses on the last hallmark,
avoiding immune destruction. Tumour cells are able to manipulate the immune system
and consequently escape from the immune response. A large body of research has docu-
mented a strong relationship between cancer cell survival and inhibition of immune sys-
tem, and however, the first observations were made long ago. The next section will high-
light the main discoveries that allowed this field to progress.
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Figure 1.1: The original Hallmarks of Cancer (Hanahan & Weinberg, 2000). Representation of fundamental
acquired capabilities in cancer. All characteristics are thought to be shared across all types of cancer and allow
the disease to originate and progress. Sustaining proliferation signalling promotes continuous cell growth (i.e.
Ras oncoprotein) (in green). In parallel, cancer evades growth suppressors activating different mechanisms
(e.g. alterations in pRb and TP53 activities) (in brown). Overactivation of these pathways can lead cell senes-
cence as intrinsic cellular self-defence to inhibit uncontrolled growth. Resting cell death is characterised by
inhibiting apoptosis programs (in grey). Enabling replicative immortality is acquired by unrestricted replica-
tive potential (in blue). Inducing angiogenesis is essential to maintain a sustained source of nutrients and
oxygen (in red). Finally, activating invasion and metastasis allow the tumour to spread in other tissues to
acquire the final and most aggressive state leading to the death of the host (in black).
Figure 1.2: The Next Generation Hallmarks of Cancer (Hanahan & Weinberg, 2011). Four new hallmarks are
believed to be involved in pathogenesis in most cancers. They are subdivided into two pairs of characteris-
tics. The first, emerging hallmarks comprises two blocks: avoiding immune destruction (cancer capability of
scape immunological recognition) and deregulating cellular energetics (alteration of cellular metabolism to
facilitate cancer proliferation). The second, enabling characteristics comprised two further blocks: tumour-
promoting inflammation (benefitting from the inflammation characteristics to progress, thus inflammation
will positively influence other hallmarks), and genomic instability (accumulation of genetic mutations that
allow cancer to acquire its tumourigenic phenotype).
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1.2 Cancer Immunosurveillance and Immunoediting
There are many examples in scientific history where it has been shown that the im-
mune system is implicated in tumour recognition and elimination. For instance, in the
late 19th century Bradley Coley observed that immune responses activated by streptococ-
cal bacteria provoked tumour remission after patients with inoperable bone sarcoma were
inoculated with the “Coley vaccine” (Coley, 1893; McCarthy, 2006). The results achieved
great success and it was routinely used as one of the earliest immunotherapies for decades.
However, Coleys toxins were strongly criticized by the scientific community, gradually fell
into disuse, and finally were disapproved by the Food and Drug Administration (FDA). This
therapy was replaced with novel radiation and chemotherapy treatments developed at that
time.
It was back in 1909 that Paul Ehrlich formally proposed, for the first time, that the im-
mune system plays an active role in tumour elimination (Ehrlich, 1909). He postulated
that there was a higher risk of developing cancer if the immune system was compromised.
Some studies in murine models supported this hypothesis finding that tumour-specific
neoantigens were able to alert the immune system (Gross, 1943; Klein & Klein, 1956).
For a long time, this revolutionary concept was discarded and even forgotten due to
the lack of experimental evidence that supported the idea. In the late 1950s, the concept
was revived with the immune surveillance hypothesis proposed by Burnet and Thomas
(Burnet, 1955; Thomas, 1959). Intensive studies on immune responses conducted in mice
revealed rejection of tumour allografts induced by carcinogens (Klein, 1966; Old & Boyse,
1964). It was suggested that the immune system can recognize and eliminate sponta-
neously generated malignant cells. They proposed that this feature arose from the nat-
ural necessity of protecting the host from malignant cell transformation. The hypothesis
was seriously debated and again abandoned in the mid 1970s due to contradictory results;
several different types of immunocompromised mouse models showed no significant dif-
ferences in tumour formation compared to wild type (Rygaard & Povlsen, 1974; Stutman,
1979a). Further experiments of Stutman were those that disproved the hypothesis (Stut-
man, 1979b). Thus, the limited immunological knowledge at the time led to the dismissal
of the immune surveillance hypothesis.
During the following 20 years there were several advances in the field. The discovery
that self-produced interferon gamma (IFNγ) repressed formation of transplanted, induced
or spontaneous tumours was particularly groundbreaking. Extensive work on depleting
a wide range of IFNγ-signal molecules such as INFγ receptor and STAT1 made murine
models more prone to develop tumours. Indeed, absence of perforin also increased spon-
taneous tumour formation. Perforin is known to be essential for cytotoxic T cells, and at
the time the recently-discovered NK cells to mediate tumour eradication (Russell & Ley,
2002; Smyth et al., 2000; Van den Broek et al., 1996). These experiments, in concordance
with others, gave some insights into tumour recognition, where many immune cell types
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and molecules are implicated in the process. Another example is the revolutionary work of
Ciampricotti et al. in which they generated a RAG2-/-MMTV-NeuT transgenic mice model
of breast carcinoma that supported the theory. Their experiments found that sponta-
neous malignant cell transformations can escape from the immune system in implanted
or chemically induced tumours (Ciampricotti et al., 2011).
However, how cancer originated in humans and, more importantly, how it happened
in immunocompetent individuals were still open questions. In consequence, the immune
surveillance hypothesis was re-evaluated and finally resurrected at the end of the 20th cen-
tury with the cancer immunoediting theory of Robert Schreiber and colleagues (Dunn et
al., 2002). After compiling results from several studies, they proposed a new model com-
prising a multi-step process to fit the tumour immune recognition events in which innate
and adaptive immune systems participate. What follows is named “the three Es” phases:
elimination, equilibrium, and escape (Figure 1.3). Immune surveillance only covers the
first phase: elimination. The immune system can actively detect and enhance inflamma-
tory cascades, antiproliferative and apoptotic programs, repress angiogenesis and activate
other mechanisms that can mediate tumour elimination. On this matter, there is support-
ing evidence from a large-scale study on patients with breast, bladder, colon, prostate,
ovarian and neuroblastoma tumours, indicating that the presence of tumour infiltrated
lymphocytes, specifically CD8+ T cells, correlates with a favourable prognosis (Deligdisch
et al., 1982; Epstein & Fatti, 1976; Jass, 1986; Lipponen et al., 1992; Nacopoulou et al.,
1981; Naito et al., 1998; Palma et al., 1978; Rilke et al., 1991). But certain tumour cells
adapt to evade immune recognition, surviving and growing in a positive selection pro-
cess to achieve the equilibrium phase. This phase can extend for several years until this
lethargy transitions into the last step: escape. In this phase, tumour cells are no longer
immunogenic and remain non-responsive to any immune attack. By these means, they
can proliferate without control, metastasize and manifest as a relapse of the disease.
In this context it is mandatory to emphasize the tight relationship between IFNs as
part of the host immune response and tumour recognition. Both type I and type II IFNs,
play active roles as immunomodulators and suppress tumourigenesis. It has also been de-
scribed that IFNγ has independent roles in this process. A singular feature of IFNγ is that
it promotes tumour rejection by stimulating CD4+ and CD8+ T cells and consequently ac-
tivating the MHC pathway associated to tumour–antigen recognition (Figure 1.4) (Dunn
et al., 2006). This characteristic will be relevant to the development of this thesis. In con-
trast, emerging studies suggest that sustained IFNγ signalling is closely related to chronic
inflammation and elevates the risk of developing cancer (Cheon & Stark, 2009). Such con-
tradictory outcomes require deeper understanding of the IFNγ physiology and its cross-
talk with tumour structures and microenvironments. Nonetheless, description of IFNγ
pathway and immune-effects will be reviewed in detail in upcoming sections.
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Figure 1.3: The Three Es of cancer immunoediting (Dunn et al., 2002). Cancer immunoediting is described
in a 3-step process that explains tumour progression in relation to tumour immunogenicity events. This new
concept opens new insights into the cancer immunosurveillance hypothesis, a less refined and elaborated
hypothesis. The three immunoediting phases are: elimination, equilibrium, and escape. (a) Elimination is
explained by the immunosurveillance hypothesis. (b) Equilibrium refers to those tumour cells (blue) and
tumour variants (red) that have adapted and survived the elimination phase. (c) Escape is when adapted
tumour cells (red) including new tumour variants (orange) grow unrestricted, evading the immune system
(yellow, green, and purple).
Figure 1.4: Cancer immunogenicity activates IFNγ and MHC molecules as downstream effectors (Dunn et
al., 2006). Schematic representation of the cancer immunoediting hypothesis. During the first stages of tu-
mour development, MHC class I and II molecules are able to recognize and eliminate malignant cells by selec-
tively recognizing tumour-specific peptides (transformed cell and elimination section). At advanced stages,
surviving tumours develop mechanisms to decrease MHC-polypeptide-related sequences (depicted as MICA
and MICB), enhancing tumour evasion and prompting adverse outcomes (escape box).
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1.3 Genesis of cancer by viral infection
It remains an open question which cancer variants will be more immune-reactive.
High tumour heterogeneity displays a wide landscape of interactions between the immune
system and malignant cells. Indeed, tumour cells will spontaneously generate a complex
variety of mutations to tolerate the continuous immune-scanning of their surroundings.
However, it seems a reasonable observation that immunosuppressed patients, either after
transplantation or with an immune abnormality, are more prone to grow tumours (Penn,
1978). This correlation reinforces the idea of the equilibrium phase in cancer immunoedit-
ing theory, where unstable tumour cells find ways to bypass immune system recognition
and remain undetected in the host until relapse of the disease. Nonetheless, it is not known
why some tumour types, such as cervical carcinoma or Kaposi’s sarcoma, tend to be of viral
nature while others like breast or colon cancers seem to have completely different origins
(Lunn et al., 2017).
In fact, the idea that tumour malignancies can be originated by viruses goes back a
long time. In 1909, Peyton Rous studied the spreading of avian tumours by injecting small
“filtrates” (then considered virus) of chicken donor sarcoma into healthy chickens, these
developing tumours in weeks. His revolutionary work inspired others and he was awarded
the Nobel Prize for Medicine and Physiology in 1966. Decades later, Howard Temin con-
tinued working with Rous sarcoma virus, finding that continued infection caused normal
cells to transform into tumour-like cells (Weiss & Vogt, 2011). This observation had great
consequences, changing the perspective on cancer from being abnormal tissue to a dis-
ease of the cell. In the mid-1950s, some scientists still considered that cancer was a para-
sitic disease (Burnet, 1955). This lack of understanding generated misleading assumptions
and wrong conclusions.
Nowadays, the view that all cancers are virus-initiated has been discarded. Neverthe-
less, there still exists a high association between viral infections and the manifestation of
particular cancer types. Actually, it is believed that around 12–15% of cancer cases are
caused by viruses; Epstein-Barr, hepatitis B, and papillomavirus being most well-known.
Viral infection is not sufficient to trigger cancer but there is evidence to suggest that some
viruses establish the perfect conditions for development of a specific cancer. The process
normally requires a long period of time in which cumulative changes in host cells and tu-
mour environment result in carcinogenesis (Hausen, 1991; Liao, 2006; Lunn et al., 2017).
A proof of this is an exhaustive epidemiological study in Uganda of individuals infected
with HIV, conducted over four decades. Individuals with AIDS suffered from a wide range
of infection-related illnesses, and also had increased likelihood of having Kaposis sarcoma
but not other cancer types such as cervical or Hodgkins disease (Parkin et al., 1999). AIDS
dysregulates natural killer and dendritic cells, and decreases the activation of CD4+ and
CD8+ T cell response (Boasso et al., 2009). This acquired immunodeficiency may create a
suitable environment to carcinogenesis (Mortaz et al., 2016).It remains unclear why some
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cancers are associated with viruses and others are not. Moreover, it is very difficult to con-
clude that HIV is the main reason why the incidence of Kaposis sarcoma has increased
drastically, but it definitely indicates that cancer and virus infection are closely related.
HPV infection is a risk factor for cervical cancer, and persistent infection leads to ran-
dom integration of the viral particles to the host genome promoting cell immortalization.
The E6 and E7 viral oncoproteins facilitate tumour malignancy. E6 inactivates p53-MDM2
pathway, targets P53 to proteosomal degradations, and prevents shortening of the telom-
erase promoting DNA replication. E7 is critical in tumour transformation as it represses
the G1 to S phase transition by targeting pRB for degradation (Tomaic, 2016).
Interferon induced transmembrane protein 1 (IFITM1), the protein of study for this
thesis, is an example of a protein with a pivotal role in viral restriction and cancer disease.
However, its mechanisms of actions remain poorly understood. As such, this thesis is en-
tirely dedicated to dissecting IFITM1 cellular functions. But first, some relevant IFITM1
features will be disclosed to frame this protein in its cellular and biochemical context.
1.4 Interferon signalling
IFN signalling is a very sophisticated and complex system. Great work has been done
in recent years to better comprehend the conditions in which IFN pathways are activated,
how cells respond to IFN and which elements are mediated by the IFN response. Nonethe-
less, more research is needed to fully understand the IFN signalling landscape.
IFNs are pleiotropic cytokines produced by the innate immune system as a defensive
response (Takaoka & Yanai, 2006). Many biological functions have been described for the
IFN pathway. Among them, the best characterized are anti-tumour activity, immunomod-
ulatory effects, anti-pathogen, and anti-viral activities (Platanias, 2005).
IFN effects rely on the interaction with three different types of receptors: type I (IFNα,
IFNβ and IFNω), type II (IFNγ) and type III (IFNλ) (Bekisz et al., 2004; Borden et al., 2007).
All types accomplish redundant cellular effects. Some evidence shows that type I influ-
ences IFNγ responses by modulating STAT1, a key mediator shared by both IFN types
(Gough et al., 2010). Moreover, supressing type I receptors attenuates IFNγ effects (Hamil-
ton et al., 1996; Takaoka et al., 2000) and, conversely, activating type I pathway enhances
IFNγ responses (Hamilton et al., 1996; Marie et al., 1998; Vogel & Fertsch, 1984)
Nonetheless, there is a biological reason why different IFN types exist and that is so that
specific IFN ligands can bind to specific receptor types and can activate unique pathways.
IFNγ responds to immune and inflammatory stimuli, whereas IFNα and β are known to
be secreted by virus-infected cells. As such, type I and type II IFNs have different protein
structures, chromosomal location and bind to different receptor types (Staeheli, 1990).
Once the ligand binds to its receptor, the signalling cascade begins by phosphoryla-
tion of Janus Kinases (JAK) at a tyrosine residue. Sequentially, phosphotyrosine will fa-
cilitate interactions between two elements of the signal transducer and activator of tran-
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scription signal transducer (STAT), forming a heterodimer for type I IFN or homodimer
for type II IFN. STAT dimerization involves interactions at the SH2 domains. Then, STAT
homodimers bind to a gamma-interferon activation site (GAS) that facilitates specificity
on genes expressed on the first IFN-stimulated gene (ISG) factor synthesis wave, where
rapidly-induced genes will be transcribed. STAT also binds to an interferon regulatory
factor (IRF) member forming the IFN-stimulated gene factor 3 (ISGF3) trimer in type I
and this will bind to genes containing IFN-stimulated regulatory element (ISRE). Conse-
quently, gene regulation by IFN type I will differ from that regulated by type II. However,
the system is promiscuous in that both STAT1–STAT2 heterodimers and STAT1–STAT1 ho-
modimers form in response to IFN type I. Moreover, genes containing ISRE elements are
mostly regulated by IFN type I but some of them are also induced by IFN type II (Stark et
al., 1998) (Figure 1.5).
It is been shown that interferon induced transmembrane proteins (IFITMs) are a family
of proteins induced by IFN. Work done in rat neonatal cardiomyocytes, at the mRNA level,
shows that IFITM3 is mainly inducible by IFN type I whereas IFITM1 greatly responds to
IFN type II. IFITM2 does not respond to either type of IFN (Lau et al., 2012). Nonetheless,
it is been shown that IFITM1 gene induction can also be regulated through the IFN–STAT2
pathway by BRG1, a chromatin-remodelling factor (Huang et al., 2002). Even so, both iso-
forms may contribute to the same cellular processes; this project has a particular interest
in how IFITM1 contributes to cancer events. For this reason, IFNγ signalling will be de-
scribed with special emphasis.
1.4.1 Interferon gamma
Immunomodulatory effects of IFNs have been widely studied. Here we will focus on
those immune responses orchestrated by IFNγ. Previously, it is been described that IFNs
are the first defence in response to pathogens. If the IFNγ-pathway is inactivated, by being
IFNγ, IFNGR1 or STAT1 deficient, but the IFNα/β pathway is otherwise intact, this results
in catastrophic disruption of the innate immunity, exposing the host to higher risk of infec-
tion in front of Influenza A virus, Listeria monocytogenes, Tuberculosis, and Mycobacteria,
among others. This finding is relatable to studies conducted with mice as translatable to
humans (Dalton et al., 1993; Durbin et al., 2016; Huang et al., 1993; Jouanguy et al., 1997;
Marc & Moulin, 2003; Newport et al., 2017; Price et al., 2000). Thus, physiological role of
IFNγ in immune surveillance is undeniable.
IFNγ is selectively produced by Natural Killer (NK) cells (Perussia, 1991), type 1 T helper
cells (Th1) (Mosmann & Coffman, 1989), and CD8+ T cells (Subash Sad & Tim, 1995). But
IFNγ receptors are present in practically all cell types (Bach et al., 1997). IFN pathway
activation requires the participation of Interferon Gamma Receptor 1 (IFNGR1) (90 kDa
receptor α-chain) and Interferon Gamma Receptor 2 (IFNGR2) (62 kDa receptor β-chain)
receptor subunits; IFNGR1 is implicated in ligand binding, ligand trafficking through the
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cell and signal transduction, while IFNGR2 is mostly implicated in signalling. In these re-
gards, IFNGR1 is moderately but constitutively expressed on the cell membrane, whereas
IFNGR2 is expressed at low levels and is inducible under certain stimuli. IFNγ receptor
subunits remain unphosphorylated until the binding of the ligand to the receptor. Ligand
binding promotes oligomerization between two IFNGR1 subunits that creates two bind-
ing sites for two IFNGR2 subunits. Intracellular JAK1 and JAK2 tyrosine kinases bind re-
ciprocally to the IFNGR1 and IFNGR2 (C. Schindler, 1995; Darnell et al., 1994). Signal
transduction occurs when JAK 1 and JAK2 are auto- and trans-phosphorylated providing
a unique phosphotyrosine binding site on the receptor for STAT1, the key element of the
pathway (Bach et al., 1997). STAT1 undergoes to Tyr701 phosphorylation, liberating it from
the receptor to form a homodimer which will translocate to the nucleus. Transcriptional
activity of STAT1 is increased by Ser727 phosphorylation. Interestingly, emergent studies
have identified alternative functions for IFNγ through STAT1-independent pathways. De-
pletion of STAT1 alters the canonical gene expression profile of IFNγ (Ramana et al., 2002),
for example it decreases the generation of pro-apoptotic molecules but increases the gen-
eration of other molecules such SOCS3. Nonetheless, the STAT1-independent pathway
remains unexplored (Figure 1.5).
IFITM1, initially known as 9-27 gene, was firstly identified as an IFN-inducible gene in
the early 90s. IFITM1 contains a 13 bp IFN-stimulated response element (ISRE). This motif
(GGAAATAGAAACT) is located in the 5’ flanking sequence and is thought to be necessary
and sufficient to induce response. Importantly, not only the ISRE motif itself but also the
position in which it is found will determine how inducible it will be by each IFN type (Lewin
et al., 1991; Reid et al., 1989). Moreover, additional elements apart from the transcription
factor may affect the affinity of DNA-binding (i.e. STAT homodimer along with p48 com-
plex binds to ISRE rather than to the GAS element in IFITM1–IFNγ induction) and impact
on gene inducibility (Bluyssen et al., 1995; Muller et al., 1993).
It is been known for a long time that IFNs have different mechanisms of regulating the
transcriptional process of target genes. A given gene may be IFNγ as well as IFNα inducible
but its response may differ; IFITM1 is IFNγ and IFNα inducible but mature mRNA accu-
mulates in a sustained and more rapid manner with IFNα compared to a more transient
and slower accumulation with IFNγ (Friedman et al., 1984; Kelly et al., 1985). However, no
differences in IFITM1 mRNA stability are found after IFNγ stimulation. That implies that
IFN may also operate at a post-transcriptional level (Ackrill et al., 1991).
IFNγ has a tumour cell immunogenicity function. It is involved in tumour rejection
by enhancing tumour-specific T cells that will detect and eliminate tumour primary cells
(Dighe et al., 1994). In addition, experimental procedures probed that mice deficient in the
IFNγ pathway developed more spontaneous tumours after being exposed to a carcinogen,
in comparison to wild type mice. Inactivated IFNγ signalling in conjugation with p53-/-
tumours were developed even more rapidly (Kaplan et al., 1998).
IFNγ exhibits a dose-dependent apoptotic effect on normal endothelial cells. Further-
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Figure 1.5: IFNγ signal transduction (Dunn et al., 2006). IFNγ facilitates the rearrangement of IFNGR1 and
IFNGR2 (IFNγ-receptor subunits) and trigger the signal cascade by activating JAK1 and JAK2 associated ki-
nases. Phosphorylation of JAK kinases leads to homodimerization of the key signal transducer STAT1. IFN
type I can also enhance IFN type II signalling by enhancing STAT1 activation. Once phosphorylated, STAT1
will translocate to the nucleus and bind to promoters at IFNγ-activated sites (GAS), such as IRF1 and HLAs
(codify for MHC proteins) promoters. The signal cascade will be inactivated by receptor dephosphorylation,
suppression of JAKs (mediated by SOCS1), proteosomal degradation of JAKs, or suppression of STAT1 (medi-
ated by PIAS1).
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more, IFNγ shows a dual effect on transformed endothelial cell growth; low concentrations
stimulate cell proliferation while high doses have the opposite effect. Indeed, IFNγ recep-
tor increases in coordination with IFNγ stimulus. IFNγ effects switch from proliferation to
apoptosis according to the number of receptor units displayed in the cell membrane; high
receptor expression triggers IFNγ-signal transduction activating apoptosis while consti-
tutive low levels induce cell growth (Bernabei et al., 2001). Related to this, normal cells
tend to have high levels, dictating apoptosis, and tumour cells exhibit low levels promot-
ing proliferation (Maier et al., 1995). This may be explained by the dynamic expression
of IFNγR2 receptor in T cells, B cells, and myeloid cells. Unresponsiveness to IFNγ may
be a key event in malignant transformation, although doses of exogenous IFNγ (i.e. im-
munotherapy) may reverse the effect.
The first function described for IFNγwas as a molecule with anti-viral activity (Whee-
lock, 1965). As such, IFNγ has physiological relevance in immunomodulation and proin-
flammatory activities. A wide variety of functions have been described for IFNγ, among
which it is implicated in antigen presentation, leukocyte-endothelium interactions, cell
proliferation, apoptosis, and controlling gene expression.
One of the key functions of IFN is that it enhances major histocompatibility complex
(MHC) class I as well as β-2-microglobulin (B2M) transcription, promoting the activation
of CD8+ T cell response (Boehm et al., 1997; Schroder et al., 2004), mainly by IRF1 (Chang
et al., 1992; Reis et al., 1992). Absence of STAT1 or IRF1 attenuates MHC class I proteins
on the cellular membrane in response to IFN stimulus. IFNγ is also responsible for MHC
class II expression and, in consequence, enhancement of CD4+ T cell responses (Mach et
al., 1996). Additionally, IFNγ regulates antigen processing by regulating some proteasomal
subunits such as increasing expression of enzymatic subunits LMP2, LMP7 and MECL1 or
decreasing the non-enzymatic subunit PA28 (Boes et al., 1994; Groettrup et al., 1996). IFNγ
also stimulates overexpression of transporter associated with antigen presentation 1 and
2 (TAP1 and TAP2), proteins that are responsible for guiding peptides from the proteaso-
mal complex to the endoplasmic reticulum, where they will interact with the MHC class
I (Epperson et al., 2018; Trowsdale et al., 1990). Taking all together, IFNγ impacts on the
production of peptides; tailoring which types of peptides will be generated and recognized
by the MHC class I complex.
IFNγ acts as a tumour suppressor by promoting recognition of the transformed cells
by the immune system. Certain types of naturally arising human tumours become un-
responsive to IFNγ (i.e. IFNγR-/-), bypassing the tumour-suppressor mechanisms of the
host. This phenotype will confer tumour selectivity as it will be advantageous for survival.
IFNγ has a pivotal role between innate and adaptive immunity; it can enhance innate im-
munity by recruiting NK cells, macrophages and neutrophils to eliminate tumour cells but
it can also promote adaptive immunity by tumour-antigen processing and presentation
activating MHC class I and II pathway.
Gene regulation is a fundamental and yet complicated activity of IFNγ. In 1990, Stae-
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heli identified several IFNγ-stimulated genes (Staeheli, 1990), but the list currently extends
to hundreds. To begin with, many transcription factors are IFNγ inducible, generating a
sequential cascade of induced expressed genes. For example, IFNγ attenuates viral infec-
tion by controlling transcription of double-stranded RNA activated protein kinase (PKR),
2–5oligoadenylate synthetase (2–5A synthetase), and dsRNA-specific adenosine deami-
nase (dsRAD). Viral RNA and DNA interacts with PKR producing autophosphorylation and
phosphorylation of the α- subunit of eukaryotic initiation factor (eIF2) blocking the gen-
eration of eIF-2-GTP (active form) and resulting in inhibition of translation (Hovavessian,
1993). Type I and II IFNs control the induction of PKR. The 2–5A synthetase degrades viral
and host ssRNAs, preventing viral protein expression (Greenlund et al., 1993). The dsRAD
edits mRNA producing aberrant viral proteins (Bass et al., 1989). Nonetheless, it is still un-
clear which are the functional implications for many of the induced genes. IFNγ is also
involved in further cellular programs such macrophage activation.
Physiological properties of IFNγ involving activation of innate and adaptive immune
system have led to this versatile leukokine becoming exploited as immunotherapeutic
agent. Manguso et al. showed that negative response to immunotherapy is connected to
malfunctions in the IFNγ pathway (Manguso et al., 2018). IFNγ suppresses development
of transplanted tumours via anti-proliferative and pro-apoptotic cellular programs, but
also by inhibiting angiogenesis and boosting the antigen presentation pathway (Ikeda et
al., 2002).
Some of the key reasons why IFNγ is a potent molecule capable of achieving tumour
rejection will be described below. IFNγ is responsible for inhibiting angiogenesis by de-
creasing levels of vascular endothelial growth factor (VEGF). Also, it blocks differentia-
tion into tumour-associated macrophages (TMAs), one of the main sources of VEGF in
a cancer microenvironment (Allavena et al., 2008), increasing infiltrating monocytes and
macrophages as well as anti-tumour chemokine and cytokine secretion (Briesemeister et
al., 2011; Sun et al., 2014). As such, it has exhibited great potential as an anti-tumour drug.
Positive responses to IFNγ therapy have been found in bladder and ovarian cancers (Gi-
annopoulos et al., 2003; Marth et al., 2004; Stavropoulos et al., 1998; Wall et al., 2003; Wind-
bichler et al., 2000).
Conversely, some studies have noted that IFNγ also has pro-tumourigenic effects, so
it has to be carefully administered. For instance, a study found that a physiological dose
of IFNγ confers cell growth arrest but also enhances cell invasiveness of lung metastasis
in a melanoma mouse model (Taniguchi et al., 1987). Additionally, an independent small-
scale clinical trial conducted on patients with cutaneous malignant melanoma, treated
with recombinant IFNγ, did not show a favourable outcome (Meyskens et al., 1990). Ad-
verse effects have also been found in metastatic renal-cell carcinoma, colon cancer, and
small-cell lung cancer (Gleave et al., 1998; Jett et al., 1994; Wiesenfeld et al., 1995).
Why does IFNγ show these antagonistic effects? The reality is that uncontrolled im-
munological pathways may put host survival at risk; unrestrained IFNγwill activate cellu-
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lar programs to terminate “non-self” structures, also leading to indiscriminate attacking of
healthy cells. This leads to the Mellor and Munn hypothesis in which focalised persistent
inflammation induces immunosuppression (Mellor & Munn, 2008) (Figure 1.6). Paradoxi-
cally, inflammatory events can confer favourable conditions to the tumour microenviron-
ment. Tumours tend to promote a moderate local inflammation so they can benefit from
growth but without alerting the immune system (Balkwill F., 2001). As an example, tumour-
associated macrophages (TAM), attracted by secreted tumour chemokines, are notori-
ously present in the tumour surroundings. Under appropriate conditions, TAM can facil-
itate angiogenesis, proliferation, invasion and metastasis. Also, tumour-associated den-
dritic cells are often immature and not capable of fully activating antigen-specific recog-
nition. Other inhibitory mechanisms comprise T cell stimulation by APC impairment and
suppression of effector activity of tumour infiltrating T cells. As proposed in Dvarak’s re-
view tumours behave, in many ways, as wounds that do not heal (Dvorak, 2016).
Due to antagonistic responses in different cancer types, IFNγ effects in tumourigenic
events need to be evaluated. At this point many efforts have driven to the very power-
ful approach of using the host immune system to cure cancer malignancies, despite the
scientific debate about how successful it may be. Thus far, we are still in the early days of
fully understanding the whole system and any possible adverse effects that may arise while
boosting the immune system. But what it is even more important, we still need to compre-
hend the biology of the cancer in each patient to deliver the appropriate immunotherapy.
Figure 1.6: Immunogenic and non-immunogenic responses to antigenic stimuli (Mellor & Munn, 2008).
Optimal fitness of the immune system is essential to differentiate between self- and non-self antigen. Dys-
regulation of the immune response may lead it to consider chronic pathogens or malignant cells as non-
immunogenic. Alternatively, hyper-activation of the immune response may lead to recognition of self-
antigens (i.e. auto-immune disease or allergy) as well as transplant rejection. Immunotherapeutic interven-
tion aims to correct these undesirable effects.
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1.5 Interferon resistance DNA-damage signature
For the last century, radiotherapy and chemotherapy have been the traditional anti-
cancer therapies. A conventional point of view considers that IFNs activate pro-apoptotic
and anti-proliferative programs. As such, elevated doses of IFNs are routinely adminis-
trated for anti-cancer therapy. Interestingly, Gerber et al. proposed that radiation not only
promotes DNA damage but also boosts the CD8+ T cells and the antigen presentation
pathway. Their study found significantly less tumour regression in murine colon adeno-
carcinoma deficient in IFNγ compared to control mouse (Gerber et al., 2013).
Unfortunately, IFN signalling is more complicated in that it also activates immunosup-
pressive and tumour-survival pathways. In consequence, tumour resistance in response
to IFNs as chemotherapeutic agents have given rise to great concern (Minn, 2015). Noto-
riously, many cancer therapies are not successful in eliminating all malignant cells; a few
cancer cells manage to survive, by positive selection, often giving more aggressive features.
Intrigued by these poor outcomes, continuous scientific effort is attempting to identify al-
ternative IFN pathways. Weichselbaum et al. found an IFN-dependent protein signature
in a variety of cancer types after chemotherapy failure. As described previously, IFNs are
responsible for expressing a wide range of ISGs, usually associated with anti-cancer effects.
By studying consistent gene overexpression across several cancer cell types, they were able
to define a subset of ISG genes they called the IRDS signature (Table 1.1). Intrigued by this
observation, further investigation of clinical data on breast cancer revealed positive re-
sponses to chemotherapy associated with low expression of IRDS signature. This was ad-
ditionally corroborated with other breast cancer data sets (Weichselbaum et al., 2008a).
Another pioneer study also reported poor prognosis correlated with IRDS signature in
glioblastoma (Duarte et al., 2012), and an independent study also found upregulation of
the IRDS gene profile after radiation in breast, prostate and glioma cancer cells (Tsai et al.,
2007).
Underlying molecular mechanism by which IFNs confer cancer protective effects
through IRDS genes are being explored (Figure 1.7). In a healthy cellular state, one could
expect that the STAT1/IFN pathway will be activated in response to cellular DNA damage.
In fact, sensitivity to DNA damage is closely related to responsiveness to IFNs (Khodarev
et al., 2007). In normal conditions, no free DNA or RNA is expected to be in the cytosol.
Therefore, under pathogen attack host cells will activate immune-related pathways (i.e.
IFN-signalling) that recognize non-self genetic material (Takeuchi & Akira, 2010). Para-
doxically, in pathological conditions (i.e. cancer and chronic inflammation) there is a sus-
tained infusion of low levels of IFN and, in cancer, this leads to tumour resistance. In fact,
studies are emerging that suggest that resistance to DNA damage is caused by chronic IFN
stimulation (Cheon et al., 2014; Weichselbaum et al., 2008a)). In brief, it is hypothesized
that ssDNA fragments originating in the nucleus, caused by the DNA-damaging effect of
cancer therapy, will accumulate in the cytosol. As a consequence, immune responses will
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be continuously activated (Erdal et al., 2017).
IRDS genes enhance pro-tumour phenotypes such as resistance to DNA damage, sup-
pression of T cell toxicity, metastasis, and facilitation of epithelial–mesenchymal transition
(Wallace et al., 2011). Thus, the IRDS gene signature is proposed as a therapy-predictive
marker for anticipating negative responses prior to chemotherapy and radiation (Weich-
selbaum et al., 2008b). In summary, IRDS are thought to be oncogenic genes modulated by
STAT1. However, how the IRDS signature confers a protective effect against radiotherapy
and chemotherapy has not been investigated in detail. A better understanding of the com-
plexity of this genetic signature needs to be addressed to improve cancer therapy. There-
fore, in this study we explore the oncogenic implications of IFITM1, one component of the
IRDS signature. By extension, we will also investigate other IRDS genes that we suspect are
also implicated with IFITM1 cellular roles. The next section will be dedicated to describing
essential features of IFITM1 and other interesting members of the IRDS signature featur-
ing in this research.
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Table 1.1: IRDS protein list (Weichselbaum et al., 2008a).
Gene symbol Alternative symbols Gene Name
BST2 Tetherin Bone marrow stromal cell antigen 2
CCNA1 Cyclin A1
CXCL1 GRO1; GROA; SCYB1 Chemokine (C-X-C motif) ligand 1
CXCL10 IP10; SCYB10; INP10 Chemokine (C-X-C motif) ligand 10
EIF2AK2 PRKR; PKR; p68 Kinase Eukaryotic translation initiation factor 2-alpha
kinase 2
HERC6 FLJ206371 Hect domain and RLD 6
HLA-B SPDA1 Major Histocompatibility complex class I, B
HLA-G TCA; HLA6.0; HLA60 Major Histocompatibility complex class I, G
IFI27 ISG12 Interferon, alpha-inducible protein 27
IFI35 IFP35 Interferon-induced protein 35
IFI44 p44 Interferon-induced protein 44
IFI44L C1orf29 Interferon-induced protein 44 like
IFI6 G1P3 Interferon, alpha-inducible protein 6
IFIH1 MDA5 Interferon induced with helicase C domain 1
IFIT1 IFI56; G10P1; ISG56 Interferon-induced protein with
tetratricopeptide repeats 1
IFIT3 RIGG; IFI60 Interferon-induced protein with
tetratricopeptide repeats 3
IFITM1 IFI17; leu13; fragilis; 9-27 Interferon induced transmembrane protein 1
IRF7 IRF7A Interferon regulatory factor 7
ISG15 G1P2; IFI15 ISG15 ubiquitin-like modifier
LAMP3 DCLAMP Lysosomal-associated membrane protein 3
LGALS3BP MAC2BP; L3 ANTIGEN Lectin galactoside-binding soluble binding
protein
LY6E RIGE; TSA1 Lymphocyte antigen 6 complex, locus E
MCL1 BCL2L3 Myeloid cell leukemia sequence 1 (BCL2-related)
MX1 IFI78, MxA Myxovirus (influenza virus) resistence 1
MX2 MxB Myxovirus (incluenze virus) resistence 2
OAS1 OIAS 2-5’-oligodenylate synthetase 1, 40/46 kDa
OAS3 p100 2-5’-oligodenylate synthetase 3, 100 kDa
OASL TRIP14; p59 OASL 2-5’-oligodenylate synthetase-like
PLSCR1 MMTRA1B Phospholipid scramblase 1
STAT1 STAT91 Signal transducer and activator of transcription
1, 91 KDa
USP18 USP43 Ubiquitin specific peptidase 1
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Figure 1.7: Role of the IRDS signature in the tumour resistance (Khodarev et al., 2012). Anti-tumour treat-
ments confer a positive selection to radio- and/or chemoresistant tumour clones. (A) IFN/STAT1 pathway
highlighting most common anti-cancer drug targets. (B) Majority of tumour cells will be eliminated after can-
cer treatment in cooperation with immune-system activity. (C) A discrete subset of tumour cells is insensitive
to genotoxic therapy and progresses. (D) Clonal expansion of those tumour clones resistant to cytotoxic stress.
(E) Resistant tumour variants populate tumour microenvironment.
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1.5.1 IFITM1
This section will serve as a brief description of IFITM1 implications in relation to
chemotherapeutic drug resistance. Additional IFITM1 features will be discussed in more
detail in upcoming sections. IFNs are widely administrated as anti-cancer drugs and it is
reported that IFNs are able to induce IFITM1 expression. Nonetheless, the role of IFITM1
in this respect is controversial. On one hand, low level expression of IFITM1 is found in
high-risk leukemia patients who are less responsive to IFNγ therapy (Akyerli et al., 2005),
and an independent study of cisplatin treatment in oesophageal squamous cell carcinoma
identified an inverse correlation between IFITM1 levels and tumour resistance after treat-
ment with cisplatin (Fumoto et al., 2008). On the other hand, cisplatin treatment also iden-
tified IFITM1 as a candidate for tumour resistance in lung cancer cells (Whiteside et al.,
2004). Another study argued that continuous treatment of type I IFN promotes cell resis-
tance to X-rays and correlates with induction of IFITM1 expression (Kita et al., 2003). As
previously stated, Khodarev et al. identified overexpressed STAT1 in tumour-radioresistant
human tumour xenografts (Khodarev et al., 2004). Notoriously, IFITM1 as well as other
IRDS genes were highly induced in this subset. This observation indicated that IFITM
contributes to cancer cell survival and leads to tumour relapse. Taking in consideration
the antiproliferative role of IFITM1 associated with constitutively activated IFN, it may
be possible that IFITM1 confers advantages to tumour cells in the presence of anticancer
treatments (i.e. radiotherapy) that select for proliferative cells. However, no convincing
proof has been revealed about which specific mechanism(s) is activated by IFITM1 in can-
cer therapy. Interestingly, another study suggested that absence of IFITM2/IFITM3 could
be used as a predictor for poor response to chemotherapy in osteosarcoma (Salas et al.,
2009).
In conclusion, it is difficult to identify biomarkers responsible of drug resistance. It
may be possible that cancer cell survival in the presence of chemotherapeutic agents is
conferred by accumulative effects prompted by several molecules. Despite this, IFITM1
gene expression is enhanced after administration of different chemotherapeutics. Even
so, there is no consensus on how this protein functions at the molecular level. In fact,
it may have a pleiotropic effect depending on cancer type and/or tumour stage, where
overexpression as well as depletion may have an impact on cancer relapse. Consequently,
there is a need to elucidate both alternative cellular functions of IFITM1.
1.5.2 ISG15
Interferon-stimulated gene of 15 kDa (ISG15) is another molecule upregulated by IFNs
(Farrel et al., 1979), particularly by type I IFN (Haas et al., 1987; Korants et al., 1984). In
fact, it is considered to be one of the most highly expressed genes in response to IFN treat-
ment (Der et al., 1998), and it contains two ISRE sequences responsible for activation of its
transcription by IFNs (Zhang & Zhang, 2011). In addition, transcription and expression of
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ISG15 are induced by other stress stimuli such as DNA damage, radiation and chemother-
apeutic drugs (Gentile et al., 2003; Liu et al., 2004; Park et al., 2016). Nonetheless, it re-
mains uncertain whether ISG15 confers a protective effect or enhances cancer malignan-
cies in drug therapy. For example, ISGylation of proliferating cell nuclear antigen (PCNA)
enhances the DNA repair mechanism promoting a chemoresistant phenotype (Park et al.,
2014). Alternatively, it is suggested that ISGylation of a splice variant of the transcription
factor p63 confers a chemosensitive phenotype by promoting cell arrest and apoptosis
(Jeon et al., 2012).
There are many ways to regulate the fate and function of proteins after their synthesis.
ISG15 is a great example of covalent conjugation to proteins by ISGylation: a process very
similar to ubiquitination (Liu et al., 2013), one of the most well-studied type of posttrans-
lational modification (PTM) (Weston et al., 2014). Ubiquitin was discovered in the late
1970s (Ciehanover et al., 1978; Hershko et al., 1980), and since then many other homologs
have been classified as ubiquitin-like proteins (Ubls), the first identified being ISG15 (Far-
rel et al., 1979). In contrast to other ubiquitin-like proteins, ISG15 is exclusively found in
vertebrates but is not well conserved across species (Zhang & Zhang, 2011).
ISG15 is composed of two Ubl domains linked by a proline residue. It has the same
C-terminal motif (LRLRGG) as mature ubiquitin, and the last glycine of the motif binds
to a lysine located in the target protein. This motif is essential to form ISG15, as well as
ubiquitin, conjugates (Haas et al., 1987). The mature ISG15 form undergoes an N-terminal
methionine cleavage (Blomstrom et al., 1986) and the last C-terminal eight amino acids
(GTEPGGRS) are also removed from the precursor polypeptide (Knigth et al., 1988). As
in ubiquitination, ISGylation is a multistep process that also requires a series of specific
enzymes; ISG15-activation enzyme (E1-UbE1L) (Yuan & Krug, 2001), ISG15-conjugating
enzyme (E2-UbcH8) (Zhao et al., 2004), ISG15-protein ligases (such as E3-Herc5) (Dastur et
al., 2006), and ISG15-specific protease (USP18/UBP43, enzyme that liberates ISG15 from
the target protein) (Malakhov et al., 2002).
A substantial amount of work remains to be done before the molecular implications of
ISG15 are fully understood i.e. which proteins are ISGylated, and what are their functions.
Despite this, continuous scientific efforts aim to identify new ISG15-target proteins (Gian-
nakopoulos et al., 2005; Takeuchi et al., 2006), and several hundreds of protein candidates
have been identified (Durfee et al., 2010). Some of these protein targets are defined as
IFN-related proteins such as STAT1 or JAK1 (Zhao et al., 2005). Based on the broad biolog-
ical roles of these proteins, it presents a real challenge to determine fundamental cellular
implication(s) for ISG15.
There are two forms described for ISG15: free, and in conjugation. Cellular functions
of free and conjugated ISG15 differ and free ISG15 is found both intra- and extracellularly.
Interestingly, IFN induction of ISG15 in its free form does not necessarily lead to an in-
crease of ISGylation. ISG15 stimulation or depletion of UBP43 protease sustains type I
IFN signalling (Malakhova et al., 2003). Moreover, the free ISG15 form is able to induce
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production and secretion of IFNγ from CD3+ cells to activate the cytotoxic effect of NK
cells (Recht et al., 2018) . In addition, ISG15 associates with target proteins (Loeb & Haas,
1994; Loeb & Haas, 1992) while in its free form is generally related to cytokine generation
and enhancing the immune system (Cunha et al., 1996; Recht et al., 2018).
Similar to IFITM1, ISG15 also has roles in both antiviral activity and cancer. Initially,
ISG15 was described as anti-viral molecule and is upregulated with bacterial and viral in-
fection (Mossman et al., 2001; Nicholl et al., 2000). ISG15 deficiencies increase susceptibil-
ity to infection; for example Isg15 -/- mice are more prone to influenza, herpes, and Sindbis
infections. In fact, lack of LRLRGG motif in ISG15 (responsible of intracellular ISG15 conju-
gation) abrogates protection from Sindbis virus (Hsiang et al., 2009; Lenschow et al., 2007;
Lenschow et al., 2005). In addition, free ISG15 inhibits ubiquitylation of Ebola virus VP40
protein by intercepting Nedd4 (ubiquitin E3). Mechanistically, ISG15 (even in its free form)
inhibits the interaction of Nedd4-like E3 ligase with viral PPXY motifs by preventing its in-
teraction with the E2 and the substrate protein complex. Consequently, VP40 protein is not
ubiquitinated and the viral particles are not released extracellularly (Malakhova & Zhang,
2008). Likewise, ISG15 restricts the release of HIV-1 virions by inhibiting the ubiquitina-
tion of Gag and Tsg101 viral particles, consequently impeding their interaction (Okumura
et al., 2006). In response, viruses engineer new mechanisms to inhibit the anti-viral effect
of ISG15. For example, influenza B virus NS1 protein inactivates ISG15 conjugation (Yuan
& Krug, 2001). Other viruses also inactivate the protective effect of conjugated ISG15 by
having a de-ISGylated activity (Clementz et al., 2010; Lindner et al., 2007).
From the cancer perspective, emerging studies have related ISG15 to tumourigenic-
ity. ISG15 overexpression has been reported in several cancer types (Andersen et al., 2006;
Darb-Esfahani et al., 2014; Vincent-Chong et al., 2012; Wood et al., 2012). In this regard,
high-grade serous carcinoma, the most recurrent type of ovarian carcinoma, is responsive
to chemotherapy, but the incidence of tumour relapse is also high and this usually leads
to a low survival rate (Thigpen et al., 2011). There is an increase in ISG15 expression in pa-
tients with relapsed ovarian carcinomas and this significantly correlates with a favourable
prognosis, possibly by mediation of the NF-kB factor (Darb-Esfahani et al., 2014). In con-
trast, ISG15 is related to carcinogenesis; ISG15 expression and global protein ISGylation
are elevated in distinct types of cancer cells compared to normal cells (Desai et al., 2006;
Kiessling et al., 2009). Moreover, ISG15 shows an inhibitory effect on protein polyubiqui-
tination, altering protein degradation in the ubiquitin/26S proteasome pathway (Desai et
al., 2006; Desai et al., 2012). Immunochemistry analysis of breast cancer tissue shows ele-
vated ISG15 in comparison to normal tissue and, in addition, ISG15 has poor response to
chemotherapy or radiation. In fact, it is proposed as tumour-associated antigen suitable
for cancer immunotherapy (Wood et al., 2012).
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1.5.3 HLA-B
HLA-B is a gene member of the human leucocyte antigen (HLA) complex. This gene
complex is located on human chromosome 6 and it encodes the major histocompatibility
complex (MHC). The MHC is divided into three groups: class I (HLA-A, HLA-B, HLA-C);
class II (HLA-DR, HLA-DQ, HLA-DP); and class III (genes that complement the MHC sig-
nalling cascade). Additional allelic variants have been described, but they are less well
characterized (Dendrou et al., 2018). Because HLA-B (in conjugation with HLA-G) is iden-
tified as a component in the IRDS signature and is a member of the MHC class I molecules,
this section will concentrate on describing the main features of the MHC class I pathway
(Figure 1.8). Furthermore, the principal focus of this thesis is to investigate those proteins
related to IFITM1, and HLA-B is relevant to this study.
The MHC is one of the most hypervariable loci in the human genome, and this makes
it extremely difficult to study. Each allelic variant has specific affinity for a subset of pep-
tides, and each differs in expression as well as complex assembly. As a consequence, the
physiological functions of these molecules are essential for cell survival; these complexes
are critical factors in the immune response to viruses and other intracellular aberrations.
If dysregulated, the MHC is associated with most autoimmune diseases, but also with tu-
mour–antigen recognition and transplant rejection.
Both MHC class I and MHC class II molecules, effectively present peptides (typically
8–10 amino acids in length) (Rammensee et al., 1993) at the cell surface, and theses are rec-
ognized by CD8+ and CD4+ T cells respectively. From a mechanistic point of view, they are
implicated in the cell-defence mechanism that distinguishes self-proteins from proteins
produced by foreign invaders (i.e. viruses or bacteria). In particular, CD8+ T cells (also
known as cytotoxic T lymphocytes or CTL) are responsible of eliminating the infected or
tumour cell by releasing cytotoxic granules that contain perforin and granzymes. Perforin
attacks the cell membrane, making pores, and granzymes cleave intracellular proteins; all
together result in cell death by activating the apoptosis program. Additional Fas/FasL in-
teractions between CTL and infected cells also enhances apoptosis by activation of the
caspase cascade. CTL also secrete TNF-α and IFNγ which have anti-microbial and anti-
tumour effects (Halle et al., 2017). In addition, IFNγ induces HLA genes, as well as other
components of the cascade, consequently enhancing the antigen-presentation pathway
(Früh & Yang, 1999; Rosa & Fellous, 1988).
MHC class I molecules are comprised of two subunits synthesized in the ER: a variable
heavy α-chain (the most well-known haplotypes are: HLA-A, HLA-B, and HLA-C) and an
invariable light β-chain (B2M). HLAs are highly polymorphic and this feature impacts on
protein structure. Each variant has a different peptide-binding groove and consequently,
this increases the repertoire of peptides displayed in association with MHC class I (Trows-
dale, 2005). HLA-B is loaded with peptide and guided to the cell membrane more rapidly
than the other two counterparts, HLA-A and HLA-C (Peh et al., 1998). In addition, HLA-B
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Figure 1.8: MHC class I antigen presentation pathway (Neefjes et al., 2011). The initial step involves pro-
tein degradation in the proteasome to obtain antigenic peptides. Peptides will then be incorporated to the
endoplasmic reticulum (ER) via transporter associated with antigen processing (TAP). Once inside the ER,
peptides will be loaded onto the MCH class I complex, sent to the Golgi apparatus and finally guided to the
plasma membrane. Optimal assembly on the cell surface is required for it to be recognized by T cell receptor
(TCR) on the CD8+ T cell.
(in most of its polymorphic variants) tends to be successfully loaded with peptide more
frequently than HLA-A and HLA-C (Neefjes & Ploegh, 1988). Once at the cell membrane,
MHC class I molecules loaded with peptide are highly stable. In contrast, the dissociated
heavy chain has a very short life (Neefjes et al., 1992). The complex is normally recycled by
the endocytic pathway (Adiko et al., 2015).
MHC class I molecules are ubiquitous and present peptides of an intracellular nature.
Peptides are cell-associated antigens of different types: tumour-, viral- or self-antigens. An
alternative and non-canonical presentation pathway has been described, in which there
is cross-presentation of exogenous peptides via MHC class I found in dendritic cells (Vyas
et al., 2008). Antigen presentation requires the proteolysis of the protein to produce the
antigenic peptide. Theoretically, the half-life is highly variable between proteins and it
will determine the frequency with which the MHC class I presentation machinery will be
able to expose the antigenic peptide for CD8+ T cell recognition (Figure 1.9). Nonetheless,
empirical observation shows that viral proteins are presented more rapidly than expected.
In fact, many proteins are degraded before being functional as a result of synthesis defects.
These products known as defective ribosomal products (DRiPs) are degraded and used as a
substrate for the MHC class I-peptide loading (Reits et al., 2000). In addition to DRiPs, age-
associated damage or incorrectly folded proteins are another source of peptide formation
(Yewdell, 2001).
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Figure 1.9: Trafficking of MHC class I molecules to the cell surface (Vyas et al., 2008). (1) The first event
involves the production of an aberrant protein. Oncoproteins could also be interpreted as aberrant by the cell.
(2) Protein is targeted with ubiquitin for degradation. (3) Proteasome is responsible of degrading the protein
to produce peptides. (4) Peptides are translocated into the ER by TAP and tapasin; TAP channels cytosolic
peptides into the ER and tapasin, also known as TAPBP, is a chaperone that promotes peptide folding and
correct binding to the MHC class I. (5) Nascent MCH class I becomes accessible in the ER to load the peptide.
This process will be facilitated by tapasin and other ER proteins such as calreticulin and ERp57. (6) Once the
MCH class I is loaded with the peptide it guided to the cell membrane through the Golgi apparatus.
A large amount of MHC class I molecules are unable to correctly bind to peptides and
so they are eliminated by the ER-associated protein degradation system (Hughes et al.,
1997). As such, antigen presentation is limited by rate of protein synthesis but also by
the pool of completely functional MHC class I molecules. If peptide binding to the MHC
class I complex fails, peptides are trimmed, recycled back to the ER lumen and subjected
to another round of recognition. Alternately, they are eliminated by peptidases after be-
ing released into the cytosol (Koopmann et al., 2000; Roelse et al., 1994). Strikingly, the
proteasome produces 104–106 fold more peptides than MHC class I molecules are able to
bind. This is compensated by the rapid rate of the antigen presentation cycle and addi-
tional massive degradation of those peptides that are unbound (Figure 1.10) (Princiotta
et al., 2003; Yewdell et al., 2003).
From a clinical perspective, Ferrara et al. revealed that radiation in combination with
immunotherapy leads to a better outcome than each alone. Radiation has negative col-
lateral effects producing a suboptimal immunological response. To overcome this, anti-
cancer immunotherapies have been designed to enhance CTL–tumour cell recognition
to specifically target cancer neoantigens (Ferrara et al., 2009). Paradoxically, radiation
also upregulates expression rates of immune-related mediators in surviving radiated tu-
mours, making them more susceptible to immuno-recognition. Among these, MHC class
I-peptide presentation is enhanced (Garnett et al., 2004; Reits et al., 2006). Interest-
ingly, the MHC class I antigenic peptide repertoire changes after irradiation. This ef-
fect is in accordance with the fact that HLA-B is a component of the IRDS genes and
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Figure 1.10: Cellular efficiency of MHC class I antigen processing (Yewdell et al., 2003). Representation
of the estimated efficiency of antigen processing by the MCH class I complex. These results are based on
empirical work, and results should be considered as average; physiological and pathological conditions will
alter the outcome. This work is based on measurements taken on L929 cells where it is predicted that only 1 or
2 in 10,000 peptides will bind to the MHC class I complex. DRiPs correspond to approximately 30% of the total
protein amount synthetized by ribosomes. The number of MHC class I molecules loaded with peptide per
second was measured considering their half-life and the number of molecules assembled at the cell surface.
these have been found upregulated after chemo- and radiotherapy. In contrast, tumours
evolve rapidly and activate immune escape mechanisms such depletion of MCH class I
and tumour-antigens to attenuate the immune attack. Changes in HLA function inhibits
the HLA–oncopeptide–TCR interactions decreasing tumour recognition by immune sys-
tem (Dendrou et al., 2018). In this respect, loss of MHC is a widespread mechanism iden-
tified in multiple cancer types. Several MHC alterations have been described in cancer;
HLA defects are found at gene level with loss of heterozygosity, hypermethylation, and
mutations of the HLA and β2M genes; and at transcript level by decreasing HLA and β2M
mRNA (Garrido et al., 2010). MHC class I molecules have been found recurrently mutated
across several human cancer types, thus producing differences in the functional nature of
these proteins. Systematic patterns in somatic mutations are identified for specific can-
cers such as HLA single mutations found in glioblastoma and lack of mutations in liver
cancer (Shukla et al., 2015). In addition, somatic HLA mutations are highly prevalent in
head and neck, lung squamous and stomach cancer (Shukla et al., 2015).
1.5.4 Description of additional IRDS components of interest: STAT1, Mx1, and
IFIT1
STAT1 is the putative downstream effector of INFγ signalling. Gene expression profil-
ing of multiple cancer types consistently identified induced STAT1 and IFITM1 in breast,
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prostate, and gliosarcoma cells exposed to radiation (Tsai et al., 2007). Interestingly, it is
believed that tumours with persistent IFN exposure will overexpress STAT1, but in contrast
cells will fail in activating a cytotoxic response when irradiated or externally stimulated
with IFN (Khodarev et al., 2007). In fact, an IFN non-canonical pathway leads to induction
of IRDS genes through unphosphorylated STATs. As a result, the expression of immune-
related genes, IRDS, is sustained for a longer time in comparison to phosphorylated STATs
(Cheon & Stark, 2009; Cheon et al., 2011). In addition, unphosphorylated STATs were found
to promote a gene expression profile related to anti-viral and DNA damage resistance by
binding to alternative ISRE sites (Cheon et al., 2013). Increased STAT1 correlates with a
radiation-resistance phenotype in injected head and neck cancer xenografts in a murine
model (Khodarev et al., 2004). Moreover, STAT1 protein amount is elevated after ioniz-
ing radiation but IFNγ remain unchanged (Sreekumar et al., 2001). An independent study
also argues that constitutive expression of STAT1, mediating the expression of other IRDS,
is responsible for the protective effect in radiation (Khodarev et al., 2004). These findings
were also demonstrated in a murine model of melanoma where sustained activation of
STAT1 has been correlated with metastasis and resistance to chemotherapy (Khodarev et
al., 2009).
Mx1 is repeatedly identified as a component of the IRDS signature in several indepen-
dent studies (Duarte et al., 2012; Erdal et al., 2017; Weichselbaum et al., 2008a). Mx1 are
IFN-inducible proteins belonging to the GTPases-dynamin superfamily. They attenuate
a wide diversity of RNA viruses by detecting viral nucleocapsid structures and blocking
viral replication. For example, an Mx1 murine model restricts influenza by inhibiting the
interaction of virus polymerase subunit PB2 and nucleoprotein (Strandem et al., 1993; Ver-
helst et al., 2012). Human Mx proteins are accumulated in the cytoplasm and distributed
in granules. In fact, Mx1 has been found in the smooth endoplasmic reticulum (Haller &
Kochs, 2002).
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) is one of the first
described ISG genes. IFIT1 is clustered with IFIT3, another gene from the same family
that is also identified as IRDS. Both genes are induced by IFN, virus attack, dsRNA or LPS
structures. IFIT1 suppresses translation by interacting with eIF3 and inhibiting the forma-
tion of eIF3–GTP–Met-tRNA ternary complex (Fensterl & Sen, 2011). Additionally IFIT1 is
associated with IFIT2 which has an apoptotic role (Stawowczyk et al., 2011). Association of
IFIT1 in translational complexes in the ribosome affect the replication of viruses, such as
Hepatitis C or West Nile (Wacher et al., 2007; Wang et al., 2003). Moreover, IFIT1 interacts
with E1 protein in HPV virus, impeding the viral DNA replication (Terenzi et al., 2008).
1.6 IFITM phylogenetic features and study of IFITM topology
The interferon-induced transmembrane (IFITM) gene family is comprised of the fol-
lowing members: IFITM1, IFITM2, IFITM3, IFITM5, IFITM6, IFITM7, IFITM10 and addi-
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Figure 1.11: Chromosome location of the human IFITM genes (adapted from (Zhang et al., 2012)). Order
and orientation of IFITM genes in the gene-cluster. Two connected boxes represent two exons of each IFITM
gene and the arrow indicates the orientation of transcription. Only chromosomes containing genes from the
IFITM gene-cluster and IFITM10 are shown in the panel.
tional IFITM-like genes. All of them, except IFITM5 and IFITM10, are IFN inducible. They
are present in a wide range of cell types and their expression levels vary during develop-
ment and in malignancies. IFITM6 and IFITM7 are only identified in rats and mice (Zhang
et al., 2012) whereas IFITM5 is associated exclusively with bone formation (Hanahan &
Weinberg, 2011; Moffatt et al., 2008).
IFITMs were first discovered in IFN stimulated T98G neuroblastoma cells by Friedman
et al. (Friedman et al., 1984). Some years later, further work conducted by Reid et al. and
Lewin et al. established IFITMs as a protein family and corroborated their inducibility by
IFN (Reid et al., 1989; Lewin et al., 1991). Other family members, like IFITM5, were re-
ported after searching for genetic homology.
An extensive phylogenetic analysis in 27 vertebrate genomes stratified IFITM genes
in three clades: IFN-related, IFITM5 and IFITM10. The IFN-related IFITMs are clustered
in the same group in different mammalian species suggesting that they are conserved
through evolution. Interestingly, mammals contain more IFN-related IFITMs compared
to other vertebrates. Analysis showed that IFITM2 and IFITM3 originated in a common
ancestor between humans and other hominids. Moreover, it is suggested that during evo-
lution the IFITM1 gene was duplicated, producing IFITM2 and IFITM3 (Zhang et al., 2012).
IFITM1, IFITM2 and IFITM3 have been described as restriction factors, providing antiviral
activity in the presence of a wide range of pathogens. Their role in viral inhibition will be
discuss in detail in later sections.
Homologues of IFITMs have been identified in several species, although their specific
chromosomal arrangement differs even between hominids. The focus of this study is hu-
man IFITM1 and, by extension, IFITM2 and IFITM3. Human IFITM1 is encoded by the
IFITM1 gene located on chromosome 11p15.5 and is flanked by the IFITM2 and IFITM3
genes. IFITM5 is located 8.5 kb upstream and IFITM10 1.4 Mb downstream (Figure 1.11).
It remains unclear if absence of IFITM1 promotes cancer development by increasing
aggressiveness and invasiveness or, on the contrary, it has a protective effect. What seems
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Figure 1.12: Alignment of IFITM1, IFITM2, and IFITM3 amino acid sequences. Isoform sequences were
taken from Uniprot; IFITM1 (accession number: P12164), IFITM2 (accession number: Q01629), and IFITM3
(accession number: Q01628) and aligned using CLUSTAL2.1 multiple sequence alignment by MUSCLE (3.8)
online tool. Predicted transmembrane residues are highlighted in bold.
consistent is that IFITM1 is the main isoform found dysregulated in many types of can-
cer. Understanding the peculiarities of this isoform and how it differs from other family
members may help in elucidating this issue.
A close look at IFITM topology may give some clues as to how these isoforms may
have redundant roles and yet small differences in sequence may give rise to unique cel-
lular functions (Figure 1.12). All three family members share high sequence identity (68%
IFITM1:IFITM2, 71% IFITM1:IFITM3, and 87% IFITM2:IFITM3). Additionally, all three
IFITM proteins share a large CD225 domain in which two transmembrane domains are
predicted. However, terminal regions are not conserved between isoforms; IFITM1 con-
tains an additional 13 amino acids at the C-terminus whereas IFITM2 and IFITM3 have a
larger N-terminus with an extra 20 (IFITM2) and 21 (IFITM3) amino acids (Siegrist et al.,
2011). Nonetheless, all three have a very similar molecular weight; 13.9 KDa IFITM1, and
14.6 KDa IFITM2/IFITM3.
The IFITM immunity-related protein family are composed of short amino-terminal
and carboxy-terminal domains, two transmembrane domains, and a cytoplasmic domain.
IFITM1 is slightly different from IFITM2 and IFITM3, with some studies demonstrating
that IFITM1 is widely expressed at the cell surface (Weston et al., 2014; Jia et al., 2015).
Several posttranslational modifications have been described for IFITM3. To begin
with, IFITM3 is been mapped with S-palmitoylation sites at Cys71, Cys72, and Cys105,
closely related to maintaining its cell membrane localization (Yount et al., 2010). Con-
versely, palmitoylation modifications on murine IFITM1 enhances its anti-viral effect
(Hach et al., 2013). In addition, IFITM3 is ubiquitylated at Lys24, Lys83, Lys88 and Lys104.
If IFITM3 is not ubiquitylated at these residues it is transported to the late endosomes in-
creasing its antiviral activity (John et al., 2013; Yount et al., 2010). Finally, phosphorylation
at Tyr20 affects its endocytic process (Bonifacino & Traub, 2003; Jia et al., 2012). Almost all
these residues are shared between these proteins suggesting that these isoforms may also
be subjected to these modifications.
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Indeed, these modifications have an impact on IFITM molecular functions. It is been
reported that particular posttranslation modifications on IFITM3 are implicated in viral
resistance mechanisms (Yount et al., 2010). For example, specific S-palmitoylation and
ubiquitination decrease antiviral activity. Alternatively, it can also modulate protein traf-
fic to other subcellular compartments. A non-canonical C-terminus signal sequence is
responsible for internalizing IFITM1 protein to the early endosomes (Li et al., 2015).
A variety of models have been proposed to explain the dynamic topology of IFITMs,
but their topology remains controversial; studies have predicted different arrangements
in the cellular membrane. It is clear that they contain an intracellular domain, but it re-
mains under discussion which is the orientation of N-terminus and C-terminus. A study
on leukaemia proposed that N-terminus sequence of IFITM1 could be exposed extracel-
lularly (Chen et al., 1984). This hypothesis was also supported by an independent study
where IFITM1 was immunoprecipitated from the cell surface (Takahashi et al., 1990). Flow
cytometry experiments suggested that the N-terminus and C-terminus can be exposed in
the cell membrane (Brass et al., 2009; Li et al., 2013). On the contrary, others concluded
that the N-terminus is orientated towards the cytosol by studying residue modifications
catalysed by cytoplasmic enzymes (Jia et al., 2012).
In summary, cell type may have an active influence on IFITM1 topology. But regardless
of cell type, IFITM1 continues to be remodelled in response to particular stimuli, some of
them having potentially the same effect across all IFN-related proteins. That is why there
is a need to characterise the different protein conformations and the conditions under
which they occur, so as to better understand their functional implications.
1.6.1 IFITMs in cancer malignancy
IFITM1 is a pro-oncogenic receptor and a component of the IRDS pathway. Basal ex-
pression of IFITM proteins is observed in some cells and expression can also be induced
by type I and type II IFN (Yang et al., 2005). IFITM1 is upregulated during development
of radiation resistance, as cells escape from pro-apoptotic and anti-proliferative effects.
Therefore, it is present in chemoresistant tumours, with forced expression generating a
multi-drug resistant phenotype (Weichselbaum et al., 2008a; Yang et al., 2007).
The functions of IFITM1 in carcinogenesis are poorly understood. Nonetheless,
IFITM1 expression has been extensively reported to be dysregulated in many types of can-
cer (i.e. breast, cervix, colon, ovary, brain and oesophagus) and its high degree of over-
expression correlates well with tumour progression and poor prognosis (Borg et al., 2016;
Györffy et al., 2008; Novita Sari et al., 2016; Seyfried et al., 2008a; Weichselbaum et al.,
2008a; Ogony et al., 2016; Yu et al., 2015). Extensive research has been conducted on this
topic. For example, proteomic analysis of purified membrane fraction of mouse astrocy-
toma cells by LC-MS/MS followed by RT-PCR validation found upregulated IFITM1 and
IFITM3, but not IFITM2, in comparison with mouse astrocyte cells (Seyfried et al., 2008b).
Chapter 1 - Introduction 30
In addition, a large-scale study of gene expression in murine colorectal tumours identi-
fied IFITMs as highly expressed in adenomas from a murine familial adenomatous polypo-
sis model; expression increased rapidly in response to β-catenin activation. Interestingly,
aberrant adenomatous polyposis coli (APC) causes β-catenin accumulation and Wnt sig-
nalling impairment, thought to be a key event in development of sporadic cancer in famil-
ial adenomatous polyposis (Radtke & Clevers, 2005). Importantly, Radtke & Clevers could
not differentiate IFITM2 and IFITM3 isoforms, so it is open to speculation whether both
are involved in colorectal carcinogenesis. Moreover, IFITMs are highly expressed at dif-
ferent tumour stages and expression closely correlates with adenoma formation. Thus, it
is proposed as a potential biomarker in colorectal cancer diagnosis (Andreu et al., 2006).
Another study found upregulated IFITM1 in colorectal cancer where the levels of expres-
sion closely correlate with lymph-node and distant metastasis, both being independent
prognosticators for poor survival (Liu et al., 2008). In addition, IFITM3, also upregulated,
is proposed as a tumour-associated antigenic candidate suitable for developing a cancer
vaccine to treat colon carcinoma (Tirosh et al., 2007).
A meta-analysis of ovarian carcinoma gene expression revealed dysregulation of
IFITM1 in a variety of the studies analysed (Györffy et al., 2008). Moreover, alteration
of IFITM1 and Isg15 mRNA levels are seen in nude mice with human ovarian carcinoma
xenografts treated with paclitaxel, also known as Taxol (Bani et al., 2004). The drug desta-
bilizes microtubule assembly causing cell division inhibition at the mitotic phase (Jordan
& Wilson, 1998). Paclitaxel is regularly administrated in ovarian carcinomas, but there is
risk of development of chemotherapy-resistant tumours (Rowinky & Donehower, 1995).
Another study screened the molecular profiling of oesophageal cancer tissue extracted
from patients with familial oesophageal cancer antecedents and IFITM1 was identified
in the cluster of upregulated genes. However, after RT-qPCR and TMA validation it was
concluded that there was no difference between individuals with familial and non-familial
related oesophageal tumours. This indicates that, for the identified group of genes tested,
oesophageal cancer development is due to environmental effects (Chattopadhyay et al.,
2009).
Proliferative and antiproliferative effects of IFITM proteins prove to be quite cell type-
specific. IFITM1 gene transcripts directly correlate with favourable prognosis in chronic
myeloid leukaemia patients (Akyerli et al., 2005). On the contrary, IFITM3 was greatly ex-
pressed in glioma patients and loss of IFITM3 on glioma cells decreased proliferation and
promoted cell arrest in G0/G1 (Zhao et al., 2013). A study of colorectal cancer gene expres-
sion found overexpression of IFITM proteins in early and late stage of intestinal neoplasm
in mice as well as in humans (Andreu et al., 2006). In addition, depletion of IFITM1 per-
formed in five different human glioma cell lines decreased proliferation, migration and in-
vasion (Yu et al., 2011). Similarly, IFITM1 is implicated in invasion and migration in head
and neck cancer types (Hatano et al., 2008).
It remains unknown which IFN-dependent genes affect the cell cycle but IFITMs may
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be participating in this function. A study conducted by Yang et al. correlated IFITM1 to the
antiproliferative effect of IFNγ (Yang et al., 2007). It was found that IFITM1 plays a funda-
mental role in inhibiting cell growth and tumourigenesis. Additionally, IFITM1 arrests cell
cycle progression in G1 phase in a p53-dependent manner, promoting p53 transcription
and stabilization through inhibiting Thr55 phosphorylation. Several studies have found
evidence that the IFN-dependent antiproliferative effect extends the cell cycle by inhibit-
ing G0/G1 and prolonging S phase (Murphy et al., 2001; Sangfelt et al., 1999; Vannucchi
et al., 2005).
IFITM1 mRNA is overexpressed in gastric tumour tissue as well as in cell lines. Remark-
ably, it was induced by IFNγ but not by TNFα or TGFβ1 stimulation. IFITM1 induced by
IFNγ for 24 hours confers a cell phenotype more prone to migrate, invade and is resistant
to NK cell neutralization. Using a gastric cell model, IFITM1 was proposed as a cell surface
receptor that inhibits NK cytotoxicity, conferring immune-evasion (Yang et al., 2005).
Given the highly heterogeneous nature of cancer, it is difficult to conclude at which
stage of the disease IFITM1 may have an impact, or if IFITM1 has different effects depend-
ing on the cancer type and stage. All-in-all, it is essential to better understand the type of
cancer under study. High heterogeneous tumour formation and environment can com-
pletely change the status of the cancer and, therefore, the proteome expressed as well as
the pathways activated.
1.7 IFITMs in viral pathology
Organisms are constantly threatened by the invasion of viral pathogens. Mammalian
cells have developed self-defence mechanisms involving the activation of restriction fac-
tors that mediate viral suppression. Viral invasion, in RNA or DNA form, triggers almost
immediately the production of type I IFN (Stetson & Medzhitov, 2006). However, im-
munomodulatory effects of type II IFN are essential in the longer term. Secreted IFN will
alert neighbouring cells of the pathogenic presence and consequently ISG expression will
be induced to neutralize the virus. Both IFN types are extremely versatile and are involved
in the activation of several cellular pathways in health and disease. Thus, viral inhibition
is the result of cooperative effects of several ISGs (Schoggins et al., 2011). In combination,
they confer one of the first described and more fundamental immune responses.
Viruses are considered to be the most abundant biological entities. Their molecular
diversity and high predisposition to continuous mutations challenge mammalian cells
to develop cellular systems to attenuate infection. Moreover, it is complicated to iden-
tify molecules capable of broadly targeting several virus types. Nonetheless, IFITM fam-
ily members are one of the most dominant anti-viral ISGs, capable of attenuating the
pathogenic effect of many human and animal viruses. Interferon stimulated-IFITM1/2/3
proteins repress viral replication of influenza A and flaviviruses, including dengue virus
and West Nile, among others. Interestingly, each IFITM family member exhibits specific
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viral preferences; in the case of IFITM1, it is particularly known for its attenuation of HCV,
influenza A and SARS coronavirus (Bailey et al., n.d.; Brass et al., 2009; Huang et al., 2011;
Wilkins et al., 2013).
IFITM family proteins inhibit cytosolic entry of viruses by preventing fusion of viral
and host membranes. The protein–protein interaction networks by which IFITM proteins
inhibit membrane fusion still remain unclear. Interestingly, all these viruses contain vi-
ral envelope proteins. One study proposed IFITM2/3 as one of the most dominant ISG-
stimulated genes involved in suppressing viral entry in Nile virus and dengue virus (Jiang
et al., 2010). Similarly, the N-terminal sequence of IFITM2/3 is capable of inhibiting entry
of HIV-1 virus, possibly by interfering in HIV-1 endocytosis and dynamin-dependent cell
fusion (Miyauchi et al., 2009). Additionally, IFITM1/2/3 depletes virus production by in-
terfering with the viral Gag expression (Lu et al., 2011). It is suggested that IFITM3 resides
in endosomes where it is able to interfere with influenza A endosomal trafficking. High
levels of IFITM3 prevent incorporation of the viral genome in the host cell nucleus and
promote formation of late endosomes and lysosomes that will potentially degrade viral
particles (Feeley et al., 2011). Mice with Ifitm3 gene deleted are more susceptible to in-
fluenza A. Indeed, people who have certain IFITM3 polymorphisms are more susceptible
to infection and more risk to be hospitalized. For instance, SNP rs12252 C allele induces
an alternative splicing variant that lacks the first 21 amino acids (Everitt et al., 2012).
Consistently, IFITMs are described as restriction factors. Several studies have hypoth-
esized that IFITM are able to block viral entry by inhibiting fusion between host plasma
membrane and virus, and by suppressing viral traffic in early endosomes. However, the
exact mechanism by which IFITM1 inhibits viral endocytosis remains unclear. Comparing
IFITM isoforms, IFITM1 lacks the first 20 N-terminal amino acids and it compensates with
a larger C-terminal sequence. These structural differences between IFITM1 and IFITM3
may indicate why they are prone to restrict different (or with different intensity) types of
virus. For instance, a study described the 20-YEML-23 motif in IFITM3, which is absent in
IFITM1, promotes endocytic influence on pH-dependent viral restriction (Jia et al., 2014).
This sorting signal, however, is not associated with attenuation of HIV, as wild type IFITM3
and the 21-amino acid deletion mutant show equal inhibition. Thus, IFITM3 should have
alternative mechanisms to repress viruses (Jia et al., 2012). In addition, S-palmitoylation
posttranslational modification of IFITM3 increases attenuation of influenza (H1N1 and
PR8 strain) virus (Yount et al., 2010). IFITM1 represses HCV entry by interacting and redis-
tributing CD81 (HCV coreceptor) in hepatic tight junctions (Narayana et al., 2015; Wilkins
et al., 2013). Moreover, truncation of C-terminal 117-QIIQEKRGY-125 of IFITM1 dimin-
ishes HIV-1 replication but not that of VSV virus. This mutant is able to trap IFITM1 in the
cell membrane as it perturbs the natural subcellular distribution (Jia et al., 2015). Support-
ing research shows that mutation of two residues in the C-terminal (KR/AA) diminishes
IFITM1 ubiquitination and alters IFITM1 endocytic trafficking (Li et al., 2015).
Continuous scientific effort has begun to elucidate the molecular mechanism(s) of
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IFITMs as a restriction factor, however there is still a lot to be investigated. This thesis fo-
cuses on understanding IFITM1 from a cancer perspective but ideally, we aim to translate
our findings to a viral point of view.
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1.8 Aims of the project
The initial goal of the present study was to better understand the molecular function(s)
of IFITM1 and IFITM3 proteins. The IFN pathway is very complex and is able to mediate
the expression of hundreds of genes. As such, the greatest challenge of this thesis was to be
able to dissect IFITM1/IFITM3–IFNγ dependencies. The ultimate aim was to understand
the fundamental roles of IFITM1/IFITM3 after IFNγ stimulation in the cancer context. To
answer these questions:
• An isogenic IFITM1 null and IFITM1/IFITM3 double null cervical cancer model
was depeloved employing CRISPR/Cas9 system to define dependent pathways of
IFITM1/3 signalling (chapter 3).
• We aimed to define new IFITM1 interacting partners by mass spectrometry method-
ologies to start characterizing new pathways involved in cancer progression (chap-
ter 4).
• Moreover, we studied the RNA loading on the ribosome and the emerging polypep-
tides by polysome profiling, subcellular SWATH-MS, and pulse SILAC (chapter 5).
• RNA-seq analysis was performed to investigate possible differences in the transcript
expression associated with IFITM1/IFITM3 loss (chapter 6).
All-in-all, the final goal was to propose an IFNγ-responsive biochemical model for the





The plasmids used throughout this thesis are: pEXPR-IBA105-SBP-tagged (IBA Life-
sciences); pMA-T-15ADAZQP wild type IFITM1 (Invitrogen); pEXPR-IBA105-SBP-tagged
wild type IFITM1 (IBA Lifesciences); pcDNA3.1 (Addgene), pcDNA3.1 wild type IFITM1
(Addgene); pSF-CMV-FLuc-CMV-Zep-BgH-sbf1 (Oxford Genetics); pCMV-myc-hIFITM3
(Clontech); pSF-CMV-FLuc-CMV-Zep-BgH-sbf1-IFITM3 (Oxford Genetics); pCG T7-
SF2/ASF (Addgene); pT-Rex-DEST30TM SBP-tagged (Thermo Fisher); pT-Rex-DEST30TM
SBP-tagged wild type ISG15 (Thermo Fisher) and pT-Rex-DEST30TM SBP-tagged mutated
ISG15AA (Thermo Fisher).
2.2 Cell culture
2.2.1 Cell lines and maintenance
Wt-SiHa cells, IFITM1 null cells, IFITM1/IFITM3 double null cells, IFITM3 null cells,
and SBP-IFITM1 SiHa cells were grown in RPMI 1640 media (Invitrogen) (Table 2.1). Cells
were supplemented with 10% (v/v) foetal bovine serum (FBS) (Labtech) and 1% (v/v) 0.5
U/ml penicillin/ 500 ng/ml streptomycin (P/S) (Invitrogen) and incubated at 37°C with
5% CO2. Cell culture work was carried in a category 1 tissue culture room.
Cells were routinely sub-cultured in 10 cm tissue culture dishes (Greiner CELLSTAR,
Sigma), according to cell growth, 1 to 3 times per week. Cells were washed with 10 ml
of sterile 1x phosphate buffered saline (PBS) and trypsinised with 2 ml of warmed 1x
Trypsin–EDTA 0.5% (Gibco, Life Technologies). Cells were kept in the incubator for 10 min
to detach and then 8 ml of fresh warm media was added. Cells were seeded in a new 10 cm
tissue culture dish at the required dilution, typically 1:5.
Cells were counted by mixing 10 µl of trypsinised cells in fresh media 1:1 with trypan
blue stain 0.4% (Labtech) and 10 µl were added to Luna counting slides (Labtech) and
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counted in a Luna Automated BF cell counter (Labtech). An appropriate number of cells
was seeded, according to each experimental design.
Table 2.1: Cell lines used.
Cell line Description
wt-SiHa Human cervical carcinoma cells, wild type
IFITM1 null Human cervical carcinoma cells, IFITM1 knock out
IFITM1/IFITM3 double null Human cervical carcinoma cells, IFITM1/IFITM3 knock out
IFITM3 null Human cervical carcinoma cells, IFITM3 knock out
SBP-IFITM1 SiHa Human cervical carcinoma cells, SBP tagged-IFITM1 knock in
2.2.2 Cell storage
Around 1 x106 to 5 x106 viable cells per vial were resuspended in 1 ml of freezing me-
dia; 50% FBS, 20% DMSO, and 30% RPMI media (not supplemented with FBS or P/S). Cells
were in 1 ml aliquots in cryotubes. Vials were placed in a freezing container (Nalgene Cryo)
and kept at -80 ºC for progressive cooling down to -80 ºC. Finally, frozen cells were trans-
ferred to liquid nitrogen for long-term storage.
2.2.3 Cell recovery
Cell vials were warmed up at 37ºC then transferred to a Falcon tube and centrifugated
at 1,000 rpm for 5 min to remove toxic DMSO. The cell pellet was transferred into a new 10
cm dish with appropriate fresh media supplemented with FBS and P/S antibiotics.
2.2.4 IFNγ treatment
SiHa cells were stimulated with a final concentration of 100 ng/ml recombinant hu-
man interferon-gamma (Gibco, PHC4031) (henceforth IFNγ) for 24 hours, except other-
wise stated.
2.2.5 SILAC labelling
Fully labelled cells by SILAC media
For performing SILAC experiment, wt-SiHa cells, IFITM1 null cells, and
IFITM1/IFITM3 double null cells were grown in SILAC media as biological tripli-
cates over 5 generations to fully incorporate (if grown in heavy media) the heavy isotopic
amino acids from the media. Before harvesting, cells were stimulated for 24 or 48 hours
with or without 100 ng/ml IFNγ before harvesting. Cells were isotopically labelled using
SILAC RPMI-heavy media (Dundee Cell Products, UK); L-[13C614N4] arginine (R6) and
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L-[13C614N2] lysine (K6). Cells were harvested in a buffer containing 8 M urea, 0.1 M Tris
pH 8.5. Total protein in extracts was measured by Bradford assay (section 2.6.3).
Partially labelled cells by pulse SILAC
For performing pulse SILAC experiment, wt-SiHa cells, IFITM1 null cells, and
IFITM1/IFITM3 double null cells were grown as biological triplicates and incubated with
SILAC heavy media for 6 and 24 hours with or without 100 ng/ml IFNγ before harvesting.
Cells were isotopically pulse-labelled using SILAC RPMI heavy media (Dundee Cell Prod-
ucts, UK); L-[13C614N4] arginine (R6) and L-[13C614N2] lysine (K6). Cells were harvested in
a buffer containing 8 M urea, 0.1 M Tris pH 8.5. Total protein extracts were measured by
Bradford assay (section 2.6.3).
2.2.6 Transient transfection of plasmid DNA
For transfection, cells were grown to approximately 80% confluency. SiHa cells showed
a good transfection efficiency using Attractene transfection reagent (Qiagen, 301007).
Manufacturers recommendations were followed; preliminary titrations of DNA (µg) as well
as Attractene volume was performed to determine optimal conditions (data not shown).
A 6-well plate transfection mixture was : 1.2 µg of DNA, 4.5 µl of Attractene, and 100 µl
serum-free media without antibiotics; A 10 cm dish transfection mixture was: 4µg of DNA
and 15 µl of Attractene, 300 µl serum free media without antibiotics; A 15 cm dish trans-
fection mixture was: 6µg of DNA and 24µl of Attractene, 500 µl serum free media without
antibiotics . In the case of co-transfection, smaller amounts of each vector was transfected
to maintain the same total amount of DNA. All the reagents were mixed and incubated at
RT for 15 min. Finally, the transfection mixture was added dropwise to the plate and cells
were transfected for 24 or 48 hours, depending on experimental requirements.
2.2.7 Harvesting cells and cell lysis
Cells were harvested on ice to avoid proteolysis. Cells were washed twice in ice-cold
PBS, then scraped from the surface and collected for centrifugation at 2,600 rpm at 4 ºC
for 10 min. The cell pellet was snap-frozen and kept at -80ºC for future use or lysed with
denaturing urea lysis buffer (unless stated otherwise) (Table 2.2). Then, the cell pellets
were lysed in four times their volume by adding urea lysis buffer and mixed by pipetting
up and down. Lysis was performed for 30 min on ice followed by a 20 min centrifugation
at 13,000 rpm at 4 ºC. Supernatants were transferred to a new Eppendorf tube.
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Table 2.2: 8 M urea lysis buffer.
8 M urea lysis buffer
8 M urea
0.1 M DTT
0.1% (v/v) Triton X-100
25 mM NaCl
20 mM HEPES pH 8
1x Protease inhibitor mix (20 µg/µl leupeptin, 1 µg/µl aprotinin, 2 µg/µl pepstatin, 1 mM
benzamidine, 10 µg/µl soybean trypsin inhibitor, 2 mM pefabloc, and 1 mM EDTA- final
concentrations).
2.3 Microbiological Techniques
Bacterial cultures were grown in Luria–Bertani (LB) broth in an incubator-shaker at
200 rpm at 37ºC. They were grown in Erlenmeyer flasks or Falcon tubes, always four times
bigger than the culture volume, to provide enough oxygen.
2.3.1 Glycerol stocks
Glycerol stocks were prepared using 800 µl of the bacterial culture grown overnight an
mixed with 200 µl of 80% (v/v) sterile glycerol in a sterile microcentrifuge tube. The tube
was snap-frozen using liquid nitrogen and stored at -80°C.
2.4 Preparation of DH5α competent cells
DH5α competent cells from a glycerol stock were incubated in a mini-culture with 5 ml
of LB at 200 rpm at 37ºC overnight. An aliquot of this culture was transferred into 100 ml LB
at 200 rpm at 37 ºC and grown until OD600nm reached 0.4. The culture was centrifuged at
4,000 rpm at 4ºC for 15 min. The following steps were carried out on ice in the cold room:
The pellet was resuspended with 32 ml ice-cold competent buffer I (Table 2.3). After 10 min
incubation on ice, cells were centrifuged at 4,000 rpm at 4 ºC for 15 min. The pellet was
resuspended in 4 ml of ice-cold competent buffer II (Table 2.3). After 10 min incubation
on ice, 30 µl of competent cells were aliquoted into pre-chilled sterile Eppendorf tubes,
immediately snap-frozen in liquid nitrogen, and stored at -80ºC.
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Table 2.3: Buffers for making competent cells.
Competent cells buffer I Competent cells buffer II
100 mM RbCl 10 mM RbCl
40 mM MgCl2 · 6 H2O 10 mM MOPS
60 mM CH3COOK
100 mM CaCl2 · 2 H2O 75 mM CaCl2 · 2 H2O
15% (v/v) glycerol 15%(v/v) glycerol
pH 5.8 (adjusted with CH3COOH) pH 6.5 (adjusted with NaOH)
Sterilised with 0.22 µm filter Sterilised with 0.22 µm filter
2.4.1 Bacterial transformation using heat shock
Competent cells were stored at -80°C. First, 50 µL of DH5α E. Coli competent cells
were thawed on ice. Then, 1 to 10 µl of ligation reaction or vector (1–100 ng of plasmid
DNA) was added, and tubes were incubated on ice for 30 min. In the meantime, 250 µL of
autoclaved LB without antibiotics was warmed at 37°C. Competent cells with the ligation
reaction or vector were heat shocked at 42°C for 90 sec and immediately replaced on ice for
2 min. Finally, 250 µL of pre-warmed LB was added and the bacterial cells were incubated
with shaking at 250 rpm at 37°C for 1 h and 30 min.
LB agar (Table 2.4) was melted by heating and cooled down before being supplemented
with appropriate antibiotic, typically ampicillin at 100 µg/ml final concentration (Sigma,
A9518). The media was poured into sterile 90 mm petri dishes (Sterilin) solidified and then
plates were dried at 37°C before use.
Between 20–200 µl of transformation product was spread onto LB agar plates with ap-
propriate antibiotic. The pipetting was done under aseptic conditions next to a Bunsen
burner, using sterile tips and a sterile spreader. Plates were incubated, inverted, at 37°C
overnight for bacterial growth.
Table 2.4: LB broth and LB agar composition.
Luria–Bertani (LB) broth LB Agar
25 g LB in 1 L dH20 40 g LB agar in 1 L dH20
1% (w/v) Tryptone 1% (w/v) Tryptone
0.5% (w/v) Yeast extract 0.5% (w/v) Yeast extract
1% (w/v) NaCl 1% (w/v) NaCl
1.5% (w/v) Agar
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2.5 Molecular Biology Techniques
2.5.1 Plasmid DNA purification and quantification
The day after bacterial transformation (subsection 2.4.1), a single colony was picked
and inoculated into a tube of LB containing 1:1,000 ampicillin (100 µg/ml) and grown
shaking at 220 rpm overnight, then, 3 mL or 150 mL of the culture was used for mini-preps
and maxi-preps of DNA, respectively. Bacterial cells were centrifuged at 4,000 rpm from
the overnight culture and Plasmid DNA extracted using a QIAprep Spin Miniprep Kit (Qi-
agen, 27104) and GeneJET Plasmid Maxi Prep Kit (Thermo Scientific, K0492) respectively.
DNA obtained was quantified using a NanoDrop ND-1000 Spectrophotometer.
2.5.2 DNA extraction
Chromosomal DNA was extracted from frozen cell pellets following the Gentra Pure-
gene Cell kit instruction manual (Qiagen).
2.5.3 Total RNA isolation and cDNA synthesis
Non-stimulated or IFNγ-stimulated for 24 hours wt-SiHa cells, IFITM1 null cells and
IFITM1/IFITM3 double null cells were grown in triplicate on 6-well plates. Cells were
grown in parallel until 90% cell confluency and then were harvested at the same time and
frozen prior to RNA extraction. Total RNA was extracted from frozen cell pellets of 6-well
plates following the RNeasy Mini kit instruction manual (Qiagen). RNA samples were pre-
treated with RNase-free DNase I (Qiagen) to remove DNA contaminant. The quality and
purity of the total RNA were analysed using a NanoDrop 2000c Spectophotomer (Thermo
Scientific). The cDNA was used for RNA-Seq and RT-qPCR. Equal amounts of three RNA
biological replicates were combined in a single sample and 1 µg RNA (at 50 ng/µl) was
analysed for RNA-Sequencing by Otogenetics (Atlanta, USA). The remaining RNA (for in-
dividual biological replicates) was reverse transcribed into cDNA using qScript cDNA Su-
perMix in a total volume of 20 µl following the manufacturer’s instructions (Quantabio)
(Table 2.5).
Table 2.5: PCR conditions for cDNA synthesis.
PCR conditions
5 min at 25ºC
30 min at 42ºC
5 min at 85ºC
Hold at 4ºC
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2.5.4 Real-time quantitative PCR analysis
The PCR reaction was carried out using cDNA as template. The reaction mixture con-
tained 2 µl of synthesized cDNA mixed with 7.5 µl SYBR green (Sybr Select Master mix,
Applied Biosystems), 0.3 µl of mixed specific forward and reverse primers (Sigma, 5 µM
stock) (Table 2.6) in a final volume of 20 µl. The PCR was carried out under the cycling
conditions described in Table 2.7. Melting curve analysis was performed under the condi-
tions described in Table 2.8.
Table 2.6: Genes and primer pairs used for RT–qPCR.
Gene Primer Amplicon
IFITM1 Forward 5’ ACTGGTATTCGGCTCTGTGAC 3’ 172 bp
Reverse 5’ GCTGTATCTAGGGGCAGGAC 3’
IFITM3 Forward 5’ CAAACCTTCTTCTCTCCTGTCAA 3’ 129 bp
Reverse 5’ GATGTGGATCACGGTGGAC 3’
IRF1 Forward 5’ CTCTGAAGCTACAACAGATGAG 3’ 218 bp
Reverse 5’ GTAGACTCAGCCCAATATCCC 3’
ISG15 Forward 5’ CTGCTGGTGGTGGACAAATG 3’ 162 bp
Reverse 5’ TCAGCCAGAACAGGTCGTC 3’
B2M Forward 5’ CTCGCTCCGTGGCCTTAG 3’ 153 bp
Reverse 5’ GGATGAAACCCAGACACATAGC 3’
HLA-B Forward 5’ CACTGAGCTTGTGGAGACCA 3’ 219 bp
Reverse 5’ ATGACCACAACTGCTAGGACA 3’
STAT1 Forward 5’ GAGCTTCACTCCCTTAGTTTTGA 3’ 84 bp
Reverse 5’ CACAACGGGCAGAGAGGT 3’
β-ACTIN Forward 5 CATGTACGTTGCTATCCAGGC 3 250 bp
Reverse 5’ CTCCTTAATGTCACGCACGAT 3’
Table 2.7: PCR cycling conditions used for RT–qPCR.
PCR cycling conditions
Holding Stage 95ºC 10 min
Cycling Stage (40 times) 95ºC 15 sec
60ºC 30 sec
72ºC 15 sec
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Table 2.8: Melting curve parameters.
Melting curve parameters
95ºC 15 sec
60ºC 1 min (increasing temperature 0.3ºC)
95ºC 15 sec
2.5.5 Cloning by PCR
pSF-CMV-IFITM3 primer design
The IFITM3 cDNA was cloned by PCR amplification into untagged pSF-CMV-FLuc-
CMV-Zep-BgH-sbf1 (henceforth EV, standing for empty vector) expression vector. Primers
were designed to amplify IFITM3 cDNA in the pCMV-myc-hIFITM3 donor vector; for-
ward primer was 5’-GATTGGTACCATGAATCACACTGTCCAAACC-3’ and reverse primer
was 5’-CGTAGGATCCCTATCCATAGGCCTGGAAGAT-3’. Primers contain recognition sites
for KpnI and BamHI restriction enzymes respectively.
SBP-IFITM1 primer design
The IFITM1 cDNA was cloned by PCR into pEXPR-IBA105 (henceforth EV, standing for
empty vector) expression vector containing the SBP tag at the N-terminus of the coding
region. Primers were designed to amplify IFITM1 cDNA in the pcDNA3.1 donor vector;
forward primer was 5’-GGGGGGTACCGATGCACAAGGAGGAA-3’ and reverse primer was
5’-CCCCGATATCCTAGTAACCCCGTTT-3’. Primers contain recognition sites for KpnI and
EcoRV restriction enzymes respectively.
PCR mix
PCR reaction (20 µl) was performed using the following reagents:
Table 2.9: PCR reagent mix.
PCR reagent mix
x2 Pfu Mastermix (Rovalab) 10 µl
Forward primer (10 µM) 1 µl
Reverse primer (10 µM) 1 µl
Template vector 5-50 ng dsDNA
Nuclease free H2O to up to final volume 20 µl
PCR conditions
PCR amplifications were performed using the following conditions:
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Table 2.10: PCR cycling conditions.
PCR cycling conditions
Hot start 95°C 2 min
Denature DNA* 95°C 45 sec
Annealing* 62°C 45 sec
Elongation* 72°C 1 min
*Cycle repeated 35 times
Last elongation 72°C 3 min
2.5.6 CRISPR/Cas9 clone validations by Sanger sequencing
Primer design
A PCR technique was used to successfully validate knock out clones generated by
CRISPR/Cas9 system. The genomic DNA region of interest was amplified by PCR using
the primers in Table 2.11. Note that in some constructs, recognition sites for restriction
enzymes were included in the designed primer sequence for further cloning.
Table 2.11: Primers used to sequence the CRISPR/Cas9 clones.
1st set of primers: 475 bp amplicon
2nd set of primers: 1102 bp amplicon
3rd set of primers: 443 bp amplicon
4th set of primers: 976 bp amplicon
1st set of primers:
Forward primer IFITM1: 5’-TACAAACAGCAGGAAATAGAAACTT-3’
Reverse primer IFITM1: 5’-ACTCACAGTCACAGGGACAC-3’
2nd set of primers:
Forward primer IFITM1: 5’-GGGGGGTACCGATGCACAAGGAGGAA-3’
Reverse primer IFITM1: 5’-CCCCGATATCCTAGTAACCCCGTTT-3’
3rd set of primers:
Forward primer IFITM3: 5’-AGCCCCTCTTTCCTCCCT-3’
Reverse primer IFITM3: 5’-TCACGGAGTAGGCGAATG-3’
4th set of primers:
Forward primer IFITM3: 5’-GATTGGTACCATGAATCACACTGTCCAAACC-3
Forward primer IFITM3: 5’-CGATGAATTCCTACTATCCATAGGCCTGGAAGAT-3’
PCR conditions
PCR amplifications were performed using the following conditions:
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Table 2.12: PCR cycling conditions for the 1st set of primers.
PCR cycling conditions
Hot start 95°C 2 min
Denature DNA* 95°C 45 sec
Annealing* 48°C 30 sec
Elongation* 72°C 1 min
*Cycle repeated 35 times
Last elongation 72°C 3 min
Table 2.13: PCR cycling conditions for the 2nd set of primers.
PCR cycling conditions
Hot start 95°C 2 min
Denature DNA* 95°C 20 sec
Annealing* 58°C 45 sec
Elongation* 72°C 1 min
*Cycle repeated 35 times
Last elongation 72°C 5 min
Table 2.14: PCR cycling conditions for the 3rd set of primers.
PCR cycling conditions
Hot start 95°C 2 min
Denature DNA* 95°C 45 sec
Annealing* 51 °C 30 sec
Elongation* 72°C 1 min
*Cycle repeated 35 times
Last elongation 72°C 3 min
Table 2.15: PCR cycling conditions for the 4th set of primers.
PCR cycling conditions
Hot start 95°C 2 min
Denature DNA* 95°C 20 sec
Annealing* 62 °C 45 sec
Elongation* 72°C 1 min
*Cycle repeated 35 times
Last elongation 72°C 5 min
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2.5.7 Agarose gel electrophoresis
Once the amplicon was amplified (subsection 2.5.5 and subsection 2.5.6), a 1.5–2%
(w/v) agarose gel was prepared by heating ultrapure agarose (Electrophoresis-grade, Invit-
rogen) dissolved in 1x TAE (Table 2.16) and DNA gel stain 1:10,000 SYBR safe (Invitrogen)
was added. Then, it was poured immediately into a gel chamber. The sample was mixed
with 6x DNA loading dye (New England Biolabs) before loading. Gel was run at 100 V.




pH 8.0 (adjusted with glacial acetic acid)
2.5.8 Gel extraction
If the amplified band had the desired molecular weight, the gel band was cut and pu-
rified following the protocol of the GenJet Gel Extraction Kit (Thermo Fisher, K0691) or
QIAquick Gel extraction kit (Qiagen, 28714).
2.5.9 Digestion
Then, if required, vector and amplicon were digested with the appropriate restriction
enzymes typically at 37°C for 2 hours (Table 2.17).
Table 2.17: Digestion reaction.
Digestion reaction
Vector, amplicon 0.5 to 2 µg
Smart Cut Buffer (NEB) 2 µl
Restriction enzyme 1 (NEB) 1 µl (10 units)
Restriction enzyme 2 (NEB) 1 µl (10 units)
H2OMQ top up to final volume 20 µl
2.5.10 Ligation
After digestion, the vector product was run on a 1–2% agarose gel and purified follow-
ing subsection 2.5.7 and subsection 2.5.8. Then vector and insert were ligated at RT for 15
min or 16°C overnight (Table 2.18).
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Table 2.18: Ligation reaction.
Ligation reaction
T4 DNA Ligase Buffer 10x (NEB) 2 µl
Vector 50 ng for 3 Kb
Insert 50 ng for 1 Kb
T4 DNA ligase (NEB) 1 µl
H2OMQ top up to final volume 20 µl
2.5.11 Validation by DNA sequencing
Validation of cloning as well as edited DNA sequences were confirmed by Sanger se-
quencing at Source BioScience Service (Scotland or Nottingham). Sample and primers
conditions were sent following their requirements. Chromas v1.45 version was used to
visualise the sequence chromatogram, SnapGene v3.0 version and Clustwl Omega were
used to perform alignment of the DNA sequence.
2.6 Biochemical Techniques
2.6.1 Affinity purification in label-free cells
Wt-SiHa cells were grown in heavy RPMI media in duplicate. Cells were transfected
with pEXPR-IBA105-SBP-tagged or pEXPR-IBA105-SBP-tagged full length IFITM1 for 24
and 48 hours. Then, cells were stimulated with 100 ng/ml IFNγ (Invitrogen) for 24 hours
for one replicate in order to “stabilize” potential IFNγ-activated SBP-IFITM1 interacting
proteins. Cells were washed twice in ice cold PBS and scraped into Triton X-100 buffer con-
taining: 100 mM KCl, 20 mM HEPES pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na3VO4,
10 mM NaF, 10% (v/v) glycerol, protease inhibitor mix, and 0.1% Triton X-100, then incu-
bated for 30 min on ice and centrifuged at 13,000 rpm at 4 °C for 15 min. Equal amounts
of protein (at least 250 ng of protein) were used to perform the affinity capture. Strepta-
vidin agarose-conjugated beads (Millipore) were pre-washed with PBS, then cell lysate was
added and incubated at RT for 2 hours with gentle rotation. Binding proteins were eluted
by heating at 85°C for 5 min with a buffer containing 20 mM HEPES pH 8, 2 mM DTT, and
8 M urea buffer.
2.6.2 Subcellular protein fractionation
A subcellular protein fractionation kit for cultured cells (Thermo Fisher) was used to
obtain cytoplasmic, membrane, nuclear soluble, chromatin-bound and cytoskeletal frac-
tions, following protocol instructions.
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2.6.3 Protein quantification, SDS-PAGE, and Western blotting
Protein quantification
Protein from lysed samples was quantified using Protein Assay Dye Reagent (Bio-Rad,
based on the Bradford protein assay). Bovine serum albumin (BSA) (Sigma) was used as
protein standards at concentration rage 0–10 mg/ml was used to determine protein con-
centration. Bradford reagent was diluted five times in ultrapure water (Milli-Q). The assay
consisted of 200 µl of Bradford reagent plus 1 µl of protein standard or lysate mixed in a
96-well plate. After gentle shaking for 10 min, the samples were measured at OD595nm us-
ing Bio-rad, iMark microplate reader coupled to MPM 6-microplater Manager software.
Protein concentration was determined from the linear standard curve obtained from the
BSA standards.
For SDS polyacrylamide gel electrophoresis (SDS–PAGE) protein lysate (normally 20
µg) was mixed 1:1 with 2x SDS sample buffer (Table 2.19 ) and heated at 85 ºC for 5 min.
Table 2.19: 2x SDS sample buffer.
2x SDS sample buffer
125 mM (5% (w/v)) SDS
25% (v/v) glycerol
0.3 M Tris pH 6.8
200 mM DTT
Bromophenol blue (to desired colour)
SDS-PAGE
Polyacrylamide gels (typically 1.5 mm thick) were prepared in a Mini-PROTEAN 3 Cell
apparatus (Bio-Rad) (Table 2.20). Pre-stained protein standard (PageRuler Plus prestained
protein ladder; Thermo Fisher) was loaded as a marker and proteins were separated at
100–180 V in 1x SDS running buffer (Table 2.21).
Table 2.20: Resolving and stacking reagents to prepare gels for SDS-PAGE.
Resolving Gel Stacking Gel
15% Acrylamide mix (Protogel, 30% (v/v)) 5% Acrylamide mix (Protogel, 30% (v/v))
39 M Tris-HCl pH 8.8 0.13 M Tris-HCl pH 6.8
0.1% (w/v) SDS 0.1% (w/v) SDS
0.1% (w/v) Ammonium persulphate (APS) 0.1% (w/v) Ammonium persulphate (APS)
0.04% (v/v) TEMED 0.04% (v/v) TEMED
top up to final volume with dH2O op up to final volume with dH2O
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Western blotting
After resolution by SDS-PAGE (often using 15% resolving gels), proteins were trans-
ferred onto nitrocellulose membranes (Amersham Protran, GE Healthcare) in a Mini
Trans-Blot wet electroblotting systems (Bio-Rad) in transfer buffer (Table 2.21) at 100 V
for 60–90 min. Membranes were stained with ink (Pelican Black), washed with 0.1% PBS-
Tween 20 (PBS-T), and blocked with 5% dried skimmed milk (Marvel) in PBS-T at RT for
1 hour (Table 2.22). Appropriate primary antibody diluted in blocking solution was incu-
bated at 4ºC for 1 hour or overnight. The next day, the blot was washed three times with
PBS-T and incubated with appropriate secondary antibody at RT for 1 hour. The blot was
washed three more times for 5 min in PBS-T and then processed using enhanced chemi-
luminescence (ECL) reagents 1:1 for 1 min (Table 2.23). Blot was sequentially exposed to
X-ray film (SLS) or Amersham hyperfilm ECL (GE Healthcare) increasing exposure time
and finally developed (SRX-101A film processor, Konica Minolta).
Table 2.21: Running and transfer buffers.
Running Buffer Transfer Buffer
192 mM glycine 192 mM glycine
25 mM Tris-HCl pH 6.8 25 mM Tris-HCl pH 6.8
0.1% (w/v) SDS 20% (v/v) methanol
top up to final volume with dH2O top up to final volume with dH2O
Table 2.22: Washing and blocking buffers.
PBS PBS-T 5% dried skimmed milk in PBS-T
1.37 M NaCl 1x PBS 1x PBS-T
0.1 M Na2HPO4 0.1% (v/v) Tween 20 5% w/v dried skimmed milk
27 mM KCl
18 mM KH2PO4
Table 2.23: ECL reagents.
ECL Solution 1 ECL Solution 2
100 mM Tris-HCl pH 8.5 100 mM Tris-HCl pH 8.5
2.5 mM luminol stock 0.02% (v/v) H2O2
0.4 mM p-coumaric acid
top up to final volume with dH2O top up to final volume with dH2O
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2.6.4 Coomassie staining of SDS-PAGE gels
Coomassie brilliant blue staining was used to visualize proteins; SDS-PAGE gels were
fixed at RT for 10 min, and then stained with Coomassie blue stain for 1 hour (Table 2.24).
Stained gels were then de-stained overnight, washed in water and visualised with a LI-COR
Odyssey, using Odyssey Sa Version 1.1.4 software.
Table 2.24: Fixation, staining and de-staining buffer.
Fixation buffer Staining buffer
50% (v/v) methanol 50% (v/v) methanol
10% (v/v) glacial acetic acid 10% (v/v) glacial acetic acid
0.2% (w/v) Coomassie brilliant blue R-250
top up to final volume with dH2O top up to final volume with dH2O
De–staining buffer
7.5% (v/v) methanol
10% (v/v) glacial acetic acid
2.6.5 Antibodies
Proteins were detected using the primary antibodies described in Table 2.25. Mouse
monoclonal antibodies were generated against a peptide that is identical in IFITM1 and
IFITM3 (MHK4.1 or MHK2.1) (Moravian Biotechnologies). This antibody cannot distin-
guish between IFITM1 and IFITM3 and it is specifically stated that IFITM1/IFITM3 were
measured. Detection of primary antibody was performed using the following secondary
antibodies: Swine anti-rabbit 1:1,000 (Dako, PO217) and rabbit anti-mouse 1:1,000 (Dako,
PO260).
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Table 2.25: List of primary antibodies.
Antibody Company Dilution
Mouse monoclonal anti-β-ACTIN Sigma (a5441) 1:4,000
Rabbit monoclonal anti-BIOTIN Cell Sigaling (5597S) 1:200
Mouse monoclonal anti-GAPDH Abcam (a5441) 1:1,000
Rabbit polyclonal anti-HLA-B Thermo Scientific (PA5-29911) 1:1,000
Mouse monoclonal anti-HSP-90 Stressgen (SPA-830) 1:1,000




Mouse monoclonal anti-IFITM1 Proteintech (60074IG) 1:1,000
Rabbit monoclonal anti-IFITM1 (CVY) Moravian Biotechnologies 1:500
Mouse monoclonal anti-IFITM2 Proteintech (66137IG) 1:1,000
Rabbit polyclonal anti-IFITM3 Cell Signaling (59212) 1:1,000
Mouse monoclonal anti-IRF1 BD transduction Laboratories (612047) 1:1,000
Rabbit polyclonal anti-ISG15 Cell Signaling (2743S) 1:500
Rabbit polyclonal anti-RPL7a Cell Signaling (2415S) 1:1,000
Mouse monoclonal anti-SBP-tag EMD Millipore (MAB10764) 1:1,000
Rabbit polyclonal anti-SRSF1 Thermo Scientific (PA5-30220) 1:1,000
Rabbit monoclonal anti-STAT1 Cell Signaling (9172S) 1:1,000
Rabbit polyclonal anti-T7-tag EMD Millipore (AB3790) 1:1,000
2.7 Cell biology techniques
2.7.1 Immunofluorescence
Wt-SiHa and IFITM1/IFITM3 double null cells were grown on 16 mm diameter glass
coverslips. Cells were stimulated with 100 ng/ml IFNγ for 24 hours, then fixed with 4%
(v/v) paraformaldehyde in PBS at RT for 15 min, washed with PBS three times, and perme-
abilised using 0.25% Triton X-100 in PBS at RT for 10 min. Cells were again washed three
times with PBS and blocked with 3% BSA in PBS for 1 hour. The primary antibody was in-
cubated at the appropriate dilution (typically 1:1,000) overnight. In colocalization assays,
two primary antibodies from different species (mouse monoclonal anti-IFITM1/IFITM3
and rabbit polyclonal anti-T7-tag) were incubated simultaneously. The next day, Alexa
Fluor (Invitrogen) secondary antibody (Table 2.26) was incubated for 1 hour at RT. Cover-
slips were washed three times with PBS between each step. Cells were incubated in DAPI
(Invitrogen) diluted at 1:10,000 with dH2O for 5 min to stain the cell nucleus. After an
additional 3 washes with dH2O, a single drop of Fluorescence Mounting Medium (Dako,
S3023) was used to mount the cells onto the slide. Images were observed using a Zeiss
Axioplan 2 microscope (63x or 100x oil immersion objective). Images were acquired by
Micro-Manager 1.4 software, and processed in ImageJ 2.0.
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Table 2.26: Secondary antibodies for immunofluorescence.
Secondary antibody Dilution
Alexa Fluor 488 goat anti-mouse IgG (H+L) (Invitrogen, A11029) 1:2,000
Alexa Fluor 488 donkey anti-rabbit IgG (H+L) (Invitrogen, A11034) 1:2,000
Alexa Fluor 594 goat anti-mouse IgG (H+L) (Invitrogen, A11032) 1:2,000
Alexa Flor 594 donkey anti-rabbit IgG (H+L) (Invitrogen, A21207) 1:2,000
2.7.2 Proximity ligation assay (PLA)
Wt-SiHa and IFITM1/IFITM3 double null cells were grown and processed as described
in the Immunofluorescence method (subsection 2.7.1). Primary antibody pairs from dif-
ferent species were incubated overnight on the fixed, permeabilised, and blocked cells
(subsection 2.7.1): mouse monoclonal IFITM1/IFITM3 (1:500 dilution) with rabbit poly-
clonal SRSF1 (1:250 dilution), or mouse monoclonal IFITM1/IFITM3 (1:500 dilution) with
rabbit polyclonal HLA-B (1:250 dilution), or mouse monoclonal IFITM1/IFITM3 (1:500
dilution) with rabbit polyclonal RPL7a (1:250 dilution). The next day, samples were in-
cubated with the PLA probes (4 µl probe-mouse MINUS (Sigma, DUO92004) , 4 µl probe
anti- rabbit PLUS (Sigma, DUO92002), 32µl blocking solution) at 37ºC for 1 hour. Samples
were washed three times with buffer A for 5 min and then incubated with ligation buffer (8
µl 5x ligation stock, 1µl ligase and 31µl of ultrapure water on each coverslip) at 37ºC for 30
min. Samples were again washed three times with buffer A for 5 min and incubated with
amplification buffer (8µl 5x amplification stock, 0.5µl polymerase and 31.5µl of ultrapure
water on each coverslip) at 37ºC for 2 hours. Reagents were from Duolink in Situ Detec-
tion Reagents Green assays (Sigma, DUO92014). Samples were then washed twice with
buffer A, three times with buffer B, and once with 0.01x buffer B (Table 2.27). Cells were
incubated in DAPI (Invitrogen) diluted at 1:10,000 with 0.01x buffer B for 5 min to stain
the cell nucleus. An additional 2 washes with 0.01x buffer B for 5 min were performed and
cells were mounted as described in immunofluorescence method (subsection 2.7.1). The
fluorescent signal was detected using a Zeiss Axioplan 2 microscope (63x or 100x oil im-
mersion objective). Images were acquired by Micro-Manager 1.4 software, and processed
in ImageJ 2.0.
Table 2.27: Buffer A and buffer B.
Buffer A Buffer B
150 mM NaCl 100 mM NaCl
10 mM Tris base 50 mM Tris base
0.05% (v/v) Tween 20
Adjust pH to 7.4 Adjust pH 7.5
Filter sterilize (0.22 µm) Filter sterilize (0.22 µm)
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2.7.3 RNA In Situ Hybridization-PLA (rISH-PLA)
Wt-SiHa cells and IFITM1/IFITM3 double null cells were plated on 12 mm-diameter
coverslips in 24-well plates and duplicates were IFNγ-stimulated for 24 hours. Cells
were fixed with 4% paraformaldehyde in PBS at RT for 20 min and washed with PBS
for 10 min, then incubated in 70% (v/v) ethanol at 4ºC overnight. The next day, sam-
ples were washed in PBS for 30 min and permeabilised with 0.05% CHAPS and 0.4% Tri-
ton X-100 for 10 min at RT. Next, samples were incubated with hybridization buffer (Ta-
ble 2.28) for 30 min at RT then incubated for hybridization with 40 µl of hybridization
buffer containing 50 ng of heat-denatured (80ºC for 5 min ) HLA-B-biotin DNA probe (5’-
TGTCCTAGCAGTTGTGGTCATCGGAGCTGTGGTCGCTGCTGTGAT-biotin-3’) (Sigma) in a
humidified chamber overnight. Then, samples were washed for 20 min each with 2x SSC
and 10% formamide at RT, twice with hybridization buffer at 37ºC, 2x SSC at RT, and fi-
nally with PBS at RT. Next, samples were blocked with 3% BSA and 0.1% saponin in PBS
at RT for 30 min. After that, they were incubated with mouse monoclonal IFITM1/IFITM3
(1:500 dilution) and with rabbit monoclonal anti-biotin (1:200 dilution) antibodies at RT
for 2 hours.




0.2 mg/ml E. coli 522 tRNAs
0.2 mg/ml sheared salmon sperm DNA
2 mg/ml BSA
Samples were incubated with the PLA probes(4 µl probe-mouse MINUS (Sigma,
DUO92004) , 4 µl probe anti- rabbit PLUS (Sigma, DUO92002), 32 µl blocking solution)
at 37ºC for 1 hour. Samples were washed three times with buffer PBS for 5 min and then
incubated with ligation buffer (8 µl 5x ligation stock, 1 µl ligase and 31 µl of ultrapure wa-
ter on each coverslip) at 37ºC for 30 min. Samples were again washed twice times with
PBS for 5 min and incubated with amplification buffer (8 µl 5x amplification stock, 0.5 µl
polymerase and 31.5 µl of ultrapure water on each coverslip) at 37ºC for 1 hour 40 min.
Reagents are from Duolink in Situ Detection Reagents Green assays (DUO92014, Sigma).
Finally, samples were washed twice with PBS and incubated in DAPI (Invitrogen) diluted
at 1:10,000 with PBS for 5 min to stain the cell nucleus and an additional 2 washes of PBS
for 5 min were performed before mounting (subsection 2.7.1).
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2.7.4 Sucrose gradient sedimentation
Wt-SiHa and IFITM1/IFITM3 double null cells grown in 15-cm dish. Depending on
the experiment, cells were transfected with IFITM1 and IFITM3 (or the respective empty
vectors) for 48 hours and cells were stimulated with 100 ng/ml IFNγ for 24 hours. If trans-
fected, cells were split between two plates prior to IFNγ stimulation to reach an 80% cell
confluence before collection. Cells were treated with 50 µg/ml cycloheximide (Merck
Chemicals) for 30 min before collection, to inhibit translation elongation and preserve
mRNA on the ribosome. Cells were washed in PBS containing 1x RSB and harvested. Cell
pellets were collected after centrifugation at 7,000 rpm for 1 min at 4 ºC, then lysed by
resuspending the cell pellets in 250 µl of 1x RSB/RNasin buffer and 250 µl PEB buffer (Ta-
ble 2.29). Mechanical disruption of the cell lysate was carried out by passing the lysate
though a needle (25G) five times. Lysates were incubated on ice for 10 min and cen-
trifuged at 10,000 g for 10 min at 4ºC. Supernatant was transferred into a new tube and RNA
concentration was measured by NanoDrop 2000c spectophotometer (Thermo Scientific).
Lysates were processed as described by Sanford et al. (Sanford et al., 2004). Sucrose gra-
dients (10–45%) containing 1x RSB were generated in centrifuge tubes (Beckman Coulter,
344059) using a BioComp gradient master (SW41, 10–45% w/v 1st program). Preparation
of the linear sucrose gradient was a critical step and perturbation of the gradient by air
bubbles can interfere with successful ribosomal subunit separation. For the same reason,
ultra-centrifugation was carried out at maximum speed for acceleration and at minimum
speed for deceleration. Samples were kept at 4ºC at all times and immediately processed to
fractionation to maintain RNA integrity. Lysates were applied onto the gradient and cen-
trifuged at 41,000 rpm for 2 hours 30 min at 4ºC using a SW41 rotor. The IFNγ-stimulated
wt-SiHa cells and IFNγ-stimulated IFITM1/IFITM3 double null cell lysates were subjected
to sucrose density gradient sedimentation. The aim was to extract the free mRNA, 40S,
60S, 80S, and polysomes in different fractions. Fractions, each containing 500 µl of the
elute, were collected in 18 x 1.5 ml sterile screw tubes (SSIbio, 2231-S0), using a BioComp
gradient station model 153 (BioComp Instruments, New Brunswick, Canada). While elut-
ing, samples were measured at OD254; elutes corresponding to the same subpolysomal
and polysomal fractions were pooled together for further analysis by SWATH-MS to define
changes in ribosomal protein profile in the wt-SiHa and IFITM1/IFITM3 double null cells.
Samples were processed for SWATH-MS in technical triplicates.
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Table 2.29: 10x RSB stock buffer, 1xRSB/RNasin buffer, and PEB buffer.
10x RSB stock buffer 1xRSB/RNasin (2 ml)
200 mM Tris pH 7.5 200 µl 1x RSB
1 M KCl 50 µl RNasin (Promega, N2511)
100 mM MgCl2
Polysome extraction buffer (PEB) (10 ml)
1 ml 1x RSB
50 µl NP-40
1 pill cOmplete Tablets, Mini EDTA-free, EASYpack
(Roche-Sigma, 04693159001)
2.7.5 Trichloroacetic acid (TCA) precipitation
Protein fractions, as collected, were in a very dilute 500 µl sucrose buffer solution. In
order to concentrate them, they were precipitated using TCA; 1µg/µl of BSA was added to
each prechilled fraction, then, 90µl of ice-cold TCA was mixed and incubated on ice for 60
min. Eluates were centrifuged at maximum speed at 4ºC for 10 min, the supernatant was
carefully saved and the pellet was again centrifuged to remove the remaining supernatant.
The pellet was not visible at this stage. The pellet was washed with 250 µl of ice-cold ace-
tone and centrifuged for 5 min at 4ºC. Finally, the supernatant was discarded, and a visible
small white precipitate was air dried. If the recovery is very low, the saved supernatant was
incubated with TCA on ice for 4 hours and centrifugation and wash steps were repeated.
Protein was then resuspended in 2x sample buffer to proceed with a Western blot.
2.8 Mass spectrometry; free-labelled SWATH and SILAC Orbitrap
methodology
2.8.1 Sample preparation for mass spectrometry (MS)
Peptide generation using FASP
Cell lysates, immunoprecipitates, or gradient fractions were processed using a filter-
aided sample preparation protocol (FASP)(Wiśniewski et al., 2009). Urea buffer (8 M urea
in 0.1 M Tris pH 8.5) was added to a 30 kDa cut-off spin-filter column (MRCPRT010, Mi-
crocon). Protein concentration was determined using the RC-DC method (Bio-rad). Nor-
malized samples (20-100 µg of protein) were added to the spin filter column and cen-
trifuged at 12,200 rpm for 15 min at 20°C. Urea buffer was added again with 100 mM Tris (2-
carboxyethyl) phosphine hydrochloride (Aldrich) and mixed. The column was incubated
for 30 min at 37°C on a shaking thermo-block at 600 rpm and then centrifuged at 12,200
rpm for 15 min at 20°C. Urea buffer and 300 mM of iodoacetamide (Sigma) were mixed
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using a thermo-mixer at 600 rpm in the dark for 1 min, then was maintained statically at
RT for a further 20 min in the dark. The sample was centrifuged at 12,200 rpm for 15 min
at 20°C and the supernatant was discarded. A solution containing 100 µM ammonium
bicarbonate were added to the column and then it was centrifuged at 12,200 rpm for 20
min at 20°C . This step was repeated once more. The column was placed in a new collect-
ing tube (low binding affinity) and 50 mM ammonium bicarbonate was added, along with
trypsin diluted in trypsin buffer (Promega) at a 1:100 ratio. The column was incubated at
37°C overnight. The following day the column was centrifuged at 12,200 rpm for 15 min at
20°C. Determination of the peptide concentration was performed using the Quantitative
Colorimetric Peptide Assay (Pierce, ThermoScientific).
Desalting peptides using C18 column
Peptides were desalted on micro-spin columns C-18 (Harvard Apparatus, USA). The
columns were conditioned 3 times with 100% acetonitrile (AcN) and 0.1% formic acid (FA)
and centrifuged at 1,200 rpm for 2 min at RT. The column was washed with 0.1% FA and
centrifuged at 1,200 rpm for 2 min at RT then hydrated in 0.1% FA for 15 min following cen-
trifugation at 1,800 rpm for 3 min at RT. The sample was loaded into the column and cen-
trifuged at 2,300 rpm for 3 min. After washing the column 3 times with 0.1% FA, the pep-
tides were eluted in 3 consecutive centrifugations at 2,300 rpm for 3 min using 50%–80%
and 100% AcN with 0.1% FA. Subsequently, peptide eluates were evaporated and dissolved
in 5% AcN with 0.05% FA.
LC-MS/MS analysis
Enzymatically digested samples were processed using isotopically-labelled amino
acids and were separated using UltiMate 3000 RSLCnano chromatograph. Peptides were
loaded on a pre-column (µ-precolumn, 30 mm i.d., 5 mm length, C18 PepMap 100, 5 µm
particle size, 100 Å pore size) and further separated on an Acclaim PepMap RSLC column
(75 mm i.d., length 500 mm, C18, particle size 2 mm, pore size 100 Å) with a 300 nl/min
flow rate using a linear gradient: 2% B over 4 min, 2 – 40% B over 64 min, 40–98% B over
2 min, with A = 0.1% aq. formic acid and B = 80% ACN in 0.08% aq. formic acid. Pep-
tides eluting from the column were introduced into an Orbitrap Elite operating in Top20
data dependent acquisition mode. A survey scan of 400–2000 m/z was performed in the
Orbitrap at 120 000 resolution with an AGC target of 1 x 106 and 200 ms injection time fol-
lowed by twenty data-dependent MS2 scans performed in the LTQ linear ion trap with 1
microscan, 10 ms injection time and 10 000 AGC.
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2.8.2 Database searching and analysis
Orbitrap-MS
The data from the mass spectrometer were processed using either Proteome Discov-
erer 1.4 or Proteome Discoverer 2.2 that is equipped with statistical tools. Proteome Dis-
coverer 1.4 processed the data using Mascot search engine with the following search set-
tings: database Swiss-Prot human (April 2016); enzyme trypsin; 2 missed cleavage sites;
precursor mass tolerance 10 ppm; fragment mass tolerance 0.6 Da; dynamic modifica-
tions: carbamidomethyl [C], oxidation [M], acetyl [protein N-terminus]. The results of the
search were further submitted to generate the final report considering 1% FDR on both
PSM and peptide group levels. For the protein quantification we used only unique pep-
tides. SILAC labels of R6 and K6 were chosen for heavy and R0 and K0 for light. The relative
quantification value was represented as heavy/light ratio (Table B.2). The higher version
of Proteome Discoverer 2.2 was used for processing of the same raw files, but different
settings for the data evaluation were used according to the requirements of this program.
The processing and consensus workflows used subsequent nodes: the Minora feature de-
tector, the Precursor ion quantifier, and the Feature mapper. The data were processed
using Sequest HT engine with the following search settings: database Swiss-Prot 2017-
10-25, # sequences 42252, taxonomy: Homo sapiens (updated February 2018); enzyme
trypsin; 2 missed cleavage sites; precursor mass tolerance 10 ppm; fragment mass toler-
ance 0.6 Da; static modification carbamidomethyl [+57.021 Da, (C)], label 13C(6) [+6.020
Da (K, R)]; dynamic modifications oxidation [peptide terminus, +15.995 Da (M)], Met-
loss+Acetyl[protein terminus, -89.030 Da (M)]. The results of the search were further sub-
mitted to generate the final report with a 1% FDR using Percolator. For the protein quan-
tification and statistical assessment of the biological triplicates, only unique peptides and
razor peptides were used. The relative quantification value is represented as the relative
peak area of the peptides with the heavy isotope labels with IFNγ-stimulated cells/IFNγ
non-stimulated cells ratios (Table B.5). This work was conducted by Prof. Ing. Lenka
Hernychova, in Regional Centre for Applied Molecular Oncology, Masaryk Memorial Can-
cer Institute, Brno.
SWATH-MS
Label free quantitation was performed using FASP-processed tryptic digests with liq-
uid chromatography coupled to tandem MS on an Eksigent Ekspert nanoLC 400 (SCIEX,
Dublin, Caliorwaornia), inline connected to a TripleTOF 5600+ (SCIEX, Toronto, Canada)
mass spectrometer. Cell lysates were processed in technical triplicates. Prior to separa-
tion the peptides were concentrated and desalted on a cartridge trap column (300 µm i.d.
× 5 mm) packed with C18 PepMap100 sorbent with 5 µm particle size (Thermo Fisher Sci-
entific, Waltham, MA, USA). After a 10-min washing using 0.05% trifluoroacetic acid in 5%
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acetonitrile and 95% water, the peptides were eluted using a gradient of acetonitrile/water
(300nL/min) using a capillary emitter column PicoFrit® nanospray columns 75 µm × 210
mm (New Objective, Woburn, USA) self-packed with ProntoSIL 120-3-C18 AQ sorbent with
3µm particles (Bischoff, Leonberg, Germany). Mobile phase A was composed of 0.1% (v/v)
formic acid in water, and mobile phase B was composed of 0.1% (v/v) formic acid in ace-
tonitrile. Gradient elution started at 5% mobile phase B for the first 30 min, then the pro-
portion of mobile phase B increased linearly up to 40% B for the following 120 min. Output
from the separation column was directly coupled to an ion source (nano-electrospray). Ni-
trogen was used as a drying and nebulizing gas. Temperature and flow of the drying gas
was set to 150ºC and 12. Voltage at the capillary was 2.65 kV. Pooled sample for the spec-
tral library was measured in data-dependent positive mode. The MS precursor mass range
was set from m/z 400 up to m/z 1250 and from m/z 200 up to m/z 1600 in MS/MS. Cycle
time was 2.3 seconds and in each cycle 20 most intensive precursor ions were fragmented.
Subsequently, their corresponding MS/MS spectra were measured. Precursor exclusion
time was set to 12s. Precursor ions with intensity below 50cps were suspended from the
IDA experiment. The extraction of mass spectra from chromatograms, their annotation
and deconvolution were performed using Protein Pilot 4.5 (SCIEX, Toronto, Canada). MS
and MS/MS data were searched using the Uniprot+swissprot database (02. 2016) non-
redundant restricted to H. sapiens taxonomy. Fixed modification – alkylation on cysteine
using iodoacetamide and digestion using trypsin was set for all searches. The resulting
group file was imported into Peakview 1.2.0.3 (SCIEX, Toronto, Canada), where only pro-
teins with FDR below 1% were imported into the spectral library (465 proteins for SBP-
IFITM1 pull down SWATH and 1320 proteins in polysomal SWATH). In SWATH mode, the
mass spectrometer operated in high sensitivity positive mode. Precursor range was set
from m/z 400 up to m/z 1200. It was divided into 67 precursor ion windows with the width
of 12 Da and 1 Da overlap. Accumulation time was 50 ms per SWATH window and the duty
cycle was 3.0 seconds, which enabled acquisition of at least 10 data points across a chro-
matographic peak. Product ions were scanned from m/z 400 up to m/z 1600. Data extrac-
tion was performed in Peakview 1.2.0.3 (SCIEX, Toronto, Canada) with the spectral library.
The retention time window for extraction was manually set to 4 min for SBP-IFITM1 pull
down SWATH (Table B.3) and 10 min in polysomal SWATH (Table B.4). SWATH protein
quantification was performed using up to 4 peptides and 6 transitions per protein. Scope
of peptides used for quantification was narrowed to only those with peptide confidence
higher than 99% and without any variable modification. Protein summed peak areas were
normalized using total area sums option in MarkerView 1.2.1.1 (SCIEX, Toronto, Canada).
Samples were compared pairwise using a paired t-test. Statistics was done on 3 technical
replicates from each polysomal fraction. Resulting protein fold-changes were considered
as statistically significant at p-value<0.05. This work was conducted by Dr. Jakub Factor,
in Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute,
Brno.
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2.9 Bioinformatic analysis of the RNA-sequencing
RNA samples of IFNγ-stimulated and non-stimulated wt-SiHa cells, IFITM1 null cells
and IFITM1/IFITM3 double null cells were processed by Otogenetics for paired end RNA-
sequencing analysis, using an Illumina HiSeq 2500 and designated 20 million reads. The
pair of fastq files obtained from the sequencer were checked for quality control, merged
and processed using CLC Genomic Workbench 12.0 to obtain the total RNA expression
levels. GRCh38 was taken as the human reference genome with the following settings:
mismatch cost: 2, insertion cost: 3, deletion cost: 3 (Table B.6). The results were compared
using RNA gene expression for each condition, creating seven different scatter plots that
compared IFNγ stimulated to non-stimulated conditions, and wt-SiHa cells to IFITM1 null
cells or IFITM1/IFITM3 double null cells (Figure 6.6). Comparisons were performed taking
the TPM values as reporting abundances and log2 (TPM condition 1 versus log2 (TPM
condition 2) as comparison values. An additional heat map was generated with the list
of IRDS genes to compare the gene expression of these genes of interest across samples
(Figure 6.7 A). Following the same parameters, another heat map was created to compare
isoform switches using sum of RNA transcript expression levels (Figure 6.7 B) or the RNA
transcript expression level of particular transcripts (Figure 6.7 C). This work was conducted
by Marcos Yébenes Mayordomo, in ECRC–IGMM, University of Edinburgh.
Chapter 3
Generating isogenic IFITM knock out
cervical carcinoma cell models
3.1 Introduction
Cervical cancer is the most common cancer among females in developing countries
and the second most common cancer type manifested in women across all countries
(Callahan & Caughey, 2013). It is been postulated that the disease arises from continu-
ous infection by human papilloma virus (HPV) (Burd, 2003). In this regard, a study per-
formed in the late 90s reported that 99.7% of women with cervical cancer were infected
with HPV, and 75% of them were carrying HPV-16 and HPV-18 virus strands (Walboomers
et al., 1999). Sadly, the most economically deprived areas do not have access to routine
screening programs and preventive vaccine. Therefore, current efforts are focused on de-
veloping affordable diagnostic assays and therapeutic tools for the less developed coun-
tries.
3.1.1 Clinical relevance of IFITM1 in cervical cancer
IFITM1 is dysregulated in cervical cancer. Pan et al. conducted a RNA screening and
identified IFITM1 related to cervical carcinogenesis (Pan et al., 2010). Tumour and nor-
mal cervix tissue were extracted from 16 women who did not receive chemotherapy or
radiotherapy prior to biopsy resection. This study showed 46 genes dysregulated in tu-
mour tissue compared to normal cervix tissue, and IFITM1 was found to be one of the 22
downregulated genes in cervical tumours.
Using immunohistochemistry (IHC) on tissue microarrays (TMA) of cores from squa-
mous cervix carcinoma we have shown a direct correlation between IFITM1/IFITM3 stain-
ing and advanced cervical cancer stage (Gomez Herranz et al., 2019). The microarray panel
contained samples of both normal tissue and cancer tissue at different stages. This work
was conducted by Dr. Rudolf Nenutil and Dr. Marta Nekulová, in the Regional Centre for
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Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno. Biopsies for sam-
ple preparation were extracted from women who did not have preoperative treatment. The
results presented a dynamic range of staining in 74 cervical cancer tissues, where some
samples had a high presence of IFITM1/IFITM3 staining and others were completely neg-
ative (Figure 3.1 A and C). Squamous cervical carcinoma exhibited differential expression
(Figure 3.1 A-C) while high expression was observed for cervical adenocarcinoma (Fig-
ure 3.1 D). Remarkably, 10 out of 74 specimens showed no staining (Figure 3.1 F). After
stratifying samples by manifestation of metastases, there was a statistically significant in-
verse correlation between IFITM1/IFITM3 staining and presence of nodal metastases (Fig-
ure 3.1 F II). This result suggested that IFITM1/IFITM3 proteins may be playing a dual role
where overexpression, but also loss of expression, facilitates cervical cancer development.
Interestingly, a gene expression study also revealed inverse correlation between IFNγ and
lymph node metastases in women with cervical cancer and this association was confirmed
by immunochemistry analyses (Kim et al., 2007).
3.1.2 Study of IFITM1-dependent signalling pathways in a cervical cancer cell
model
The immunohistochemistry study presented in the previous section led to continued
exploration of the molecular role of IFITM1. As such, additional work performed in our
group explored pathways by which IFITM1 is implicated in cervical cancer. An assay to de-
fine IFITM1 dependence on the steady-state protein levels was developed using IFITM1-
targeted small interfering RNA (siRNA) in wt-SiHa cells coupled to mass spectrometry (MS)
analysis.
The use of siRNA is a powerful tool to determine gene dependencies in cell models. In
this assay was asked whether transient reduction in IFITM1 protein might affect steady-
state levels of the related cluster of IFN responsive proteins. Wt-SiHa cells were treated for
48 and 72 hours with either control siRNA or IFITM1-targeted siRNA (Figure 3.2 A, lanes 4
and 2 vs lanes 3 and 1) to identify IFITM1 dependent proteins. This work was performed
by Dr. Elisabeth Sinclair, in ECRC–IGMM, University of Edinburgh.
However, similar to plasmid transfection, siRNA itself can activate an IFN response
and that may impact on IFITM1 signalling (Huerfano et al., 2013). In fact, previous work
from our group found that siRNA can also induce an IRF-1 dependent IFN response (data
not shown). IRF-1 is a key transcription factor that coordinates the expression of multiple
IFN-related genes. That is why an alternative methodology is developed in this thesis, in
which an isogenic gene-edited null cell model is generated to interrogate which are the
IFITM1-IFNγ dependent signalling responses.
Nevertheless, a close look at the above effects of IFITM1-targeted siRNA revealed that
there was a striking and selective reduction in IFN-responsive proteins, 8 of which are
components of the IRDS (Figure 3.2 B, highlighted in orange)(Weichselbaum et al., 2008a),
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Figure 3.1: Tissue microarray suggests inverse correlation between IFITM1/IFITM3 presence and nodal
metastasis (Gomez Herranz et al., 2019). TMA was performed on formalin-fixed, paraffin-embedded cervi-
cal carcinoma tissues. Representative slides showing grades of IFITM1/IFITM3 staining; high expression in
squamous cell carcinoma (A), discrete expression in squamous cell carcinoma (B), absence of expression in
squamous cell carcinoma (C), high expression in adenocarcinoma (D), and expression in basal stem cell layer
in normal tissue (E) Quantification of IFITM1/IFITM3 expression in cervical cancer in relation to histology
type (I) and metastasis (II) (F).
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Figure 3.2: The impact of IFITM1 targeted siRNA on the steady-state proteome (Gomez Herranz et al.,
2019). (A) IFITM1-targeted siRNA can attenuate IFITM1and IFITM3 protein levels. Cells were treated with
control siRNA (lanes 1 and 3) or IFITM1 siRNA (lanes 2 and 4) for 48 and 72 hours to study the overlapping
dynamic in the IFITM1 signalling pathway. Lysates were immunoblotted with the IFITM1/IFITM3 antibody
and GAPDH was used as loading control. (B) Representation of the proteome in response to siRNA targeting
of IFITM1 in two time points (48 and 72 hours) in wt-SiHa cells using SWATH-MS. These data are plotted as
log2 fold change (Fch) in protein levels (IFITM1 siRNA vs control siRNA) as a function of either the 48 hour
time point (x-axis) and 72 hour time point (y-axis). The proteins of interest whose levels were decreased af-
ter IFITM1-targeted siRNA treatment are highlighted in orange (bottom left quadrant). Data extracted from
Table B.1.
specifically ISG15 and HLA family members as well as other proteins of the MHC class I
pathway. This finding is consistent with further results presented in this thesis (chapter 4
and chapter 5). In addition, this assay shows decreased CD81 expression with IFITM1 de-
pletion, which is particularly interesting as interaction of CD81:IFITM1 has been reported
in homotypic cell adhesion in leukocytes and growth arrest (Matsumoto et al., 1993; Taka-
hashi et al., 1990).
All-in-all, this was the first evidence that IFITM1 may be a dominant receptor that me-
diates induction of other IRDS members. Collectively, the described experiments above
set the foundations for this thesis.
3.2 Developing new strategy for understanding the role of
IFITM1/IFITM3
The first goal of this thesis was to generate and validate cell models to study the role of
IFITM1, using CRISPR/Cas9 methodology. As previously described, IFITM1 and IFITM3
play different roles in the cell. However, both isoforms are highly homologous suggesting
that IFITM1 and IFITM3 may have overlapping functions or orchestrate cellular processes
together. Thus, we decided to generate IFITM1, IFITM3 and IFITM1/IFITM3 knock out cell
models (henceforth IFITM1, IFITM3 and IFITM1/IFITM3 null cell models)
SiHa cells, which originated from squamous cell carcinoma of cervix, were chosen as a
model because they express IFITM1/IFITM3 at detectable endogenous levels with higher
Chapter 3 - Generating isogenic IFITM knock out cervical carcinoma cell models 63
protein expression after IFNγ stimulation (Figure 3.11). Interestingly, SiHa cells (repre-
sentative of the majority of cervical cancer cells) are infected by human papillomavirus
16 (HPV 16) and IFITMs were initially considered to be a restriction factor. Despite the
fact that HPV virus was not the main theme of this study, it is interesting to highlight that
infection with HPV 16 and 18 strains are considered to be one of the main causes of tu-
mourigenesis in the precursor cervical intraepithelial neoplasia/squamous intraepithe-
lial lesions (CIN/SIL) for this cancer type. IFITM1 may have unknown implications in the
very early events of HPV-driven cervical cancer but the current studies suggest that HPV
inhibits IFITMs effects by downregulating their expression (Warren et al., 2014; Ma et al.,
2016). However, the central goal was to understand the cellular functions of IFITM1 in re-
lation to the IFNγ signalling landscape. The study of IFNγ effects on IFITM1 signalling is
a significant challenge. Clinical data as well as studies in vitro showed inconsistent results
and it has been suggested that IFN will reduce the activation of HPV virus, particularly ex-
pression of E6 and E7 oncogenes (Kim et al., 2000). Nonetheless, this effect can be only
observed in some cervical cancer cell lines or in certain patients with cervical carcinoma
tested with IFN type I and II (Chang & Laimonis, 2000). Additionally, it has been reported
that late passage cells are less responsive to IFNγ, suggesting that accumulation of mu-
tations may impact on IFNγ regulatory effects, which has also been observed in patients
with advanced cancer disease (Kim et al., 2000).
IFITM1 plays a dual role in metastatic cell growth and spread, and also in restriction
of RNA viruses. Consequently, we aim to use these functional IFITM null cell models as a
tools to compare the cellular consequences of IFITM1, IFITM3 or IFITM1/IFITM3 loss in
comparison with IFITM wild-type cells. As such, isogenic IFITM1 null, IFITM3 null, and
IFITM1/IFITM3 double null cell models of SiHa cervical carcinoma cells were generated
through genome editing using CRIPSR/Cas9 technology (Ran et al., 2013).
The Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR)/Cas9 sys-
tem is a sophisticated genome-editing tool based on the microbial adaptive immune sys-
tem, consisting of RNA-guided/Cas9 nuclease that can precisely target specific genomic
loci for cleavage. The system was originally discovered in bacteria and archaea as an evo-
lutionary mechanism in response to viral phages and plasmid threats (Wiedenheft et al.,
2012). This defence mechanism is activated after repetitive pathogen attack and relies
on genomic incorporation of short palindromic spaced repeats or protospacers that have
been excised from the pathogenic intruder and integrated into a CRISPR array in the mi-
crobial host genome. This way, the bacterial or archaeal host keeps on producing a li-
brary of CRISPR sequences for future identifications of pathogens. This repertoire is tran-
scribed and assembled into CRISPR-derived RNAs (crRNAs) containing short complemen-
tary genomic sequences of the pathogenic intruders. CrRNA are associated with trans-
activating CRISPR RNA (tracrRNA), responsible for its maturation (Deltcheva et al., 2011).
This mechanism was first observed in Escherichia coli (Ishino et al., 1987) but the system
was not completely understood until in silico analysis identified four CRISPR-associated
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(Cas) genes that encode nucleases. Remarkably, the study showed that Cas genes were
uniquely present in prokaryotes containing CRISPR loci (Jansen et al., 2002). Cas genes
are responsible for generating the Cas enzymes that are able to precisely cleave the for-
eign genome in a site-specific manner by recognition of the protospacer adjacent motif
(PAM), a flanking sequence present in the foreign genome. Then, base complementary
pairing between crRNA and the specific locus in the foreign genome enhances the inter-
action and facilitates the targeted double strand (DBS) cleavage by the Cas enzyme. Dif-
ferent CRISPR/Cas system types have been described, but all of them contain the same
core components and fundamentally function in the same manner (Jinek et al., 2012).
The CRISPR/Cas system discovery has revolutionized many fields in academia as well
as in industry and the applications are very broad. Previous genome-editing technologies
such as zinc fingers (ZFN) and transcription activator-like effector nucleases (TALEN) are
not as fast and easy to apply as CRISPR/Cas9. This targeted genome-editing machinery is
notable not only for its sophistication but also for being highly precise and effective for ma-
nipulating genetic material. As a result, this tool has been engineered for use in eukaryotic
systems to successfully target and modify particular genes of interest (Cong et al., 2013;
Jinek et al., 2013). In this work, we used the CRISPR/Cas9 system to generate isogenic cell
models to study the cellular roles of IFITM1 and IFITM3.
There are different types of CRISPR/Cas systems, but the most widely used is
CRISPR/Cas9. As in the prokaryotic system, the underlying principle of CRISPR/Cas9 is
also based on two elements; crRNA and tracrRNA. Both components together are also
referred to as single guide RNA (sgRNA) (Figure 3.3 A). The crRNA contains a cluster of
Cas genes, noncoding RNAs and an array of repetitive elements interspaced by protospac-
ers. The tracrRNA acts as an auxiliary scaffold for processing the crRNA. The system has
fused together the crRNA and tracrRNA sequences to generate a sgRNA sequence that pre-
cisely cleaves the DNA at the intended location producing a double strand break (DSB).
The crRNA sequence consists of a 20-nucleotide sequence that target gene sequence to
be modified. In the host genome this 20-nucleotide sequence is flanked by a 5’-NGG,
which is the protospacer adjacent motive (PAM) (Figure 3.3 B) (Gaj et al., 2013; Ran et al.,
2013). The Cas9 nuclease binds to the sgRNA and the host gene target sequence to pro-
duce a DSB in the desired genomic locus (Figure 3.3 C). The DSB can be repaired by either
non-homologous end joining (NHEJ), or homology directed repair (HDR) pathways (Fig-
ure 3.4). NHEJ repair machinery does not use a template and so is prone to introducing
errors, such as insertion or deletions, while repairing the DSB. In contrast, HDR is of high
fidelity and it repairs a DSB by homologous recombination directed by a double-stranded
DNA donor (template sequence) in dividing cells. The NHEJ repair is a less sophisticated
system that is activated throughout the cell cycle, so it is more frequently used by the cell
(Figure 3.4). As a result, it is more likely that some indels (insertions and/or deletions) will
be introduced into the gene of interest, resulting in gene knock out (Figure 3.3 D).
Genes for IFITM1, IFITM2 and IFITM3 are located on chromosome 11p15.5, around 5
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Figure 3.3: Schematic of CRISPR/Cas9 system. The sgRNA is composed of crRNA and tracrRNA.
crRNA sequence is specifically designed to target the gene of interest, in this case IFITM1 (5’ -
TCCAAGGTCCACCGTGATCA- 3’) and IFITM3 (5’ -GTCAACAGTGGCCAGCCCCC- 3’). (B) sgRNA binds to the
recombinant form of Cas9 nuclease from S. pyogenes. Together they target the genomic DNA by base pair-
complementary binding between sgRNA and the specific locus of interest which is flanked with a 5-NGG pro-
tospacer adjacent motif (PAM) in the host genome. (C) After sequence recognition, Cas9 will produce a DSB
approximately 3 bp upstream of the PAM motif. (D) The cleavage site can be repaired by NHEJ (an error-prone
repairing mechanism), resulting in indels that will prematurely terminate either IFITM1 and/or IFITM3 genes
and thus resulting in loss of funcitons.
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Figure 3.4: CRISPR/Cas9 system to generate targeted gene editing (Ran et al., 2013). DSB can be repaired
by either error-prone NHEJ (promoting random indel mutations) or HDR (precise editing). Indel mutations
are susceptible to production of aberrant forms of the genomic sequence, such as introducing a premature
stop codon or creating a frameshift in the nucleotide sequence.
kb apart Figure 1.11. According to the the American type culture collection (ATCC) source,
SiHa is an hypertriploid cancer cell line that originated from a human squamous cell car-
cinoma of the cervix. Aneuploidy events could have complicated the genetic editing of
these clones, but chromosome 11 is not affected. The IFITM1 gene has 855 bp that are
translated into a 13.9 kDa protein. It contains a single intron, that divides exon 1 from
exon 2, 186 and 189 base pairs long, respectively (Figure 3.5 A). The IFITM3 gene has 0.97
kb that encodes a 14.6 kDa protein and it is also divided into two exons of 249 bp and 150
bp, respectively (Figure 3.5 B). The rationale behind the sgRNA design was to target exon
1 in both the IFITM1 and IFITM3 genes in order to introduce an indel. This random indels
will either encode a premature stop codon or generate a sequence frameshift at an early
stage of protein translation.
The methodology used to produce the null cell lines required the design of sgRNAs fol-
lowed by cloning into pLentiV2 plasmid. sgRNA sequences were designed for IFITM1 (5’
-TCCAAGGTCCACCGTGATCA- 3’) and for IFITM3 (5’ -GTCAACAGTGGCCAGCCCCC- 3’).
The guide RNA was cloned into the lentiCRISPRv2 expression vector (Sanjana et al., 2014).
SiHa cells were transduced with gRNA in pLentiV2 plasmid along with viral coat protein.
After transduction, cells were selected with puromycin and single cells were sorted into
a 96-well plate using FACS. Then, cells were further selected for resistance to puromycin
to allow stable integration of the IFITM1, IFITM3, or IFITM1 in combination with IFITM3
targeting single guide RNA cassette. After a few weeks, individual clones were screened for
absence of IFITM1, IFITM3 or IFITM1/IFITM3 protein expression by Western blot (Fig-
ure A.1). This work was kindly performed by Dr. Marta Nekulová in RECAMO, Masaryk
Memorial Cancer Institute, Brno. Validation of isogenic clones by Western blot is included
in Appendix A 1. Gene editing was confirmed by Sanger sequencing.
Because IFITM1 (and not IFITM3) was the receptor oncogene and IFITM1/IFITM3 ab-
sence was found in TMA cervical staining, we started with generating isogenic cell lines
for these combinations; IFITM1 null and IFITM1/IFITM3 double null cells. During this
research, there was a need to validate our results with an IFITM3 null cell model to inves-
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tigate whether this isoform by itself also contributes to the phonotype seen (described in
upcoming chapters). Unfortunately, it took several attempts to successfully obtain IFITM3
null clones. For this reason, the IFITM3 null cells were not further analysed in this thesis.
Nonetheless, an IFITM3 null SiHa clone has been engineered and validated (data shown
in this chapter), so it is ready to be used in future projects.
3.3 Aims of the chapter
The aim of this chapter is to successfully validate an isogenic SiHa cell model panel
generated using the CRISPR/Cas9 system. Validation was performed at the genomic level
by DNA sequencing of the produced CRISPR/Cas9 indels, and at the protein expression
level by Western blotting and by immunofluorescence assays using a set of specific anti-
bodies. The cervical cancer cell panel is composed by wt-SiHa and the isogenic IFITM1
null, IFITM3 null, and IFITM1/IFITM3 double null cells. This will allow determination of
the inducibility of IFITM1 and IFITM3 by IFNγ stimulation. The panel will serve as a tool in
future chapters to validate possible protein–protein interactions between IFITM1 and its
interacting partners. In addition, this panel will allow investigation of the cellular roles of
IFITM1 and IFITM3, including their roles in cancer development, by studying the absence
of IFITM1/IFITM3 protein production in the cell. Overall, this chapter will set the foun-
dations of IFITM1/IFITM3 signalling in relation to the IFNγ landscape in the SiHa cancer
cell model.
3.4 Results
3.4.1 Genetic screening of engineered clones obtained by CRISPR/Cas9 tech-
nology in the SiHa cancer cell model panel
The production of potential cell models of gene knock outs using the CRISPR/Cas9
system ultimately relies on the capacity of the cell to repair a DSB in the genomic
DNA introducing sequence errors. Hence, the sgRNA were designed to introduce in-
dels into the target IFITM sequences that had an adjacent PAM sequence. First, primers
were designed to amplify 475 bp of IFITM1 leaving the recognition site for the sgRNA
(upstream to the PAM sequence) in the middle of the amplicon. The designed for-
ward primer was 5’ -TACAAACAGCAGGAAATAGAAACTT- 3’ and reverse primer was 5’-
ACTCACAGTCACAGGGACAC- 3’ (Figure 3.5 A I). It was also confirmed that no other IFITM
isoform shared these particular sequences. After chromosomal DNA extraction from po-
tential IFITM1 null cells, the DNA was amplified by PCR, and analysed by 2% agarose gel
electrophoresis. A single band was observed for the potential IFITM1 null cells and this
was subsequently sequenced (Figure 3.7 A, lane 2). The DNA sequence chromatogram
revealed an increased signal noise with overlapping nucleotide peaks (indicating an indel
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Figure 3.5: Designing primers to identify CRISPR/Cas9-generated indels in IFITM1 and IFITM3 genes. (A)
Genomic IFITM1 sequence organization shown at the top of the panel. Primers designed for IFITM1. (I)
Primers designed to amplify 475 bp amplicon surrounding the sgRNA recognition site (asterisk). (II) Primers
designed to amplify 1.1 kb amplicon of the whole IFITM1 gene. (III) Primers designed to amplify 192 bp am-
plicon with the forward primer covering a combination of the last few nucleotides of exon 1 and the first
nucleotides of exon 2. (B) Genomic IFITM3 sequence organization shown at the top of the panel. Primers
designed for IFITM3. (I) Primers designed to amplify 512 bp amplicon surrounding the sgRNA recognition
site (asterisk). (II) Primers designed to amplify 0.97 kb amplicon of the whole IFITM3 gene.
event), starting just after the PAM sequence (Figure 3.6 B, indicated with a black arrowhead
chevron).
This pattern of increased signal noise with overlapping nucleotide peaks (Figure 3.6
B) was an indication of a heterozygote indel where each allele had a different mutation.
To elucidate that possibility, the next approach was to carefully amplify the whole IFITM1
gene, including the single intron, and clone it into a plasmid backbone. The designed for-
ward primer was 5’ -GGGGGGTACCGATGCACAAGGAGGAA- 3’ and the reverse primer was
5’ -CCCCGATATCCTAGTAACCCCGTTT- 3’ (Figure 3.5 A II). Recognition sequences for re-
striction enzymes were included as part of the primer sequences in order to facilitate the
cloning. A single band was seen at the same size as wt-SiHa and this was cut and cloned
into a vector to be able to sequence the whole IFITM1 (Figure 3.7 A, lane 1 vs 2). Out of 12
clones sequenced, 7 of them had a single point insertion and the rest a single point dele-
tion at the target site. Following cloning, the DNA sequence chromatograms were free of
signal noise with overlapping peaks. Both IFITM1 alleles were gene edited in representa-
tive IFITM1 null clone that created frameshifts by a single nucleotide deletion or insertion,
resulting in transcripts with premature stop codon and frameshift mutation, respectively,
and consequently being eliminated by nonsense-mediated mRNA decay (NMD) pathway
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or producing a truncated protein (Figure 3.6 C and D).
Figure 3.6: Validation of IFITM1 knock out in engineered IFITM1 null cells by sequencing. (A) Gene struc-
ture of the IFITM1 gene highlighting its two coding exons and one intron. (B) Amplification of genomic IFITM1
that targets exon 1 on 475 bp amplicon surrounding the sgRNA recognition site (indicated in Figure 3.5 A I).
Representation of the wt-SiHa and IFITM1 null alignment, sgRNA is indicated in red font with the wild-type
sequence in black font. There is an increase of the signal noise with overlapping peaks starting just after the
PAM sequence (black arrowhead chevron) suggesting heterozygosity of the alleles. (C) Identification of het-
erozygote IFITM1 showing different indels after cloning the PCR amplified IFITM1 gene into a vector and then
sequencing individual clones for the type of gene edit. One allele of IFITM1 gene has one bp insertion and the
other has one bp deletion (in red) (D) Predicted amino acid sequence obtained from the ExPAsy translate tool
shows a frameshift and premature stop codon with both genes edits.
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A similar approach was followed for validation of the IFITM1/IFITM3 double null
cells. After chromosomal DNA extraction from potential IFITM1/IFITM3 double null cells,
whole IFITM1 gene was amplified (Figure 3.5 A II), and a single gel electrophoretic band
was observed below 500 bp in size, instead of an expected 1.1 kb band (Figure 3.7 A, com-
pare lane 1 to lane 3). The DNA in this band was cloned and sequenced following the same
protocol as for IFITM1 null cells. Surprisingly, sequencing showed it resulted in a precise
intron deletion in IFITM1 null cells (Figure 3.8). To rule out possible technical problems
with the sample it was corroborated, in parallel, that control wt-SiHa cells had the intron
present (data not shown).
Figure 3.7: Validating of IFITM1 knock out following CRISPR/Cas9 editing in engineered IFITM1/IFITM3
double null cells. Amplification of IFITM1 in wt-SiHa cells (lane 1), potential IFITM1 null cells (lane 2) and
IFITM1/IFITM3 double null cells (lane 3). (A) Primers to amplify full length gene were used, it was notied
that IFITM1/IFITM3 double null cells had a smaller band indicating a large deletion. After sequencing, intron
deletion was identified. (B) Forward primer was designed comprising the last few nucleotides of exon 1 and
first nucleotides of exon 2 in order to further validate the results in (A). This single band was exclusively found
in IFITM1/IFITM3 double null cells (lane 3). DNA from the single band in the IFITM1/IFITM3 double null
clone was extracted and sequenced from lane 3 in (A).
For further validation we designed a forward primer that flanked the end of
exon 1 with the beginning of exon 2 (Figure 3.5 A III). The designed forward
primer was 5’ -ACTCCGTGAAGTCTAGGGACA- 3’ and the reverse primer was 5’ -
CCCCGATATCCTAGTAACCCCGTTT- 3’. PCR amplification of DNA from wt-SiHa cells was
used as a negative control, it was observed that there was a single band of 192 bp in size
found only for IFITM1/IFITM3 double null cells (Figure 3.7 B, lane 1 vs 3). These two al-
ternative approaches give supporting evidence that IFITM1/IFITM3 double null cells have
an intron deletion in the IFITM1 gene (Figure 3.7 C).
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Figure 3.8: Investigation of the IFITM1 intron loss following engineering by CRISPR/Cas9 in potential
IFITM1/IFITM3 double null cells. Gene structure of the IFITM1 gene highlighting its two coding exons and
single intron is shown at the top of the panel. This figure shows the amplicon sequence obtained using primers
that target the whole IFITM1 gene (Figure 3.5 A II). Identification of intron loss after cloning the PCR amplified
IFITM1 DNA into a vector and then sequencing individual plasmids for the type of gene edit. Highlighted in
red is the absent region corresponding to the single intron present in IFITM1 gene. Not a single mismatch was
identified for the rest of the sequence analysed. (*) indicates sgRNA recognition site.
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To test for abnormalities of the IFITM3 gene, the designed forward primer was 5’ -
AGCCCCTCTTTCCTCCCT- 3’ and the reverse primer was 5’ -TCACGGAGTAGGCGAATG-
3’ (Figure 3.5 B-I). After PCR amplification, 2% agarose gel electrophoretic separation, ex-
cision of the band, extraction of its DNA, and sequencing, some indels surrounding the
PAM sequence in IFITM3 gene were identified (Figure 3.9 B). Interestingly, the sequenced
amplicon was free of signal noise due to overlapping peaks, suggesting that both alleles
had the same indel pattern. Predicted amino acid sequence from the DNA sequence ob-
tained indicates ablation of IFITM3 protein expression (Figure 3.9 C).
Figure 3.9: Validation of IFITM3 knock out following CRISPR/Cas9 engineering of potential
IFITM1/IFITM3 double null cells by sequencing. (A) Gene structure of the IFITM3 gene highlighting
its two coding exons and one intron. (B) PCR amplification and DNA sequencing of wild type IFITM3 gene
following CRISPR/Cas9 engineering that targets exon 1 sequence of 512 bp surrounding the sgRNA target
sequence. Representation of the wt-SiHa cell sequence and the IFITM1/IFITM3 double null sequence
alignment, with the sgRNA sequence indicated in red and wild type sequence in black font. Identification
of the homozygous IFITM3 indels after cloning the PCR amplified IFITM3 DNA into a vector and then
sequencing individual plasmids for the identification of gene edit. The IFITM3 gene has two insertions that
result in a poly-proline frame-shift introducing a premature stop codon (bottom strand in red font). (C)
Predicted amino acid sequence obtained from the ExPAsy translate tool shows a truncated protein with
insertion of prolines and alternative amino acid residues changes; as a result, full-lenght IFITM3 protein is
not predicted to be expressed.
During the course of this research, IFITM3 null cells were generated using
CRISPR/Cas9 genome editing in a similar way. IFITM3 null cells were generated for
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the purpose of resolving any findings obtained with IFITM1/IFITM3 double null cells.
We wished to identify which effects are seen for IFITM1 and IFITM3 knock out alone
or due to a combination of IFITM1/IFITM3 knock out. Generation of IFITM3 null
by CRIPSR/Cas9 technology took several attempts. Finally, we obtained clones that
were tested by amplifying and sequencing the IFITM3 gene. The designed forward
primer was 5’ -GATTGGTACCATGAATCACACTGTCCAAACC- 3’ and the reverse primer 5’ -
CGATGAATTCCTACTATCCATAGGCCTGGAAGAT- 3’ (Figure 3.5 B II). Recognitions sites for
KpnI and EcoRI restriction enzymes were included in the primers to facilitate cloning. As
previously mentioned, PCR amplicons were run in 2% agarose gel electrophoresis, excised,
and cloned into a vector (subsection 2.5.5 and subsection 2.5.7). In this case, the IFITM3
gene has a single 7 bp deletion (Figure 3.10 B) that leads to a premature stop codon and
consequent loss of expression of the full-length IFITM3 protein (Figure 3.10 C).
Figure 3.10: Validation of knock out of IFITM3 in potential engineered IFITM3 null cells by DNA sequenc-
ing. (A) Gene structure of the IFITM3 gene highlighting its two coding exons and one intron. (B) PCR ampli-
fication of genomic IFITM3 that targets exon 1 sequence of 0.97 kb surrounding sgRNA recognition site (indi-
cated in the wild type strand in red font). Identification of a 7 bp deletion (indicated with a black arrowhead
chevron) in IFITM3 after cloning the PCR amplified IFITM3 gene into a vector and then sequencing individual
plasmids for the type of gene edit. The IFITM3 gene has a single deletion that results in a frame-shift creating
a premature stop codon (bottom strand in red font). (C) Predicted amino acid sequence obtained from the
ExPAsy translate tool shows a truncated protein with a single deletion and alternative amino acid changes. As
a result, expression of normal IFITM3 protein is predicted to be ablated.
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3.4.2 Validation of IFITM1 null cells, IFITM3 null cells, and IFITM1/IFITM3
double null cells by Western blot analysis
The gene edits were confirmed by DNA sequencing, however it had to be determined
whether they were functionally null or expressed as truncated protein. A panel of com-
mercial antibodies produced to specifically bind to IFITM1 or IFITM3 were tested. How-
ever, robust antibodies that distinguish between IFITM1, IFITM2 and IFITM3 were not
available at the time. For that reason, monoclonal antibodies were generated in-house
against IFITM1 protein (Moravian Biotechnologies). A previous alanine scanning per-
formed by Dr. Elisabeth Sinclair revealed that the VLGxP motif at the N-terminus of IFITM1
showed high binding towards one representative monoclonal antibody (data not shown).
Nonetheless, the amino acidic motif is shared between IFITM1 and IFITM3, but not with
IFITM2 (Gomez Herranz et al., 2019). For accuracy, as a result of this cross-reaction be-
tween IFITM1 and IFITM3, it is stated throughout this thesis that this monoclonal anti-
body recognizes IFITM1/IFITM3 proteins.
To confirm total absence of IFITM1, IFITM3 or IFITM1/IFITM3 protein expression,
cells were stimulated with IFNγ to induce their expression. Previous studies performed in
vitro have used variable concentration of IFNγ to stimulate cells; 100 U/ml IFNγ are used
in some studies (Bernabei et al., 2001; Croitoru-Lamoury et al., 2011), but other studies
have used a higher dose (Costa-Pereira et al., 2002; Garbe et al., 1990; Gorbacheva et al.,
2002; Ha et al., 2008). To determine the appropriate dose an IFNγ dose titration (from
0–100 ng/ml) corresponding to an upper range dosage was evaluated (Appendix A, Fig-
ure A.3 A). A concentration of 100 ng/ml of IFNγ was selected for further experiments.
In addition, a time course (0, 4, 6, 24, 48, and 72 hours) with 100 ng/ml of IFNγ was
performed, and 24 hours was selected as the optimal time point to use in these experi-
ments. Higher levels of IFITM1/IFITM3 protein induction are observed at 24 hours. (Ap-
pendix A,Figure A.3 B). It was decided to stimulate SiHa cells with a higher dose of IFNγ
to ensure that any cellular dysfunctions would be more obvious in the absence of IFITM1
(IFITM1 null cells), IFITM3 (IFITM3 null cells), and IFITM1/IFITM3 (IFITM1/IFITM3 dou-
ble null cells) as a result of a dominant effect of these proteins and that IFNγ signalling will
not be able to mask their effects (Cheon & Stark, 2009; Khodarev et al., 2007).
The CRISPR guide RNA was designed to target unique regions in IFITM1 or IFITM3
genes. As such, there is no reason to expect additional knock out of the IFITM3 in
IFITM1 null cells or of IFITM1 in IFITM3 null cells. Comparing signal produced by
IFITM1/IFITM3-specific monoclonal antibody, endogenous IFITM1 (in IFITM3 null) and
IFITM3 (in IFITM1 null) proteins can be observed in Western blots from gene edited cells
(Figure 3.11 A, lanes 3 and 4, and Figure 3.11 E, lanes 11 and 12). However, neither IFITM1
nor IFITM3 was detected in IFITM1/IFITM3 double null cells (Figure 3.11 A, lanes 5 and
6). While performing this study, commercial antibodies that specifically bind to IFITM1,
IFITM2 and IFITM3 were found (Figure 3.11 B-D and Figure 3.11 E, lanes 1-9). Nonethe-
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less, the suppliers did not specify to which epitopes these antibodies bind. It is of relevance
to highlight that all three protein isoforms are highly homologous and so production of
isoform-specific antibodies is complicated.
As expected, IFITM1/IFITM3 antibody was able to detect both IFITM1 and IFITM3
(Figure 3.11 A, lane 1-4). The wt-SiHa cell line exhibits a diffused band around the pre-
dicted molecular weight (15 KDa) that is intensified after IFNγ stimulation. Both IFITM1
(Figure 3.11 B, lanes 1-2) and IFITM3 (Figure 3.11 D, lanes 1-4) may have posttranslational
modifications or may form dimers, they are manifested by the upper band running at a
higher position than its theoretical molecular weight. Comparing IFITM1/IFITM3 anti-
body detection with IFITM1- and IFITM3-specific antibodies (Figure 3.11 A and E, lanes
10-12 vs B-D and E, lanes 1-9), it is clear that IFITM1 has increased posttranslational mod-
ification after IFNγ stimulation, whereas IFITM3 does not. This suggests that IFITM1 is
the main isoform that is IFNγ inducible.
Additionally, we determined the IFITM2 status in this SiHa cell model panel. Impor-
tantly, IFITM2 is highly homologous with IFITM3, sharing 87% of its amino acid sequence,
suggesting that they could have redundant cellular roles. IFITM2 was found not expressed,
or was below the limit of detection, in the SiHa cell panel, both endogenously and after
IFNγ induction (Figure 3.11 C). It was considered the possibility that the IFITM2-specific
antibody may not be sufficiently sensitive, or had other technical problems, as an IFITM2
band was detected when used in other assays (data not shown).
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Figure 3.11: IFITM1, IFITM2 and IFITM3 induction by IFNγ in the SiHa cervical cancer cell model panel.
IFITM family proteins (approximately 15 KDa) were detected in wt-SiHa cells, IFITM1 null cells, IFITM3 null
cells, and IFITM1/IFITM3 double null cells using antibodies against; IFITM1/IFITM3 (A), IFITM1 (B), IFITM2
(C), and IFITM3 (D). SiHa cell model panel was composed of; wt-SiHa cells stimulated with IFNγ (lane 1),
wt-SiHa cells non-stimulated (lane 2), IFITM1 null cells stimulated with IFNγ (lane 3), IFITM1 null cells non-
stimulated (lane 4), IFITM1/IFITM3 double null cells stimulated with IFNγ (lane 5) and IFITM1/IFITM3 dou-
ble null cells non-stimulated (lane 6). (E) IFITM family proteins were detected in IFITM3 null using antibodies
against; IFITM1 (lane 1-3), IFITM2 (lane 4-6), IFITM3 (lane 7-9), and IFITM1/IFITM3 (lane 10-12). Cells were
non-stimulated (lanes 2, 5, 8, and 11) or stimulated with IFNγ (lanes 3, 6, 9, and 12). Wt-SiHa stimulated with
IFNγ was used as positive control (lanes 1, 4, 7, and 10). Protein induction was tested by comparing endoge-
nous levels with 100 ng/ml IFNγ stimulation for 24 hours. β-ACTIN (approximately 35 KDa) was used as a
loading control.
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3.4.3 Testing specificity of anti-IFITM1/IFITM3, IFITM1, and IFITM3 antibod-
ies by immunofluorescence and characterization of cellular localization
of IFITM1, and IFITM3 proteins in the SiHa cell model panel
After validating ablation of IFITM1, IFITM3, and IFITM1/IFITM3 genes in the respec-
tive isogenic SiHa cells by Sanger sequencing and Western blotting, protein expression
was additionally assayed using immunofluorescence (Figure 3.12, Figure 3.13, Figure 3.14,
and Figure 3.15). As stated previously, there are not many suitable IFITM antibodies avail-
able commercially. For that reason, antibodies used in Western blotting (IFITM1/IFITM3,
IFITM1, and IFITM3) were also tested by immunofluorescence as they were proven to be
IFITM isoform specific. The IFITM2 antibody was not included as SiHa cells do not express
this isoform (Figure 3.11 C and E, lanes 4-6) and it is beyond the focus of this study. Con-
trol conditions consisting of staining with secondary antibody only (in absence of primary
antibody) were included to determine the background fluorescence signal (Figure 3.12,
Figure 3.13, Figure 3.14, Figure 3.14; A and F).
This immunofluorescence assay is used to evaluate the endogenous production of
IFITM1 and IFITM3 proteins (independently by anti-IFITM1 or IFITM3 specific antibodies
or in combination with anti-IFITM1/IFITM3 antibody). IFITM1 and IFITM3 are detected
in wt-SiHa cells, with an increase in their expression after IFNγ stimulation (Figure 3.12 B
vs C). Both IFITM1 and IFITM3 are present in a perinuclear location after IFNγ stimula-
tion (Figure 3.12 C). This feature is also observed in IFITM1 null cells (Figure 3.13 C) and
IFITM3 null cells (Figure 3.15 C), but the intensity is attenuated in these cells as IFITM1 or
IFITM3, respectively, has been knocked out.
IFITM3 protein is also induced after IFNγ stimulation in wt-SiHa (Figure 3.12 H vs I)
and, in an attenuated pattern in IFITM1 null cells (Figure 3.13 H vs I). Interestingly, IFITM3
shows a more punctate pattern across the cytosol, that may correlate with vesicles as de-
scribed by Amini-Bavil-Olyaee et al. (Amini-Bavil-Olyaee et al., 2013). Moreover, it is neg-
ative in IFITM3 null cells (Figure 3.15 H and I).
IFITM1 antibody shows a low staining by immunofluorescence, slightly intensified af-
ter stimulating the cells with IFNγ in wt-SiHa and IFITM3 null cells (Figure 3.12 and Fig-
ure 3.15, E and F). The intensity observed in non-stimulated IFITM3 null cells is similar to
the background in IFITM1 null and IFITM1/IFITM3 double null cells (Figure 3.15 E vs Fig-
ure 3.13 E and Figure 3.14 E). Moreover, IFITM1/IFITM3 double null cells are negative for
both proteins using all three antibodies. This provides additional evidence that this cell
line is unable to produce either IFITM1 or IFITM3 proteins even after IFNγ stimulation
(Figure 3.14).
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Figure 3.12: Study of IFITM1 and IFITM3 cellular distribution in wt-SiHa cells. Wt-SiHa cells were grown
to 80% confluency and fixed with 4% (w/v) paraformaldehyde, permeabilised using 0.25% Triton X-100 and
blocked with 3% (w/v) BSA. (A) Control immunofluorescence staining with anti-mouse Alexa Fluor 594 sec-
ondary antibody (Invitrogen). Immunofluorescence detecting IFITM1/IFITM3 protein (1:4000 dilution of
IFITM1/IFITM3 antibody) in non-stimulated cells (B) or IFNγ-stimulated cells for 24 hours (C). Immunofluo-
rescence detecting IFITM1 protein (1:1000 dilution of IFITM1 antibody) in non-stimulated cells (D) or IFNγ-
stimulated cells for 24 hours (E). (F) Control immunofluorescence staining with anti-rabbit Alexa Fluor 488
secondary antibody (Invitrogen). Immunofluorescence detecting IFITM3 protein (1:1000 dilution of IFITM3
antibody) in non-stimulated cells (G) or IFNγ-stimulated cells for 24 hours (H). Scale bar= 10 µm.
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Figure 3.13: Study of IFITM1 and IFITM3 cellular distribution in IFITM1 null cells. IFITM1 null cells were
grown to 80% confluency and fixed with 4% (w/v) paraformaldehyde, permeabilised using 0.25% Triton X-100
and blocked with 3% (w/v) BSA. (A) Control immunofluorescence staining with anti-mouse Alexa Fluor 594
secondary antibody (Invitrogen). Immunofluorescence detecting IFITM1/IFITM3 protein (1:4000 dilution of
IFITM1/IFITM3 antibody) in non-stimulated cells (B) or IFNγ-stimulated cells for 24 hours (C). Immunofluo-
rescence detecting IFITM1 protein (1:1000 dilution of IFITM1 antibody) in non-stimulated cells (D) or IFNγ-
stimulated cells for 24 hours (E). (F) Control immunofluorescene staining with anti-rabbit Alexa Fluor 488
secondary antibody (Invitrogen). Immunofluorescence detecting IFITM3 protein (1:1000 dilution of IFITM3
antibody) in non-stimulated cells (G) or IFNγ-stimulated cells for 24 hours (H). Scale bar= 10 µm.
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Figure 3.14: Study of IFITM1 and IFITM3 cellular distribution in IFITM1/IFITM3 double null cells.
IFITM1/IFITM3 null cells were grown to 80% confluency and fixed with 4% (w/v) paraformaldehyde, per-
meabilised using 0.25% Triton X-100 and blocked with 3% (w/v) BSA. (A) Control immunofluorescence
staining with anti-mouse Alexa Fluor 594 secondary antibody (Invitrogen). Immunofluorescence detecting
IFITM1/IFITM3 protein (1:4000 dilution of IFITM1/IFITM3 antibody) in non-stimulated cells (B) or IFNγ-
stimulated cells for 24 hours (C). Immunofluorescence detecting IFITM1 protein (1:1000 dilution of IFITM1
antibody) in non-stimulated cells (D) or IFNγ-stimulated cells for 24 hours (E). (F) Control immunofluores-
cence staining with anti-rabbit Alexa Fluor 488 secondary antibody (Invitrogen). Immunofluorescence de-
tecting IFITM3 protein (1:1000 dilution of IFITM3 antibody) in non-stimulated cells (G) or IFNγ-stimulated
cells for 24 hours (H). Scale bar= 10 µm.
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Figure 3.15: Study of IFITM1 and IFITM3 cellular distribution in IFITM3 null cells. IFITM3 null cells were
grown to 80% confluency and fixed with 4% (w/v) paraformaldehyde, permeabilised using 0.25% Triton X-100
and blocked with 3% (w/v) BSA. (A) Control immunofluorescence staining with anti-mouse Alexa Fluor 594
secondary antibody (Invitrogen). Immunofluorescence detecting IFITM1/IFITM3 protein (1:4000 dilution of
IFITM1/IFITM3 antibody) in non-stimulated cells (B) or IFNγ-stimulated cells for 24 hours (C). Immunofluo-
rescence detecting IFITM1 protein (1:1000 dilution of IFITM1 antibody) in non-stimulated cells (D) or IFNγ-
stimulated cells for 24 hours (E). (F) Control immunofluorescence staining with anti-rabbit Alexa Fluor 488
secondary antibody (Invitrogen). Immunofluorescence detecting IFITM3 protein (1:1000 dilution of IFITM3
antibody) in non-stimulated cells (G) or IFNγ-stimulated cells for 24 hours (H). Scale bar= 10 µm.
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3.5 Discussion
Initially, work published by Bouchal et al. inspired the present study on the cellular role
of IFITM1 and its implications in cancer (Bouchal et al., 2009). Bouchal et al. study aimed
to discover novel biomarkers for breast cancer. Tissue biopsies from low-grade breast pri-
mary tumours in the presence and absence of metastases, along with lymph node metas-
tasis samples, were compared to non-metastatic tumour. MS was employed to identify
potential protein candidates related to the metastatic process. Among the short-listed pro-
teins presented, IFITM1 was the only cell membrane receptor. Its druggable potential and
its potential for developing other tools for diagnosis made IFITM1 an exceptional protein
candidate to study (Andreu et al., 2006; Bouchal et al., 2009; Fumoto et al., 2008). Addi-
tional work performed in our group supported the idea that IFITM1 could be a potential
biomarker for cancer.
We expanded the knowledge on IFITM1 by genetically modifying SiHa cells to ablate
IFITM1 and/or IFITM3 genes to successfully produce IFITM1 null cells, IFITM1/IFITM3
double null cells, and IFITM3 null cells. The IFITM1/IFITM3 double null cells created a cell
model that removed any redundancy of IFITM3 in the IFITM1–IFNγ interaction landscape.
Apart from removing possible synergy between IFITM1 and IFITM3, this is of particular
importance as IFITM3 is highly homologous to IFITM1 and this also eliminates antibody
cross-reactivity between IFITM1 and IFITM3.
The key approach used to evaluate the role of IFITM1 in IFNγ-dependent protein pro-
duction was the utilization of RNA-guided CRISPR/Cas9 system to create isogenic null
cells. We relied less on the use of siRNA since this would only give a transient (and often
incomplete) reduction of a target protein, but also siRNA itself can induce IFN response
(Huerfano et al., 2013). This would have complicated the analysis of the IFN-responsive
nature of any IFITM1 protein interactions to be visualized and measured. In turn, the limi-
tation of using gene knock out tools to reduce or eliminate expression of a protein requires
that loss of the protein(s) is not lethal. In this regard, lethality is related to those protein(s)
that play a central role in many cellular networks and thus their knock out compromises
cell survival (Jeong et al., 2001). Ifitm1 and Ifitm3 knock out mice are reported to be vi-
able, and mice with the entire IFITM chromosomal locus deleted are also viable (Bailey
et al., 2012). Thus, it was not unexpected to be able to generate a panel of IFITM1 null,
IFITM1/IFITM3 double null, and IFITM3 null -SiHa cells. We confirmed the loss of IFITM1
and IFITM3 at the protein level by Western blot analysis (subsection 3.4.2) and immunoflu-
orescence (subsection 3.4.3). Additionally, genetic ablation of IFITM1 and/or IFITM3 was
assessed by sequencing the genetic region where the CRISPR/Cas9 system produced the
indel mutations (subsection 3.4.1).
IFITM1 null cells produced a heterozygotic IFITM1 mutation after the DSB repair: one
single nucleotide insertion for one allele and one single nucleotide deletion in the other
(Figure 3.6). The first amino acids in the N-terminal region of IFITM1 (in IFITM1 null cells)
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are not mutated and no premature stop codon has been found in this region. However, the
IFITM1-antibody is not able to recognize this fragment by Western blotting. This suggests
that IFITM1, if induced, is being degraded as there is no protein production found on the
immunoblot (Figure 3.11 A and B). Likewise, two major insertions and minor mutations
were identified for the IFITM3 gene (Figure 3.9) in IFITM1/IFITM3 double null cells that
depleted IFITM3 protein expression (Figure 3.11 A and D). After several attempts, IFITM3
null cells were validated with a single 7 bp deletion that produced IFITM3 ablation (Fig-
ure 3.10).
Albeit far less frequently, CRISPR/Cas9 system can induce large genomic deletions
implicated in large cassette-unit skipping. A representative example is intron deletion
in IFITM1 of IFITM1/IFITM3 double null cells (Figure 3.8 and Figure 3.7 B). Moreover, it
has been reported that CRISPR/Cas9 can mediate genetic aberrations associated with al-
ternative splicing. Thus, this type of genomic lesion may generate modifications in the
recognition site for splicing, creating alternative transcripts as a collateral effect (Mou et
al., 2017). This may relate to whether repair machinery is associated with splicing regu-
lation. In fact, alternative functions of splicing factors include protecting the integrity of
the genome by actively cooperating with DNA repair proteins to correct genetic lesions
(Naro et al., 2015; Shin et al., 2007). In return, RNA splicing machinery is also influenced
by deleterious genotoxic stress and when this is severe it may lead to aberrant transcript
production (Wickramasinghe & Venkitaraman, 2016).
In addition, it remains unexplored how NHEJ repair machinery fixes DSB. The premise
is that NHEJ functions randomly and so DNA repair does not follow any specific pattern.
Nonetheless, emerging studies suggest the opposite where NHEJ mediates DNA repair in a
non-arbitrary way (Van Overbeek et al., 2016). To support this evidence, we identified the
exact same intron deletion in IFITM1 null-OE33 cells, another CRISPR/Cas9 engineered
cell line using the same sgRNA (data not shown). Both cell lines, SiHa and OE33, have
different origins and so it suggests that the repairing pattern is something fundamental
and not cell-type specific. Furthermore, there was a different indel produced for IFITM1
null cells and, it implies that there is not a unique indel produced for each sgRNA. In fact,
even though observed in few events, our results fit with Van Overbeek et al. investigation
where there is a consistent group of indels found across different cell lines tested (Van
Overbeek et al., 2016). As in OE33-IFITM1 isogenic null cells (data not shown), disruption
of the intron causes total inactivation of IFITM1 in IFITM1/IFITM3 double null-SiHa cells
and consequently there is a complete depletion of protein expression. Seeing depletion of
protein production by intron deletion, even only twice, made the finding more plausible.
Moreover, the relevance of intronic sequences linked to transcription regulation has been
reported previously. Loss of intron may interfere with mRNA production and processing
and it will ultimately impact on protein expression levels (Buchman & Berg, 1988; Chung
& Perry, 1989). Splicing is also modulated by the transcription machinery. For example,
RNA Polymerase II and promotor structure associate and regulate spliceosomes (Cramer
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et al., 1999; Hicks et al., 2006; Mortillaro et al., 1996). All three processes, including DNA
repair, are interplay almost simultaneously (Cramer et al., 1999; Muñoz et al., 2009).
In summary, based on this empirical work we provide evidence in relation to intron-
dependencies coupled to transcription of IFITM1. Even though this issue is not one of the
key focus of this study, these results suggest that IFITM1 expression is influenced by its
intronic region.
After validation of CRISPR/Cas9 gene edited SiHa cell model panel, IFITM1 and/or
IFITM3 protein expression in null isogenic cell models was characterized. Initially, our in-
terest was to study the cellular role of the oncogenic receptor IFITM1, but we also wanted
to investigate the synergetic effects between IFITM1 and IFITM3. For this purpose, the
anti-IFITM1/IFITM3 in-house antibody (Moravian Biotechnology), capable of recogniz-
ing both isoforms, was developed. Its binding domain binds to IFITM1 and IFITM3 but
not to IFITM2 (Figure 3.11 A and E). Additionally, specific anti-IFITM1/2/3 antibodies were
also used for clone validation (Figure 3.11 B-E). As seen in Figure 3.1, clinical data derived
from women with cervical cancer have a wide range of IFITM1/IFITM3 expression levels,
from totally absent signal to strong immunostaining. SiHa cells were chosen as a cervical
cancer model for this study as they present high IFITM1 and IFITM3 endogenous levels
compared with other cell lines, and they are induced upon IFNγ stimulation. Our results
show endogenous detection of IFITM1 and elevated posttranslational modification or pos-
sible dimerazation in the presence of IFNγ (Figure 3.11 A and B, upper bands in lanes 1 and
2). Besides, IFITM1 is induced by IFNγ (Figure 3.11 B, lane 1 vs 2). By contrast, IFITM3 is
not as responsive to IFNγ stimulation (Figure 3.11 D, lane 1 vs 2) (Lau et al., 2012).
Immunofluorescence assays validated total loss of IFITM1/IFITM3 expression in
IFITM1/IFITM3 double null cells, and absence of IFITM1 or IFITM3 in IFITM1 null cells
and IFITM3 null cells, respectively. The subcellular localization of IFITMs is still under
debate. Initially, IFITM1 was described at the cell surface, promoting aggregation of T-
cells (Chen et al., 1984). Nevertheless, 4% paraformaldehyde fixation for immunofluores-
cence was not able to show much cell membrane staining. Cell membrane staining was
more clear when fixed by the methanol:acetone method (data not shown). However, other
studies have found evidence of subcellular distribution of IFITM proteins in cytoplasmic
endolysosomal vesicles (Amini-Bavil-Olyaee et al., 2013; Feeley et al., 2011; Huang et al.,
2011). This could correlate with the punctuate distribution pattern seen for IFITM3, and
substantial perinuclear distribution of IFITM1/IFITM3 after IFNγ stimulation (Figure 3.12
and Figure 3.13; C and I).
Several clones for each null cell type were tested for validation. A single representative
clone was selected for IFITM1 null cells, IFITM3 null cells, and IFITM1/IFITM3 double null
cells. We are aware that some features could be produced due to clonal effects and so we
performed preliminary assays to confirm that our chosen clones behave similarly to the
parental cells. Here, some evidence is provided suggesting that isogenic SiHa cell mod-
els have the expected phenotype and do not exhibit off-target effects. Firstly, IFITM1 null
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clones were subjected to chemotherapy by cisplatin and X-ray treatment and the selected
clone showed chemosensitivity, along with other clones (data not shown). The chemosen-
sitivity experiments were kindly performed by Dr. Marta Nekulova and Miss Erisa Nita,
respectively. This outcome resembles the results obtained with cellular sensitivity stud-
ies upon 5-fluorouracil and cis-platinum treatment in depletion of IFITIM1 or in patients
diagnosed with oesophageal squamous cancer cell carcinoma (Fumoto et al., 2008).
Moreover, we compared our experiments (described in upcoming chapters) with the
signature of proteins found downregulated after depletion of IFITM1 using an siRNA ap-
proach (Figure 3.2) where several IRDS protein levels decreased. Additionally, we looked
for internal controls such as STAT1 (upstream effector of IFITM1 and IFITM3 in the IFNγ
signalling pathway) that were independent of the IFITM1 effect while some downstream
effectors, such as MHC class I and ISG15 among others, were altered (Figure 5.9). Addi-
tionally, IFITM1/IFITM3 double null cells presented a much deeper dysregulation of the
target proteins suggesting that IFITM3 is implicated and its absence produces a more aber-
rant IFNγ signature. Finally, another knock out panel of IFITM1 null, IFITM3 null and
IFITM1/IFITM3 double null cells was generated by CRIPR/Cas9 technology using A549
cells, a human lung carcinoma cell model. Preliminary results using these null cell lines
resembled those obtained with the SiHa cell model (data not shown).
Besides these, several efforts were made to rescue the wild type phenotype by comple-
mentation, creating stable cell lines by integration of transfected IFITM1 and/or IFITM3
expressing constructs in the null cells. Firstly, untagged IFITM1 and/or IFITM3 were trans-
fected and selected by drug resistance, using neomycin and zeocin markers, respectively.
As IFITM1/IFITM3 double null cells had to be complemented with two different constructs
it was important to use vectors with different antibiotic resistance. Unfortunately, untrans-
fected cells were also resistant to both drugs, even at high concentration (much higher than
the manufacturer’s recommendation). Consequently, it was not possible to select poten-
tial candidate clones. As a second approach, IFITM1-GFP tagged was transfected. In this
case, cells were FACS sorted after being transfected for 10 days to increase number of cells
expressing GFP by stable integration. Single cells were sorted in 96-well plates and grown
in sequentially bigger plates. In the end, only 4 clones grew but none of them had inte-
grated IFITM1 construct. It is difficult to provide direct evidence to support the idea that
CRISPR/Cas9 epigenetic change does not allow addition back of deleted genes, but by this
experimental approach it has not been possible to integrate either IFITM1 or IFITM3 vec-
tors. Nonetheless, alternative methods will be engineered to validate the cellular effects of
IFITM1/IFITM3 proteins.
Taking everything together, this chapter describes the construction and validation of
cervical cancer cell models that are suitable for study of IFITM1/IFITM3 signalling in IFNγ
landscape. This SiHa cell model panel will be used as a tool to study IFITM1/IFITM3 onco-





4.1.1 Interacting partners identified for IFITM1
The IFITM family of proteins have roles in oncogenic cell homeostasis. IFTM1, in par-
ticular, has pro-metastatic as well as pro-oncogenic implications. It is the only IFITM fam-
ily member with a potential extracellular role due to its partial residence outside of the
plasma membrane (Weston et al., 2014). The molecular functions of IFITM1 are largely
undefined and not many interacting partners have been identified so far. In this chapter,
we begin to set up assays that identify IFITM1 binding proteins in a cervical cancer cell
model in order to understand possible dominant protein–protein interactions that might
be involved in IFITM1 signalling, and to identify how it can impact on signal transduction
in cancer cells.
The IFITM protein family was identified in whole genome siRNA screens as having a
dominant role as RNA virus restriction factors (Brass et al., 2009). Additionally, a yeast two-
hybrid screen, with IFITM3 as a bait, identified new protein–protein interactions within
the IFITM family. IFITM3 was found identified to interact with the vesicle membrane
protein associated protein A (VAPA). It was not possible to distinguish between IFITM3
to IFITM1 or to IFITM2 isoforms in this assay. Despite this, the study focused on defin-
ing how VAPA interaction with IFITM3 results in reduction of VAPA binding to oxysterol-
binding protein (OSBP), disrupting cholesterol homeostasis and preventing viral matura-
tion. As IFITM1 and IFITM2 are also reported to bind to VAPA, it is not yet clear whether
they play minor and/or redundant roles in controlling cholesterol-mediated viral matura-
tion (Amini-Bavil-Olyaee et al., 2013).
Prior to that discovery, IFITM1, known at the time as leukocyte antigen Leu-13 (Deb-
landre et al., 1995), was characterized as a component of a cell surface complex. Another
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component identified was TAPA-1, also known as CD81, which closely relates to ME491
and CD37 proteins. Collectively, these are involved in homotypic cell adhesion in leuko-
cytes and growth arrest (Takahashi et al., 1990). In this respect, an independent study
found CD19, TAPA-1, CD21, and IFITM1 forming a complex in B cells (Matsumoto et al.,
1993).
Another study described in B lymphocytes involves IFITM1 in cell-to-cell homotypic
adhesion (Evans et al., 1993; Evans et al., 1990). This role is dependent on IFNα stimulation
and not significantly related to IFNγ. As a result, it causes aggregation of B lymphocytes in
Daudi B lymphoid cells as well as in peripheral blood. IFNα significantly increases IFITM1
expression but does not induce other adhesion-related molecules such as LFA-1, ICAM-1,
VLA-4 and CD44. It was also tested whether other cytokines are involved in this process,
but IL-2, IL-6, and TNF-α showed no effect on stimulating IFITM1 production (Evans et
al., 1993; Evans et al., 1990). This finding is also supported by Bradbury et al. (Bradbury
et al., 1992).
Moreover, IFITM1 has been associated with caveolin 1 (CAV1) which is implicated in
cell proliferation and migration processes. A study of 229 colorectal cancer tissues from
human patients identified an inverse correlation between IFITM1 and CAV1 (Novita Sari
et al., 2016). This was further supported by another study that found IFITM1 suppresses
CAV1 to facilitate metastasis in colorectal cancer and this event is also a key components
in the epithelial mesenchymal transition. Additionally, depletion of IFITM1 rescues CAV1
levels, inhibiting the migration process (Yu et al., 2015).
To the best of our knowledge, these are the major interacting partners described on
IFITM1 but we suspect that other proteins are implicated in IFITM1 cellular functions.
MS methodologies were used to discover novel protein binders.
4.1.2 Mass spectrometry
Proteins govern most cellular events. They do not tend to function in isolation, in-
stead they form complexes, making cellular processes even more complicated to analyse.
In addition, the proteome is very dynamic; it varies between spatial (i.e. cell type) and
temporal (i.e. time point or stimulus response) conditions. The described proteins above
are the most well characterized IFITM1 interacting partners, but considering the few pro-
teins identified, one can suspect that most of IFITM1 interactome is still to be discovered.
Trying to define a novel protein interaction presents a great challenge. To simplify our sys-
tem, our focus was to characterize IFITM1 protein–protein dominant interactions after
IFNγ stimulation to enrich IFITM1 expression in a cervical cancer cell model.
Sample preparation is essential to obtain a desirable MS analysis and consequent pro-
tein identification. After lysis, analytes are subjected to filter aided sample preparation
(FASP). This step removes any contaminants (i.e. sodium dodecyl sulphate, other deter-
gents), denaturant or incompatible species (i.e. salts and lipids, among others). The pur-
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pose is to purify proteins to obtain high peptide quality. In brief, the process followed in-
cludes reduction, alkylation and tryptic digestion of proteins and was performed in a spin
filter column (Manza et al., 2005). FASP method has been considerably improved but it
still has a relatively poor peptide recovery, implying the loss of proteins during the process
(Hernandez-Valladares et al., 2016). This presents a substantial limitation as consequently
not all the proteins contained in the mixture will be subjected to the MS analysis. In that
sense, the non-identification of a specific protein does not necessarily mean that the pro-
tein was not in the protein mixture.
Prior to MS analysis, the protein mixture was incubated with trypsin to generate pep-
tides. We relied on the capacity of trypsin to produce similar amounts of tryptic peptides
in relation to protein abundance. Breaking down proteins facilitates the study of insoluble
membrane proteins, such as IFITM1, as it increases protein solubility. Therefore, peptides
are easily ionized to produce precursor ions. Many peptide species from the same protein
will be produced and they will be discriminated according to their mass-to-charge ratios
(m/z). They will be sorted depending on their mass into separated ion peaks. It is assumed
that trypsin will equally dissociate proteins by proteolysis throughout the protein mixture
but, nevertheless, intrinsic characteristics of certain peptides could make some proteins
less disposed to be trypsinized and, consequently, poorly detected by MS.
MS is a technique widely used for the study of the proteome and it allows the identifica-
tion and quantification of proteins in a complex analyte. MS instruments consist of three
different parts: an ionization chamber, a mass analyser and an ion detector. After pep-
tides are produced and separated by liquid chromatography, they are coupled to tandem
mass spectrometry (MS/MS) which is a combination of two mass spectrometers. Firstly,
a set of ions of interest, called precursor ions (MS1), are specifically chosen and further
fragmentated into product ions (MS2). As such, MS2 is a selection of a particular peak
(each corresponding to a peptide) from MS1. It is a multistep process comprised of selec-
tion, fragmentation and detection of the ion (Niessen, 1999). Several types of MS analysers
have been developed, those used in the present study are the Orbitrap and SWATH, which
will be described in more detail in the upcoming sections.
The assignment of MS/MS spectra is obtained by the optimal match between a theo-
retical peptide spectrum and the empirical peptide spectrum. A theoretical spectrum is
obtained from online available data sets that use algorithms to predict the peptide spec-
trum. The empirical peptide spectrum is obtained after in the MS/MS analysis. Therefore,
peptide identification is limited by finding an exactly-matching empirical peptide in one
of the theoretical peptide libraries and matching this peptide to a unique protein. In this
circumstance, an additional limitation is presented: not only it is extremely complicated
to determine the sequence of the peptide but also to assign that sequence to a unique
protein. Even though MS technology has profoundly evolved in the last years, the average
protein coverage remains low. This aspect greatly impacts on the protein identification
confidence and on the overall reliability of the analysis (Huang et al., 2012; Meyer et al.,
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2011). Even so, MS is a powerful tool with tremendous potential to identify new IFITM1
interacting proteins. To overcome the limitations described above, candidate binding pro-
teins will be further validated by alternative biological assays.
4.1.3 Orbitrap-MS
Orbitrap is a modification of Kingdom trap, an ion trap analyser from 1923 (Kingdom,
1923). Traditional ion trap mass analysers had limited mass accuracy and reduced charge
capacity. The Orbitrap mass analyser can deal with analysis of heavy and multiply-charged
molecules (Figure 4.1). It consists of an outer barrel-like electrode and a central spindle-
like electrode. Injected ions cycle in the space between electrodes, around the central
electrode and at the same time oscillate along the horizontal axis (Perry et al., 2008). The
principle of the orbital mass analyser is based on the orbital trapping of ions. A positively
charged ion of a particular mass (m) and charge (z) is introduced inside the analyser with
an initial velocity perpendicular to the orbital trapping. The difference of potential be-
tween the central electrode and the outer electrode will promote an ion rotation around
the central electrode. The ion will achieve an axial frequency independent of inherited
properties used to calculate the m/z ratio, producing more accurate mass measurement
and giving higher resolution. In order to be able to measure a wider mass range, ions
are subjected to an electrodynamic squeezing produced by a monotonic electric field in-
creased when ions enter the orbitrap chamber. Once ions rotate in harmonic oscillation,
the voltage is kept constant to avoid possible mass changes during detection (Makarov,
2000).
To ionize the peptides in our experiments, the MS is equipped with an electrospray ion-
ization source (ESI). Ions are then transferred to quadrupole chamber where the pressure
allows ion accumulation until they are released to the Orbitrap analyser. In order to obtain
high resolution, ions with mass/charge ratio must have similar movement. To achieve this,
they are injected almost simultaneously. The continuous ion movement inside the Orbi-
trap is achieved by the modification of the electric field. To proceed to MS2 in the Orbitrap,
precursor ions are selected and fragmented in an external ion trap. Mass/charge values are
measured from the frequency of harmonic ion oscillations after hitting the detector by fast
Fourier transform algorithm (Guan & Marshall, 1993).
MS is not a quantitative method; detector, trypsinization, ionization and other factors
may produce some variability between sample populations. Nonetheless, some experi-
mental approaches have been developed to allow protein quantification between sam-
ples. Among all the possible quantitative methods developed, stable isotope labelling with
amino acids in cell culture (SILAC) was selected for this study. It was firstly described by
Ong et al. (Ong et al., 2002), and shortly after used for protein quantification (Ong & Mann,
2005). It is a metabolic labelling technique that allows quantification of protein mixtures
by incorporating specific stable isotope amino acid residues in live cells. One of the main
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Figure 4.1: Schematic representation of ion trajectory in Orbitrap mass analyser (from Thermo Fisher Sci-
entific). A continuous voltage increase is applied upon ion packet entry into the Orbitrap. Once ions move in
harmonic circular rotation around the central electrode (ring-like trajectory) the voltage is kept constant.
advantages is that different cell populations can be labelled, and then can be mixed at very
early stage in the experiment and the analysis can be carried out in a single mixture, min-
imizing the experimental error between samples and producing a more reliable protein
quantification (Mann, 2006).
Being a data dependent acquisition method (DDA), Orbitrap has some limitations.
This approach implies that only a group of the whole mixture of compounds will be se-
lected for ion fractionation. It is usually based on the most abundant set of ions, but other
criteria can be applied. It means that a limited amount of ion precursors will be processed,
and the rest will not be considered for analysis. In consequence, this not only means that
some compounds will never be identified, but also that reproducibility between replicates
will be affected as ion selection will be determined by the abundance of peptides in the
sample mixture (Gillet et al., 2012).
4.1.4 SWATH-MS
In contrast to DDA, data independent acquisition (DIA) allows complete identification
of all the analytes in a sample mixture. The best example of the DDA method is the se-
quential window acquisition of all theoretical mass spectra (SWATH-MS). To achieve this,
sequential data acquisition of specific mass window of ion precursors is selected. Here, the
mass window can be modified to cover the entire precursor mass range and will compile all
the MS/MS data from every single ion (Figure 4.2). As a result, all the fragmented ions will
be considered for analysis. In that sense, reproducibility between replicates will be more
consistent. By applying highly complex algorithms SWATH is able not only to identify, but
also quantify, label-free samples (Gillet et al., 2012). This approach allows the analysis of
all the peptides present in the analyte by separating the peptides in groups. But, reducing
the level of complexity of the data acquisition requires prior knowledge of the sample.
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Figure 4.2: Representation of SWATH-MS cycles (Comai & Katz, 2017). (A) In each cycle, eluted peptides
from LC are sequentially scanned in MS1 spectrum and a selection of peptides of similar m/z will be recruited
over time for fractionation to produce the MS2 spectrum, shown in isolation windows (not included). As a
result, each window will represent a group of high-resolution peptides in a particular m/z range. All together
these will form a combination of high resolution MS2 spectrum covering the whole m/z range. (B) Intensities
of individual fragment ions are extracted for each window and combined to generate ion chromatogram peak
groups as a function of retention time and intensity. Importantly, m/z range and time of scanning are metic-
ulously chosen so it is quick enough to cover all the m/z range and to fragment the peptides without losing
resolution. Intensities of fragmented ions of interest are generated from the MS2 spectrum and presented as
an extracted ion chromatogram (XIC)
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It is of great importance to have a high-resolution instrument; as many precursor ions
will be fragmented at the same time, it has to be capable to produce well-resolved ion
peaks to obtain an error-free identification. A good analyser for this task is the TripleTOF.
This is a powerful analyser that allows high speed scanning of the ion-mass dynamic range
without compromising resolution.
TripleTOF configuration is comprised of three quadrupoles, the last being the TOF
analyser (Chernushevich et al., 2001) which measures the ‘time of flight’ of a given ion
before hitting the detector placed at the end of the analyser. Ions are generated by an
ESI source as in the Orbitrap. To achieve MS2 in SWATH, precursor ions are selected in
the quadrupole and then sent to the collision cell for fragmentation. A high voltage pulse
creates an electric field that initiates the ion travel through the quadrupole. The acceler-
ation of the ion depends on the energy applied, the distance it has to travel and its mass-
to-charge ratio (inherent feature of each ion). Following kinetic laws, smaller masses will
achieve high speed and, on the contrary, larger masses will move at a slower velocity. Based
on this principle, the detector positioned at the end of the quadrupole will deconvolute
the mass-to-charge ratio of each ion, measuring arrival times (Figure 4.3) (AgilentTech-
nologies, 2011).
Figure 4.3: Schematic representation of ‘time of flight’ analysis mass sorting (adapted from (AgilentTech-
nologies, 2011)). According to its mass-to-charge ratio, ions will be sorted; small ions will be more accelerated
than larger ions. As a result, they will travel at different velocities through the quadrupole, striking the detector
at different time points.
4.2 Aims of the chapter
In this chapter we aim to identify dominant IFITM1 interacting partners after INFγ
stimulation. Firstly, ectopically transfected IFITM1, with a streptavidin binding protein
(SBP) tag at the N-terminus, will be pulled down by affinity enrichment. The mixture of
proteins will then be determined to identify novel protein binders. To accomplish this, MS
technology will be applied i.e. Orbitrap-MS and SWATH-MS. Subsequently, we will focus
on validating a few candidate proteins of interest; SRSF1, ISG15, and HLA-B.
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4.3 Results
4.3.1 Cloning IFITM1 into pEXPR-IBA105
The initial goal was to characterize the IFITM1 interactome. The first approach was
to pull down IFITM1, along with its binding protein partners, by affinity enrichment cou-
pled with LC-MS/MS analysis of the eluate. Isolation of IFITM1 interacting partners by
immunoprecipitation would be ideal so we could work on an endogenous cellular system.
But, as stated in chapter 3, IFITM proteins are highly homologous which complicates spe-
cific binding of the protein to the antibody. For this reason, an assay was developed using
ectopically-tagged IFITM1.
The system consisted of tagging IFITM1 at its N-terminus with SPB that binds by affin-
ity to streptavidin agarose conjugated beads. The first step was cloning to incorporate
the SBP tag at the N-terminus of IFITM1 (Figure 4.4). Codon optimized IFITM1 was in-
serted into a pMA-T-15ADAZQP backbone and then cloned into pEXPR-IBA105, a vector
containing two SPB tags in tandem (henceforth EV, standing for empty vector). Cloning
by enzymatic digestion was not possible as the position of restriction enzyme recognition
sites were not compatible. Instead, IFITM1 from pMA-T-15ADAZQP vector was amplified
by PCR (section 2.5.5). Restriction enzyme recognition sites were included in the design
of the primers to facilitate cloning in later steps: KpnI for the forward primer and EcoRV
for the reverse primer. These restriction sites were not present in the IFITM1 sequence. To
maintain the reading frame between the SBP tag and the IFITM1, a single nucleotide was
added between the KpnI recognition site and the IFITM1 start codon (Figure 4.4 I).
The PCR product was run on a 1.5% agarose gel, which showed a single band at around
1 kb. This band was excised, purified and digested, along with the EV, with KpnI and EcoRV
restriction enzymes (Figure 4.4 II). The purified IFITM1 amplicon along with EV were lig-
ated (Figure 4.4 A III). The ligation mixture was transformed into DH5α competent cells
which were plated in LB agar plates containing ampicillin antibiotic for selection (sec-
tion 2.4) (Figure 4.4 A IV). The growing colonies were selected and the plasmid DNA was
isolated by miniprep. Successful cloning of pEXPR-IBA105-SBP-IFITM1 (henceforth SBP-
IFITM1) was confirmed by Sanger sequencing (subsection 2.5.11).
The SBP-IFITM1 sequence was aligned using SnapGene software to validate success-
ful cloning. Appropriate expression in mammalian cells was tested by transfecting SBP-
IFITM1 into wt-SiHa for 24 hours. Immunoblotting revealed a single band detected by
mouse monoclonal anti-SBP-tag antibody and a double band with mouse monoclonal
anti-IFITM1/IFITM3 antibody. As expected, the lower band (around 15 kDa) corre-
sponded to the endogenous IFITM1/IFITM3 and the upper band, around 5 kDa higher,
was SBP-IFITM1 (Figure 4.4 B, lane 2). After validation, a maxiprep (subsection 2.5.1) was
performed to obtain enough product for further transfection assays.
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Figure 4.4: Cloning of IFITM1 into EV. (A) Workflow describing the steps followed to clone IFITM1 into EV;
(I) PCR amplification of IFITM1 cDNA, (II) enzymatic digestion using KpnI and EcoRV, (III) ligation, and
(IV) transformation in DH5α competent cells. (B) Immunoblot testing protein expression of the ectopically
transfected SBP-IFITM1 in wt-SiHa cells. SBP panel shows no band for EV (lane 1) and a single band corre-
sponding to tagged SBP-IFITM1 (lane 2). The IFITM1/IFITM3 panel shows a single band for the endogenous
IFITM1/IFITM3 in EV (lane 1) as well as SBP-IFITM1 (lane 2). There is an additional band (around 5 kDa
higher) corresponding to SBP-IFITM1, only seen in the SBP-IFITM1 transfected cells (lane 2).
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4.3.2 Isolation of IFITM1 interacting proteins employing isotopically-labelled
peptides
We focused on identifying the IFITM1 interactome to define pathways that function
over the IFNγ signal landscape. At first, SILAC pull down methodologies were applied.
Wt-SiHa cells were grown in either heavy or light SILAC media supplemented with 10%
dialyzed FBS. The media used were RPMI-K6R6 (heavy media) and RPMI-R0K0 (light me-
dia) from Dundee Cell Products. The heavy media contained a metabolic labelling of L-
Arginine and L-Lysine with six carbon-13 atoms (13C) instead of normal carbon-12 atoms
(12C). These isotopic amino acids were fully incorporated into the cells after growth in the
media over five generations to allow complete isotopic labelling of proteins at lysine and
arginine residues. Light media does not have heavy isotopic amino acids and has the same,
or similar, composition as standard RPMI media. Nonetheless, it was bought from the
same supplier to avoid small differences in batches. Dialyzed FBS does not contain de-
tectable free amino acids thus the cells cannot use the serum as an amino acid source.
Standard FBS is not compatible with this assay as it contains free arginine and lysine that
could interfere with the protein quantification; incorporation of these amino acids would
have had a negative impact on the MS analysis (Ong et al., 2002).
Wt-SiHa cells were transfected with EV (used as negative control) and SBP-IFITM1 vec-
tor for 24 and 48 hours before harvesting (subsection 2.2.6). Initially, the reciprocal com-
bination was included in the experimental design; both transfections were tried in heavy
and light SILAC media to determine optimal conditions. The affinity purification protocol
using streptavidin agarose beads was designed to capture SBP-IFITM1 and associated pro-
teins. Immunoblotting showed that less SBP-IFITM1 was pulled down from cells grown
in light media, compared to those grown in heavy media (Figure 4.5 B, lanes 3-4 vs 11-
12). This poorer affinity purification resulted in unsatisfactory protein identification by
MS (data not shown). For this reason, the MS analysis was performed using cells with the
SBP-IFITM1 (and associated proteins) grown in heavy media, whilst the transfected EV
was expressed in cells grown in light media (Figure 4.5 A). Before proceeding to MS prepa-
ration, the pull down samples from cells in both heavy and light media were combined:
cells transfected with EV grown in light media and cells transfected with SBP-IFITM1 in
heavy media. Consequently, technical variability was decreased as both samples, EV and
SBP-IFITM1, were combined prior to MS analysis. After mixing, there were two analytes:
one transfected for 24 hours and the other for 48 hours.
MS can distinguish heavy-labelled proteins as they will have two amino acid types
isotopically labelled; L-[13C614N4]-Arginine (R6) and L-[13C614N2]-Lysine (K6), giving a
higher mass compared to proteins from cells grown in the light media. Heavy labelled
peptides will be shifted slightly to the right in the MS chromatogram at the m/z axis in
comparison to light labelled peptides. Thus the MS detector can distinguish the incorpo-
ration of the heavy carbon (13C), due to the molecular mass difference (Mann, 2006).
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Figure 4.5: SBP-IFITM1 protein enrichment after affinity purification in isotopically labelled wt-SiHa cells.
(A) Workflow describing the steps followed to perform isolation of IFITM1 interacting partners in SILAC-
labelled wt-SiHa cells. Cells were grown in SILAC media to fully isotopically label all proteins. Cells were
transfected with SBP-tagged IFITM1 or EV for 24 and 48 hours and lysates were subjected to pull down by
affinity enrichment using streptavidin agarose beads. Eluates were processed and analysed by LC-MS/MS
analysis. (B) Immunoblot showing cells transfected with SBP-tagged IFITM1 or EV. Wt-SiHa cells were har-
vested after 24 and 48 hours following SBP-IFITM1 or EV transfection. Lanes were loaded with lysate (20µg of
protein) [L] and pull down (10% v/v of total elute) [affinity enrichment; PD]. Transfections were performed in
cells grown with heavy and light SILAC media with dialyzed serum. Both combinations were used to optimize
the pull down of SBP-tagged IFITM1 and to enrich for co-associating proteins.
After elution and sample mixing, preparation was followed by FASP to produce a high-
quality peptide, and a C18 column step for desalting and sample concentration was per-
formed to produce MS compatible probes (see section 2.8.2). The high-resolution LC-
MS/MS Orbitrap analyser was employed to process the samples thanks to Prof. Lenka
Hernychova in the Regional Centre for Applied Molecular Oncology, Masaryk Memorial
Cancer Institute, Brno. Samples were analysed by the Orbitrap Elite ETD (Thermo Fisher
Scientific) and the data obtained were processed with a Proteome Discoverer 1.4 for pro-
tein identification.
Approximately three times more proteins were identified in the 48 hour transfection
(1342 proteins) compared to in 24 hour transfection (478 proteins). The output of identi-
fied proteins gave a fold change ratio of heavy/light. Interpretation rationale was as fol-
lows: in transfected SBP-IFITM1 samples there were proteins at high intensity that were
either absent, or at very low intensity, in the transfected EV samples. This is the principle
for distinguishing specific SBP-IFITM1 interacting partners from non-specific interacting
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proteins. The higher the ratio, the more specific the interaction.
IFITM was dominantly enriched in both 24 and 48 hour time points following process-
ing in the SILAC workflow; this formed an internal positive control, providing confidence
that the method was able to enrich the bait protein. The same single peptide (MVGDVT-
GAQAYASTAK) was identified for IFITM in both conditions; it was enriched in samples
transfected with the bait (heavy) in comparison to the control (light). This peptide corre-
sponds to an amino acid region shared with IFITM1 and other two isoforms, IFITM2 and
IFITM3, however, we speculate that it belongs to the ectopically transfected SBP-IFITM1.
Fold-change ratio was measured, comparing ion intensities from heavy and light inputs
(Figure 4.6).
Figure 4.6: IFITM1 annotated ion product for the MVGDVTGAQAYASTAK peptide identified in the two repli-
cates. (I) IFITM1 MS/MS spectrum from the spectral library. There is a∆6 Da shift to the right for heavy pep-
tides. (II) The quantification channel values plot for precursor ion quantification displays the relative peak
area for EV in light isotope and SBP-IFITM1 in heavy isotope labels. The x-axis displays the quantification
channel and the y-axis displays the detected area of the selected protein for the given quantification channel
defined by counts x seconds. (A) Corresponds to 24 hours after transfection and there is 10.586 times increase
in heavy vs light peptide. (B) Corresponds to 48 hours after transfection and there is 3.970 times increase in
heavy vs light peptide.
The overall protein enrichment was reduced 48 hours post-transfection, including the
SPB-IFITM1 used as a bait. Therefore, we focused on interacting proteins identified 24
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hours post-transfection. Taking the top 5% of proteins that had the largest fold change
(heavy/light), the most common targets identified were the splicing regulatory factors
within the SRSF superfamily of serine–arginine-rich splicing factors (Table 4.1) (Das &
Krainer, 2014). As with IFITM, SRSF1 peptides were also enriched in heavy over light sam-
ples; which was also the case for other SRSF family members (Figure 4.7). By contrast,
taking tubulin as an internal control for normalization there was a very similar intensity
for the tubulin peptide peaks between both, heavy and light samples (data not shown).
SRSF peptides identified were manually checked to determine if they were unique for the
specific isoform (Figure 4.7).
Other proteins detected in SBP-IFITM1 complexes commonly identified in 24 or 48
hour time points might be important in IFITM1 signalling. Nevertheless, we focused on
validating SRSF interactions with IFITM1 to define the intracellular location of this pro-
tein–protein interaction and to evolve models of how IFITM1 might affect signal trans-
duction.
Table 4.1: Main proteins identified using SILAC media coupled to Orbitrap. Table with selected binding
proteins and fold change (Fch) ratios SBP-IFITM1/EV detected by MS for SBP-IFITM1 enrichment 24 and 48
hours post-transfection (from Table B.2)
Accession number Protein name Fch 24 h Fch 48 h
Q01130 Serine/arginine-rich splicing factor 2 12.056 0.428
P13164 Interferon-induced transmembrane protein 10.586 3.970
P53999 Activated RNA polymerase II transcriptional
coactivator p15
8.211 0.294
P19338 Nucleolin 5.599 0.370
Q01105 Protein SET 4.228 0.170
Q13247 Serine/arginine-rich splicing factor 6 3.752 0.435




Q92945 Far upstream element-binding protein 2 2.710 0.183
P06748 Nucleophosmin 2.127 0.222
Q9BVC6 Transmembrane protein 109 2.022 0.112
Q07955 Serine/arginine-rich splicing factor 1 1.977 0.568
Q9Y2W1 Thyroid hormone receptor-associated protein 3 1.950 0.452
P84103 Serine/arginine-rich splicing factor 3 1.860 0.380
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like
protein 1
1.500 0.193
Q01081 Splicing factor U2AF 35 kDa subunit 1.024 0.172
P57088 Transmembrane protein 33 0.978 0.157
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Figure 4.7: Identified SRSF proteins using SILAC media coupled to Orbitrap. Heavy isotopically labelled
tryptic peptides identified from the SBP-IFITM1 affinity enrichment are highlighted in red for the SRSF family
of proteins (SRSF1, SRSF2, SRSF3, SRSF6 and U2AF1). Underlined unique peptides confirm that these pro-
teins are SRSF isoforms that shuttle between the cytoplasm and nucleus. SRSF2 is not considered a nuclear
to cytoplasmic shuttled protein, however it has its C-terminal enriched in arginine and serine
4.3.3 Study of IFITM1/IFITM3 implications on SRSF1
Considering all the candidate proteins identified by SILAC-MS, we focused on the SRSF
family. Out of the five SRSF proteins identified by MS analysis, SRSF1 was selected for val-
idation as this is the best-studied isoform. First, we interrogate whether there was a direct
interaction, or very close association, between IFITM1/IFITM3 and SRSF1 proteins. Even
though the IFITM1 is the isoform related to cancer, it is possible that IFITM1/IFITM3 co-
operate together and so focusing on one isoform only will not give the full picture of what
is occurring at cellular level. For this reason, we began studying both isoforms simultane-
ously. Must be borne in mind that the IFITM1/IFITM3 antibody is not able to recognize
IFITM2 isoform (Figure 3.11 C). Moreover, the specific antibody against IFITM2 did not
identify IFITM2 expression, not even after IFNγ stimulation (Figure 3.11 C, lane 1 and 2).
In that sense, IFITM2:SRSF1 interaction will not be evaluated.
To assess the interactions, in situ proximity ligation assays (PLA) were performed
(Figure 4.8). This is an emerging methodology that assesses the interaction between
two endogenously expressed proteins in fixed cells. It can recognize a protein–protein
association with less than 30–40 nm separation and can detect endogenous proteins
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Figure 4.8: Principle of proximity ligation assay. (A) Binding of the specific primary antibodies (of different
species) to the proteins of interest (i.e. mouse anti-IFITM1/IFITM3 and rabbit anti-SRSF1). (B) Binding of
the secondary antibody, named as probe MINUS (mouse) and PLUS (rabbit). (C) Proteins closer than 30–40
nm will allow oligos to hybridize and amplify by rolling circular amplification. (D) Further amplification and
increase of the signal by adding a fluorophore labelled probe.
in situ without relying on transfected or artificially tagged protein vectors (Koos et al.,
2014). Taking advantage of this method, we identified endogenous interaction between
IFITM1/IFITM3:SRSF1.
In brief, PLA principle relies on the addition of two secondary antibodies with species-
specific binding to the primary antibodies (Figure 4.8 A and B); in this case a mouse anti-
IFITM1/IFITM3 antibody and rabbit anti-SRSF1 antibody. The secondary antibodies have
unique DNA strands that will be used for hybridization in further steps when complemen-
tary oligonucleotides are added. Only when the two proteins of interest are in close prox-
imity is sufficient to create a circular ssDNA molecule in the presence of a ligase, forming a
template for the DNA polymerase (Figure 4.8 C). In the final steps, a fluorescently labelled
probe is added to bind to the circular ssDNA to produce the signal that is visualised as a
distinct spot under the microscope (Figure 4.8 D). This is a quantitative technique where
the fluorescent signal is proportional to the protein–protein association.
Wt-SiHa cells and IFITM1/IFITM3 double null cells were used to validate
IFITM1/IFITM3:SRSF1 interaction. Four different conditions were set up: single an-
tibody (IFITM1/IFITM3 or SRSF1 antibodies) was used to determine the background
of non-specific signal, and cells without IFNγ stimulation to see the baseline signal in
comparison with IFNγ-stimulated cells. Cells were stimulated with IFNγ for 24 hours. A
0–72 hour time course experiment showed major induction of IFITM1/IFITM3 protein
expression after 24 hours with IFNγ (Figure A.3 B, lane 10). This time point was consistent
over replicates, thus 24 hours of IFNγ stimulation was chosen.
The results show a very low autofluorescence signal in the controls (Figure 4.9 A and
B), when using a single antibody only, suggesting that the signal is only produced in com-
bination of both antibodies. A similar signal intensity is found in the absence of IFNγ stim-
ulation (Figure 4.9 C), whereas wt-SiHa cells stimulated with IFNγ revealed a substantial
signal increase (Figure 4.9 D). This outcome was confirmed by quantification of number
of foci per cell in at least 50 cells, in three independent experiments (Figure 4.9 I). Each
experiment had two biological replicates. To assess primary antibody specificity, the ex-
Chapter 4 - Defining IFITM1-IFNγ dependent signalling pathways 101
periment was also performed in parallel with IFITM1/IFITM3 double null cells. In this
case, there was only background signal for all the conditions, including IFNγ stimulated
cells (Figure 4.9 E-H). Quantification of foci per cell signal confirmed the result (Figure 4.9
J).
Figure 4.9: Evaluation of the IFITM1/IFITM3:SRSF1 protein–protein interaction in situ after stimulation
with IFNγ by PLA. Proximity ligation assay was used to study the endogenous interaction between SRSF1 and
IFITM1/IFITM3 proteins in wt-SiHa (A-D) and IFITM1/IFITM3 double null cells (E-H) FITC images identify
the protein–protein association foci (depicted in green) and DAPI was used for nuclear staining (depicted in
blue) (A–B and E–F). Cells were incubated as negative controls using IFITM1/IFITM3 or SRSF1 antibodies
only. Cells were incubated with both IFITM1/IFITM3 and SRSF1 antibodies to define protein–protein foci
in non-stimulated cells (C and G). Cells were incubated with both IFITM1 and SRSF1 antibodies to define
protein–protein foci in IFNγ-stimulated cells (D and H). Representative quantification of the protein–protein
interaction foci per cell in presence or absence of IFNγ stimulation in wt-SiHa (I) and IFITM1/IFITM3 double
null (J). At least 50 cells were counted for each condition. Statistical study was performed with one-way ANOVA
and Bonferroni correction (****p < 0.0001; ns, not significant). n=3. Scale bar: 10 µm.
To further validate SRSF1 association to IFITM1/IFITM3, an experiment based on im-
munofluorescent colocalization was designed. Initially, a small interfering RNA approach
to deplete the levels of SRSF1 was tested, but SRSF1 protein levels did not decrease satis-
factorily (data not shown). Instead, an assay was designed using ectopically transfected
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SRSF1 with N-terminus T7-tagged peptide. Even though exogenously expressed forms of
the protein may alter protein interactions, we aimed to confirm the protein–protein asso-
ciation using an alternative antibody. The pCG T7-SF2/ASF vector (henceforth T7-SRSF1)
was kindly provided by Dr Magda Maslon in Dr Cáceres group (Cáceres et al., 1997). Prior
to its use, T7-SRSF1 was sequenced confirming it had the epitope T7 at N-terminal in frame
with the SRF1 sequence.
Figure 4.10 A–E is a representative image of the immunofluorescence assay performed
using three channels: IFITM1/IFITM3 (red channel), SRSF1 (green channel) and DAPI
(blue channel) was used for nuclei staining. Overlapping red and green channels would
show yellow signal suggesting IFITM1/IFITM3:T7-SRSF1 colocalization as shown in Fig-
ure 4.10 A and B.
IFITM1/IFITM3 are transmembrane proteins but they can also be internalised inside
the cells under certain stimulus (Weston et al., 2014). In this case, they are distributed
throughout the cell and not particularly abundant in the cell membrane. Fixation with 4%
paraformaldehyde may produce a cryptic epitope in the cell membrane and so the primary
antibody is unable to recognize the IFITM1 and IFITM3 proteins. However, fixation with
acetone:methanol (1:1) (data not shown) is able to reveal a better cell membrane staining
of these proteins. In the case of SRSF1, it is mainly located in the cell nucleus (Figure 4.10 E)
but, remarkably, it is also present in the cytoplasm. This isoform is able to translocate to the
cytoplasm under particular circumstances (Das & Krainer, 2014) and this assay provides
supporting evidence of this event.
Nonetheless, the focus of this experiment was to determine the interaction between
IFITM1/IFITM3:SRSF1. In this respect, several yellow spots can be seen, corresponding to
protein–protein interaction, mainly accumulated around the nucleus (Figure 4.10 B). One
could speculate that at least some of them may be located at the inner nuclear compart-
ments, but visualization using confocal microscopy was not conclusive. At this point it can
only be confirmed that IFITM1/IFITM3:SRSF1 do interact in the wt-SiHa cell model.
We next examined the possible cellular redistribution of SRSF1 in presence of
IFITM1/IFITM3-IFNγ stimulation compared to non-stimulated cells (Figure 4.11). Ini-
tially, we investigated whether there was any global difference in SRSF1 between wt-SiHa
and IFITM1/IFITM3 double null cells. Figure 4.11 A shows that expression of SRSF1 in wild
type and null cells remains very similar.
Of note, there are two SRSF1 isoforms; isoform ASF-1 (identifier: Q07955-1) of ex-
pected 24 kDa, and isoform ASF-2 (identifier: Q07955-2) of expected 30 kDa. The ma-
jor difference between them is that the isoform ASF-1 is enriched with arginine and ser-
ine residues at its C-terminus and so is predicted to be in the cytoplasm, apart from
its canonical nuclear location. The SRSF1 antibody is able to recognize both isoforms,
showing a double band in blots (Figure 4.11, SRSF1 long exposure panel). The lower
panel corresponds to IFITM1/IFITM3 and it was included to monitor the expression of
IFITM1/IFITM3 proteins as a control.
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Figure 4.10: Evaluation of the IFITM1/IFITM3:SRSF1 protein–protein colocalization by immunofluores-
cence. Wt-SiHa cells were transfected with T7-SRSF1 for 24 hours. Immunofluorescence assay performed
to assess the interaction between IFITM1/IFITM3:T7-SRSF1. Cells were fixed with 4% paraformaldehyde.
(A) Merge channel, (B) ROI from (A) highlighting the overlapping channels, (C) DAPI, (D) endogenous
IFITM1/IFITM3, (E) ectopically transfected T7-SRSF1. Scale bar 10 µm.
Subsequently, a cell fractionation assay was performed to determine if SRSF1 subcel-
lular location was modulated by IFITM1/IFITM3. Coomassie blue staining was performed
in parallel to the blots to show global protein loading. The total protein amount in cellular
compartments, as well as buffer volume, are not the same and this is reflected between
lanes (Figure 4.11 B I). Even so, similar protein amounts were loaded in the same fraction
across the different samples/conditions: cytoplasmic (lanes 1, 6, 11, and 16), membrane
(lanes 2 , 7, 12, and 17), nuclear (lanes 3, 8, 13, and 18), nuclear chromatin bound (lanes 4,
9, 14, and 19), and cytoplasmic (lanes 5, 10, 15, and 20).
Simultaneously, IFITM1/IFITM3 subcellular distribution was studied (Figure 4.11 B II,
IFITM1/IFITM3 panel). As expected, IFITM1/IFITM3 are mainly located in the membrane
fraction, increasing after IFNγ stimulation (Figure 4.11 B II, IFITM1/IFITM3 panel, lanes 2
and 12). This feature was consistent across replicates. Importantly, there is a clear increase
of IFITM1/IFITM3 in the nuclear fraction obtained after IFNγ stimulation. It cannot be
concluded if it is in the inner or the outer nuclear side but, nonetheless, it is interesting to
observe a change in IFITM1/IFITM3 location produced by IFNγ signalling. Additionally,
there is no trace of IFITM1/IFITM3 expression in IFITM1/IFITM3 double null cells, not
even after IFNγ stimulation (Figure 4.11 B II, lanes 6–10 and 16–20), confirming the knock
out.
According to the supplier, this assay is limited by an established 15% cross-
contamination between fractions. In that sense, it should be seen as a chemical separation
rather than purely cell fractionation. Nonetheless, HSP90 (Figure 4.11 B II, HSP90 panel)
for cytoplasmic fraction and H3 (Figure 4.11 B II, H3 panel) for nuclear fraction were ad-
ditionally blotted as internal controls.
This first approach using SILAC identified SRSF proteins as major IFITM1 protein in-
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teracting candidates, and this is found to be true association after SRSF1 validation. Even
so, the confidence of detection was very poor and so we evaluated the IFITM1 interactome
by employing an alternative MS method.
Figure 4.11: Evaluation of SRSF1 protein expression in wt-SiHa and IFITM1/IFITM3 double null cells. (A)
Immunoblots examining the endogenous levels of SRSF1 protein in wt-SiHa or IFITM1/IFITM3 double null
cells in presence or absence of IFNγ. (B) Subcellular fractionation assay with wt-SiHa or IFITM1/IFITM3 dou-
ble null cells was performed. (I) Coomassie gel of the fractions to define the distribution of dominant proteins
as a loading control. (II) Immunoblot shows subcellular distribution of SRSF1 and IFITM1/IFITM3; Histone-
3 (nuclear fraction) and HSP90 (cytoplasmic fraction) were used as a specific fractionation loading controls.
After cellular fractionation the following fractions were obtained; cytoplasmic (lanes 1, 6, 11, and 16), mem-
brane (lanes 2, 7, 12, and 17), nuclear (lanes 3, 8, 13, and 18), nuclear-chromatin bound (lanes 4, 9, 14, and
19), and cytoplasmic (lanes 5, 10, 15, and 20).
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4.3.4 Isolation of IFITM1 interacting proteins employing label-free peptides
We employed label-free MS to see if this gave a similar dominant protein interactome
signature as that obtained by SILAC – thus comparing the two methods. The experimen-
tal design was same as that followed in subsection 4.3.2 but this time wt-SiHa cells were
grown in label-free media and samples were not combined prior to SWATH-MS analysis
(Figure 4.12 A).
Figure 4.12: SBP-IFITM1 protein enrichment after affinity purification in label-free wt-SiHa cells. (A)
Workflow describing the steps followed to perform isolation of IFITM1 interacting partners in wt-SiHa cells
grown in label-free media. Cells were grown in RPMI and transfected with SBP-tagged IFITM1 or EV for 24
and 48 hours, non-stimulated and stimulated with IFNγ for 24 hours. The lysates were subjected to IFITM1
pull down by affinity enrichment using streptavidin agarose beads and the eluates were processed and anal-
ysed by LC-MS/MS analysis. (B) Immunoblot showing cells transfected with SBP-tagged IFITM1 or EV. Cells
were harvested after 24 and 48 hours following SBP-IFITM1 or EV transfection. Lanes were loaded with lysate
(20 µg of protein) [L] and pull down (10% v/v of total elute) [i.e. affinity enrichment; PD]. Transfections were
performed in cells grown in label-free media. Using normal media with optimized serum to stimulate cell
growth, the maximum IFITM1 protein enrichment was observed in 24 hour IFNγ-stimulated cells at the 48
hour post-transfection time point (lane 16) vs the 24 hour post-transfection time point (lane 8).
To find out which condition was optimal to study IFITM1 interactome, wt-SiHa cells
were transfected with SBP-IFITM1 or EV for 24 hours (Figure 4.12 B, lanes 1–8) and 48 hours
(Figure 4.12 B, lanes 9-16). The wt-SiHa cells were non-stimulated (Figure 4.12 B, lanes 1-
4 and 9-12) or IFNγ-stimulated for 24 hours (Figure 4.12 B, lanes 5–8 and 13–16). There
was no SBP-IFITM1 enrichment when cells were transfected and IFNγ-stimulated for 24
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hours (Figure 4.12 B, lane 8 vs lane 16). It was suspected that IFNγmay inhibit the entry of
the vector inside the cell as happens with foreign particles or pathogens. In contrast, SBP-
IFITM1 transfection for 48 hours in 24 hours IFNγ-stimulated wt-SiHa cells resulted in the
most significant affinity purification (Figure 4.12 B, lane 16). Due to technical problems
the non-stimulated and 48 hours transfected samples had a non-satisfactory MS analysis
(Figure 4.12 B, lanes 9–12). SWATH-MS analysis was performed with the affinity purified
material (SBP-IFITM1 vs EV) of 24 hours post-transfection non-stimulated and 48 hours
post-transfection stimulated for 24 hours with IFNγ (Figure 4.12 B, lanes 1–4 and 13-16,
respectively).
These data highlight the detection of peptides belonging to a homologous sequence for
IFITM1/2/3 proteins in absence of IFNγ stimulation (Figure 4.12 B, lanes 1–4) or after IFNγ
stimulation (Figure 4.12 B, lanes 13–16). As previously, it was presumed that IFITM1 was
the detected isoform, as it was the bait protein, and so it was considered as internal positive
control (Figure 4.13 A and B, indicated as IFITM1/2/3). Nevertheless, IFITM1 may also be
interacting with IFITM2 or IFITM3. Additionally, VAPA (a co-associated IFITM1/2/3 inter-
acting protein) was non-significantly detected without IFNγ (Figure 4.13 A) whereas it was
significantly detected after IFNγ stimulation (Figure 4.13 B and Table 2). It was also con-
sidered as internal positive control as its interaction with IFITM1 is further supported in
studies performed by Amini-Bavil-Olyaee et al. (Amini-Bavil-Olyaee et al., 2013). Remark-
ably, this result suggests that a low-confidence identified protein can be a real interacting
partner.
Overall, there are more SBP-IFITM1 associated proteins with a significant p-value de-
tected in the 48 hour post-transfection time point. This 48 hour post-transfection time
point was used to highlight the SBP-IFITM1 associated proteins of interest including
proteins related to cell-to-cell communication such as cornifin, galectin-7, desmocolin,
JUP, hornerin and desmoglein, as well as interferon responsive proteins such as ISG15
and HLA-B (Table 4.2). A comparison between the enriched proteins identified in non-
stimulated and IFNγ-stimulated wt-SiHa cells reveals that the IFITM1 interactome may
be further activated after IFNγ stimulation (Figure 4.13 A vs B). We had particular interest
in HLA-B and ISG-15 as they are components of the IRDS signature (related to IFNγ sig-
nalling) and they are closely associated with immune evasion and restriction of infection,
as IFITM1 (Weichselbaum et al., 2008a).
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Figure 4.13: Identification of the most dominant SBP-IFITM1 interacting proteins. An affinity purification
using streptavidin agarose beads was performed in non-stimulated (A) or IFNγ-stimulated (B) wt-SiHA cells.
The wt-SiHa cells were either transfected with SBP-IFITM1 or EV for 24 hours (A) and 48 hours (B). Volcano
plot showing the relative quantification for binding proteins by log2 fold change of cells transfected with SBP-
IFITM1 versus SBP empty vector in the x-axis and -log10 p-value in the y-axis. IFITM1/2/3 is highlighted
as it was used as a bait in this assay, also VAPA which is a well-known IFITM1/2/3 interacting protein. In
addition, ISG15 and HLA-B are highlighted as interferon responsive proteins. The analysis was conducted in
R and figures were produced using the enhanced volcano, R package version 1.0 (Blighe, 2019). Horizontal
dashed lines delimit the fold-change cut-off >1.5 for upregulated and <0.5 for downregulated in the x-axis
and vertical dashed line delimits the p-values cut-off <0.05 in the y-axis. Significant values for fold change
and p-value are depicted in red, right quadrant as overrepresented and left quadrant as underrepresented
proteins. Significant values for fold change are depicted in green. Significant values for p-value are depicted
in blue. Non-significant (NS) values are depicted in grey.
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Table 4.2: Selected interacting partners identified by MS for SBP-IFITM1 affinity enrichment in wt-SiHa
cells stimulated with IFNγ (Figure 4.13 B) (from Table B.3)
Accession number Protein name p-value Fch
E9PS44 Interferon-induced transmembrane protein 3.91E-7 32.764
Q01469 Fatty acid-binding protein, epidermal 1.07E-5 5.380
P22528 Cornifin-B 2.39E-05 5.364
P47929 Galectin-7 1.63E-2 3.023
Q9P0L0 Vesicle-associated membrane protein-associated
protein A
5.04E-2 2.890
Q08554 Desmocollin-1 2.98E-3 2.387
P26038 Moesin 2.82E-3 2.375
P14923 Junction plakoglobin 4.5E-4 2.342
Q86YZ3 Hornerin 1.07E-2 2.153
Q02413 Desmoglein-1 2.88E-3 2.070
A0A096LPJ4 Ubiquitin-like protein ISG15 7.20E-4 1.999
Q04826 HLA class I histocompatibility antigen, B-40 alpha
chain
7.01E-4 1.628
A0A0A0MTC5 Double-stranded RNA-binding protein Staufen
homolog 2
1.00E-3 1.514
4.3.5 Study of IFITM1/IFITM3 implications on HLA-B and ISG15 proteins
Next, we validated ISG15 and HLA-B, two of the top protein candidates identified by
SWATH-MS (Figure 4.13 A and B). First, it was tested by affinity purification if these pro-
teins interact directly or form a complex with IFITM1 (Figure 4.14). Protein enrichment by
affinity purification using ectopically transfected SBP-IFITM1 in wt-SiHa cells was unable
to capture the interaction between IFITM1 with ISG15 or with HLA-B (data not shown). Al-
ternatively, affinity purification was performed using isogenic SBP-IFITM1 SiHa cells gen-
erated by CRISPR/Cas9 system by knocking in the SBP tag to the IFITM1 gene. A genetic
study showed that these cells had SBP tag in both alleles of the IFITM1 gene. Generation
of the isogenic SBP-IFITM1 SiHa cell line was performed by Miss Erisa Nita, who kindly
provided the cells.
SBP-IFITM1 SiHa cells were either non-stimulated or IFNγ-stimulated for 24 hours
(Figure 4.14 A and B, lanes 2 and 3 vs lanes 4 and 5). Streptavidin agarose beads with-
out lysate (Figure 4.14 A and B, lane 1) and wt-SiHa cells transfected with the SBP-tagged
empty vector were used as negative controls (Figure 4.14 A and B, lane 6 and 7) which tested
any possible non-specific interaction with the streptavidin agarose beads or SPB tag, re-
spectively. At the same time, detection with SBP antibody was used as a positive control
(Figure 4.14 A and B, bottom panel). As it can be observed in Figure 4.14 A and B, lane 3
and 5, SBP-IFITM1 is highly enriched after affinity purification whereas negative controls
do not show any signal (Figure 4.14 A and B, lanes 1, 6 and 7).
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Figure 4.14: SBP-IFITM1 protein enrichment after affinity purification in wt-SiHa cells and isogenic SBP-
IFITM1 SiHa cells. Immunoblot showing the pull down using wt-SiHa cells and engineered SBP-IFITM1 knock
in by CRISPR/Cas9 technology. Wt-SiHa cells were transfected with SBP-tagged empty vector for 24 hours
and SBP-IFITM1 SiHa cells were non-stimulated or stimulated with IFNγ for 24 hours. Lanes were loaded
with streptavidin agarose beads [B], lysate (20 µg of protein) [L] and pull down (20% v/v of total elute) [affinity
enrichment; PD]. Beads without lysate were carried out in parallel with the rest of the conditions (lane 1),
non-stimulated SBP-IFITM1 SiHa cells (lanes 2 and 3), IFNγ-stimulated SBP-IFITM1 SiHa cells (lanes 4 and
5), SBP-tagged empty vector was transfected in wt-SiHa cells (lanes 6 and 7). (A) The upper panel was detected
with ISG15 antibody, and the bottom panel was detected with SBP antibody. (B) The upper and middle panel
were probed with HLA-B antibody at lower and higher exposure times. The bottom panel was probed with
SBP antibody.
ISG15 protein is successfully enriched after affinity purification in the presence and
absence of IFNγ stimulation (Figure 4.14 A, top panel, lanes 3 and 5). ISG15 is detected in
the lysate of wt-SiHa cells but absent after affinity purification (Figure 4.14 A, top panel,
lanes 6 vs 7) and not detected in the negative control with streptavidin agarose beads (Fig-
ure 4.14 A, lane 1). Notably, ISG15 shows a double band only observed after the antibody
batch was changed, possibly detecting an unspecific protein.
HLA-B protein was also captured after affinity purification in the presence of IFNγ
stimulation (Figure 4.14 B, top panel, lane 5). Additionally, HLA-B was very weakly de-
tected, after long exposures, in non-stimulated SBP-IFITM1 SiHa cells (Figure 4.14 B, mid-
dle panel, lane 3). However, this could be unspecific binding to SBP tag as a similar signal is
seen in wt-SiHa cells transfected with the empty vector containing SBP tag (Figure 4.14 B,
middle panel, lane 7). The negative control with streptavidin agarose beads did not show
any signal (Figure 4.14 B, top panel, lane 1).
The association of IFITM1/IFITM3:HLA-B was also studied by an alternative method.
As previously explained, a PLA assay was designed following the same principle: wt-SiHa
and IFITM1/IFITM3 double null cells, stimulated and non-stimulated with IFNγ. As men-
tioned, IFITM1/IFITM3 proteins may be cooperating at the molecular level so it was used
IFITM1/IFITM3 double null cells as a negative control. As such, depleting IFITM1 only
may not give a very distinct phenotype in comparison to depleting both, IFITM1 and
IFITM3. The PLA results only show signal in wt-SiHa cells after IFNγ stimulation (Fig-
ure 4.15 H and J vs D and I). This result was obtained in three independent replicates. In
fact, it is been previously reported that IFITM3:HLA-B interact using a colocalisation assay
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in a different system, i.e IFNγ stimulated melanoma cells (Brem et al., 2003).
It was investigated if IFITM1/IFITM3 could alter protein expression of HLA-B. It was
tested if there was any difference in HLA-B protein expression in wt-SiHa compared to in
IFITM1/IFITM3 double null cells by immunofluorescence microscopy. IFNγ-stimulated
and non-stimulated cells were also compared. Controls were performed in the absence of
HLA-B primary antibody (Figure 4.16 A and D). Three independent experiments were per-
formed, and HLA-B intensity signal was quantified using ImageJ software (version 2.0.0-
rc-68/1.52e).
Although there is a basal HLA-B expression in IFITM1/IFITM3 double null cells, it
seems to be non-reactive or very attenuated after IFNγ stimulation, as intensity levels are
very similar (Figure 4.16 B and C vs E and F). This observation may not be obvious in Fig-
ure 4.16 A–F, but after quantification (Figure 4.16 G and H), there is a more sustained level
of HLA-B in IFITM1/IFITM3 double null cells compared to wt-SiHa cells where it increases
after IFNγ stimulation. As other MHC class I molecules also came up in the SWATH-MS
screening we decided to address the same question to HLA-A and HLA-C. Similar results
were obtained with HLA-A and HLA-C immunofluorescence (data not shown); there was
greater induction in the null cells compared to wild type. In further work, we focused on
investigating the effects of IFITM1/IFITM3 on HLA-B.
To further corroborate this result, an IFNγ time course was performed; at 0, 2, 6, 24,
48, and 72 hours, to monitor HLA-B protein changes (Figure 4.16 I). Consistently, there is a
progressive induction of HLA-B after IFNγ stimulation in wt-SiHa (Figure 4.16 I, lanes 1–6).
In contrast, HLA-B remains less induced after IFNγ stimulation in IFITM1/IFITM3 double
null cells (Figure 4.16 I, lanes 7–12). This result was observed in other replicates. Moreover,
Dr. Marta Nekulová studied the presence of HLA-B in the cell membrane in wt-SiHa and
two different IFITM1/IFITM3 double null cells arising from two different knock out clones.
There was a significantly lower expression of HLA-B on the cell surface in IFITM1/IFITM3
double null cells (data not shown).
It was investigated whether HLA-B was relocated in an IFITM1/IFITM3-IFNγ-
dependent manner. Cells were fractionated to compare cellular distribution of HLA-B in
wt-SiHa and IFITM1/IFITM3 double null cells (Figure 4.16 J). Immunoblotting shows in-
duction of HLA-B after IFNγ stimulation, as already reported (Chang et al., 1992). HLA-B
is mainly located in the membrane fraction (Figure 4.16 J II, HLA-B panels, lanes 2, 7, 12
and 17). However, it appears that after IFNγ stimulation HLA-B also goes to the nuclear
fraction (Figure 4.16 J II, HLA-B panels, lanes 3, 8, 13, and 18). Small differences were ob-
served in HLA-B location between wt-SiHa and IFITM1/IFITM3 double null; HLA-B was
more extensively present in all the fractions in IFITM1/IFITM3 double null-IFNγ, but this
was not entirely consistent in all replicates.
IFITM1/IFITM3 was also detected by Western blotting to determine its subcellular
distribution in wt-SiHa (Figure 4.16, IFITM1/IFITM3 panel, lanes 1–10), as well as to
ensure the complete depletion of IFITM1/IFITM3 in IFITM1/IFITM3 double null cells
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Figure 4.15: Evaluation of the IFITM1/IFITM3:HLA-B protein–protein interaction in situ after stimula-
tion with IFNγ by PLA. Proximity ligation assays were used to study the endogenous interaction between
IFITM1/IFITM3 and HLA-B proteins in wt-SiHa (A–D) and IFITM1/IFITM3 double null cells (E–H). FITC im-
ages identify the protein–protein association foci (depicted in green) and DAPI was used for nuclear staining
(depicted in blue). (A–B and E–F) Cells were incubated as negative controls using IFITM1/IFITM3 or HLA-B
antibodies only. (C and G) Cells were incubated with both IFITM1/IFITM3 and HLA-B antibodies to define
protein–protein foci in non-stimulated cells. (D and H) Cells were incubated with both IFITM1/IFITM3 and
HLA-B antibodies to define protein–protein foci in IFNγ-stimulated cells. Representative quantification of
the protein–protein interaction foci per cell in presence or absence of IFNγ stimulation in wt-SiHa (I) and
IFITM1/IFITM3 double null (J). At least 50 cells were counted for each condition. Statistical study was per-
formed with one-way ANOVA and Bonferroni correction (****p < 0.0001; ns, not significant). n=3. Scale bar:
10 µm.
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(Figure 4.16, IFITM1/IFITM3 panel, lanes 11–20). IFITM1/IFITM3 are mainly present in
the membrane fraction and induced after IFNγ stimulation (Figure 4.16, IFITM1/IFITM3
panel, lanes 2 and 7). This observation was consistent across replicates.
Possible association of IFITM1/IFITM3:ISG15 was studied. A PLA assay was performed
to validate the interaction of IFITM1/IFITM3: ISG15 in the presence or absence of IFNγ
stimulation, but no signal was identified in any of the cases (data not shown). It was sus-
pected that the ISG15 IgG antibody class was not suitable for PLA Duolink probes. Alter-
nately, ISG15 could be part of a complex interacting indirectly with IFITM1/IFITM3. In
that case, PLA is not able to recognise protein–protein associations greater than 40 nm
apart.
Presented with this scenario, it was opted to study the ISG15ylation state of the isogenic
cervical cell panel: wt-SiHa; IFITM1 null; IFITM1/IFITM3 double null cells. The rationale
was that if interaction between the proteins could not be detected by PLA or immunopre-
cipitation, at least we may be able to identify differences in some downstream effects on
the global ISG15ylation levels between wt-SiHa and IFITM1 null and/or IFITM1/IFITM3
double null cells. Although ISG15 synthesis by IFN stimulation is very rapid, ISGylation
needs between 18 to 24 hours to be detected (Loeb & Haas, 1992). Actually, it is thought that
E1, E2 and E3 enzymes are expressed at much lower levels (Dastur et al., 2006). The pT-Rex-
DEST30TM SBP-tagged wild type ISG15, pT-Rex-DEST30TM SBP-tagged mutated ISG15
and empty vector were a gift from Miss Ainhoa González Urionabarrenetxea. Throughout
this thesis they will be called SBP-ISG15, SBP-ISG15AA, and EV, respectively. SBP-ISG15AA
has a diglycine mutated C-terminus; these mutated residues are responsible for conjugat-
ing ISG15 to target proteins and therefore, ISG15ylation will be inhibited in this construct,
serving as a negative control.
Cells were transfected with SBP-ISG15 for 48 hours and stimulated with IFNγ for 24
hours. Two experimental approaches were designed: firstly, transfecting cells with EV to
enhance ISG15ylation (Figure 4.17) and, secondly transfecting SBP-ISG15 or SBP-ISG15AA
constructs (Figure 4.18 A and B, respectively). Additional conditions were included in
which null cells were complemented with full-length IFITM1 or IFITM3 constructs; un-
tagged IFITM1 and IFITM3 were added back by transfection to asses if the wild type phe-
notype could be rescued (Figure 4.18 A, lanes 5, 8, 9, and 10). Prior to this, IFITM3 cDNA
was cloned from pCMV-myc-hIFITM3 (Oxford Genetics) to pSF-CMV untagged backbone,
following a similar strategy as in section 2.5.5. IFITM1 cDNA was kindly borrowed from the
Hupp group.
The initial approach was to maintain the cellular system without major perturbations:
ISG15 conjugation was assessed by examining endogenous levels before and after IFNγ
stimulation in wt-SiHa and IFITM1/IFITM3 double null cells (data not shown). Differences
were subtle, and it was not possible to determine if the changes were significant. The next
strategy was to transfect with EV in IFNγ-stimulated wt-SiHa and IFITM1/IFITM3 dou-
ble null cells (Figure 4.17). The mere transfection with EV induces the activation of the
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Figure 4.16: Evaluation of HLA-B levels in wt-SiHa and IFITM1/IFITM3 double null cells. (A-F) SiHa cells
were non-stimulated (B and E) or IFNγ-stimulated for 24 hours (C and F) prior to 4% paraformaldehyde fixa-
tion. Cells were incubated with HLA-B specific antibody overnight. FITC images identify HLA-B (green) and
DAPI was used for nuclear staining (blue). n=3. Scale bar: 10 µm. Representative quantification of HLA-B
total fluorescence per cell in presence or absence of IFNγ stimulation in wt-SiHa (G) and IFITM1/IFITM3
double null cells (H). At least 50 cells were measured in each condition. Statistical study was performed
with 1-way ANOVA and Bonferroni correction (****p < 0.0001). (I) A time course of 0, 4, 6, 24, 48, and 72
hours with 100 ng/ml INFγ stimulation in wt-SiHa and IFITM1/IFITM3 double null cells to measure levels
of HLA-B and IFITM1/IFITM3. GAPDH was used as loading control. Relative concentration (%) was mea-
sured using Fiji software by taking the higher IFITM1/IFITM3 intensity (lane 4) as 100% intensity, and other
lanes were normalised to lane 4 (indicated on top of HLA-B panel). (J) Subcellular fractionation assay in wt-
SiHa or IFITM1/IFITM3 double null cells was performed. (I) Coomassie gel was run to define the distribu-
tion of dominant proteins as a loading control. (II) Immunoblot shows subcellular distribution of HLA-B
and IFITM1/IFITM3; Histone-3 (nuclear fraction) and HSP90 (cytoplasmic fraction) were used as a specific
fractionation loading controls. After cellular fractionation the following fractions were obtained; cytoplasmic
(lanes 1, 6, 11, and 16), membrane (lanes 2, 7, 12, and 17), nuclear (lanes 3, 8, 13, and 18), nuclear chromatin-
bound (lanes 4, 9, 14, and 19), and cytoplasmic (lanes 5, 10, 15, and 20).
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Figure 4.17: Study of endogenous ISG15ylation levels in wt-SiHa and IFITM1/IFITM3 double null cells.
Wt-SiHa cells (lane 1) and IFITM1/IFITM3 double null (lane 2) cells were transfected with EV for 48 hours and
IFNγ-stimulated for 24 hours. Detection of conjugated ISG15 was performed using ISG15 antibody (middle
panels). β-ACTIN was used as a loading control (top panel) and IFITM1/IFITM3 antibody determined deple-
tion of IFITM1/IFITM3 proteins (bottom panel).
IFN signalling cascade and ISG15 is one of the downstream induced genes (Huerfano et
al., 2013). On this occasion, there was a clear increase of ISG15ylation in wt-SiHa, com-
pared to IFITM1/IFITM3 double null cells. There was a 50% reduction of conjugated ISG15
in IFITM1/IFITM3 double null cells, compared to wt-SiHa, and a similar reduction was
observed in replicates. Measurement of the signal intensity was performed using ImageJ
software (version 2.0.0-rc-68/1.52e). A loading control with β-ACTIN shows that the pro-
tein loading was the same in both cell lines, and detection with IFITM1/IFITM3 antibody
shows that IFITM1/IFITM3 proteins are depleted in IFITM1/IFITM3 double null cells.
Next, it was studied whether ectopic ISG15 leads to the same effect. For this, wt-SiHa,
IFITM1 null, and IFITM1/IFITM3 double null cells were transfected with tagged SBP-ISG15
(Figure 4.18). The expected molecular weight for ISG15, around 15 kDa, is indicated as free
ISG15 (endogenous) in the ISG15 panel (Figure 4.18 A). Additionally, the transfected free
ISG15 (SBP-ISG15) is detected 5 kDa above it (Figure 4.18 A, lanes 2, 4, 5, 7, 8, 9, and 10)
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and is absent when transfected with EV (Figure 4.18 A, lanes 1, 3, and 6). The ladder at the
top of the lane corresponds to the ISG15 conjugated proteins (Figure 4.18 A). Absence of
free ISG15 (endogenous) is observed in the SBP panel.
In contrast to the previous experiment (Figure 4.17), ISG15ylation levels in wt-SiHa are
lower than in IFITIM1/IFITM3 double null cells when detected by SBP (Figure 4.18 A, lanes
2 vs 6). Nonetheless, ISG15ylation in wt-SiHa is higher than in IFITM1 null cells (Figure 4.18
A, lanes 2 vs 4). In addition, ISG15ylation decreases once IFITM1 or IFITM3 (individually)
were complemented in IFITM1/IFITM3 double null cells (Figure 4.18 A, lane 7 vs 8 and 9).
Furthermore, ISG15ylation reduction is observed when IFITM1/IFITM3 double null cells
are complemented with IFITM1 and IFITM3 constructs (Figure 4.18 A, lane 1 vs 10). This
further supports the suspicion, stated previously, that IFITM1/IFITM3 proteins may be
cooperating.
Moreover, complementation of IFITM1 in IFITM1 null cells does not rescue the
ISG15ylation state of wt-SiHa (Figure 4.18 A, lane 5 vs 2). Profound genetic and epigenetic
changes in this isogenic cell line or the nature of transfection as well as vector used may in-
terfere in the regulation of conjugated ISG15, consequently no major differences are seen
in SBP-ISG15 complemented with EV or IFITM1 (Figure 4.18 A, lane 4 vs 5). Additionally,
expression of IFITM1 in rescued IFITM1 null cells is lower than in wt-SiHA (Figure 4.18
A, IFITM1 panel, lane 5 vs 2). Likewise, deficiencies in posttranslational modification of
transfected IFITM3 are also observed (Figure 4.18 A, IFITM3 panel, lane 2 vs 9 and 10).
That indicates that the system cannot be completely and fully restored.
Surprisingly, the ISG15 panel did not show similar ISG15ylation. There was a depletion
of conjugated ISG15 in IFITM1 null cells and IFITM1/IFITM3 double null cells that was not
rescued after complementation (Figure 4.18 A, ISG15 panel, lanes 3-5 and lanes 6-10). This
correlates with the result observed in Figure 4.17. To shed some light to this observation,
mutated SBP-ISG15, indicated as SBP-ISG15AA, was transfected to assess if the SBP anti-
body was detecting specific conjugated ISG15 proteins (Figure 4.18 B). As predicted, there
was a large depletion of global ISGylation of the aberrant SBP-ISG15AA form (Figure 4.18
B, lanes 2 vs 3). Possibly, SBP-ISG15 competes with endogenous ISG15 and, additionally,
SBP-ISG15 may have a cryptic peptide not recognised by the ISG15 antibody.
Even though contradictory, these observations were consistent across replicates. At
this point it should be noted that both systems, endogenous (Figure 4.17) vs transfected
(Figure 4.18), are fundamentally different and should not be compared. We should rely
on the outcome in Figure 4.17 as the system remains less manipulated. Nonetheless, the
assay in Figure 4.18 A suggests a profound IFITM1/IFITM3 influence on global ISGylation.
Moreover, major ISGylation change observed in the absence of IFITM1 or IFITM1/IFITM3
cannot be underestimated. Additionally, complementation by transfection suggests that
this effect is due to the action of IFITM1/IFITM3 proteins, and rules out the possibility of
it being a CRISPR clone-dependent artifact.
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Figure 4.18: Study of exogenous ISG15ylation levels in wt-SiHa, IFITM1 single null, and IFITM1/IFITM3
double null cells. (A) Wt-SiHa (lanes 1 and 2), IFITM1 null (lanes 3-5), and IFITM1/IFITM3 double null
(lanes 6–10) cells were ectopically transfected with tagged SBP-ISG15 and occasionally complemented with
full length IFITM1 (lanes 5, 8, and 10) and IFITM3 (lanes 9 and 10) for 48 hours and IFNγ-stimulated for 24
hours. Transfections were carried out with EV to maintain the same total amount of DNA in all conditions.
(B) IFITM1/IFITM3 double null cells were transfected with SBP-ISG15 (lane 2) or mutated SBP-ISG15AA (lane
3). Conjugated and free ISG15 are indicated in SBP and ISG15 panels. Protein loading control is assessed in
β-ACTIN panel.
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4.4 Discussion
This chapter is entirely dedicated to identifying new proteins associated with IFITM1.
For this purpose, affinity purification of SBP-tagged IFITM1 was used to identify enriched
proteins using SILAC (subsection 4.3.2) and label free-MS (subsection 4.3.4) approaches
in a SiHa cervical cancer cell model.
Firstly, the SILAC methodology was applied. Among the proteins listed, an interesting
group of splicing factors, SRSF, was recognised as IFITM1 interacting proteins (Figure 4.7).
Splicing is a crucial and complex mechanism that allows generation of protein diversity.
Altering this sophisticated system may lead to the production of deleterious splice variants
that may impede and/or modify proper protein expression, including the generation of
protein variants associated with cancer.
The splicing factor proteins SRSF1, SRSF2, SRSF3, SRSF6 and U2AF were identified in
the overlapping top 50 protein candidates at two time points: transfected SBP-IFITM1 for
24 and 48 hours (Table 4.1). These proteins are part of the SR protein family. Its basic struc-
ture comprises one or two domains for RNA recognition motifs (RRM) and a C-terminal
RS domain of multiple arginine and serine repeats (Long & Caceres, 2009). It is remarkable
that most of the isoforms identified in our study have this C-terminal domain enriched in
arginine and serine residues (Figure 4.7). These have been classically implicated in alter-
native splicing and pre-mRNA splicing. In addition to their canonical function, they also
have an important role in post-splicing activities. In this regard, some studies show that
some SRSF proteins have roles not only involving nuclear splicing but also in processes oc-
curring in the cytoplasm, such as mRNA nuclear export, nonsense-mediated mRNA decay
(NMD) and mRNA translation (Das & Krainer, 2014).
SRSF is a family of 12 proteins predominantly located in the nucleus, where six of
them (including SRSF1 and SRSF3) shuttle continuously between the nucleus and the cy-
toplasm to export mRNA out of the nucleus (Cáceres et al., 1998). The presence of some
SRSF proteins in the cytoplasm is not well understood. Nonetheless, it is been postulated
that SRSF1 (the prototypical SRSF protein) transitions between nucleus and cytoplasm is
closely related to its phosphorylation state. Phosphorylation in the RS domain is crucial
to initiate export activity; extensive posttranslational phosphorylation of SRSF1 in the nu-
cleus enhances splicing reactions. During splicing it returns to the hypophosphorylated
state and is directly transported to the cytoplasm by interaction with the nuclear export
factor TAP. Shuttling SRSF proteins are dephosphorylated after splicing and remain asso-
ciated with spliced mRNA during mRNA export. Repeated SRSF1 dephosphorylation in
the cytoplasm produces intermediate phosphorylation states that allow interaction with
other proteins until the protein is hypophosphorylated. It is then imported back into the
nucleus, interacting with the transportin-SRSF protein and accumulating until the cycle is
initiated again (Ding et al., 2006; Huang et al., 2004).
To shed some light on this matter, IFITM1/IFITM3:SRSF1 interaction was validated
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by PLA. Remarkably, there was a higher association between IFITM1/IFITM3:SRSF1 after
IFNγ stimulation, whereas in absence of IFNγ there was a very low signal, very similar to
the background signal obtained in the controls (Figure 4.9). Interestingly, the signal was
present mainly in the cytosol suggesting that IFITM1/IFITM3 association with SRSF1 may
be implicated in protein synthesis. To provide more corroboration, a colocalization assay
was designed to characterize association between ectopically transfected SRSF1 tagged
with T7 at its N-terminus with endogenous IFITM1/IFITM3 (Figure 4.10). An overlap be-
tween both signals was observed, also located in the cytosol.
To give a wider view of this protein, SRSF1 has been also reported to function in trans-
lation and IRES-mediated translation of viral RNA (Bedard et al., 2007). It is been postu-
lated that SRSF1 binds with the cellular RNA binding protein PCBP2 that in turn binds to
an IRES sequence within the genomic RNA of particular RNA-viruses and is furthermore
required for translation. The new role identified here suggests a new function for SRSF pro-
teins in mediating cap-independent translation initiation (Bedard et al., 2007). This find-
ing links with IFITM1 canonical function as a viral restriction factor. As mentioned previ-
ously, IFITM1 is implicated in viral inhibition. Interestingly, most of the viruses described
have ssRNA and normally replicate in the cytosol. Taken together, it may be possible that
IFITM1 interferes with viral replication, altering the splicing of the virus in the cytosol but
also affecting the expression of oncoproteins. During the course of this research, Lee et al.
proposed that IFITMs are able to interfere in HIV-1 protein synthesis. That finding con-
solidated our speculation regarding IFITM1 implications in protein translation (Lee et al.,
2017). There are further examples in which SRSF proteins modulate viral gene expression,
such as herpes simplex virus 1 protein ICP27 interaction with SRSF protein and SRSF pro-
tein kinases (responsible of SRSF protein regulation) (Sciabica et al., 2003). In addition,
they interact with binding sites that are required for export of un-spliced herpesvirus mR-
NAs, and influence other viruses such as human rhinovirus and hepatitis A virus.
To further investigate whether IFITM1/IFITM3 could have some additional effect on
SRSF1, we looked at the global protein levels for SRSF1 but did not find any major differ-
ence between wt-SiHa and IFITM1/IFITM3 double null cells. We next asked if, instead of
altering the total SRSF1 protein amount, it may be influencing its subcellular localization;
to answer this we carried out a cell fractionation assay (Figure 4.11). Several replicates
of this experiment were performed, and no major difference in SRSF1 subcellular loca-
tion was identified. Even though minor difference between fractions may be caused by
IFITM1/IFITM3, it can also be due to technical variability or small cross-contamination
between fractions. In that respect, these results suggest that IFITM1/IFITM3 cooperates
with SRSF1 rather than SRSF1 being a downstream effector of IFITM1/IFITM3. Even so,
it is remarkable that SRSF1 was also found in the cytoplasmic fraction where it interacts
with IFITM1/IFITM3.
Nevertheless, SRSF1 serves as a good example of how low significance proteins iden-
tified by MS methodology could have a real biological impact. In summary this is the first
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evidence suggesting that IFITM1 may have an active role in protein translation. At that
stage we aimed to redefine the biological importance of IFITM1, describing implications
of this protein in a novel cellular role.
SWATH-MS was also applied to compare it with Orbitrap-MS methodology. Ideally,
we would expect these to identify the same interacting partners, but these instruments are
fundamentally different. Initially, we choose SILAC labelling as it allows combining of sam-
ples at an early stage and processing them in the same sample mixture, thus minimizing
handling errors. The expression of the SBP-IFITM1 construct in cells labelled with light or
heavy isotopic amino acids (SILAC media) resulted in the efficient capture of IFITM1 pro-
tein. However, a limitation of the SILAC-MS methodology was found as the dialyzed serum
used in combination with spiked SILAC compatible amino acids produced pronounced
morphological changes in the wt-SiHa cells. Alternatively, it was used a label-free method
(SWATH-MS) that included the use of non-dialyzed serum, which maintained normal cell
morphology. These effects could have given rise (at least partially) to observed differences
in the SiHa cell model proteome, and so impact on the IFITM1 interactome.
Applying label-free methodology, a new interesting set of cell membrane-localized
proteins (Table 4.2) were identified, suggesting a role for IFITM1 in cell–cell communi-
cation. These proteins were not validated as they were beyond the scope of the current
study, although their p-values were more significant in IFNγ-stimulated cells. This might
suggest that the interactions are induced by IFNγ and that they are not constitutive. We
focused more on the possible significance of the co-association of IFITM1 with some of
the classic IFN-inducible proteins, HLA-B and ISG15 (Table 4.2 and subsection 4.3.5).
Results show that IFITM1/IFITM3 are not totally responsible for the HLA-B fate in sub-
cellular compartments. Nonetheless, it may be ventured that it may have some impact on
stability, consequently altering the appropriate trafficking of HLA-B and potentially the
half-life of this protein. In this regard, 2D-gels were performed by our collaborator Prof.
Lenka Hernychova in wt-SiHa and IFITM1/IFITM3 double null cells (data not shown).
There was a shift to the left of HLA-B on comparing IFITM1/IFITM3 double null cells to wt-
SiHa cells, suggesting a deficiency in the integrity of HLA-B in absence of IFITM1/IFITM3
expression. One can speculate that in the absence of IFITIM1/IFITM3 expression, post-
translational modification of some residues (i.e. phosphorylation) may be facilitated, in-
creasing protein stability. On taking a close look at HLA-B in IFITM1/IFITM3 double null
cells by immunofluorescence, HLA-B shows aberrant distribution in IFITM1/IFITM3 dou-
ble null cells compared to that in wt-SiHa cells (Figure 4.16 A-F).
Disclosing results from chapter 5, IFITM1/IFITM3 may have an active role in HLA-
B translation in the presence of IFNγ. If this is true, IFITM1/IFITM3 would not be to-
tally responsible for activating the expression of HLA-B. They would be enhancing HLA-
B expression in a very particular circumstance i.e. in the presence of IFNγ stimulation,
boosting the antigen presentation machinery. In this respect, affinity purification and the
IFITM1/IFITM3: HLA-B proximity ligation assay supports the hypothesis that there is di-
Chapter 4 - Defining IFITM1-IFNγ dependent signalling pathways 120
rect interaction between these proteins only after IFNγ stimulation (Figure 4.14 and Fig-
ure 4.15). Supporting evidence by an independent study concluded that IFITM3 may be
associated with MHC class I molecules, HLA B included, by immunostaining assays. Both
proteins colocalized along with CD81 in exosome-like organelles, particularly after IFNγ
stimulation (Brem et al., 2003). In turn, CD81 is known to be an IFITM1 interacting partner
(Deblandre et al., 1995; Matsumoto et al., 1993; Takahashi et al., 1990) . This matter will be
further discussed in chapter 5.
Significant effort was made to identify differences in the ISG15ylation state in wt-SiHa
and IFITM1/IFITM3 double null cells. We aimed to keep the system as endogenous as
possible, and cells were only stimulated with IFNγ. That proved not enough to activate
the system and thus SiHa cells were additionally transfected with EV to enhance IFNγ sig-
nalling activation (Figure 4.17). Under these conditions, a substantial decrease in total
ISG15ylation levels in IFITM1/IFITM3 double null compared to wt-SiHa cells was found.
This result suggests that IFITM1 and/or IFITM3 are modulating ISG15 conjugation to tar-
get proteins. Nonetheless, it was not determined whether this happened at the protein
level, during protein synthesis or at an even earlier stage. To start assessing this, next chap-
ter will study the implication of IFITM1/IFITM3 dependencies on ISG15 protein produc-
tion.
Another experiment provided conflicting evidence regarding global ISG15 conjuga-
tion. In this case cells were transfected with SBP-ISG15 construct for 48 hours and IFNγ-
stimulated for 24 hours. The outcome of this experiment was consistent between repli-
cates but here ISG15ylation was considerably higher in IFITM1/IFITM3 double null cells
than in wt-SiHa cells (Figure 4.18 A, lane 2 vs lane 7). More evidence comes from the
observation that ISG15ylation is reduced in the presence of IFITM1 or IFITM3 by com-
plementation and this phenotype is more dramatic with the additional loss of the other
IFITM (IFITM1 or IFITM3), artificially resembling the wt-SiHa phenotype (Figure 4.18 A).
Moreover, SBP-ISG15AA (unable to conjugate ISG15) clearly shows a global inhibition of
ISG15ylation (Figure 4.18 B).
What remains consistent between experiments is that IFITM1/IFITM3 directly affects
the levels of global ISG15ylation. Nonetheless, results are contradictory and so it is neces-
sary to think about both experimental designs. Transfected SBP-ISG15 will by-pass some
steps of natural protein synthesis and additionally it does not provide the usual endoge-
nous regulatory gene induction, and thus the system is over-saturated with enormous
amounts of synthetized protein. For these reasons, studying endogenous ISG15 is more
reliable (Figure 4.17).
In summary, we took the results from both MS methodologies and focused on vali-
dating some interesting IFITM1 interacting partners; SRSF1, HLA-B, and ISG15. Taking
everything together, and considering previous work performed in our lab (Figure 3.2), we
suspected that IFITM1 could have a major role in modulating some IRDS, the subset of ISG
proteins found upregulated in chemoresistant tumours (Cheon et al., 2014; Weichselbaum
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et al., 2008a). Furthermore, in this work it is noted that with siRNA depletion of IFITM1
(Figure 3.2), IFITM3 expression was also decreased. Nonetheless, due to high homology it
cannot be completely assured that the protein identified was in fact IFITM1. In any case,
protein interactions have been studied from the IFITM1 perspective, but it remains un-
known if IFITM3 also contributes to IFTIM1 functions. For instance, ISG15 is initially pro-
posed as an interacting partner of IFITM1 by MS (Figure 4.13) but it can be observed that
IFITM3 can also play an active role on ISG15ylation by Western blotting (Figure 4.17 and
Figure 4.18). This would imply that both proteins have synergetic effects over their effec-
tors. Moreover, association of IFITM1 with SRSF1 may be implicated in mediating mRNA
guidance to the ribosome.
All-in-all, it could be argued that IFITM1 (maybe in cooperation with IFITM3) may
have an effect on protein production, possibly by altering either trafficking or protein
translation. As such, in the upcoming chapter 5, we will concentrate on understanding
the impact of the IFITM1 pathway on IFNγmediation of protein synthesis.
Chapter 5
Analysis of IFITM1/IFITM3 roles in
ribosomal integrity and protein
synthesis in the SiHa cervical cancer
cell model
5.1 Introduction
The cytokine IFNγ is able to induce expression of a wide range of genes, and the aim of
this study was to investigate the potential IFITM1/IFITM3-dependent expression of some
of these genes. In the last chapter, we showed that IFITM1 could be involved in the pro-
cess of protein translation. Firstly, we described SRSF1 as a novel interacting partner of
IFITM1/IFITM3. This association occurs in the cytoplasm and is significantly increased
after IFNγ stimulation (Figure 4.9). An alternative role of the SRSF1 splicing factor relates
to guiding of mRNA to the ribosome. Together, these findings highlight the importance of
studying protein synthesis. Secondly, two other novel IFITM1 interaction partners, HLA-B
and ISG15, were found to be associated with IFITM1/IFITM3 proteins in IFNγ-stimulated
wt-SiHa cells. Both proteins are encoded by IRDS genes, which represent a subset of 32
interferon-stimulated genes including IFITM1, but not IFITM3, proteins. The data pre-
sented in chapter 4 demonstrated that loss of IFITM1/IFITM3 expression results in alter-
ations in HLA-B protein abundance and globally they also change protein ISG15ylation
(subsection 4.3.5).
Thus far, these results have been considered from a proteomic perspective. However,
protein synthesis is the final stage of gene expression, which is a highly regulated process
influenced at various stages by physiological and/or pathological factors. As such, IFITM1,
along with IFITM3, may interact with and regulate ISG15 and HLA-B (and potentially other
molecules) at different stages. Nonetheless, previous empirical work has served to focus
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attention on translation at the ribosome, one of the core events of protein regulation. We
hypothesised that IFITM1, along with IFITM3, may control the protein synthesis of par-
ticular ISG genes. To study this possibility, we examined the ribosomal status in wt-SiHa
cells and IFITM1/IFITM3 double null cells after IFNγ stimulation.
5.1.1 Defining the approach applied to study ribosome integrity
Translation is a complex multi-step process which takes place on the ribosome. Ribo-
somes are composed of two major ribonucleoprotein structures, the 40S and 60S subunits.
In brief, the 40S subunit facilitates the appropriate codon-anticodon pairing to deter-
mine the correct amino acid sequence while the 60S subunit contains the peptidyl trans-
ferase centre which catalyses peptide bond formation in the synthesised peptide (Wilson
& Doundna Cate, 2012). Being a fundamental biological process, translation requires the
active and precise participation of many proteins, and even subtle defects in the transla-
tional machinery can lead to catastrophic effects which may compromise cell health.
Sucrose density gradient ultracentrifugation is a technique that enables the separa-
tion of mRNA and ribosomal subfractions. In the present study, this technique was used
to investigate the roles of IFITM1/IFITM3 proteins at the ribosome. Polysome profiling
was then used to identify and distinguish actively translated mRNAs from those that re-
main untranslated. Additionally, this technique provides some insights into possible al-
terations in ribosomal proteins in the absence of IFITM1/IFITM3 protein expression. The
assay is based on a sucrose gradient separation of ribosomes and associated mRNAs. Sub-
ribosomal fractions (40S, 60S, 80S and polysome) separate based on their sedimentation
coefficient along the sucrose gradient in the following order from bottom to top of the gra-
dient: polysome, 80S, 60S, 40S and free mRNAs (Figure 5.2 II). Finally, the sub-ribosomal
fractions were analysed by SWATH-MS.
5.1.2 Pulse SILAC, an emergent technique to study protein turnover
The results relating to ribosomal status highlighted the need to investigate whether
IFITM1/IFITM3 proteins are involved in the control of protein synthesis. Analysis of the
correlation between mRNAs and protein expression levels is challenging. Protein expres-
sion and regulation are influenced by many described cell perturbations (including IFNγ
signalling). Expressed proteins undergo posttranslational modifications, and degradation
rate changes alter their half-life, therefore it is difficult to predict the protein fate. We
are particularly interested in the rapid IFITM1/IFITM3-dependent protein expression that
occurs in response to IFNγ stimulation, and therefore aimed to explore the capacity of
IFITM1/IFITM3 proteins to precisely regulate protein synthesis.
Applying MS methodologies that analysed the whole cell proteome provide little in-
formation about the proteins that are being actively translated during IFNγ stimula-
tion. Thus, label-free SWATH-MS and SILAC-Orbitrap-MS (subsection 4.3.4 and subsec-
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tion 4.3.2) cannot be used as they measure the accumulated abundance of proteins. An
alternative MS approach is therefore required to measure protein abundance in a more
dynamic way.
Pulse SILAC is a relatively new MS technique, which allows the measurement of protein
turnover. It follows the same principles as conventional SILAC labelling but, in this case,
cells are labelled (spiked) with SILAC media for a short period of time. This allows the in-
corporation of isotopic amino acids only in newly synthesized polypeptides (Figure 5.1).
In this experimental approach, the cell proteome is partially labelled (previously trans-
lated proteins in light media and new synthesized proteins in heavy media). As in conven-
tional SILAC, protein quantification is determined by the fold-change ratio of heavy/light
labelled proteins. Fold-change ratio is a relative measurement, and it is limited by the in-
dividual amount of protein present in cells. By applying this methodology it is possible
to determine the immediately translated proteins on a global scale (Doherty et al., 2009;
Doherty & Beynon, 2006).
Figure 5.1: Schematic of pulse SILAC principle for measuring protein turnover. Protein turnover is a very
dynamic process in which protein levels are constantly balancing between protein synthesis and degradation
to maintain cellular homeostasis. (I) Schematic representation of the continuous cellular renewal of proteins
from assembly (protein synthesis) to breakdown (protein degradation). (II) To analyse protein turnover, cells
were labelled with SILAC media for a short time (spiked) to isotopically label arginines and lysines. Only newly
synthesized proteins contain the isotopically labelled amino acids.
5.2 Aims of the chapter
In the previous chapter it was speculated that IFITM1/IFITM3 proteins may have a role
in the translation process. To further study whether ISG/IRDS gene synthesis is modulated
by IFITM1/IFITM3 proteins, sucrose density gradient separation coupled to MS-SWATH
and pulse SILAC experiments were performed to evaluate the implications of IFITM1 and
IFITM3 proteins in the IFNγ gene expression pathway.
CRISPR/Cas9 engineered IFITM1 null cells, and IFITM1/IFITM3 double null cells
(chapter 3) along with wt-SiHa cells were used to define IFITM1 and IFITM3 effects on ri-
bosomal integrity, to understand whether IFITM1/IFITM3 proteins interact with polyso-
mal fractions, to determine whether the interactions are IFNγ-dependent, and whether
IFITM1/IFITM3 are required for protein synthesis of IFNγ-responsive proteins.
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5.3 Results
5.3.1 Study of ribosomal integrity in IFNγ-stimulated wt-SiHa cells vs IFNγ-
stimulated IFITM1/IFITM3 double null cells and the IFITM1/IFITM3 lo-
cation in the ribosome
First, we aimed to define ribosomal integrity by studying its structural protein compo-
nents. To address this, ribosomal profiles were analysed in IFNγ-stimulated wt-SiHa cells,
compared with IFNγ-stimulated IFITM1/IFITM3 double null cells; both cell types were
stimulated with 100 ng/ml IFNγ for 24 hours (Figure 5.2). It was predicted that wt-SiHa
cells would differ significantly in comparison to IFITM1/IFITM3 double null cells. The
IFITM1/IFITM3 double null cells (instead of IFITM1 null cells) were used, as it was sus-
pected that IFITM3 can partially replace or compensate for some IFITM1 molecular func-
tions. This isogenic cell model has only depleted the expression of two proteins, IFITM1
and IFITM3. In addition, the ribosome machinery has compensatory mechanisms to by-
pass malfunctions, consequently identification of ribosomal integrity defects (even subtle
ones) is difficult.
Figure 5.2: Overview of ribosomal profiling method to study ribosomal integrity. (I) Cells were treated
with cycloheximide for 30 minutes. (II) Ribosomal subunits were separated by sucrose density gradient ultra-
centrifugation and followed by fractionation (III). Fractions of the same ribosomal subunits were combined
and sequentially analysed by Western blotting after trichloroacetic acid (TCA) protein precipitation (IV) or by
SWATH-MS (V).
The IFNγ-stimulated wt-SiHa cells and IFNγ-stimulated IFITM1/IFITM3 double null
cells were treated with cycloheximide for 30 min prior to collection, to maintain interaction
of ribosome-associated proteins and retain ribosomal integrity, as cycloheximide prevents
polysome run-off during cell lysis (Figure 5.2 I). Cycloheximide is a translation elongation
inhibitor that binds to the 60S ribosomal subunit and stops the translation elongation step
by blocking the release of deacylated tRNA from the ribosome E site (Del Prete et al., 2007).
The lysis buffer contained EGTA and a high salt concentration to preserve RNA (Brand-
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horst, 2004), and an anti-protease cocktail to prevent protein degradation.
Fractions containing ribosomal subunits, were monitored by absorbance at 254 nm.
The representative A254 peaks of 40S, 60S, 80S and polysomal ribosomes are depicted
in the absorbance profile for the RNA in Figure 5.2 III. The major difference observed
was a significantly lower 80S subunit fraction in IFNγ-stimulated IFITM1/IFITM3 double
null cells compared to IFNγ-stimulated wt-SiHa cells; this was seen in three independent
replicates (Figure 5.3). Furthermore, the 80S peak difference was partially recovered after
transfecting IFITM1 and IFITM3 in the IFITM1/IFITM3 double null cells, resembling the
80S peak in wt-SiHa cells in three independent replicates (Figure 5.4, wt-SiHa cells trans-
fected with empty vectors vs IFITM1/IFITM3 double null cells transfected with IFITM1
and IFITM3). These results are of great interest, even though transfection efficiency was
not good enough, transfected cells with IFITM1 and IFITM3 were enough to partially re-
store the 80S peak (Figure 5.4, IFITM1/IFITM3 double null cells transfected with empty
vectors vs IFITM1/IFITM3 double null cells transfected with IFITM1 and IFITM3). These
data indicate an impairment in the 80S monosome subunit after losing IFITM1/IFITM3
protein expression.
Then, ribosomal fractions from a representative replicate were combined (Figure 5.3
A); fractions belonging to the same ribosomal subunit were pooled. Protein was sequen-
tially concentrated by trichloroacetic acid (TCA) protein precipitation, and immunoblots
(Figure 5.2 IV) were performed to validate the appropriate ribosomal subunit separation;
IFITM1/IFITM3 proteins were present but, progressively decreasing in amounts, in all
ribosomal fractions; 40S, 60S, 80S, and polysome, from IFNγ stimulated wt-SiHa cells.
There was no trace, in any fraction, of IFITM1/IFITM3 proteins in the IFNγ-stimulated
IFITM1/IFITM3 double null cells (Figure 5.5 B). As a positive control, RPL7a protein was
included; this is a component of the 60S ribosomal (Robledo et al., 2008) and is associated
with the endoplasmic reticulum (Wei-Cheng et al., 2007). RPL7a was detected in IFNγ-
stimulated wt-SiHa cells and IFNγ-stimulated IFITM1/IFITM3 double null cells (Figure 5.5
B). As indicated in Figure 5.5 A, fractions 7–9 correspond to 60S subunit in the cartoon.
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Figure 5.3: Original scans of the mRNA trace after sucrose density gradient fractionation in three indepen-
dent replicates. (A–D). Sucrose density gradient was performed in wt-SiHa cells and IFITM1/IFITM3 double
null cells stimulated with IFNγ for 24 hours to activate the IFN-protein synthesis response. The original mRNA
trace depicted in (A) is the replicate used to perform the ribosomal SWATH-MS (Figure 5.5). (A). A higher 80S
peak (A254) was observed in wt-SiHa cells compared to in IFITM1/IFITM3 double null cells in all three repli-
cates (A-C).
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Figure 5.4: Original scans of the mRNA trace after sucrose density gradient fractionation to recapitulate the
wt-SiHa 80S peak in IFITM1/IFITM3 transfected IFITM1/IFITM3 double null cells. (A-C) Sucrose density
gradient was performed in wt-SiHa cells and IFITM1/IFITM3 double null cells stimulated with IFNγ for 24
hours to activate the IFN-protein synthesis response. The IFITM1/IFITM3 double null cells were transiently
transfected with IFITM1 or IFITM3 to recapitulate the 80S peak seen in the wt-SiHa cells. The wt-SiHa cells
as well as IFITM1/IFITM3 double null cells were transfected with EV to compensate possible change in the
protein synthesis induced by the transfection method or presence of plasmid inside the cell.
Another representative replicate was processed by label-free SWATH-MS (Figure 5.2
V). Analysis was performed in three technical replicates. The purpose was to define
whether there were global proteomic changes in the protein constituents of the ribosome
following depletion of IFITM1/IFITM3 proteins in the IFNγ-stimulated cells. A volcano
plot was used to quickly identify differential expression of ribosomal proteins and newly
synthesised polypeptides between IFNγ-stimulated wt-SiHa cells and IFNγ-stimulated
IFITM1/IFITM3 double null cells. The differential protein expression of the quanti-
fied fold-change ratio (heavy/light) in IFNγ-stimulated wt-SiHa cells vs IFNγ-stimulated
IFITM1/IFITM3 double null cells is represented in Figure 5.5 C-F. The 40S associated pro-
teins throughout the ribosomal peak fractions were similar in IFNγ-stimulated wt-SiHa
and IFNγ-stimulated IFITM1/IFITM3 double null cells (Figure 5.5 C), with only a few 40S
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components over-represented (Figure 5.5 C). Similarly, the 60S protein family members
were almost equivalent, with a few over-represented proteins (Figure 5.5 D, polysome frac-
tion). Other over-represented non-related ribosome structure proteins were evaluated in
IFNγ-stimulated wt-SiHa cells.
Interestingly, CAV1 protein, identified in the 80S and polysome fraction, was
over-represented in the IFNγ-stimulated wt-SiHa cells compared to IFNγ-stimulated
IFITM1/IFITM3 double null cells and it served as internal positive control as it is been
proposed an IFITM1 interacting partner (Novita Sari et al., 2016; Yu et al., 2015) (Figure 5.5
E and F). CAV1 was validated by PLA, however these IFITM1-associated proteins were
beyond the scope of the current study and they were not further investigated (data not
shown). Likewise, VAPB protein was also detected in the 40S and the polysome fraction
and it is also a well-defined IFITM1-associated protein (Amini-Bavil-Olyaee et al., 2013)
(Figure 5.5 C and F).
The 40S ribosomal fraction had over-represented U2AF1 in IFNγ-stimulated wt-SiHa
vs IFNγ-stimulated IFITM1/IFITM3 double null cells (Figure 5.5 C). This is a splicing fac-
tor that has been proposed as interacting partner for IFITM1 (Table 4.1). In fact, U2AF1
can associate with mature RNAs to guide them to the ribosome. Once on the ribosome,
Palangat et al., 2019 proposed that U2AF1 can also function as a translation regulator by in-
hibiting the synthesis of selected peptides. It is suggested that U2AF1 forms a heterodimer
with U2AF2 factor and binds in a region close to the mRNA start codon, possibly regulating
the initiation of specific transcripts (Palangat et al., 2019). Our results show higher U2AF1
association to the 40S fractions of IFNγ-stimulated wt-SiHa cells (Figure 5.5 C), fraction
where the mRNA is initially loaded into the ribosomes (Walsh & Mohr, 2013).
To our surprise, STAT1 was also over-represented in the wt-SiHa vs IFITM1/IFITM3
double null cells, both stimulated with IFNγ. This is a key factor in the IFNγ pathway and
was identified in the 40S, 60S, and 80S fractions. Little is known about the role of STAT1 in
protein translation, but Wang et al. propose that it can regulate mRNA translation by in-
duction of the phosphoinositide 3-kinase (PI3K) and 4E (eI4E)-binding protein 1 (4EBP1),
a repressor of the translation initiation. These leads to increase in the translation of cap-
independent transcripts (Wang et al., 2015). STAT1 has not been reported as having a direct
association with the ribosome.
The results suggested that IFITM1/IFITM3 were present in the ribosome fractions (Fig-
ure 5.5 B), so we explored the possibility that IFITM1/IFITM3 could associate to ribosome
proteins by studying the protein–protein interaction between IFITM1/IFITM3 and RPL7a.
RPL7a is a ribosome-specific protein used as a marker to identify the ribosomes in the cell.
It is a component of the 60S ribosomal subunit and it contains two nucleic acid-binding
domains, one at the N-terminus and the other at the C-terminus. Interestingly, RPL7a is in-
volved in translation and so it can also regulate the expression of some mRNAs (Neumann
& Krawinkel, 1997; Neumann et al., 1995). Moreover, it is also implicated in ribosomal
biogenesis (Robledo et al., 2008) and translation (Neumann et al., 1995).
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Figure 5.5: Ribosomal analysis by SWATH-MS in wt-SiHa IFNγ-stimulated cells and IFITM1/IFITM3 dou-
ble null IFNγ-stimulated cells. (A) Following the stimulation of wt-SiHa cells and IFITM1/IFITM3 double null
cells with IFNγ for 24 hours, cells were lysed with ribosome stabilization buffer, and applied to a sucrose gra-
dient to separate individual components of the large and small ribosomal subunits, and polysomes. Eluted
fractions were scanned at A254 nm. As indicated in the diagram; 40S subunit was eluted in fractions 3–5,
60S subunit in fractions 6–8, 80S subunit in fractions 9–11, and polysomes in fractions 12-18. The dotted
line highlights the reproducible 80S peak reduction in the A254 signal in eluates from IFITM1/IFITM3 double
null cells. (B) Following fractionation, samples from fractions 1–18 were precipitated by trichloroacetic acid
(corresponding to samples in Figure 5.3 A) and were analysed for key proteins as indicated, including RPL7a
(enriched from 60S as defined by sucrose gradient), and IFITM1/IFITM3 proteins (enriched in all wt-SiHa
fractions). Following SWATH-MS of eluted samples from IFNγ-stimulated wt-SiHa cells and IFNγ-stimulated
IFITM1/IFITM3 double null cells (Table B.4). Visualisation of the volcano plot by plotting the log2 fold-change
ratio (wt/null) of 40S (C) 60S (D) 80S, (E) and polysome (F) fractions represented on the x-axis and -log10 p-
value on the y-axis. (C-F) The analysis was conducted using R software and figures were produced using the
Enhanced volcano, R package version 1.0 (Blighe, 2019). Horizontal dashed lines delimit the fold-change cut-
off> 2 for upregulated and<0.5 for downregulated in the x-axis and vertical dashed line delimits the p-values
cut-off<0.05 in the y-axis. Significant values for fold-change and p-value are depicted in red, right quadrant as
overrepresented and left quadrant as under-represented proteins. Significant values for fold-change are de-
picted in green. Significant values for p-value are depicted in blue. Non-significant (NS) values are depicted
in grey.
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In the attempt to validate IFITM1/IFITM3 protein presence in the ribosome, IFNγ-
stimulated and non-stimulated wt-SiHa cells were fixed for a proximity ligation assay (Fig-
ure 5.6 A-D). The IFITM1/IFITM3 double null cells were used as a negative control (Fig-
ure 5.6 E-H). The Figure 5.6 D shows a representative image of IFNγ-stimulated wt-SiHa
cells in which there is a high association between IFITM1/IFITM3-RPL7a proteins in the
cytosol. The assay shows a significantly increased protein–protein association between
IFITM1/IFITM3-RPL7a after IFNγ-stimulation compared to that in non-stimulated wt-
SiHa cells (Figure 5.6 C vs D and I). In contrast, there is no detectable signal in IFNγ-
stimulated IFITM1/IFITM3 double null cells (Figure 5.6 H and J).
Figure 5.6: Evaluation of the IFITM1/IFITM3:RPL7a protein–protein expression and interaction in situ af-
ter stimulation with IFNγ. Proximity ligation assays were used to study the endogenous interaction between
RPL7a and IFITM1/IFITM3 proteins in wt-SiHa (A–D) and IFITM1/IFITM3 double null cells (E–H) FITC im-
ages identify the protein–protein association foci (green) and DAPI was used for nuclear staining (blue). (A–B
and E–F) Cells were incubated as negative controls using IFITM1/IFITM3 or RPL7a antibodies only. (C and
G) Cells were incubated with both IFITM1/IFITM3 and RPL7a antibodies to define protein–protein foci in
non-stimulated cells. (D and H) Cells were incubated with both IFITM1 and RPL7a antibodies to define pro-
tein–protein foci in IFNγ-stimulated cells. Representative quantification of the protein–protein interaction
foci per cell in presence or absence of IFNγ stimulation in wt-SiHa (I) and IFITM1/IFITM3 double null (J).
At least 50 cells were counted for each condition. Statistical study was performed with one-way ANOVA and
Bonferroni correction (****p < 0.0001; ns, not significant). n=3. Scale bar: 10 µm.
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5.3.2 Pulse SILAC to identify IFITM1- and IFITM1/IFITM3- dependent protein
synthesis in response to IFNγ signalling
The cytokine IFNγ is capable of inducing expression of a wide range of genes
through the activation of the JAK kinase–STAT pathway (Darnell et al., 1994; Williams,
1991). We evaluated whether IFNγ responsive protein synthesis is impaired by loss
of IFITM1/IFITM3 protein expression. The wt-SiHa cells, IFITM1 null cells, and
IFITM1/IFITM3 double null cells were grown in parallel with SILAC heavy isotopic amino
acid labelling media for 6 or 24 hours, non-stimulated or stimulated with 100 ng/ml IFNγ
for 6 or 24 hours, respectively (Figure 5.7 A). The 24-hour time point was the maximum
IFITM1 peak induction on IFNγ stimulation (Figure 4.16 I). The earlier 6-hour time point
was included to study which proteins were initially activated and if their induction var-
ied with time. This time point was a compromise between capturing the first wave of
IFNγ-activated effectors but not so early that there would not be enough heavy-isotope-
labelled newly synthetized proteins to be identified in the MS analysis (Figure 5.7). More-
over, the classic IFNγ-responsive synthesis of proteins is observed in this SiHa cell line
(Figure 5.8), indicating that these cells are a good model to dissect the IFNγ-signalling cas-
cade. Cell lysates were processed by FASP section 2.8.1 and analysed by MS for IFNγ and
IFITM1/IFITM3-dependent protein synthesis (Figure 5.8 B, D, F vs A, C, E; Figure 5.9B, D,
F vs A, C, E).
This experiment was designed to determine those proteins after IFNγ stimulation that
are IFITM1/IFITM3-dependent. The induced proteins identified in IFNγ stimulated wt-
SiHa cells were compared to those in IFNγ stimulated IFITM1/IFITM3 double null cells.It
was determined whether these identified IFNγ-induced proteins were indeed IFITM1-
dependent. Hence, the induced proteins identified in IFNγ stimulated wt-SiHa cells were
compared to those in IFITM1 null-IFNγ stimulated SiHa cells.
The first step was determining which proteins are significantly induced after IFNγ
stimulation in wt-SiHA cells. A preliminary analysis to address this question was kindly
performed by Prof. Lenka Hernychová using the Proteome Discoverer 2.2 platform
(Thermo Fisher Scientific). This was used to compare those proteins significantly ex-
pressed in wt-SiHa cells with or without IFNγ stimulation. Strikingly, MHC class I
molecules (HLA-A, HLA-B, and HLA-C) were the major dominant ISG genes induced (Fig-
ure 5.7 B and C) and were consistently identified across all three replicates. Two additional
proteins were heavily induced; B2M which is the light chain of MCH class I complex, and
STAT1 which is the key transducer effector of the IFNγ signalling pathway. Several studies
have demonstrated that these proteins are upregulated upon IFNγ stimulation (subsec-
tion 1.5.3).
The novelty of this experimental approach is determining whether these differences
are IFITM1 and/or IFITM1/IFITM3-dependent. For this reason, the same comparison of
stimulated and non-stimulated cells was made in both isogenic knock out SiHa cell lines.
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In this case, a more exhaustive analysis was performed on all the proteins identified by
MS (Figure 5.8 for 6 hours IFNγ stimulation and Figure 5.9 for 24 hours IFNγ stimula-
tion). Interestingly, not many over-represented proteins were identified, suggesting that
IFITM1 and IFITM1/IFITM3 are modulating very specific targets. This finding supports
the previous outcome where global ribosomal integrity was not drastically perturbed but
the 80S peak was decreased, denoting a certain limited impairment in protein synthesis
(Figure 5.3).
The experiment was designed with two different time points; initially 6 hours of pulse
SILAC was analysed. The first dominant protein of note is STAT1 which was only induced
after IFNγ-stimulation in the entire cervical cancer cell panel i.e. wt-SiHa cells, IFITM1
null cells, and IFITM1/IFITM3 double null cells (Figure 5.9 A-F and I). STAT1 was used
as an internal positive control as an example of a protein that is IFNγ-dependent but
IFITM1/IFITM3 independent.
Other proteins whose synthesis rates were evaluated at 6 hours post-labelling included:
ISG15, EIF1, B2M, and HLA-B (Figure 5.8 G, J, K, and L). Peptides identified from EIF1 and
B2M were not substantially different between wild type and both isogenic null cells. EIF1
is a key component for the assembly of the translation initiation complex. It facilitates 40S
conformation and, consequently, allows the mRNA scan to precisely select the AUG start
codon (Cheung et al., 2007; Passmore et al., 2007; Pestova et al., 2001). B2M is the light
chain of MHC molecules (Neefjes et al., 2011). In addition, ISG15 and HLA-B were not
detected at early stages. Likewise, another member of MHC class I molecules, HLA-C, was
not detected (Figure 5.9 A-F).
IRF1 protein synthesis was IFNγ-dependent after 6 hours post-labelling in wt-SiHa
cells, but IRF1 peptide recovery was attenuated in all triplicates in IFITM1/IFITM3
double null cells (Figure 5.8 H). This suggested that IRF1 is partially dependent upon
IFITM1/IFITM3 signalling at a very early stage. IRF1 is an IFN regulatory factor induced
by type I and type II IFN and it is involved in mediating antiviral and immunomodulatory
roles(Harada et al., 1994; Tamura et al., 2008).
Overall, very few proteins were overrepresented in the 6 hour pulse SILAC. Possibly,
there was not enough time to fully induce all the dominant effectors. Moreover, protein
synthesis is evaluated by comparing the fold-change rate between heavy (already synthe-
sized proteins) vs light (newly synthesized proteins). Taking this into consideration, it may
occur that even if the cell is synthesizing new proteins, these are not significantly increased
enough to be compared to the total amount of protein present in the cell and consequently
the ratio heavy/light is very low. Therefore, the 24 hour pulse SILAC was analysed.
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Figure 5.7: Pulse SILAC to identify global changes in protein synthesis in wt-SiHa cells, IFITM1 null cells,
and IFITM1/IFITM3 double null cells. (A) Workflow describing the steps followed to perform pulse SILAC;
SILAC heavy medium was introduced for 6 and 24 hours to non-stimulated and IFNγ-stimulated cells for 6
and 24 hours. (B) Volcano plot was used for quick identification of protein changes of wt-SiHa cells cultivated
for 24 hours in heavy SILAC media (Table B.5). This analysis was performed using the Proteome Discoverer
2.2 platform (Thermo Fisher Scientific). The right upper quadrant (highlighted in red) displays significantly
upregulated proteins that were newly synthesized in 24 hour INFγ-stimulated wt-SiHa cells compared to non-
stimulated wt-SiHa cells. The x-axis displays the abundance ratio (fold-change) in log2 with initial setting 1,
and the y-axis displays p-values in log10 with initial setting 0.05. (C) The quantification channel values plot
for precursor ion quantification displays the relative peak area with the standard deviation of the biological
replicate measurements for HLA-A, HLA-B, HLA-C, B2M, and STAT1 proteins with the heavy isotope labels
(non-stimulated and IFNγ-stimulated for 24 hours). The x-axis displays the quantification channel and the
y-axis displays the detected area of the selected protein for the given quantification channel defined by counts
x seconds.
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Figure 5.8: Defining dominant proteins whose synthesis is IFITM1/IFITM3-IFNγ attenuated at an early
stage. SILAC pulse labelling was performed in wt-SiHa cells (A–B); in IFITM1 null cells (C–D); and in
IFITM1/IFITM3 double null cells (E–F) (Table B.5). Cells were stimulated with IFNγ for 6 hours in B, D and F.
Samples were plotted as a function of log10 fold-change of heavy/light peptide intensities. Biological tripli-
cates are represented in the x, y, and z- axis (B–F), whereas only two biological replicates were available in (A).
Graph bars showing the most significant synthetized protein in each of the three biological replicates for 6
hours pulse labelling: IRF1 (H); non-stimulated at early stage: ISG15 and HLA-B (G and L); proteins that were
taken as internal controls at the indicated pulse labelling time points such as: STAT1, EIF1, and B2M (I–K).
By 24 hours of IFNγ stimulation (Figure 5.9 A-F), the isotopically labelled IRF1 pep-
tides recovered were attenuated (Figure 5.9 H). This is consistent with the early and tran-
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sient induction of IRF1 by IFNγ. Previous work performed by Dr Elisabeth Sinclair con-
firmed, using a luciferase reporter assay, that IRF1 transcription activity is attenuated in
cells with a targeted depletion of IFITM1 (data not shown). In contrast to IRF1, the el-
evation in STAT1 (internal positive control) synthesis after 24 hours with IFNγ appears
largely IFITM1/IFITM3-independent (Figure 5.9 B, D, F, and I). Another well-known in-
ducible IFNγ protein, B2M, also appears to be IFITM1/IFITM3-independent (Figure 5.9
A–F and K). Moreover, there is an elevation in amount of HLA-A, HLA-B, and HLA-C at 24
hours of IFNγ stimulation in wt-SiHa cells (Figure 5.9 A vs B). Together, these data indi-
cate that the SiHa cervical cancer cell model activates the classic IFNγ response i.e. able
to induce STAT1, IRF1, B2M, and MHC class I molecules.
Strikingly, there was an absence of HLA-A, HLA-B, and HLA-C protein synthesis af-
ter 24 hours with IFNγ in the IFITM1/IFITM3 double null cells compared to wt-SiHa cells
(Figure 5.9 B vs F). Similar results were observed in the IFITM1 null cells (Figure 5.9 B vs
D). Furthermore, isotopically labelled ISG15 tryptic peptides are not observed in the early
IFNγ response (Figure 5.8 A-G), but the isotopically labelled ISG15 peptide recovery after
24 hours with IFNγ is elevated in the wt-SiHa cells (Figure 5.9 B and G) and not seen in
IFITM1 null cells or IFITM1/IFITM3 double null cells (Figure 5.9 D, F and G) suggesting
that ISG15 protein synthesis is largely IFITM1/IFITM3 dependent in the late stage.
MHC class I molecules (HLA-A, HLA-B, HLA-C) along with ISG15 were by far the ma-
jor dominant proteins induced by IFITM1/IFITM3-IFNγ stimulation. Considering that
HLAs have homologous regions, peptides identified by MS methodology were manually
validated and unique peptides for each HLA type are indicated with a red asterisk in Fig-
ure 5.10.
In summary, IFNγ-dependent induction of IRF1 protein synthesis is attenuated at 6
hours post-labelling in IFITM1/IFITM3 double null cells but also in IFITM1 null cells (Fig-
ure 5.8 H). This suggests that IRF1 is dependent upon IFITM1. ISG15 tryptic peptides are
not observed in the early IFNγ response (Figure 5.8 G) but are only overexpressed as a late
response in wt-SiHa IFNγ-stimulated cells (Figure 5.9 G). In contrast, elevations in STAT1
protein synthesis are IFITM1-independent, based on the equivalent induction of STAT1
in the IFITM1 null cells and IFITM1/IFITM3 double null cells in comparison with wt-SiHa
cells (Figure 5.9 I). HLA-A, HLA-B, and HLA-C protein synthesis is also attenuated after 24
hours IFNγ stimulation in the IFITM1 null cells and IFITM1/IFITM3 double null cells (Fig-
ure 5.9). Together, these data indicate that MHC class I family members, as well as ISG15,
require IFITM1 for rapid IFNγ-induced protein expression.
These results provide further evidence to support previous work performed in our
group (Figure 3.2) where attenuation of IFITM1 by siRNA decreased protein levels of MHC
class I molecules as well as ISG15. Moreover, it is consistent with findings described in the
previous chapter where HLA-B and ISG15 were identified as novel interacting partners for
IFITM1. Nonetheless, the possibility cannot be ruled out that IFITM1 and IFITM3 proteins
are modulating HLA-B and ISG15 at stages other than protein synthesis.
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Figure 5.9: Defining dominant proteins whose synthesis is IFITM1/IFITM3-IFNγ attenuated in the late
stage. SILAC pulse-labelling was performed in wt-SiHa cells (A, B); in IFITM1 null cells (C, D); and in
IFITM1/IFITM3 double null cells (E, F) (Table B.5). Cells were stimulated with IFNγ for 24 hours in B, D and
F including the pulse label. Data were plotted as a function of log10 fold change of heavy/light peptide in-
tensities. Biological triplicates were represented in x, y, and z- axis. In samples (G–I), representative peptides
used for quantification in biological triplicates are highlighted to demonstrate a protein that is induced inde-
pendent of IFITM1/IFITM3 (STAT1; I, EIF1; J, and B2M; K), IFITM1/IFITM3-dependent at a later time point
(ISG15; G vs Figure 5.8 G and HLA-B; L vs Figure 5.8 L), and IFITM1/IFITM3-dependent at an earlier time
point (IRF1; H vs Figure 5.8 H).
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Figure 5.10: Tryptic peptides identified for HLA-A, HLA-B and HLA-C. Underlined are the peptides identified
in HLA-A, HLA-B and HLA-C for wt-SiHa cells, wt-SiHa-IFNγ stimulated cells, IFITM1 null cells, IFITM1 null-
IFNγ stimulated cells, IFITM1/IFITM3 double null cells, and IFITM1/IFITM3 double null-IFNγ stimulated
cells. Additionally, highlighted (*) are the unique peptides characteristic for each MHC class I orthologue.
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5.3.3 Dissecting IFITM1/IFITM3-IFNγ dependencies in the SiHa cervical can-
cer cell model by Western blot analysis
The IFN signalling pathway is a complicated system in which many components inter-
act throughout a cellular cascade of events. Though this project has a particular focus on
IFNγ signalling, it is known that all three IFN types can affect each other, promoting cross-
activation of their pathways. As a result, effectors may have redundant roles, making it
complicated to dissect individual protein functions (Dunn et al., 2006).
We tested our SiHa cancer cell model (comprised of wt-SiHa cells, IFITM1 null cells,
and IFITM1/IFITM3 double null cells) to determine if there were any differences in the
IFNγ activation cascade as well as in IFITM1/IFITM3 protein expression. In brief, the IFNγ
signalling pathway initiates with the cross-tyrosine phosphorylation of JAK-kinases that
facilitate dimerization of signal transducer STAT1. The STAT1 dimers forms a complex
with the regulatory factor IRF9 and this induces expression of the first wave of ISG genes,
among them IRF1 transcription factor (Boehm et al., 1997).
Cells were IFNγ stimulated for 6 and 24 hours to determine early and more sustained
responses, respectively. In this sense, IFNγ stimulation mimics the same conditions per-
formed for the pulse SILAC (subsection 5.3.2). Importantly, this experiment evaluates
the total amount of protein present in the cell. This approach does not take into ac-
count any possible cellular compensatory effects to overcome the absence of IFITM1 or
IFITM1/IFITM3.
There is a subtle reduction in STAT1 induction in IFITM1/IFITM3 double null cells
compared to wt-SiHa cells (Figure 5.11, STAT1 panel). Similarly, there is a pronounced
reduction of IRF1 expression in IFITM1/IFITM3 double null cells, more noticeable in the
long exposure panel (Figure 5.11, IRF panel). A delay in the STAT1 induction, in compari-
son to IRF1, is also observed (Figure 5.11, STAT1 and IRF1 panel), and there is a reduction
in HLA-B as well as ISG15 expression in IFITM1/IFITM3 double null cells compared to
wt-SiHa cells. Overall, the IFNγ system is attenuated in IFITM1/IFITM3 double null cells,
whereas IFITM1 null cells resemble wt-SiHa cells in terms of IFNγ signature expression.
These observations are not comparable with the results of the pulse SILAC experiments in
the previous section as total protein expression is assessed in this section whereas pulse
SILAC experiments study the synthesized proteins after IFNγ stimulation.
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Figure 5.11: Identifying global changes in IFN signature in wt-SiHa cells, IFITM1 null cells, and
IFITM1/IFITM3 double null cells after IFNγ stimultaion. Wt-SiHa cells (lanes 1-3), IFITM1 null cells (lanes
4-6), and IFITM1/IFTIM3 double null cells (lanes 7-9) were stimulated in absence or with 100 ng/ml IFNγ for
6 hours (lanes 2, 5, and 8) and 24 hours (lanes 3, 6, and 9). Western blotting was used to characterize the ex-
pression of key IFN-induced proteins; STAT1, IRF1, HLA-B, IFITM1/IFITM3, and ISG15. β-ACTIN was used
as a loading control.
5.4 Discussion
It has been widely argued that overexpression of the IFITM1 receptor has a pro-
oncogenic role. Besides, evidence shows that IFITM1 mediates pleiotropic effects: on one
hand, it is involved in antiproliferative programmes causing growth arrest, enhanced by
IFNγ-stimulation, and on the other hand, IFITM1 also inhibits NK-mediated cytotoxic-
ity signalling, allowing tumour cell immune evasion (Yang et al., 2005). Several studies
found IFITM1 overexpressed in many cancer types (Akyerli et al., 2005; Borg et al., 2016;
Hach et al., 2013; Ogony et al., 2016; Yu et al., 2015), but it remains poorly understood why
the opposite situation i.e. absence of IFITM1 also induces metastatic outcomes. In this
respect, a study found significant differences in the IFITM1 expression profiles of cervical
squamous cell carcinoma compared to normal tissue and IFITM1 mRNA in cervical cancer
tissues was decreased in comparison to chronic cervicitis tissue. This is possibly explained
by elevated methylation in the IFITM1 gene promoter in cervical cancer tissues compared
to normal cervical tissues and that may affect cell proliferation, suggesting implication for
cervical carcinogenesis. Additionally, ectopically transfected IFITM1 in HeLa cells reduced
cell migration and invasion, but promoted apoptosis and cell arrest in S phase (Zheng et
al., 2017).
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Each cancer type has a unique physiology, and dysfunction of particular molecular
pathways may be favourable or disadvantageous to its development and progression. In
this context, it is possible that IFITM1/IFITM3 proteins promote pleiotropic functions,
and this chapter gives some insights on how loss of IFITM1/IFITM3 protein expression
may be also implicated in poor cancer prognosis.
Data from the polysome analysis suggests that there is a defect in the assembly of the
RNA components of the 80S ribosomal complex when IFITM1/IFITM3 proteins are not
expressed, recapitulated with ectopic transfection of IFITM1/IFITM3 (Figure 5.4). Addi-
tionally, CAV1, U2AF1, and VAPB are examples of non-ribosomal proteins significantly
overrepresented during IFNγ-stimulation of wt-SiHa cells vs IFITM1/IFITM3 double null
cells (Figure 5.5 C-F). In particular, U2AF1 was proposed as a novel IFITM1 interacting
partner (Table 4.1) and is implicated the regulation of the protein synthesis (Palangat et
al., 2019). Along with its association with the 40S ribosomal subunit, this emphasizes
the hypothesis that IFITM1/IFITM3 proteins guide and regulate specific transcripts. This
study also locates IFITM1/IFITM3 to the ribosome by studying the association between
IFITM1/IFITM3 and RPL7a ribosomal protein (Figure 5.6)
The fact that protein translation is not globally affected suggested that IFITM1 (and
IFITM3) loss may act as exclusion binding proteins for certain mRNA targets. In the pulse
SILAC assay, HLA-B in coordination with other MHC class I molecules is expressed in an
IFITM1/IFITM3-IFNγ dependent manner (Figure 5.9 B, D, F, L). MHC class I molecules are
the core components of the antigen presentation pathway, having an important involve-
ment in tumour–antigen presentation, recognition and elimination. In addition, IFNγ is
one of the best-characterised immune regulatory cytokines, with a key role in tumour neo-
antigen recognition and elimination. Any malignant cell with immune-evasive capabil-
ity will be positively selected and expanded during tumour evolution (Pettit et al., 2000).
Among many other mechanisms, it has been extensively reported that downregulation of
MHC class I molecules leads to immune-therapy failure (Garrido et al., 2016; Garrido et al.,
1993; Garrido et al., 2017; Seliger et al., 2002).
In this context, HLA-B protein synthesis would be increased as part of a rapid IFNγ
response in addition to its constitutive expression. In fact, IFNγ signalling would be acti-
vated by any molecule recognized as “non-self” such as pathogen attack or tumour. HLAs
are physiologically over-induced for a short time under particular circumstances and then
restored to their basal expression levels. But, constitutive exposure to discrete levels of
IFNs induced by infection (i.e. HPV), or other causes, may contribute to increased resis-
tance to DNA damage by expression of IRDS gene products (Cheon et al., 2014). Under
pathological conditions, such as cancer, it may sustain the activated signalling pathway
conditioning immune-escape and therefore risking the host survival.
IFNγ is a good candidate for immunotherapy as it induces tumour antigen–MHC com-
plex presentation (Propper et al., 2003). In addition, it enhances tumour-specific cytotoxic
T lymphocyte (CTL) which in turn is dependent on appropriate MHC class I expression.
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But what happens if there are some defects in the IFNγ pathway? In the SiHa model we
see deficiencies in MHC class I molecule expression when IFITM1/IFITM3 protein expres-
sion is lost. Depletion of key factors in mouse models result in blockage of the MHC class I
induction, rapid tumour growth and more resistance to immunotherapy (Manguso et al.,
2018). Actually, SiHa cells express low levels of MHC class I molecules in comparison to
other cervical cell lines. Downregulation of MHC class I expression (not found for MHC
class II) affects tumour elimination activity by tumour-specific cytotoxic T lymphocytes
(CTLs). These CTL-resistant tumour cells survive by positive selection even if they are sur-
rounded by tumour-specific CTLs (Street et al., 1997).
Nevertheless, such a fundamental cellular mechanism must be robustly regulated
by other alternative pathways to guarantee appropriate protein expression. Absence of
IFITM1/IFITM3 protein expression may not abolish exposure of antigen presentation on
the cell membrane completely, but may contribute to its impairment . Impairment of anti-
gen presentation complexes by decreasing the MCH class I protein expression (or other as-
sociated molecules) may lead to aberrant recognition of cancer neo-antigens by the CD8+
T cell, promoting immune evasion and causing immunotherapy failure.
In summary, IFITM1/IFITM3 are viral restriction factors and HPV infection is corre-
lated with development of cervical cancer. There is a close relationship between persis-
tent viral infection, development of cancer and failure in immune response. For example,
cervical and vulvar intraepithelial neoplasias are pre-cancerous conditions characterized
by sustained HPV-16 infection. A clinical study showed a favourable prognosis related to
an increase in IFNγ-producing CD8+ cytotoxic T cells following a robust cell response in-
duced by vaccination (Kenter et al., 2009). Vaccination delivered a high dose of specific
antigen for HPV-16 oncoproteins E6 and E7 and mediated MHC-binding peptide complex
presentation (Melief & Van Der Burg, 2008). A similar outcome was also observed after
vaccination of a preclinical mouse model of HPV-positive cervical cancer (Zwaveling et al.,
2002). There is a significant correlation between MHC class I (not MHC class II) expression
on malignant cells and T-cell infiltrates (TIL) in human ovarian cancer (Kooi et al., 1996)
and is a positive prognostic factor (Hamanishi et al., 2007). An independent study also
correlated viral infection with cancer pathology; bioinformatic analysis of gene expres-
sion in several lymphoblastic leukaemia types identified a cluster of IFN-induced genes
in 40% of patients, corresponding to those leukemic types more susceptible to infection.
Similar proportions were found in breast and ovarian cancer analyses. Actually, many of
these IFN-stimulated genes are members of the IRDS signature. Additionally, UBE2L6,
the ubiquitin/ISG15-conjugating enzyme, is also found amongst these genes (Einav et al.,
2005).
Interestingly, ISG15 was also identified as a dominant protein expressed in a
IFITM1/IFITM3-IFNγ dependent manner (Figure 5.9 B, D, F and G). Integrating cellular
functions between ISG15 and MHC class I, Burks et al. proposed that free extracellular
ISG15 has anti-tumour properties, promoting increased infusion of MHC class I presenta-
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tion molecules on the cell surface in breast cancer cells (Burks et al., 2015).
ISG15 gene expression by IFN type I has been widely explored but there is little ex-
perimental work in relation to IFNγ signalling. An ISG15 study revealed that free, as well
as conjugated, ISG15 levels are increased upon IFNγ stimulation (Tecalco-Cruz & Cruz-
Ramos, 2018). Interestingly, they stimulated breast cancer cells with IFNγ using the same
conditions as in the present thesis. ISG15 is coupled to the translation machinery and
so it directly conjugates to target proteins that are newly synthesized. Herc5, the E3 lig-
ase for ISG15 conjugation, is proven to be associated with the polysomes. As postulated
by Durfee & Huibregtse, ISG15 is able to specifically target a small pool of viral proteins in
IFN-stimulated cells. Even if ISG15 conjugates to few viral proteins, that would have major
consequences for correct viral protein assembly and activity. To support this hypothesis,
they studied the ISGylation of HPV-L1 capsid protein, a viral component of the HPV16 virus
and one of the two major viral strains involved in cervical cancer (Durfee et al., 2010). Sim-
ilarly, HERC5 also restricts HIV-1 infection through ISGylation of viral Gag protein (Woods
et al., 2011). These studies suggest that perturbation of IFITM1/IFITM3 protein expression
may reduce viral protein ISGylation resulting in decreased cell protection from HPV-16 in-
fectivity, and that in the long term they facilitate cervical carcinogenesis.
One can speculate that interaction of IFITM1/IFITM3 with ISG15 may occur immedi-
ately after ISG15 is synthesized, as IFITM1/IFITM3 may be in close association with the
ribosomes. In this regard, it has been postulated that ISG15 is also located in the ribo-
some and actually modifies target proteins (including viral proteins) right after their syn-
thesis. Analysis of global ISGylation by Western blotting analysis has identified a defect in
ISG15 conjugation in the absence of IFITM1/IFITM3 proteins (Figure 4.17). Maybe there
is less ISG15 expressed under these conditions. Besides contributing to ISG15 synthesis,
IFITM1/IFITM3 may also be implicated in the conjugation of target proteins to ISG15.
This experimental work shows that IFITM1/IFITM3 proteins govern, at least partially,
the fate of ISG15. In the first place, IFITM1/IFITM3 controls the expression of ISG15 by
its protein synthesis. It is still to be determined how absence of IFITM1/IFITM3 protein
expression precisely affects the protein synthesis of ISG15 and other ISG proteins from
mRNA, such as by exclusion of the mRNA loading into the ribosome or appropriate guid-
ance to the ribosome. For this reason, the next chapter investigates IFITM1/IFITM3-IFNγ
dependencies on mRNA production and regulation.
Bringing everything together, IFITM1 and ISG15 may be related at two different cell
stages; firstly, IFITM1 affects ISG15 synthesis (Figure 5.9), and secondly, IFITM1 associates
with ISG15 (Table 4.2). It is still to be determined if there is a direct interaction or if they
form a complex. This study was performed after IFNγ stimulation, but these findings may
not be exclusive to type II IFN, and may also happen with other IFN types.
In summary, we investigated to what extent loss of IFITM1/IFITM3 protein expres-
sion changed the proteome in a SiHa-IFNγ stimulated cancer cell model panel. Presum-
ably, the perturbation of protein translation machinery would be conferred by a combina-
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tion of several proteins. Thus, it is relevant that there is a consistent impairment of IRDS
protein expression, particularly HLA-B and ISG15, with depletion of only IFITM1/IFITM3
proteins. This observation has been demonstrated in several experiments in this the-
sis: IFITM1 siRNA depletion coupled to SWATH-MS (performed in a prior study by Dr
Elisabeth Sinclar, section x introduction); SBP-IFITM1 interactomics (chapter 4); and in
this chapter by sucrose density gradient ultracentrifugation coupled to SWATH-MS (sub-
section 5.3.1) and pulse SILAC coupled to Orbitrap-MS (subsection 5.3.2). Additional
immunofluorescence assays (subsection 4.3.5) and Western blotting analysis (subsec-
tion 5.3.3) support HLA-B and ISG15 protein alterations in absence of IFITM1/IFITM3
protein expression.
To conclude, the evidence suggests that IFITM1/IFITM3 are key regulation factors for
the expression of a specific subset of proteins induced in IFNγ signalling. To the best of
available knowledge there is only one study that hypothesises IFITM1 being involved in a
translational role (Lee et al., 2018) . In that case the study was performed in a virus con-
text where they propose that IFITMs attenuate HIV replication through inhibition of viral
protein translation. In this sense, IFITMs may be able to modulate (enhancing or atten-
uating) particular target proteins according to the cells needs. All-in-all, these findings
provide more evidence for the pivotal function of IFITM1 (and IFITM3); expanding the
range of IFITM1 roles in cancer pathology and pathogen protection.
Chapter 6





In chapter 4, SRSF1 protein was identified as a protein that binds IFITM1 (Table 4.1 and
Figure 4.9). This novel interacting partner can guide mRNA to the ribosome. In chapter 5,
the analysis of ribosomal integrity showed an impairment of the 80S ribosomal subunit in
IFNγ-stimulated IFITM1/IFITM3 double null cells compared to wt-SiHa cells (Figure 5.3).
In addition, there was also a major defect in the production of HLA-B and ISG15 proteins in
IFNγ-stimulated IFITM1/IFITM3 double null cells compared to wt-SiHa cells (Figure 5.9).
Taken together, these results suggest that IFITM1/IFITM3 may be implicated in pro-
tein synthesis, but it may also be possible that these observations are a consequence of a
reduction in transcript synthesis, and decreased mRNA production would thus decrease
the synthesis of protein. To investigate this hypothesis RNA-Seq and RT-qPCR methodolo-
gies were applied.
6.1.1 Next Generation Sequencing as a tool to study RNA
The RNA profile is dynamic and highly dependent on physiological and pathological
stimuli. So far, many different types of RNA have been identified. Collectively they are cat-
egorised as coding and non-coding RNA (Ewing & Green, 2000; Eddy, 2001). Coding RNAs
are those species that will ultimately code for a protein. Non-coding RNAs have been fur-
ther subdivided into many more types of which two representative subtypes are transfer
RNA (tRNA) and ribosomal RNA (rRNA), both involved in translation (Eddy, 2001). In some
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contexts, the term transcriptome may be defined as all the RNA molecules expressed, in-
cluding non-coding RNAs. This chapter will study only those polyadenylated and messen-
ger RNA (mRNA) species that encode proteins. Consequently, in this thesis, transcriptome
will refer to the polyadenylated and mRNA molecules exclusively.
Multiple methods have been developed to investigate and understand the complexity
of RNA species. RNA sequencing (RNA-Seq) is a very powerful tool that allows the study
of the transcriptome by accurately measuring gene expression. In addition, RNA-Seq is
a deep-sequencing technology that gives information on the RNA sequences. Due to its
potential, and the simplified workflows, RNA-Seq is used in a broad range of studies; it
is a high-throughput methodology based on next-generation sequencing (NGS), and is
composed of a multi-step process where a sample library of RNA is prepared, amplified,
and finally sequenced (Figure 6.1) (Buermans & Dunnen, 2014; Dijk et al., 2014).
Figure 6.1: Workflow of RNA sequencing by synthesis. The Illumina process is composed of three steps: sam-
ple library preparation (A), cluster generation by bridge PCR (B), and sequencing by synthesis (C). Total RNA
is extracted and polyadenylated and mRNA transcripts are purified. The input DNA is obtained by reverse
transcription and then fragmented. Adaptors are added at the end of the cDNA fragments to allow amplifica-
tion, and additional motifs are introduced to the adaptors, such as the sequencing binding site and regions
complementary to the flow cell oligos (A). Clustering is a process where each fragment molecule is amplified.
The cell contains two types of oligos that hybridize with one adaptor of the DNA fragment. A complementary
strand will by synthesized by polymerisation. Then, the two fragments are denatured, and the template is
washed away. Amplification occurs by bridge PCR, in which a DNA fragment bends over to bind the neigh-
bouring complementary oligo displayed on the flow cell. Next, a polymerase produces two identical copies
that are sequentially denatured, resulting in two single stranded copies bound on one end to the flow cell.
The process is repeated sequentially for all the clusters of DNA present in the flow cell (B). After the clonal
expansion of all the clusters of DNA the sequencing begins. Fluorescent nucleotides are tagged with different
dyes and they bind by complementation to the single strand. In each cycle one fluorescent nucleotide will be
added and detected when a fluorescence signal is emitted. All clusters are read simultaneously (C). a
ahttps://www.illumina.com/documents/products/illumina-sequencing-introductiOn.pdf
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6.2 RT-qPCR using SYBR green dye
The real-time reverse transcription polymerase chain reaction (RT-qPCR) is a quantita-
tive technique used to quantify nucleic acids (Gibson et al., 1996). The RNA material must
be previously transcribed into complementary DNA (cDNA). This is based on the same
principle as PCR, where the DNA is amplified by denaturation, annealing and elongation,
but in RT-qPCR, the addition of a fluorescent reporter allows the detection and quantifi-
cation of the cDNA material in each cycle of amplification (Figure 6.2) (Nolan et al., 2006).
Real-time PCR (qPCR) requires a fluorescent reporter dye to detect the amplified PCR
product in each cycle of the reaction. There are many available types of dye to detect and
quantify the amplified cDNA. We used SYBR green which is a non-specific detection flu-
orescent dye that allows the measurement of new strands of DNA in a quantitative man-
ner during each cycle of amplification. The SYBR green probe can only bind to the minor
groove of the double stranded DNA (dsDNA). It has a weak binding affinity with ssDNA
producing only a very weak green fluorescent signal but when bound to the dsDNA it be-
comes strongly fluorescent. One disadvantage is that it can also bind to unspecific dsDNA
(Pochel et al., 2003)).
Figure 6.2: RT-qPCR amplification principle. This method has four steps: reverse transcription (A), denat-
uration (B), annealing (C), elongation (D). Reverse transcriptase takes the initial RNA material as a template
to generate complementary DNA (cDNA) (A). The following steps are common to standard PCR. The cDNA
is denatured by increasing the temperature to 95ºC to separate the double strand cDNA (B). The next step
allows the annealing of the primers to the single strand. One primer is specifically designed to bind by com-
plementation to the forward strand and the other binds the reverse strand. The annealing temperature varies
depending on the composition of the primers but typically it is carried out at 55–65ºC. (C). The extension step
is carried out around at 72ºC and synthesizes the new complementary cDNA strand (D). Steps (B), (C), and
(D) are repeated for several cycles to amplify the starting cDNA material. SYBR green dye fluoresces when it
binds to the dsDNA and allows DNA quantification.
SYBR green dye gives a relative quantification of how much cDNA material is present
in each cycle of amplification. The amplification curve is a representation of the accu-
mulated synthesised cDNA over the PCR cycles (Figure 6.3). The plot in Figure 6.3 shows
the PCR cycle number (x-axis) versus fluorescent signal (y-axis). Each reaction will define
a PCR cycle at which fluorescence exceeds an established background fluorescence; this
corresponds to the threshold cycle (Ct) (Nolan et al., 2006). Prior to the comparison it is
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crucial to normalise the genetic material between samples and remove any technical er-
rors while preparing the samples. For this purpose, the measurement of a housekeeping
gene, that is expected to maintain the same expression in all conditions, is included. We
used β-ACTIN. Relative expression between samples is compared by the cycle in which
they reach the threshold (Ct). If the starting material is very low, it will take many cycles to
reach the threshold giving a high Ct number.
Figure 6.3: Amplification curve. RT-qPCR amplification curve (in red) is divided into four stages: baseline,
early exponential phase, linear exponential phase, and plateau phase. In the baseline stage the PCR is in the
early cycles and fluorescent signal is below the threshold (dashed line). The early exponential phase is where
the signal is just above the threshold, also referred as cycle threshold (Ct). In the linear exponential phase,
conditions are optimal and the amplification products double in each cycle. In the plateau phase, there is not
enough substrate available and the fluorescent signal stops increasing.
6.3 Aims of the chapter
In this chapter we aim to study whether there is any observable change in the tran-
scriptome when IFITM1/IFITM3 protein expression is lost. RNA-Seq analysis will provide
some insights into the expressed genes and whether there are major differences between
wt-SiHa cells, IFITM1 null cells and IFITM1/IFITM3 double null cells. Relative comparison
of the transcripts of interest by RT-qPCR will provide further validation of the analysis.
6.4 Results
6.4.1 Transcriptome analysis of differentially expressed genes after
IFITM1/IFITM3 loss
We aimed to investigate whether there are major differences in the transcript ex-
pression. RNA-Seq analysis was performed to reveal the global RNA quantity in non-
stimulated and IFNγ-stimulated wt-SiHa cells, IFITM1 null cells, and IFITM1/IFITM3 dou-
ble null cells. RT-qPCR technique was used for validation of some transcripts of interest.
Figure 6.4 is a representation of the steps followed to extract the RNA and the sample anal-
ysis workflow.
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Figure 6.4: Workflow followed to analyse the transcript levels in wt-SiHa cells, IFITM1 null cells and
IFITM1/IFITM3 double null cells non-stimulated or IFNγ-stimulated for 24 hours. Workflow followed to
analyse the transcriptome in wt-SiHa cells, IFITM1 null cells and IFITM1/IFITM3 double null cells. RNA
was extracted from non-stimulated or IFNγ-stimulated cells. All samples passed the quality control with a
RIN number above 7.5 (I). Three biological replicates were used for RNA-Seq analysis (II) and RT-qPCR val-
idation (IV). Equal amounts of RNA were combined and sequenced by Otogenetics. Further steps include
mRNA purification and stranded cDNA synthesis; Ilumina sequencing library preparation; and PE100-125
and HiSeq2500 sequencing (II). Amplified sequences were analysed using CLC Genomics Workbench, using
GRCh38 as a reference genome (III). Transcripts of interest were further validated by RT-qPCR using the same
three biological replicates. For this purpose, the RNA was reverse transcribed into cDNA (IV), and sequentially
quantified and compared between samples (V).
The purity of the RNA was assessed after RNA extraction (Figure 6.4 I). Purity and quan-
tity of the RNA are crucial to obtaining high quality results. To ensure optimal conditions,
standardization of the RNA quality is obtained by measuring the RNA integrity number
(RIN). For this reason, after RNA extraction RNA quality was assessed by measuring RIN
values (Figure 6.4 I). Samples were tested by the Sequencing Group, a technical service
in the IGMM. The measurement of RNA was carried out in the Agilent 2100 bioanalyzer in
combination with the RNA 6000 Nano LabChip. The Figure 6.5 A and B shows the replicate
1 of the IFITM1 null cells as a representative example of the quality control output.
The RIN is an algorithm for assigning integrity values to RNA measurements
(Schroeder et al., 2006). The integrity of RNA is crucial for generating successful gene ex-
pression studies and traditionally it has been evaluated using the 28S to 18S rRNA ratio.
RIN numbers greater or equal to 7 are considered sufficient, but it is desirable to have RIN
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values above 8. In the present study all replicates have a RIN value above 8, except sample
2 IFITM1 null cells with RIN 7.5 (Figure 6.5 C).
Figure 6.5: Quality control of the total RNA extracted using the Agilent 2100 bioanalyzer. Samples were
heated at 70ºC for 2 min and immediately placed on ice prior to quality control analysis. This is based on
gel electrophoresis in a chip format. RNA molecules have an intrinsic charge and will be electrophoretically
moved and separated by size using a voltage gradient. (A) Electropherogram is displayed by plotting fluores-
cence intensity versus migration time. (B) Output is also represented as a densitometry plot, resembling a gel.
(C) RIN values for each sample.
There are three biological replicates for each condition and all of the samples have RNA
concentrations between 150–200 ng/ml. Equal amounts of RNA for each condition were
combined in a single Eppendorf tube (Figure 6.4 II). Samples were then processed to RNA-
Seq by Otogenetics Corporation (Atlanta, USA). Remaining RNA was stored at -80ºC for
future validation by RT-qPCR.
One of the main aims was to investigate whether the loss of IFITM1/IFITM3 expression
drastically impacts on gene induction. To address this question, we performed a global
study of the transcriptome. Bioinformatic analysis was carried out by Mr Marcos Yébenes
Mayordomo (Table B.6). The RNA-Seq analysis was performed using CLC Genomics Work-
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bench software (Figure 6.4 III). Transcriptomic analysis is represented in plots comparing
two by two the total transcript count (expressed in transcripts per million) in the differ-
ent conditions (Figure 6.6). All-in-all, there were no major differences between wt-SiHa
cells and isogenic IFITM1 null cells and IFITM1/IFITM3 double null cells (Figure 6.6 B-E).
Interestingly, there was clear gene induction in all three cell lines after IFNγ stimulation
(Figure 6.6 A, F and G). Transcripts of IFITM1, ISG15, HLA-B, STAT-1, and IRF1 are also
higher after IFNγ-stimulation (Figure 6.6 A, F and G, transcripts are labelled in red).
Loss of IFITM1/IFITM3 protein expression does not decrease transcript induction.
On the contrary, most of the highly-induced transcripts after IFNγ stimulation are
IFITM1/IFITM3-independent, such as HLA-DRB1, HLA-DRA, CXCL10 and GBP5 (Fig-
ure 6.6 A vs F and G, transcripts are labelled in black). All of them are well established
IFNγ-inducible genes related to tumour immunity or pathogen restriction (Feng et al.,
2017; Mach et al., 1996; Soejima & Rollins, 2001). They provided a good internal control
to test gene induction after IFNγ-stimulation and emphasised that loss of IFITM1/IFITM3
protein expression is not sufficient to inhibit IFN signalling.
Next, we concentrated on understanding the induction of some transcripts of interest,
and in particular the pattern of transcript induction in the IRDS genes (Figure 6.7 A). Over-
all, there is a clear induction of IRDS genes after IFNγ-stimulation regardless of the expres-
sion of IFITM1/IFITM3 proteins (Figure 6.7 A). Some genes are particularly induced after
IFNγ stimulation such as MX1, MX2, OASL, IFIT1, and IFIT3. In contrast, other transcripts,
such as BST2 and OAS3, remain similarly induced with or without IFNγ-stimulation. In
this case again there is no major difference between wt-SiHa cells, IFITM1 null cells, and
IFITM1/IFITM3 double null cells.
Moreover, it was investigated the induction of STAT1, IFITM1, IFITM3, ISG15, IRF1,
B2M, and HLA-B (Figure 6.7 B and C). Remarkably, ISG15 and IRF1 are highly induced
after IFNγ-stimulation. Often, the analysis is done as a sum of all the transcripts identified
in the RNA-Seq library. However, there is particular interest in the transcripts that code for
proteins as these will ultimately determine the expression of the protein. For this reason,
the total transcript was compared to expression of the transcript that codes for the protein
(Figure 6.7 B vs C). Overall, the induction remains very similar except in B2M where it is
much less induced.
Interestingly, IFITM1/IFITM3 double null cells have a very low induction of IFITM1
and IFITM3 transcripts (Figure 6.7 C). On the contrary, IFITM1 null cells do induce IFITM1
transcript after IFNγ-stimulation (Figure 6.7 C). Nonetheless, this feature does not imply
that IFITM1 protein will be expressed. IFITM3 transcript levels were similar to IFITM1 null
cells compared to wt-SiHa, even after IFNγ-stimulation (Figure 6.7 C).
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Figure 6.6: Comparison of total transcript count in wt-SiHa cells, IFITM1 null cells and IFITM1/IFITM3
double null cells. All transcript reads detected were taken to generate the final transcript count for each
gene (Table B.6). Comparisons of all transcripts identified are plotted for the following conditions: (A)
non-stimulated wt-SiHa cells vs IFNγ-stimulated wt-SiHa cells, (B) IFNγ-stimulated wt-SiHa cells vs IFNγ-
stimulated IFITM1 null cells, (C) IFNγ-stimulated wt-SiHa cells vs IFNγ-stimulated IFITM1/IFITM3 dou-
ble null cells, (D) non-stimulated wt-SiHa cells vs non-stimulated IFITM1 null cells, (E) non-stimulated
wt-SiHa cells vs non-stimulated IFITM1/IFITM3 double null cells, (F) non-stimulated IFITM1 null cells vs
IFNγ-stimulated IFITM1 null cells, (G) non-stimulated IFITM1/IFITM3 double null cells vs IFNγ-stimulated
IFITM1/IFITM3 double null cells. Each plot has highlighted in red STAT1, IFITM1, IRF1, ISG15 and HLA-B
transcripts. Other significantly induced transcripts are additionally highlighted in black. Transcript expres-
sion is measured in log2 of transcripts per million (TPM).
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Figure 6.7: Heat map of the IRDS transcripts for wt-SiHa cells, IFITM1 null cells and IFITM1/IFITM3 double
null cells. (A) Heat map representation of the expression of the 31 IRDS genes. In the y-axis is the transcript
expression corresponding to the 31 IRDS genes (Table B.6). Values in grey correspond to genes where the
transcript per million (TPM)= 0. (B) Heat map representation of IFITM1 and IFITM3 transcripts, the genes
that came up less expressed in the absence of IFITM1/IFITM3 protein expression (ISG-15, IRF1, HLA-B), and
their controls (STAT1, B2M) (Figure 5.9). (C) Heat map representation of the transcript that translates into
the full-length protein for the genes in B. (B and C) In the y-axis there are the transcripts STAT1, ISG15, IRF1,
IFITM3, IFITM1, HLA-B, and B2M. (A, B and C) In the x-axis are represented wt-SiHa cells , IFITM1 null cells,
and IFITM1/IFITM3 double null cells non-stimulated or IFNγ-stimulated with 100 ng/ml for 24 hours. Colour
scale units are log2 (TMP), becoming red when it is highly expressed and purple to blue for non-expressed and
under-expressed values.
6.4.2 Quantification of mRNA using real-time RT-qPCR
An RT-qPCR assay was performed to further investigate whether there are transcript
differences in our isogenic knock out cervical cell models. The aim was to establish if
ISG15, HLA-B and IRF1 transcripts were similarly abundant after loss of IFITM1/IFITM3
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proteins compared to wt-SiHa cells, but, the gene selection was also expanded to quantify
other gene transcripts. We included IFITM1 and IFITM3 to find out if the gene editing in
the knock out cells alters mRNA transcription. Additionally, STAT1 and B2M protein syn-
thesis were IFITM1/IFITM3-independent (Figure 5.9). We anticipated that their mRNA
levels would remain similar in the absence of IFITM1/IFITM3 protein expression. Finally,
β-ACTIN was used as housekeeping gene to normalize the output between samples.
Primer design is a crucial step in this assay; primers have to exclusively bind to the re-
gion of interest without amplifying non-specific regions. The following parameters were
considered while designing the primers: Firstly, primers were designed to the coding re-
gion of IFITM1, IFITM3, IRF1, ISG15, HLA-B, B2M, STAT1, and β-ACTIN genes; additional
parameters were that all amplicons were expected to have a product size around 150–250
bp and with a melting temperature difference under 1ºC between primers, as multiple
genes were run in parallel using the same PCR plates. Primer pairs were designed using
available public sequences on ENSEMBL (Table 6.1). Designed primer sequences were
checked by BLAST to make sure there were no additional amplicons.
Table 6.1: ENSEMBL accession number of the genes and transcript sequence used to design the primers used
in RT-qPCR.
Gene symbol Gene number Transcript Transcript number
IFITM1 ENSG00000185885 IFITM1-202 ENST00000408968.4
IFITM3 ENSG00000142089 IFITM3-201 ENST00000399808.5
IRF1 ENSG00000125347 IRF1-201 ENST00000245414.9
ISG15 ENSG00000187608 ISG15-201 ENST00000379389.4
HLA-B ENSG00000234745 HLA-B-249 ENST00000412585.7
B2M ENSG00000166710 B2M-204 ENST00000558401.6
STAT1 ENSG00000115415 STAT1-201 ENST00000361099.7
β-ACTIN ENSG00000075624 ACTB-201 ENST00000331789.11
Designing IFITM1 and IFITM3 primers was more complicated as IFITM proteins are
highly homologous. Nonetheless, IFITM1 and IFITM3 have a unique C-terminus and N-
termius, respectively, and so primers were designed in these regions. Likewise, HLA-B
sequence is very similar to the other HLA molecules, but a unique region for HLA-B was
carefully selected. RT-qPCR was run under the same conditions for all the different tran-
scripts.
Three technical and three biological replicates were set for each sample condition, the
raw Ct values of all samples are listed in Figure 6.8. To allow a stringent analysis, Ct ex-
pression values with less than one unit difference between each technical triplicate were
used for analysis. Relative Ct expression values were normalised by a housekeeping gene,
β-ACTIN. Ct values obtained by RT-qPCR (Figure 6.9) were changed into relative expres-
sion using the formula 2-∆Ct where ∆Ct is the difference between the Ct of the transcript
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Figure 6.8: Cycle threshold values. Ct values for three biological replicates in IFITM1 (A and I), IFITM3 (B
and I), IRF1 (C and I), ISG15 (D and I), HLA-B (E and I), B2M (F and I), STAT1 (G and I), and β-ACTIN (H, I,
and J) genes. Columns 1, 2 and 3 correspond to three technical replicates. Replicate with a Ct value one unit
different from the other two replicates were excluded from the analysis (indicated as -).
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of interest and the Ct of β-ACTIN (Figure 6.8).
The results show good reproducibility as the Ct is very similar between replicates (Fig-
ure 6.8). As a consequence, the standard deviation between triplicates is very low in most
of the genes studied (Figure 6.10). This feature gives more power to the RNA-Seq analysis
where a combination of all three biological replicates were run as a single sample (Fig-
ure 6.6).
Figure 6.9: Amplification plots. Amplification plots in IFITM1 (A), IFITM3 (B), IRF1 (C), ISG15 (D), HLA-B (E),
B2M (F), STAT1 (G), and β-ACTIN (H) genes. The x-axis shows the Ct cycle and the y-axis (∆Rn) represents
the fluorescence emitted by the SYBR safe reporter. Each coloured line represents a single sample (triplicates
are grouped in one colour). Basal purple line corresponds to the negative control where there was no cDNA
(template).
Overall, the transcript content is very low without stimulation and rapidly increases
after IFNγ stimulation (Figure 6.10 A-G, three first columns vs three last columns). As
expected, STAT1 and B2M are responsive to IFNγ-stimulation in wt-SiHa cells (in black)
as well as IFITM1 null cells (in green) and IFITM1/IFITM3 double null cells (in red) (Fig-
ure 6.10 A and G). This observation denotes that loss of IFITM1/IFITM3 protein expres-
sion does not affect the gene induction of STAT1 and B2M after IFNγ stimulation. ISG-15
is also more abundant after IFNγ stimulation and is especially inducible in wt-SiHa cells
(in black) compared to IFITM1 null cells (in green) and IFITM1/IFITM3 double null cells
(in red) (Figure 6.10 D).
Remarkably, HLA-B mRNA is very abundant in the non-stimulated IFITM1 null
cells and does not increase after IFNγ stimulation. In comparison, HLA-B mRNA in
IFITM1/IFITM3 double null cells is sensitive to IFNγ stimulation (Figure 6.10 F). Likewise,
a similar effect is seen in IRF-1 mRNA (Figure 6.10 E).
Interestingly, IFITM1 mRNA is detected in IFITM1 null cells and increases after IFNγ-
stimulation (Figure 6.10 B, green bars). Nonetheless, it is not as inducible as in wt-SiHa
cells (Figure 6.10 B, black bars). IFITM3 mRNA levels are similar in wt-SiHa cells compared
to IFITM1 null cells (Figure 6.10 C, black bars vs green bars). Loss of IFITM1 does not affect
the IFITM3 mRNA transcription and IFNγ-stimulation.
Furthermore, IFITM1 mRNA is barely observed in non-stimulated cells and only
slightly induced after IFNγ-stimulation in IFITM1/IFITM3 double null cells (Figure 6.10 B,
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red bars). In the same way, IFITM3 mRNA is almost undetected in non-stimulated cells and
slightly induced after IFNγ-stimulation in IFITM1/IFITM3 double null cells (Figure 6.10 C,
red bars).
Figure 6.10: Validation of the transcript levels of IFNγ-stimulated genes of interest in wt-SiHa cells, IFITM1
null cells and IFITM1/IFITM3 double null cells non-stimulated or IFNγ-stimulated for 24 hours. STAT1
(A), IFITM1 (B), IFITM3 (C), ISG15 (D), IRF1 (E), HLA-B (F), B2M (G) mRNA quantification by RT-qPCR in
wt-SiHa (in black), IFITM1 null (in green) and IFITM1/IFITM3 double null (in red) cells. Measurements were
performed in non-stimulated cells and after stimulation with IFNγ for 24 hours. Error bars are a representa-
tion of the variability between three biological replicates. Each biological sample was run in three technical
replicates. β-ACTIN was used to normalise the mRNA expression between samples. Statistical study was
performed with two-way ANOVA and Bonferroni correction (****p < 0.0001; ***p < 0.001; ** p <0.01; ns, not
significant).
6.4.3 Study of the IFITM1/IFITM3 association to mRNA
Results from the previous section suggest that global gene induction by IFNγ is not
compromised in the absence of IFITM1/IFITM3 protein expression. Nonetheless, it is still
unclear if IFITM1/IFITM3 has some effect on the guidance of the mRNA to the ribosome.
Given that IFITM1/IFITM3 associates with the splicing factor SRSF1 (Figure 4.9), we aimed
to investigate whether it is possible that IFITM1/IFITM3 proteins associate with mRNA.
To study the protein:RNA complexes we took advantage of RNA in situ hybridization–PLA
methods (Zhang et al., 2016). It follows the same principle as PLA (described in Figure 4.8)
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but includes an additional first step in which a biotinylated DNA probe hybridizes to the
mRNA of interest (Figure 6.11).
As HLA-B is one of the main proteins depleted in the absence of IFITM1/IFITM3 pro-
tein expression, we designed a specific probe to hybridize with the HLA-B mRNA. Addi-
tionally, interaction between ISG15 mRNA and IFITM1/3 protein was also studied. There
was no significant signal identified (data not shown).
Figure 6.11: Principle of RNA in situ Hybridization–PLA. (A) The mRNA of interest is annealed with a specif-
ically designed probe that is complementary to its sequence to create a double stranded DNA:RNA hybrid.
The DNA probe is biotinylated to allow its detection. (B) Binding of the specific primary antibodies (of differ-
ent species) to the proteins of interest (i.e. mouse anti-IFITM1/IFITM3 and rabbit anti-Biotin). (C) Binding of
the secondary antibody, named as probe MINUS (mouse) and PLUS (rabbit). (D) Proteins closer than 30–40
nm will allow oligos to hybridize and amplify by rolling circular amplification. (E) Further amplification and
increase of the signal by adding a fluorophore labelled probe.
Regarding IFITM1/3:HLA-B protein:RNA interaction in wt-SiHa cells, the negative con-
trol without primary antibody (Figure 6.12 B) and the negative control without secondary
antibody (Figure 6.12 C) showed no signal. On the contrary, it was not easy to quantify the
signal in the negative control without RNA probe (Figure 6.12 A) as there was some back-
ground. To show the true positive signal in Figure 6.12, the exposure time was set when the
signal was completely absent in the negative control without RNA probe (Figure 6.12 A).
A significant protein:RNA association was observed in the IFNγ-stimulated wt-SiHa cells (
Figure 6.12 E and K) and not observed in the IFNγ-stimulated IFITM1/IFITM3 double null
cells (Figure 6.12 J and L).
These data suggest that IFITM1/IFITM3 associate with HLA-B mRNA after IFNγ stim-
ulation. This serves as a proof of concept that IFITM1/IFITM3 may be playing a role in the
RNA guidance to the ribosome. In fact, IFITM1/IFITM3 proteins might also associate with
other transcripts, but this possibility has not been further explored.
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Figure 6.12: Evaluation of the IFITM1/IFITM3:HLA-B protein-RNA interaction in situ after stimulation
with IFNγ by rISH–PLA. RNA in situ hybridization–PLA assays were used to study the endogenous interac-
tion between HLA-B mRNA and IFITM1/IFITM3 proteins in wt-SiHa cells (A–E) and IFITM1/IFITM3 double
null cells (F-J). HLA-B mRNA was detected with a biotinylated probe. FITC images identify the protein–RNA
association foci (green) and DAPI was used for nuclear staining (blue). (A–C and F-H) Cells were incubated
as negative controls; without the RNA probe (A and F), using primary antibodies only (B and G), or secondary
antibodies only (C and H). (D and I) Cells were incubated with both IFITM1/IFITM3 and biotin antibodies
to define protein–RNA foci in non-stimulated cells. (E and J) Cells were incubated with both IFITM1 and
biotin antibodies to define protein–RNA foci in IFNγ-stimulated cells. Representative quantification of the
protein–RNA interaction foci per cell in presence or absence of IFNγ stimulation in wt-SiHa cells (K) and
IFITM1/IFITM3 double null cells (L). At least 50 cells were counted in each condition. Statistical study was
performed with one-way ANOVA and Bonferroni correction (****p < 0.0001). n=3. Scale bar: 10 µm.
Chapter 6 - Transcriptomic analysis to identify dominant IFITM1/IFITM3-dependencies
in protein expression 160
6.5 Discussion
In the previous chapter we showed that loss of IFITM1/IFITM3 protein expression at-
tenuates the protein synthesis of HLA-B and ISG15. There are many reasons why this can
happen. For instance, it could be a reduction of the gene induction, degradation of the
mRNA or misguiding mRNA to other subcellular locations. At that time, we had no infor-
mation about the mRNA abundance in the wt-SiHa, IFITM1 null or IFITM1/IFITM3 double
null cells. For this reason, the first question addressed was to establish if there were any
major differences in the transcriptomes of wt-SiHa cells compared to IFITM1 null cells and
IFITM1/IFITM3 double null cells.
The RNA-Seq analysis showed no major differences in the transcriptome of IFITM1 null
cells or IFITM1/IFITM3 double null cells compared to wt-SiHa cells (Figure 6.6). In addi-
tion, a similar phenomenon was observed with the IRDS genes, where most of the genes
were equally induced regardless of the expression of IFITM1/IFITM3 proteins (Figure 6.7
A). Similarly, ISG15 and HLA-B transcripts are induced after IFNγ-stimulation in wt-SiHa
cells as well as in the isogenic IFITM1 and IFITM1/IFITM3 knock out cells. Therefore, it
seems that transcript synthesis is not the limitation resulting in defective expression of
ISG15 and HLA-B proteins (Figure 5.9).
IFITM1/IFITM3 proteins are responsible for modulating, at least partially, the protein
expression of HLA-B and ISG15. There are many possibilities by which their mRNA is not
translated into protein; translation repression as well as mRNA decay are two key factors in
gene expression. For a long time, scientific efforts have concentrated on how transcription
regulation functions, but posttranscriptional regulation is equally important in determin-
ing the fate of the nascent mRNAs. The mRNA is protected from exonuclease attack by the
5’ 7-methylguanosine cap and the 3’ poly(A) tail. Nonetheless, the mRNA decay pathway
is able to recognise and eliminate aberrant mRNAs (Garneau et al., 2007).
But this does not seem to be the case: the evidence suggests that IFITM1/IFITM3 mod-
ulates HLA-B at the translational level. On the one hand, there is no detectable difference
in HLA-B gene induction between wt-SiHa cells, IFITM1 null cells and IFITM1/IFITM3
double null cells in our study. In fact, HLA-B mRNA in non-stimulated IFITM1 null cells is
highly abundant (Figure 6.10 F). But looking at protein synthesis, there is a large inhibition
by IFITM1/IFITM3 proteins (Figure 5.9). Therefore, the data suggests that the inhibition of
HLA-B synthesis is regulated during translation. Even though the mechanism is not com-
pletely understood, translation is usually regulated at the initial stage, at which it is clear
that eIFs factors, but also RNA-binding proteins, play a fundamental role. The stabiliza-
tion of the mRNA on polysomes is essential to activate the translation and, interestingly,
IFITM1/IFITM3 are localised at the ribosomal subunits (Figure 5.5 B) (Jackson et al., 2010).
The RT-qPCR assay is an efficient, sensitive and specific method to quantify the mRNA
abundance of particular genes. Based on this technique, we have reasons to believe that
IFITM1 and IFITM3 mRNA in the knock out cells are transcribed. It is possible that the
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CRIPSR indel, in the respective knock out cell lines, does not inhibit completely the tran-
scription of the IFITM1 and IFITM3 genes. In fact, cells are able to compensate genetic
mutations by upregulating the transcription of related genes or the mutated gene itself
(El-Brolosy et al., 2019). But somehow the aberrant mRNA is not being translated or at
least not functional.
The cell has multiple mRNA-surveillance mechanisms to specifically recognise and de-
grade aberrant mRNA, for instance the recognition of a premature stop codon. In fact,
CRISPR/Cas9 indels for IFITM1 in IFITM1 null cells and IFITM3 in IFITM1/IFITM3 double
null cells do contain premature stop codon sequences (Figure 3.6 and Figure 3.9). Presum-
ably, the aberrant mRNA associates with the ribosome but gets stalled upon recognition
of the premature termination codon. The SURF complex is implicated in the recognition
and dissociation of the aberrant mRNA from the ribosome and facilitates its degradation
(Garneau et al., 2007). This could explain why we are able to detect IFITM1 and IFITM3
transcripts (Figure 6.10 B and C) but their protein synthesis is inhibited (Figure 5.9).
This does not apply to the IFITM1 gene that has an intron deletion in the
IFITM1/IFITM3 double null cells. An alternative process must be happening. It is im-
portant to highlight that transcription, splicing machinery and nonsense-mediated decay
pathways are closely interconnected. On this note, the intron deletion may alter the nat-
ural processes of transcription initiation and the pre-mRNA maturation to mRNA(Chorev
& Carmel, 2012). In fact, intron sequence per se can have an inherent role in transcription
initiation being able to modulate the gene expression (Vasil et al., 1989). For instance, it
may change the exon-junction complexes whose formation is required to facilitate recruit-
ment of export factors and is implicated in mRNA degradation via nonsense-mediated de-
cay (Popp & Maquat, 2016). Another possibility is that intron loss changes the natural 3D
structure of the gene, affecting its folding and impacting on the processing and maturation
of the mRNA, generating a faulty transcript (Wang et al., 2013).
All-in-all, the evidence suggests that there is a selective mRNA exclusion at the ribo-
some that inhibits the translation of particular transcripts such as ISG15 and HLA-B. In




IFITM1 is implicated in multiple types of cancer. However, the molecular implications
of this phenomenon are not well characterized. The focus of this project was to expand our
limited understanding of the cellular role of IFITM1. Previous work with immunohisto-
chemical staining of FFPE cervical cancer tissue identified a distinct subgroup of cervical
cancer patients where IFITM1/IFITM3 protein expression inversely correlates to metas-
tasis. From there, we aimed to understand why patients who are IFITM1/IFITM3 double
negative are also susceptible to developing aggressive tumours. As IFITM1 is the main iso-
form described as a pro-oncogene, we started studying its interactome (chapter 4). During
the course of this study, we realized that IFITM1 and IFITM3 are closely related, orches-
trating overlapping functions and/or having synergistic effects, thus we needed to study
both proteins together. Some experimental work on this matter was done in our group
prior to the present study; SWATH–MS proteomic screens in cervical cancer cells treated
with IFITM1-targeted siRNA resulted in the attenuation of an IFN regulated protein sub-
population including MHC class I molecules (Figure 3.2).
Initially, SiHa cells were chosen as a cancer cell model as they had highly activated ef-
fectors of the IFNγ signal transduction pathway, including IFITM1/IFITM3 proteins. Re-
markably, these human-derived cells from cervical cancer are infected by HPV-16 virus.
The study of IFITM1/IFITM3 proteins as restriction factors was not our focus of inter-
est, nevertheless the fact that these cells are infected may have an impact on the cancer
progression, where persistent infection may lead to a sustained low activation of IFN sig-
nalling (Cheon & Stark, 2009; Cheon et al., 2011). Notoriously, this is a favourable context
where an IRDS signature could be induced. However, it is difficult to provide direct evi-
dence to support this argument.
This thesis has begun to unravel new underlying cellular functions for IFITM1 by study-
ing its interactome. SRSF1 was identified as one of the major binding partners for IFITM1
(Table 4.1). Even though we did not continue studying the cellular implications of this
interaction, it provided some evidence to prompt a study of IFITM1 function in protein
biogenesis on the ribosome (chapter 4). Ultracentrifugation sedimentation analysis of
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cell lysates from IFNγ-stimulated wt-SiHa cells and IFITM1/IFITM3 double null cells was
carried out to isolate ribosomal constituents. The results suggested a specific role for
IFITM1/IFITM3 in regulating the integrity of the 80S ribosomal subunit (chapter 5). The
subcellular localization of IFITM1/IFITM3 in the ribosome (Figure 5.5 B and Figure 5.6)
prompted an analysis of IFNγ-dependent protein synthesis using pulse SILAC-MS (Fig-
ure 5.8 and Figure 5.9). It was identified that ISG15 and MHC class I synthesis, particularly
HLA-B, requires IFITM1/IFITM3-IFNγ-mediated signal transduction (chapter 5). To con-
solidate the results, HLA-B as well as ISG15 were identified as major interacting partners
for IFITM1 (Table 4.2). Additional experimental work conducting immunohistochemistry
and proximity ligation assays indicated that HLA-B interacts with IFITM1/IFITM3 in wt-
SiHa cells and that HLA-B induction was attenuated in the IFITM1/IFITM3 double null
cells (chapter 4). In the case of ISG15, it was not possible to study its association with
IFITM1/IFITM3 by the same techniques. Nonetheless, it was noted that in the absence of
IFITM1/IFITM3 protein expression there is a decrease in global ISGylation (Figure 4.17).
Further analysis of the transcriptome in wt-SiHa cells compared to the knock out cell
lines did not find any remarkable inhibition in the synthesis of the HLA-B mRNA (Fig-
ure 6.10 F). Thus, it seems as though the abundance of the HLA-B mRNA is not a limiting
factor when IFITM1/IFITM3 proteins are not expressed. Similarly, ISG15 mRNA is also
present in the knock out cells (Figure 6.10 D).
Our findings also emphasize the importance of IFITM1/IFITM3 in increasing HLA-B
expression and that would greatly impact on the global number of neo-antigens presented
to CD8+ T cells, otherwise promoting immune-escape. In a broad cellular context, impair-
ment of antigen presentation complexes by decreasing the MHC class I expression may
lead to an aberrant recognition of oncopeptides by the CD8+ T cell, causing immunother-
apy failure, promoting immune evasion, and leading to metastatic events. In other words,
it may be possible that absence of IFITM1/IFTITM3 could contribute to acquisition of a
new cellular mechanism to decrease MHC class I molecules, resulting in immunotherapy
resistant tumours.
In fact, the identification of tumour-specific antigens, suitable to be good im-
munotherapeutic targets, has generated great interest. But this effect relies on the premise
that HLA phenotypes remain unaltered and so optimal antigen presentation is required to
effectively eliminate cancer cells via cytotoxic T lymphocyte activation. The principle of
immunotherapy is to activate specifically those tumour-specific T cells that ultimately will
be able to target and eliminate tumour cells. Cancer vaccines that boost CTL-mediated
cytolysis will be effective if key effectors remain fully active. For instance, some cancer
vaccines are designed to increase CD4+ and CD8+ T-cell populations capable of recognis-
ing tumour-associated antigens (Guo et al., 2013). On the contrary, immune check points
are largely dysregulated in cancer; tumours adapt rapidly to their microenvironment and
so develop strategies to escape immune surveillance and propagate. For instance, sev-
eral tumours are able to decrease MHC class I expression (Garrido et al., 2010; Restifo et
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al., 2002); evidence of this is found even in spontaneously originating tumours (Garrido
et al., 1997). In contrast, several tumours consistently upregulate nonclassical MHC class
I molecules such as HLA-E which prevents NK-tumour cell recognition, and so they evade
cell lysis (Monaco et al., 2011). Therefore, it is crucial to define the underlying cellular and
molecular signalling targets for immunotherapy. A lack of understanding of how some tu-
mour subclones become resistant as a result of bypassing natural immune pathways leads
to therapeutic failure.
HLA-B depletion greatly correlates with the proposed natural selection mechanism to
successfully promote tumour immune-evasion (Khong & Restifo, 2002). Tumour hetero-
geneity by genomic instability is a property widely spread in all cancer types. Those traits
that confer a positive advantage over other tumour variants will be selected and so only
these will undergo clonal expansion. In fact, suppression of the HLA-B locus is observed
in multiple colon cancer cell types (Soong & Hui, 1992). Further in silico analysis iden-
tified loss of heterozygosity in HLA haplotypes in non-small-cell lung cancers. Evidence
suggests that it is a result of positive advantage in the face of strong tumour selection by
microenvironmental pressure (Algarra et al., 1997; Cabrera et al., 1996). Actually, tumour
evasion mechanisms are in concordance with the study of how viruses also escape from
being eradicated by the immune system. It would seem logical to predict that immune
recognition and destruction of tumour cells and viruses are active in both cases.
From the cervical cancer perspective, MHC class I depletion is not correlated with HPV
positive tissues (Connor & Stern, 1990; Cromme et al., 1993). It is suggested that these
events originated at different stages of the cervical cancer progression. On the contrary,
independent studies have identified impaired MHC class I expression in cervical tumours
(and other cancer types), particularly loss of MHC class I in metastatic lesions compared to
primary tumours (Honma et al., 1994; Torres et al., 1993), including chromosomal aberra-
tions (Koopman et al., 2000; Vermeulen et al., 2005). This is of particular relevance for this
thesis as it consolidates the hypothesis that IFITM1 is able to regulate, at least partially, the
expression of MHC class I. Remarkably, several studies revealed HLA expression deficien-
cies in lymph node metastases, compared with primary tumours (Cromme et al., 1994;
Ferns et al., 2016; Hilders et al., 1995), which fits with the idea that lack of IFITM1/IFITM3
would lead to diminished HLA expression, as seen in Figure 4.16.
In summary, these data provide a novel biochemical pathway that correlates with the
IFN-responsive nature of IFITM1. It can mediate IFNγ-dependent protein production of
MHC class I proteins as well as ISG15, whilst the maintenance of STAT1 protein in response
to IFNγ involves a different signalling mechanism that is IFITM1-independent (Figure 5.9).
This work can also be used to predict that IFITM1 can mediate MHC class I antigen pre-
sentation pathways as well as ISG15 conjugation pathways. Both antigen presentation and
ISGylation signalling events are important for anti-viral signalling as well as for immune
regulation of cancer cells at the immune-cancer synapse (Bassani-Sternberg et al., 2016;
Burks et al., 2015; Santos & Mansur, 2017; Okumura et al., 2006; van Montfoort et al., 2014;
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Wahl et al., 2009). However, one should imagine these events in their natural context, and
so IFNγ stimulus is not present in cellular “steady-state”. Its signalling is activated in re-
sponse to adverse cellular events such as pathogen attack or tumour development. It is a
defence mechanism that allows recognition of foreign or un-desirable molecules. There-
fore, we need to understand that these events will occur under precise conditions.
In conclusion, the ultimate aim of this thesis is to set the foundations regarding IFITM1
cellular function and to inspire upcoming projects. We begin to understand a new fun-
damental role of IFITM1/IFITM3 as is proposed in our model (Figure 7.1). In summary,
these data have implications for the function of IFITM1/IFITM3 proteins mediating IFNγ-
stimulated MHC class I synthesis in the cancer progression sequence. All this work is been
integrated in a model (Figure 7.1) that combines the most pertinent results throughout this
thesis.
Figure 7.1: The IFITM1 signalling model (Gomez Herranz et al., 2019). IFN stimulation can lead to in-
crease in IFITM1/IFITM3 protein co-association with ribosomal proteins including SRSF1. This association
of IFITM1/IFITM3 to ribosomal fractions led us to examine whether there are any IFN-stimulated proteins
whose synthesis are IFITM1/IFITM3-dependent. Pulse labelling using SILAC methodologies identifies an
IFITM1/IFITM3-dependent synthesis of IRF1 protein early after IFN stimulation. Independent to this event,
is an IFITM1/IFITM3-independent synthesis of STAT1 (Figure 5.9) that presumably cooperates with IRF1
protein to transactivate IFN responsive genes; and the dominant proteins synthesized much later after IFN
stimulation in an IFITM1/IFITM3-dependent manner are MHC class I molecules and ISG15. Methodolo-
gies including immunofluorescence, immunoblotting, and subcellular fractionation confirm that there are
defects in HLA-B production and localization in IFITM1/IFITM3 double null cells (Figure 4.16). The siRNA-
mediated depletion of IFITM1 also represented an orthogonal assay that identified reductions in ISG15 and
MHC class I molecules (Figure 3.2). STAT1 protein reflects a distinct mechanism of control by IFITM1/IFITM3.
Although pulse SILAC revealed that its synthesis is IFITM1/IFITM3-independent (Figure 5.8 and Figure 5.9),
the steady state levels of STAT1 protein are reduced after targeted depletion of IFITM1 (Figure 3.2). These
data suggest that turnover of STAT1 protein is dependent on IFITM1/IFITM3 but its synthesis is independent
of IFITM1/IFITM3. Altogether, these data place IFITM1 as a co-ordinator of synthesis and/or steady state
levels of several key players in the IFN response. The notable induction of MHC class I molecules and ISG15,
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Figure A.1: Workflow for CRISPR/Cas9 gene editing. (A)The wt-SiHa cells were transduced with pLentiV2
plasmid containing the Cas9 cassette and either IFITM1 sgRNA or IFITM3 sgRNA to generate IFITM1 null
cells or IFITM3 null cells, respectively. The IFITM1/IFITM3 double null cells were generated by transduc-
ing pLentiV2 plasmid containing Cas9 cassette and IFITM3 sgRNA into IFITM1 null cells. (B) The next day,
medium with lentivirus was removed and the cells were resuspended in fresh media containing 10 µg/ml of
puromycin. (C) Puromycin selection was continued for about two weeks, after which single cells were sorted
by FACS into 96-well plates. (D) These cells were propagated to form colonies originating from a single cell.
(E) Finally, cell clones were tested by Western blotting. At the time IFITM1 null cells were engineered we did
not have a specific antibody for IFITM1 suitable for Western blotting. For this reason, IFITM1 null cells were
tested by immunoprecipitation using rabbit anti-IFITM1 (CVY), an antibody that detects the C-terminus of
IFITM1. Afterwards, cells were tested by Western blotting using the IFITM1/IFITM3 antibody for detection
(Figure A.2 A).
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Figure A.2: Individual clone screening for IFITM1 null, IFITM1/IFITM3 double null and IFITM3 null SiHa
candidates subjected to CRISPR/Cas9 methodology by immunoblotting. Individual clones were screened
for absence of IFITM1 (A) or IFITM1/IFITM3 (B) and IFITM3 (C) protein expression by Western blotting.
Representative blot to test the IFITM1 null clones (A), IFITM1 was immunoprecipitated using rabbit anti-
IFITM1 (CVY) antibody (specific antibody against C-terminus of IFITM1 not compatible for Western blot-
ting) as at the time there was no specific commercial antibody against IFITM1. Eluates were tested with
IFITM1/IFITM3 antibody (upper panel). CRISPR-clone 4 (lane 2) was used in this thesis. Representative blot
to test the IFITM1/IFITM3 double null clones (B), IFITM1/IFITM3 proteins were detected by Western blotting
using IFITM1/IFITM3 antibody. CRISPR-clone 5 (lane 5) was used in this thesis. Representative blot to test
the IFITM3 null clones (C), IFITM3 protein was detected by Western blotting using IFITM3 specific antibody.
CRISPR-clone 29 (lane 9) was used in this thesis. Selected clones for IFITM1 null and IFITM1/IFITM3 double
null and IFITM3 null-SiHa cells were for further validation by Sanger sequencing and immunofluorescence.
This work was performed by Dr. Marta Nekulová, RECAMO, Masaryk Memorial Cancer Institute, Brno.
Figure A.3: Determination of IFNγ dosage (A) Dose dependent titration with IFNγ for 24 hours: non-treated
(lane 1), 6.25 (lane 2), 12.5 (lane 3), 25 (lane 4), 50 (lane 5), and 100 ng/ml (lane 6). (B) Time course with 100
ng/ml IFNγ: 0 (lane 7), 4 (lane 8), 6 (lane 9), 24 (lane 10), 48 (lane 11), and 72 hours (lane 12).
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Supplementary Table B.1: Identification of IFITM1-dependent proteins by depleting IFITM1 in wt-SiHa
cells using label-free SWATH-MS analysis. Wt-SiHa cells were transfected with IFITM1-targeted-siRNA or
scrambled siRNA for 48 hours (columns A to N, in orange) and 72 hours (columns P to AC, in blue). The data
acquired from these two biological states were processed in technical triplicates for SWATH-MS analysis. The
data are summarized as peak name (columns A and P), gene name (columns B and Q), p-value (columns E
and T), and log10 fold change (IFITM1 siRNA/control siRNA) (columns N and AC). The data in this table was
used to make Figure 3.2.
Supplementary Table B.2: Identified IFITM1 interacting proteins in wt-SiHa cells by SILAC Orbitrap-MS
analysis. Wt-SiHa cells were ectopically transfected under two biological states: with SBP-IFITM1 or SBP-
empty vector for 24 hours (column K-P, in orange); or for 48 hours (column Q-V, in blue). Samples were lysed
and processed for Orbitrap-MS analysis. These two transfection times were used to cover the variability in-
herent in transfection of plasmid DNA. The aim was to capture overlapping interacting proteins in both time
points, 24 and 48 hours. The data are summarized as peak name (column A), gene name (column B), fold
change (SBP-IFITM1/SBP control) (column P and V). The data in this table were used to make Table 4.1.
Supplementary Table B.3: Identified IFITM1 interacting proteins in wt-SiHa cells by label-free SWATH-MS
analysis. Wt-SiHa cells were ectopically transfected under two biological states: with SBP-IFITM1 or SBP-
empty vectors for 24 hours (columns A-E,in orange); or for 48 hours including IFNγ stimulation for the fi-
nal 24 hours (columns G-K, in blue). Samples were lysed and processed for SWATH-MS analysis. These two
transfection times were used to cover the variability inherent in transfection of plasmid DNA. The data are
summarized as peak name (columns A and G), gene name (columns B and H), p-value (columns C and I), fold
change (SBP-IFITM1/SBP control) (columns D and J), and log10 fold change (columns E and K). The data in
this table were used to make Table 4.2 and Figure 4.13.
Supplementary Table B.4: Ribosomal SWATH-MS analysis after performing a sucrose gradient sedimen-
tation analysis of IFNγ-stimulated wt-SiHa and IFNγ-stimulated IFITM1/IFITM3 double null cells. The
wt-SiHa and IFITM1/IFITM3 double null cells were IFNγ-stimulated for 24 hours. The lysates were applied to
the sucrose gradient for sedimentation; the 40S, 60S, 80S, and polysomal fractions were pooled based on the
elution profiles derived from the A254 trace (Figure 5.3 A). The data acquired after SWATH analysis are sum-
marized in four spread sheet tabs named as 40S, 60S, 80S, and polysomes. Key information is shown as peak
name (column A), gene name (column B), p-value (column D, highlighted in yellow), and log10 fold change
(wt-SiHa cells/IFITM1/IFITM3 double null cells) (column O, highlighted in yellow). The data derived from
these tables were used to make Figure 5.5.
Appendix B - Supplementary table list 171
Supplementary Table B.5: Relative quantification values (heavy vs light ratios) in wt-SiHa, IFITM1 single
null, IFITM1/IFITM3 double null cells non-stimulated or IFNγ-stimulated for 6 and 24 hours and pulse
labelled in heavy-SILAC media for 6 and 24 hours. All samples were processed as biological triplicates.
Comparisons from heavy vs light SILAC media were performed from pulse-labelled newly-synthetized protein
(heavy) vs total protein amount in the cell (light). Each excel spread sheet tab exported from Proteome Dis-
coverer 1.4 shows one condition, from left to right: wt-SiHa cells (6 hours); wt-SiHa cells (6 hours with IFNγ);
IFITM1/IFITM3 dobule null cells (6 hours); IFITM1/IFITM3 double null cells (6 hours with IFNγ); IFITM1 null
cells (6 hours); IFITM1 null cells (6 hours with IFNγ); wt-SiHa cells (24 hours); wt-SiHa cells (24 hours with
IFNγ); IFITM1/IFITM3 double null cells (24 hours); IFITM1/IFITM3 double null cells (24 hours with IFNγ);
IFITM1 null cells (24 hours); IFITM1 null cells (24 hours with IFNγ). Key information is shown as peak name
(column A), gene name (column B), fold change (heavy/light, in three biological triplicate) (columns K, N and
Q). The data derived from these tables were used to make Figure 5.8 and Figure 5.9.
Supplementary Table B.6: Transcriptome study of wt-SiHa cells, IFITM1 null cells, and IFITM1/IFITM3
double null cells non-stimulated or IFNγ-stimulated for 24 hours. Three biological replicates for wt-SiHa
cells, IFITM1 null cells, and IFITM1/IFITM3 double null cells non-stimulated or IFNγ-stimulated for 24 hours
were combined in equal RNA amounts and processed to study their transcriptome using RNA sequencing.
In the RNA-Seq spread sheet tab, key information is shown as gene name (column A), identifier (column D).
Gene counts (TPM) for each cell type are represented as wt-SiHa cells (column G), IFNγ-stimulated wt-SiHa
cells (column K), IFITM1 null cells (column O), IFNγ-stimulated IFITM1 null cells (column S), IFITM1/IFITM3
double null (column W), and IFNγ-stimulated IFITM1/IFITM3 double null cells (column AA). The data derived
from these tables were used to make Figure 6.7. In the comparison spread sheet tab, key information is shown
as gene name (column A), identifier (column D). Gene comparison between to cell conditions are represented
as log2 (wt-SiHa cells vs IFITM1 null cells) (column N), log2 (wt-SiHa cells vs IFITM1/IFITM3 double null cells)
(column O), log2 (IFNγ-stimulated wt-SiHa cells vs IFNγ-stimulated IFITM1 null cells) (column P), log2 (IFNγ-
stimulated wt-SiHa cells vs IFNγ-stimulated IFITM1/IFITM3 double null cells) (column Q), log2 (wt-SiHa cells
vs IFNγ-stimulated wt-SiHa cells) (column R), log2 (IFITM1 null cells vs IFNγ-stimulated IFITM1 null cells)
(column S), and log2 (IFITM1/IFITM3 double null cells vs IFNγ-stimulated IFITM1/IFITM3 double null cells)
(column T). The data derived from these tables were used to make Figure 6.6.
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MHC Class I molecule
CAS9 gene editing
A B S T R A C T
Interferon-induced transmembrane proteins IFITM1 and IFITM3 (IFITM1/3) play a role in both RNA viral re-
striction and in human cancer progression. Using immunohistochemical staining of FFPE tissue, we identified
subgroups of cervical cancer patients where IFITM1/3 protein expression is inversely related to metastasis.
Guide RNA-CAS9 methods were used to develop an isogenic IFITM1/IFITM3 double null cervical cancer model in
order to define dominant pathways triggered by presence or absence of IFITM1/3 signalling. A pulse SILAC
methodology identified IRF1, HLA-B, and ISG15 as the most dominating IFNγ inducible proteins whose synthesis
was attenuated in the IFITM1/IFITM3 double-null cells. Conversely, SWATH-IP mass spectrometry of ectopically
expressed SBP-tagged IFITM1 identified ISG15 and HLA-B as dominant co-associated proteins. ISG15ylation was
attenuated in IFNγ treated IFITM1/IFITM3 double-null cells. Proximity ligation assays indicated that HLA-B can
interact with IFITM1/3 proteins in parental SiHa cells. Cell surface expression of HLA-B was attenuated in IFNγ
treated IFITM1/IFITM3 double-null cells. SWATH-MS proteomic screens in cells treated with IFITM1-targeted
siRNA cells resulted in the attenuation of an interferon regulated protein subpopulation including MHC Class I
molecules as well as IFITM3, STAT1, B2M, and ISG15. These data have implications for the function of IFITM1/3
in mediating IFNγ stimulated protein synthesis including ISG15ylation and MHC Class I production in cancer
cells. The data together suggest that pro-metastatic growth associated with IFITM1/3 negative cervical cancers
relates to attenuated expression of MHC Class I molecules that would support tumor immune escape.
1. Introduction
Interferons (IFNs) are pleiotropic cytokines produced by the innate
immune system as a defensive response [1]. Many biological functions
have been described for the interferon pathway. Among them, the best
characterized are anti-tumor activity, immunomodulatory effects, anti-
pathogen, and anti-viral activity [2]. IFN effects rely on three different
types of receptors: Type I (IFNα, IFNβ and IFNω), Type II (IFNγ) and
Type III (IFNλ) [3,4]. IFNs increase in response to a broad range of
factors such as persistent viral infection or DNA damaging agents which
activate the JAK kinase-STAT pathway. Ultimately, this signalling cas-
cade will regulate the transcriptional synthesis of interferon stimulated
genes (ISGs) [5,6].
Type I IFNs facilitate anti-proliferative and pro-apoptotic pathways
in a wide range of cell types and it has been extensively used as anti-
tumor therapeutic agent. High doses of IFNs are used for cancer therapy
and can activate anti-tumor immunity as well as pro-apoptotic and anti-
proliferative programs. By contrast, it has been demonstrated that
sustained low level of IFN causes a steady-state expression of the in-
terferon resistance DNA damage signature (IRDS) which is comprised of
a subset of interferon-stimulated genes [7]. IRDS proteins promote
phenotypes that contribute to the tumor development such as resistance
to DNA damage, suppression of T cell toxicity, metastasis, and facil-
itation of epithelial–mesenchymal transition [8].
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IFITM1 is a pro-oncogenic receptor which is a component of the
IRDS pathway. Basal expression of IFITM proteins is observed in some
cells and expression can also be induced by Type I and Type II inter-
ferons. IFITM1 is up-regulated during development of radiation re-
sistance, escaping from pro-apoptotic and anti-proliferative effects
[9,10]. IFITM1 expression has been extensively reported in many types
of cancer; breast, cervix, colon, ovary, brain and oesophagus cancer and
its high expression correlates with tumor progression and can lead to a
poor outcome [10–16].
IFITM1 was previously known as IFI 17 (interferon induced protein
17), IFI 9–27 (interferon inducible protein 9–27), CD225 (cluster of
differentiation) and Leu-13 (leucocyte surface protein). It is a mem-
brane protein that plays a key role in restriction of anti-viral immune
response and belongs to the interferon induced transmembrane family
(IFITM) [17]. IFITM1 is coded by the IFITM1 gene located on chro-
mosome 11p15.5 and flanked by IFITM2 and IFITM3 genes. The IFITM
immunity-related protein family are composed of short amino-terminal
and carboxy-terminal domains, two transmembrane domains, and a
cytoplasmic domain. IFITM1 is slightly different from IFITM2 and
IFITM3, with some studies demonstrating that IFITM1 is uniquely ex-
pressed at the cell surface [18,19].
IFITM family members are capable of attenuating the entrance of
many human and animal viruses. They suppress the entry of viruses
such as influenza A virus (IAV), West Nile virus, dengue virus, SARS
coronavirus, filoviruses, VSV, and HCV among others [20]. IFITM fa-
mily proteins inhibit cytosolic entry of viruses by preventing fusion of
viral and host membranes. The protein-protein interaction networks by
which IFITM proteins inhibit viral propagation are just emerging. One
study using yeast two-hybrid methodology has identified an interaction
of IFITM3, IFITM2, and IFITM1 with VAPA that in turn mediates an
accumulation of cholesterol in multivesicular structures [21]. This re-
duces the fusion of intraluminal virion-containing vesicles with en-
dosomal membranes and thereby inhibits virus release into the cytosol.
In addition, different family members exhibit specific viral preferences.
In the case of IFITM1, it is more active in controlling filoviruses, In-
fluenza A, and SARS [17,20,22]. In this report, we focus on applying
methodologies in interactomics, gene editing, SWATH-im-
munoprecipitation mass spectrometry, and pulse-SILAC mass spectro-




All chemicals and reagents were obtained from Sigma unless in-
dicated otherwise. All antibodies from Thermofisher unless indicated
otherwise. SiHa, IFITM1 null-SiHa, and IFITM1/IFITM3 null-SiHa cell
lines were grown in RPMI 1640 medium (Invitrogen) supplemented
with 10% (v/v) fetal bovine serum (Labtech) and 1% penicillin/strep-
tomycin (Invitrogen) and incubated at 37 °C with 5% CO2.
2.2. Tissue microarray
Cervical cancer samples were obtained at the Masaryk Memorial
Cancer Institute where patients gave written consent for tissue use ac-
cording to local ethical regulations. Tissues were fixed in 4% for-
maldehyde for approximately 24 h before processing into paraffin wax
and sectioned (4 μm). After sections were cut, the antigens were re-
trieved, and samples were probed with primary antibodies (including
those to p16 protein (data not shown), and IFITM1/3 proteins (using
the Mab-MHK); Supplementary Fig. 1). Following this stage, the tissue
sections were incubated with secondary antibodies conjugated to
streptavidin–HRP. Sections were incubated with DAB (Dako), counter-
stained with haematoxylin and mounted for visualization, as previously
described [23].
2.3. Generation of IFITM1 null and IFITM1/IFITM3 double null cell line
using CRISPR/CAS9 technology
Guide RNA sequences were designed for IFITM1 (5′ TCCAAGGTCC
ACCGTGATCA 3′) and for IFITM3 (5′ GTCAACAGTGGCCAGCCCCC 3′).
The guide RNA was cloned into the lentiCRISPRv2 expression vector
[24]. After transfection, cells were selected with puromycin and sorted
in a 96-well plate using FACS. After 3 weeks, individual clones were
screened for absence of IFITM1 and/or IFITM3 protein expression by
Western Blot using the Mab-MHK (Supplementary Fig. 1). Chromo-
somal DNA from the positive clones were sequenced for a final vali-
dation to define the precise gene edit (as in Figs. 2 and 3).
2.4. DNA extraction and sequence validation of guide RNA edits
Chromosomal DNA was extracted from frozen cell pellets following
the instruction manual (Gentra Puregene Cell kit, Qiagen). Validation of
the edited DNA sequence was confirmed by cloning the genomic IFITM1
and IFITM3 PCR products into a holding vector and by amplifying the
entire gene and 500 bp surrounding the guide RNA targeting site fol-
lowed by Sanger sequencing at Source BioScience Service (Scotland).
2.5. Cloning, transfection and affinity purification of SBP-IFITM1 protein
IFITM1 cDNA was cloned by PCR into pEXPR-IBA105 expression
vector containing SBP tag at the N-terminus of the coding region (SBP
vector (IBA)). SiHa cells were grown in RPMI as a duplicate. For
transfection, cells were grown to approximately 80% confluency and
transfected using Attractene (Qiagen). Cells were transfected with SBP-
empty vector (control cells) and SBP-IFITM1 for 48 h. 48 h after
transfection, cells were treated with carrier or with 100 ng/ml IFNγ
(Invitrogen) for 24 h in order to “stabilize” potential interferon-acti-
vated SBP-IFITM1 interacting proteins. Cells were washed twice in ice
cold PBS and scraped into buffer containing 100mM KCl, 20mM
HEPES pH 7.5, 1 mM EDTA, 1mM EGTA, 0.5 mM Na3VO4, 10mM NaF,
10% (v/v) glycerol, protease inhibitor mix, and 0.1% triton X-100, then
incubated for 30min on ice and centrifuged at 13,000 rpm for 15min at
4 °C. Equal amounts of protein were used for performing the affinity
capture. Streptavidin Agarose conjugated beads (Millipore) were pre-
washed with in PBS. Then cell lysate was added and incubated for 2 h at
RT with gentle rotation. Binding proteins were eluted with a buffer
containing 20mM HEPES pH 8, 2mM DTT, and 8M Urea.
2.6. Transient transfection of siRNA
Small interfering RNA directed against the human IFITM1 (Qiagen)
and an AllStars negative controls FlexiTube siRNA (Qiagen) were used
to transfect SiHa cells for 48 and 72 h. Cells were transfected using
HiPerFect (Qiagen) following the manufacturer's instructions.
2.7. SILAC labeling of cells for use in pulse SILAC
For performing “pulse” SILAC, Parental SiHa, IFITM1/IFITM3
double null cells, and IFITM1 single null cells were grown as biological
triplicate and incubated with SILAC heavy media for 6 and 24 h with or
without 100 ng/ml IFNγ before harvesting [25–27]. Cells were iso-
topically pulse-labeled using SILAC RPMI-heavy media (Dundee Cell
Products, UK); L-[13C614N4] arginine (R6) and L-[13C614N2] lysine
(K6). Cells were harvested in a buffer containing 8M Urea, 0.1 M Tris
pH 8.5. Total protein extracts were measured by the Bradford assay
[28].
2.8. Antibodies
Proteins were detected using the following primary antibodies:
mouse monoclonal anti-bodies generated to a peptide that is identical in
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IFITM1 and IFITM3 (Mab-MHK) (Moravian Biotechnology, this study is
their first description). The antibody we name Mab-MHK can therefore
detect co-expression of both IFITM1 and IFITM3 proteins
(Supplementary Fig. 1). Other sources include, rabbit monoclonal anti-
STAT1 (Cell Signalling), mouse monoclonal anti-IRF1 (BD Transduction
Laboratories), rabbit polyclonal anti-HLA-B (Thermo Fisher), rabbit
polyclonal antibody anti-ISG15 (Cell Signalling), mouse monoclonal
anti-SBP-tag (Sigma), mouse monoclonal anti-β-actin (Sigma), and the
mouse monoclonal anti-GAPDH (Abcam).
2.9. Western blotting
Protein from lysed samples was quantified using Protein Assay Dye
Reagent (Bio-Rad). Proteins were resolved by SDS-PAGE using 15% gels
[29] and transferred onto nitrocellulose membranes (Amersham Pro-
tran, GE Healthcare). Immunoblots were processed by enhanced che-
miluminescence (ECL).
2.10. Immunofluorescence
Parental SiHa and IFITM1/IFITM3 double null cells were grown over
16mm diameter glass coverslips. Stimulated cells were treated with
100 ng/ml IFNγ for 24 h. Cells were fixed with 4% (v/v) paraf-
ormaldehyde in PBS for 15min at room temperature and permeabilized
using 0.25% triton X-100 in PBS for 10min. Then, the cells were
blocked with 3% BSA in PBS for 30min. The primary antibody was
incubated at a 1:1000 dilution overnight. Alexa Fluor 488 goat anti-
rabbit IgG (H+L) (Invitrogen) was incubated as a secondary antibody
at 1:2000 dilution for 1 h. The fluorescent signal was detected using a
Zeiss Axioplan 2 microscope at 63×. Replicates are described in the
Fig. 6 legend. Fluorescence was measured using ImageJ software; cells
were selected, and information was extracted on the area, integrated
density, and mean gray values by selecting set measurements in the
Analyse menu. A region with no fluorescence was selected as back-
ground for each image. The following formula was applied for each 50
cells analyzed: CTCF= Integrated Density – (Area of selected
cell ×Mean fluorescence of background readings); *CTCF= corrected
total cell fluorescence.
2.11. Proximity ligation assay
Parental SiHa and IFITM1/IFITM3 double null cells were grown and
processed as described in the Immunofluorescence method (above).
Primary antibodies from different species were incubated with the fixed
and permeabilized cells: MHK mouse MAb with rabbit polyclonal anti-
HLA-B, at 1:250 dilution overnight. Duolink® assays (Sigma) were
carried out following supplier's instructions. The fluorescent signal was
detected using a Zeiss Axioplan 2 microscope at 63×. Fluorescence was
measured using ImageJ software, as above reviewed for standard im-
munofluorescence.
2.12. Mass spectrometric experimental screens
2.12.1. Peptide generation using FASP
Cell lysates, immunoprecipitates, or gradient fractions were pro-
cessed using filter-aided sample preparation protocol (FASP) [30,31].
Urea buffer (8M Urea in 0.1 M Tris pH 8.5) was added to a 30 kDa spin
filter column (MRCPRT010, Microcon). Protein concentration was de-
termined using the RC-DC method (Bio-rad). Normalized sample was
added into the spin filter column and was centrifuged at 14000 g for
15min at 20 °C. Urea buffer was added again with 100mM Tris (2-
carboxyethyl) phosphine hydrochloride (Aldrich) and mixed. The
column was left on a thermo-block set at 37 °C shaking at 600 rpm and
centrifuged at 12,210 rpm at 20 °C for 15min. Urea buffer and 300mM
of iodoacetamide (Sigma) were mixed using a thermo-mixer at 600 rpm
in the dark for 1min, then was maintained statically for a further
20min at room temperature in the dark. The sample was centrifuged at
12,210 rpm at 20 °C for 15min and the supernatant was discarded. A
solution containing 100mM ammonium bicarbonate were added to the
column and then it was centrifuged at 12,210 rpm at 20 °C for 20min.
This step was repeated one more time. The column was placed in a new
collecting tube (low binding affinity) and 50mM ammonium bicarbo-
nate was added along with trypsin diluted in trypsin buffer (Promega)
at a 1:100 ratio. The column was incubated at 37 °C overnight. The
following day the column was centrifuged at 12,210 rpm at 20 °C for
15min. Determination of the peptide concentration was performed
using the Quantitative Colorimetric Peptide Assay (Pierce, Thermo-
Scientific).
2.13. Desalting peptides using C18 column
Peptides were desalted on micro spin columns C-18 (Harvard
Apparatus, USA). C-18 columns were conditioned three times with
100% acetonitrile (AcN) and 0.1% formic acid (FA) and centrifuged at
1200 rpm at room temperature for 2min. The column was washed with
0.1% FA and centrifuged at 1200 rpm at room temperature for 2min.
The column was hydrated in 0.1% FA for 15min following cen-
trifugation at 1800 rpm at room temperature for 3min. The sample was
loaded into the column and centrifuged at 2300 rpm for 3min. After
washing the column three times with 0.1% FA, the peptides were eluted
in three consecutive centrifugations at 2300 rpm for 3min using
50%–80% and 100% AcN with 0.1% FA. Subsequently, peptide eluates
were evaporated and dissolved in 5% AcN with 0.05% FA.
2.14. LC-MS/MS analyses
There were three distinct mass spectrometric screens used in the
manuscript. The rationale for replicates in each distinct approach is as
follows; (i) the SWATH-IP (immunoprecipitation) to identify IFITM1-
enriched associated proteins (Fig. 8). The immunoprecipitation and
immunoblots of SBP-IFITM1 vs SBP control is representative of ex-
periments performed at least three times. The representative enrich-
ment of IFITM1-associated proteins (in Fig. 8 from Supplementary
Table 2) was processed by label free (SWATH) mass-spectrometry in
technical triplicates. The measured fold-changes and p-values for
quantified proteins are listed in Supplementary Table 2 and Fig. 8; (ii)
the siRNA SWATH-MS (Fig. 9A and B). Targeted siRNA to deplete
IFITM1 in SiHa cells was performed in at least three separate experi-
ments. A representative depletion of IFITM1 protein (Fig. 9A) was
performed in technical triplicates using two different biological states
(48 and 72 h). The statistical rationale for performing two biological
states (equivalent plating of cell number and differing by time of in-
terferon exposure) rather than two biological replicates at the same
time point, was due to the variable induction and suppression of the
interferon cascade over this time frame. Thus, any proteins that are
observed in two biological states as a function of time are thought to
have higher significance than an analysis performed in duplicates at
one time point. The samples in the two biological states were processed
in technical triplicate for label-free (SWATH) analysis (Fig. 8; Supple-
mentary Table 2); (iii) Pulse SILAC to measure protein synthesis as a
function of genotype. Twelve enzymatically digested samples (four
samples of parental SiHa, four samples of IFITM1 null, and four samples
of IFITM1/IFITM3 double null), each of them as independent biological
triplicates, were processed using isotopically labeled amino acids and
were separated using LC-MS/MS analysis (Fig. 5; Supplementary Fig. 2;
Supplementary Table 1). The statistical rationale for using three bio-
logical replicates with one injection per replicate, rather three technical
replicates from one biological sample, relates to the dynamics and
variability in the interferon dynamics. By using biological triplicates,
any common overlaps are deemed to be more significant because of the
possible variability in the cell plating and interferon cascade.
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2.15. LC-MS/MS analysis of SILAC labeled samples
SILAC samples were separated using UltiMate 3000 RSLCnano
chromatograph (Thermo Fisher Scientific, Massachusetts, USA).
Peptides were loaded on a pre-column (μ-precolumn, 30mm i.d., 5 mm
length, C18 PepMap 100, 5 μm particle size, 100 Å pore size) and fur-
ther separated on an Acclaim PepMap RSLC column (75mm i.d., length
500mm, C18, particle size 2mm, pore size 100 Å) with a 300 nl/min
flow rate using a linear gradient: 2% B over 4min, 2–40% B over
64min, 40–98% B over 2min, with A=0.1% aq. formic acid and
B=80% AcN in 0.08% aq. formic acid. Peptides eluting from the
column were introduced into an Orbitrap Elite (Thermo Fisher
Scientific, Massachusetts, USA) operating in Top20 data dependent
acquisition mode. A survey scan of 400–2000m/z was performed in the
Orbitrap at 120000 resolution with an AGC target of 1×106 and
200ms injection time followed by twenty data-dependent MS2 scans
performed in the LTQ linear ion trap with 1 microscan, 10ms injection
time and 10,000 AGC.
2.16. Database searching and analysis
The data from mass spectrometer were processed either using
Proteome Discoverer 1.4 or Proteome Discoverer 2.2 that is employed
with imbedded statistical tools (both programs were from Thermo
Fisher Scientific, Massachusetts, USA). Proteome Discoverer 1.4 pro-
cessed the data using Mascot engine with the following search settings:
database Swiss-Prot human (April 2016); enzyme trypsin; 2 missed
cleavage sites; precursor mass tolerance 10 ppm; fragment mass toler-
ance 0.6 Da; dynamic modifications: carbamidomethyl [C], oxidation
[M], acetyl [protein N-terminus]. The results of the search were further
submitted to generate the final report considering 1% FDR on both PSM
and peptide group levels. Only unique peptides were used for the
protein quantification. SILAC labels of R6 and K6 were chosen for heavy
and R0 and K0 for light. The relative quantification value was re-
presented as heavy/light ratio (Supplementary Table 1). In the pro-
cessing and consensus workflows subsequent nodes were used: the
Minora feature detector, the Precursor ion quantifier, and the Feature
mapper. The data were processed using Sequest HT engine with the
following search settings: database Swiss-Prot 2017-10-25, # sequences
42,252, taxonomy: Homo sapiens (updated February 2018); enzyme
trypsin; 2 missed cleavage sites; precursor mass tolerance 10 ppm;
fragment mass tolerance 0.6 Da; static modification carbamidomethyl
[+57.021 Da, (C)], label 13C(6) [+6.020 Da (K, R)]; dynamic mod-
ifications oxidation [peptide terminus, +15.995 Da (M)], Met-loss
+Acetyl [protein terminus, −89.030 Da (M)]. The results of the search
were further submitted to generate the final report with a 1% FDR using
Percolator. For the protein quantification and statistical assessment of
the biological triplicates, only unique peptides and razor peptides were
used. The relative quantification value is represented as the relative
peak area of the peptides with the heavy isotope labels with IFNγ
treated cells/IFNγ untreated cells ratios (Supplementary Table 3B).
2.17. SWATH-MS
Label free quantitation was performed using FASP-processed tryptic
digests with liquid chromatography coupled to tandem mass spectro-
metry on an Eksigent Ekspert nanoLC 400 (SCIEX, California, USA)
online connected to a TripleTOF 5600+ (SCIEX, Toronto, Canada) mass
spectrometer. Cells lysates were processed in technical triplicates. Prior
to the separation the peptides were concentrated and desalted on a
cartridge trap column (300 μm i.d.× 5mm) packed with a C18
PepMap100 sorbent with a 5 μm particle size (Thermo Fisher Scientific,
Waltham, MA, USA). After a 10 washing using 0.05% trifluoroacetic
acid in 5% acetonitrile and 95% water, the peptides were eluted using a
gradient of acetonitrile/water (300 nl/min) using a capillary emitter
column PicoFrit® nanospray columns 75 μm×210mm (New Objective,
Massachusetts, USA) self-packed with ProntoSIL 120-3-C18 AQ sorbent
with 3 μm particles (Bischoff, Leonberg, Germany). Mobile phase A was
composed from 0.1% (v/v) formic acid in water, and mobile phase B
was composed of 0.1% (v/v) formic acid in acetonitrile. Gradient elu-
tion started at 5% mobile phase B for the first 30min and then the
proportion of mobile phase B increased linearly up to 40%B for the
following 120min. Output from the separation column was directly
coupled to an ion source (nano-electrospray). Nitrogen was used as a
drying and nebulizing gas. Temperature and flow of the drying gas was
set to 150 °C and 12 psi. Voltage at the capillary was 2.65 kV.
Pooled sample for the spectral library was measured in data-de-
pendent positive mode (IDA). The MS precursor mass range was set
from m/z 400 up to m/z 1250 and from m/z 200 up to m/z 1600 in MS/
MS. Cycle time was 2.3 s and in each cycle 20 most intensive precursor
ions were fragmented. Subsequently, their corresponding MS/MS
spectra were measured. Precursor exclusion time was set to 12 s.
Precursor ions with intensity below 50cps were suspended from the IDA
experiment. The extraction of mass spectra from chromatograms, their
annotation and deconvolution were performed using Protein Pilot 4.5
(SCIEX, Toronto, Canada). MS and MS/MS data were searched using the
Uniprot+swissprot database (02. 2016, 69,987 entries) restricted to
Homo sapiens taxonomy. Fixed modification – alkylation on cysteine
using iodoacetamide and digestion using trypsin was set for all sear-
ches. FDR analysis was performed by searching the shotgun data
against the decoy search database. The resulting group file was im-
ported into Peakview 1.2.0.3 (SCIEX, Toronto, Canada), where only
proteins with FDR below 1% were imported into the spectral library
(465 proteins for SBP-IFITM1 pull down SWATH). In SWATH mode, the
mass spectrometer operated in high sensitivity positive mode. Precursor
range was set from m/z 400 up to m/z 1200. It was divided into 67
precursor ion windows with the width of 12 Da and 1 Da overlap.
Accumulation time was 50ms per SWATH window and the duty cycle
was 3.0 s, which enabled acquisition of at least 10 data points across a
chromatographic peak. Product ions were scanned from m/z 400 up to
m/z 1600. Data extraction was performed in Peakview 1.2.0.3 (SCIEX,
Toronto, Canada) with the spectral library. The retention time window
for extraction was manually set to 4min for SBP-IFITM1 pull down
SWATH and for the siRNA SWATH (Fig. 9). Protein quantification was
performed using up to 4 peptides and 6 transitions per protein to define
the statistically significant proteins. Scope of peptides used for quan-
tification was narrowed to only those with peptide confidence higher
than 99% and without any variable modification. Protein summed peak
areas were normalized using total area sums option in MarkerView
1.2.1.1 (SCIEX, Toronto, Canada). Samples were compared pairwise
using paired t-test. The mass spectrometric data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identifier PXD007562”. For Reviewers, the details in-
clude; Username: reviewer17106@ebi.ac.uk and Password: OfTomSm7.
2.18. Flow cytometry for detection of HLA on the cell surface
The parental SiHa and IFITM1/IFITM3 double null cells were grown
in RPMI (supplemented with 10% FBS, pen-strep and pyruvate) to 50%
confluence in 6-well plates and treated with 100 ng/ml IFNγ for 24 h.
Cells were harvested using Accutase (Sigma-Aldrich, A6964), cen-
trifuged 1000 rpm for 5min with RPMI and kept on ice in 1% BSA in
PBS for 20min. Primary antibodies (HLA-B: PA5-35345) were diluted
in 1% BSA/PBS to 1:100. Cells were centrifuged as before, and cell
pellets were resuspended in 100 μl of diluted primary antibodies or in
the same amount of 1% BSA/PBS (for control samples) and incubated
45min a room temperature on a tube rotator. After a triple wash in ice-
cold 1% BSA/PBS, cells were incubated with 100 μl of secondary anti-
body (Abcam, Goat Anti-Rabbit IgG H&L DyLight 488), diluted 1:200,
on a tube rotator for 30min at room temperature. After a triple wash in
ice-cold 1% BSA/PBS, cells were resuspended in 500 μl of 1% BSA/PBS
and kept on ice before measurement. Samples were measured on
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FACSVerse (BD Biosciences) and data were analyzed using FACSuite
software (BD Biosciences). A negative control without primary antibody
was prepared for each sample. HLA expression on the cell surface was
counted as FITC median fluorescence intensity (MFI) divided by the
MFI of the negative control. Two independent experiments were per-
formed, each with two independently isolated IFITM1/IFITM3 double
null cells and two different HLA antibodies (HLA-A (data not shown)
and HLA-B (Fig. 6)).
3. Results
3.1. Identifying a clinically relevant model to dissect IFITM1 and IFITM3
(IFITM1/3) signalling
IFITM1 and IFITM3 (IFITM1/3) can function as oncogenic factors in
several cancer cells [32,33]. Attenuation of IFITM1 protein expression
can inhibit growth, invasion, and/or migration of cancer cells [34].
Patient subgroups with clinically relevant expression data are not well-
defined. We developed a panel of monoclonal antibodies to a N-term-
inal peptide with a high homology between IFITM1 and IFITM3 (Sup-
plementary Fig. 1A, B). This would allow the development of mono-
clonal antibodies that detect the co-expression of both IFITM1 and
IFITM3 proteins. We aimed to use such tools to screen a large panel of
human cancers for those that express IFITM1/3 proteins. This would
identify clinically relevant models for a focus to dissect IFITM1/3-
mediated signalling pathways. The monoclonal antibody chosen
(named Mab-MHK; Supplementary Fig. 1B) can bind to IFITM1/3 an-
tigens in a range of human cancer cells (Supplementary Fig. 1C). Some
cancer cells exhibit no expression of IFITM1/3 such as the lymphoma
cell line WHU-NHL (Supplementary Fig. 1C). Further studies confirmed
that Mab-MHK can bind to both IFITM1 and IFITM3 proteins, as defined
using single IFITM1 single null and IFITM1/IFITM3 double null cells
(see below).
Mab-MHK was used to screen large panels of archival formalin-fixed
human cancer tissues to identify potential clinically relevant models.
We could detect differential expression of IFITM1/3 in breast cancer,
colon cancer, and oesophagus cancer (data not shown). We could also
detect differential expression of IFITM1/3 protein in a cervical cancer
array (Fig. 1A–F). Squamous cervical cancer samples expressed either
high levels of IFITM1/3 (Fig. 1A), lower levels of IFITM1/3 (Fig. 1B), or
undetectable levels of the antigens (Fig. 1C). Cervical adenocarcinoma
often exhibited high expression (Fig. 1D). Interestingly, some normal
squamous cervical epithelium exhibited high expression in the basal
‘stem’ cell or pluripotent layer only (Fig. 1E), but not the differentiating
cell layers. We can conclude that 64 out of 74 cervical cancer specimens
are positive for IFITM1/3 proteins using the Mab-MHK (Fig. 1F, top
panel). What is also interesting is that there is a statistically significant
inverse association between IFITM1/3 protein expression and the
number of lymph node metastases in patients (Fig. 1F, bottom panel).
This will be rationalized in the discussion based on data that emerges
below.
3.2. Developing an IFITM1 and IFITM3 double null cell line using a
CRISPR-guide RNA methodology
IFITM1 is implicated in IFNγ mediated growth control in some
cancer cells with an active p53 pathway [35]. IFITM1 is also implicated
in a growth stimulatory role in cervical squamous cancers [36] [37].
The HPV16+ and IFITM1/3 positive cervical cancer cell line SiHa [38]
[39] exhibit IFNγ inducible STAT1, IRF1, and IFITM1/3 proteins
(Fig. 1G). As such, we focused on using this cervical cancer cell line
(SiHa) as a model to identify IFITM1/3 dependent signalling pathways.
In order to continue to develop a cervical cancer cell model that
reflects the clinical data (IFITM1/3 positive or IFITM1/3 negative
cancers; Fig. 1F), we set out to develop a double null IFITM1 and
IFITM3 cell line model. We first generated an isogenic IFITM1 null cell
panel through gene editing to validate the guide RNA. IFITM1 knock-
out mice are viable [40] so it was likely we would be able to generate
IFITM1 null cells. Guide RNAs targeting exon 1 in the IFITM1 gene
(Figure 2A) were cloned into pLentiV2. Cells were transfected and se-
lected for resistance to puromycin to allow stable integration of the
IFITM1 targeting guide RNA cassette. Cell clones were chosen for se-
quencing across the guide RNA targeting site (Fig. 2A) using PCR
(Fig. 2B). Both IFITM1 alleles were gene edited in a representative
IFITM1-null clone that creates two distinct frameshifts (Fig. 2C and D).
We examined four representative IFITM1 null cells in DNA damage
response assays and all lines were shown to be either chemosensitive or
X-irradiation sensitive (data not shown). Since all single knock-out
clones behaved similarly, we chose one representative IFITM1 null cell
line for continued study. The IFITM3 gene was next targeted using
guide RNA methodologies (Fig. 3A) to to create a IFITM1/IFITM3
double null cell (Fig. 3A–C). IFITM3 null mice, and mice with the entire
IFITM chromosomal locus deleted, are also viable [40,41]. This created
an isogenic cell model that removed any redundancy of IFITM3 in the
IFITM1 interaction landscape, especially as they both are reported to
interact with VAPA [21]. Immunoblotting confirmed that IFITM1 and
IFITM3 proteins are not detected in the IFITM1/IFITM3 double null cell,
respectively (Fig. 3D; lanes 5 and 6). We chose a representative double-
null cell line for subsequent studies.
3.3. Pulse SILAC mass spectrometry methodologies identify IFITM1/3
dependent protein synthesis in response to IFNγ signalling
Given that one established effector of IFITM1 is IFNγ [35], we
evaluated IFNγ responsive protein synthesis in IFNγ stimulated parental
SiHa, IFITM1 single null, and IFITM1/IFITM3 double null cells. The
parental SiHa, IFITM1 single null, and IFITM1/IFITM3 double null cells
were treated with heavy isotopic amino acid labeling media (the SILAC
method) for 6 or 24 h, in the absence or presence of IFNγ (Fig. 4). Cell
lysates were then processed by FASP [30,31] and then analyzed for
IFITM1/3-dependent protein synthesis using mass spectrometry. The
SILAC methodology has been subjected to an analysis of random error
associated with the multiple steps in this approach including; cell
plating in biological replicates, switch to heavy isotopic media, cell
recovery from plastic plates, cell lysis, centrifugation, filter assisted
trypsinization, and tryptic peptide recovery and processing. This error
can be reduced by employing multiple replicates (n=3) as highlighted
previously [42]. To highlight the importance of biological replicates
and the inherent error in this multiple step process, we plot the data not
as an average of three replicates, but as individual points from all three
replicates (as in Supplementary Fig. 2 and Fig. 5).
The dominant IFNγ responsive protein to be identified at 6-h post
labelling is IRF1 protein (Supplementary Fig. 2B vs 2A) with an at-
tenuation of isotopically labeled IRF1 peptides recovered in the biolo-
gical triplicates from IFITM1/IFITM3 double null cells (Supplementary
Fig. 2H). This suggests that IRF1 is partially dependent upon IFITM1/3
signalling and this was confirmed using IRF1 transcriptional reporter
assays (data not shown). This data provides some degree of confidence
that the methodology is able to identify a known IFNγ responsive target
(IRF1). There are other proteins whose synthesis was detected at
6 hours post-isotopic labelling including STAT1, EIF1, and B2M
(Supplementary Fig. 2I–K). EIF1 is not known to be linked to interferon
signalling, but it is known to regulate the accuracy of AUG codon se-
lection by the scanning pre-initiation complexes [43]. EIF1 might prove
to be involved in regulating interferon dependent anti-viral mRNA se-
lection. Nevertheless, all three proteins are also IFTM1/3-independent
(Supplementary Fig. 2I–K). STAT1 and B2M are also both known IFNγ
responsive proteins further validating the methodology used to measure
quantitative changes in protein synthesis. That all three proteins
(STAT1, EIF1, and B2M) exhibit equivalent protein synthesis rates in
the parental and double-null cell model indicates that the double null
has retained many key regulatory features of the parental cell. This
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suggests that many IFN regulatory features of the double null cell have
been retained despite the selection process creating the cell model.
By 24-h post IFNγ treatment of SiHa cells, HLA family members,
B2M, and STAT1 proteins were detected (Fig. 5B vs 5A), again in-
dicating that the methodology can detected known IFNγ inducible
proteins. By 24-h post IFNγ treatment, isotopically labeled IRF1
Fig. 1. Immunohistochemical analysis of
IFITM1/3 protein expression in cervical
cancers using the Mab-MHK. Formalin-
fixed, paraffin-embedded cervical carci-
noma tissue was processed as stated in the
Experimental Procedures using the Mab-
MHK that binds to shared epitopes in the
N-terminal domains of IFITM1 and
IFITM3 (Supplementary Fig. 1A, B).
Representative images highlight grades of
IFITM1/3 protein expression; (A). high
expression in squamous cell carcinoma,
(B). medium expression in squamous cell
carcinoma, (C). absence of expression in
squamous cell carcinoma, (D). high ex-
pression in adenocarcinoma, and (E). ex-
pression in basal stem cell layer in normal
tissue. (F). (Top panel); Quantification of
IFITM1/3 protein expression in cervical
cancer in relation to histology type and
(Bottom panel) IFITM1/3 protein expres-
sion in cervical cancer in relation to
lymph node metastasis, excluding neu-
roendocrine. (G). Immunoblotting of pro-
tein expression in the parental SiHa cells
after IFNγ treatment for the indicated time
points. Proteins evaluated include; STAT1;
β-actin, IRF1, and IFITM1/3.
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Fig. 2. Validation of the IFITM1 guide RNA. (A). Gene structure of the IFITM1 gene highlighting its two coding exons and one intron. The genomic region sur-
rounding the gRNA target site (with PAM site and homology region in red) for IFITM1 was amplified and subjected to DNA sequencing. The raw DNA sequence reads
in the IFITM1 gene are highlighted in (B). Genomic DNA sequence of the heterozygote IFITM1 indels after cloning the PCR amplified IFITM1 region into a vector and
then sequencing individual plasmids for the type of gene edit. One allele of IFITM1 has a one bp insertion and the other a one bp deletion, both resulting in frame-shift
stop edits are highlighted in C. Predicted translation of each allele giving rise to premature stop codons are highlighted in D. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. Validation of the IFITM3 guide RNA. (A). Gene structure of the IFITM3 gene highlighting its two coding exons and one intron. The genomic region sur-
rounding the gRNA target site (with PAM site and homology region in red) for IFITM3 was amplified and subjected to DNA sequencing. The raw DNA sequencing
reads in the IFITM3 gene are highlighted in (B). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
The IFITM3 gene has two insertions that result in a poly-proline frame-shift creating a stop codon (C). (D). Immunoblotting was performed using Mab-MHK with
lysates from SiHa cells (lanes 1 and 2); IFITM1 single null cells (lanes 3 and 4); and IFITM1/IFITM3 double null cells (lanes 5 and 6). The cells were either untreated or
treated with IFNγ (100 ng/ml) for 24 h and processed for immunoblotting with either a β-actin antibody or Mab-MHK.
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peptides are attenuated (Fig. 5H), which is consistent with the early and
transient induction of IRF1 by IFNγ. The synthesis of MHC Class I
molecules was IFITM1/3-dependent (Fig. 5B vs 5F; quantified in bio-
logical triplicates in Fig. 5L). All three, major HLA alleles exhibited
attenuated synthesis in the double null cell, as defined using the tryptic
peptide coverage (Supplementary Fig. 3). Isotopically labeled ISG15
tryptic peptides are also not observed in the early interferon response
(Supplementary Fig. 2), and the isotopically labeled ISG15 peptide re-
covery after 24 h is attenuated in the IFITM1/IFITM3 double null cells
(quantified in biological triplicates in Fig. 5G) suggesting that ISG15
protein synthesis is largely IFITM1/3 dependent. By contrast, STAT1
protein synthesis at 24 h appears largely IFITM1/3-independent
(quantified in biological triplicates in Fig. 5I). Providing another in-
ternal control, another well-known inducible IFNγ protein, B2M, ex-
hibits equivalent synthesis in the IFITM1/IFITM3 double null cell
(quantified in biological triplicates in Fig. 5K). This indicates that one
key regulatory feature of the double null cell, STAT1 production, has
remained intact.
3.4. Orthogonal validation of IFITM1/3 dependent induction of HLA-B and
ISG15
These data first demonstrate that using the pulse-SILAC metho-
dology, the SiHa cell model reflects the classic IFNγ responsive induc-
tion of STAT1, IRF1, B2M, ISG15, and MHC Class I molecules (Fig. 5B vs
5A and Supplementary Fig. 2). Also of note is attenuation of HLA-A,
HLA-B, HLA-C, and ISG15 protein synthesis 24 h post-IFNγ treatment in
the IFITM1/IFITM3 double null cells compared to parental SiHa (Fig. 5F
vs 5B).
In order to determine if IFITM1 deletion alone impacted on this set
of gene products, the parental SiHa and IFITM1-null cells were in par-
allel treated with SILAC heavy-labeling media for 6 or 24 h. As with the
double IFITM1/IFITM3 double null cells, IFNγ dependent induction of
IRF1 protein synthesis is attenuated 6 hours post labelling in the
IFITM1-single null cells (Supplementary Fig. 2D vs 2B). This suggests
that IRF1 is dependent upon IFITM1. Elevation of STAT1 protein
synthesis are IFITM1-independent based on the equivalent induction of
STAT1 in the IFITM1-single null cells (Fig. 5I). HLA-B protein synthesis
is attenuated 24 hours post-IFNγ treatment in the IFITM1 single null
cells (Fig. 5L). ISG15 synthesis is also attenuated in the IFITM1 single
null cell (Fig. 5G). Together, these data suggest that MHC Class I family
members and ISG15 require at least IFITM1 for maximal IFNγ stimu-
lated protein synthesis.
The software used to identify HLA orthologues in the pulse-SILAC
screen (Fig. 4) can discriminate between HLA-A, HLA-B, and HLA-C
based on tryptic peptide sequences (Supplementary Fig. 3). We focus
here on HLA-B, which shows accurate identification of HLA-B specific
peptides and it is also a member of the IRDS pathway [7]. We thus
validated HLA-B protein expression in orthogonal assays to determine
whether apparent reductions in HLA-B protein synthesis reduction in
the IFITM1/IFITM3 double null cells was reflected in total steady state
protein levels and subcellular localization on the plasma membrane.
First, immunofluorescence of HLA-B was defined in parental SiHa
and IFITM1/IFITM3 double null cells. Parental SiHa cells revealed sig-
nificant induction of HLA-B immunoreactivity 24 h after IFNγ treatment
(Fig. 6C vs 6B and quantified in 6G). By contrast, basal HLA-B protein
expression was attenuated in the IFITM1/IFITM3 double null cells after
IFNγ treatment (Fig. 6F vs 6E). Quantitation of the total immuno-
fluorescence in the absence and presence of IFNγ, in the parental SiHa
and IFITM1/IFITM3 double null cells, also confirms attenuated HLA-B
induction in the null cell panel (Fig. 6H vs 6G). This is consistent with
the reduced protein synthesis observed for HLA-B in the pulse SILAC
quantitation in the IFITM1/IFITM3 double null cells.
The dominant subcellular localization of HLA-B is thought to reside
on the cell surface as an antigen presentation carrier. We therefore
evaluated whether HLA-B expression on the plasma membrane was
altered in the IFITM1/IFITM3 double null cell using FACS analysis with
non-permeabilized cells. Two independent IFITM1/IFITM3 double null
cell clones were used as a form of biological replicate in comparison to
the parental SiHa cell line. Twenty-four hours post treatment, HLA-B
was elevated on the plasma membrane in the parental SiHa cell line
(data not shown). Quantitation revealed reduced levels of HLA-B in
both independent IFITM1/IFITM3 double null biological replicates in
the absence and presence of IFNγ (Fig. 6I). These data indicate that the
Fig. 4. Methodological approach to identify signalling pathways altered in IFITM1 and IFITM3 double null cells. The indicated cells (parental SiHa, IFITM1 single
null, or IFITM1/IFITM3 double null) were pre-treated with carrier or IFNγ for 24 h. The media was replaced with R6K6 isotopically labeled media with carrier or IFNγ
for 6 or 24 h. Cells were harvested, lysed, and tryptic peptides processed for analysis by mass spectrometry (MS) as indicated in the Experimental Procedures.
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reduced synthesis of HLA-B in the IFITM1/IFITM3 double null cell
(Fig. 5) has an impact on its subcellular localization at the plasma
membrane.
We next also examine whether there is any direct protein-protein
interaction between IFITM1 and HLA-B since they are both co-synthe-
sized, have transmembrane localizations on the cell surface, and are
both IRDS components. In vivo proximity ligation assays are emerging
methodologies that have been shown to demonstrate the “association”
of two endogenously expressed proteins in fixed cells without the need
for harsh lysis [44]. The method can be considered as an in situ mimic
of an “immunoprecipitation assay”. Proximity ligation assays can
identify a protein-protein interaction/association with a distance of
10–30 nm that is in the upper range of that observed using FRET
(5–20 nm) and this methodology can detect authentic endogenous
proteins in situ that does not rely on transfected or artificially GFP-
tagged protein vectors [45]. We evaluated whether IFITM1/3 and HLA-
B co-associate using this methodology using antibodies to HLA-B and
Mab-MHK (that can bind to both IFITM1 and IFITM3 proteins; Sup-
plementary Fig. 1). A significant protein-protein interaction was ob-
served in the IFNγ treated cells (representative images; Fig. 7A–D).
These foci were absent in the IFITM1/IFITM3 double null cells
(Fig. 7E–H). Together, these data validate the pulse-SILAC data that
identified HLA-B as a downstream effector of IFITM1/3.
ISG15 was not easily visualized using immunofluorescence in situ
Fig. 5. Dominant proteins whose synthesis is attenuated after IFN-γ treatment in IFITM1 single null cells, and IFITM1/IFITM3 double null cells. SILAC pulse-labelling
for 24 h was performed (A and B) in parental SiHa cells; (C and D) in IFITM1 single null cells; and (E and F) in IFITM1/IFITM3 double null cells (Supplementary
Table 1). Cells were incubated with IFN-γ for 24 h in B, D and F. Data were plotted as a function of log10 fold change of heavy/light peptide intensities. Triplicates
were represented in the x, y, and z-axis. In samples (G-L), representative peptides used for quantification in biological triplicates are highlighted to demonstrate a
protein that is induced independent of IFITM1/IFITM3 (STAT1, I and EIF1, J) and proteins that are IFITM1/3 dependent (ISG15; G, HLA-B, L).
Fig. 6. Quantitation of HLA-B levels in parental SiHa and IFITM1/IFITM3 double null cells using immunofluorescence. (A–F). The indicated cell panels were fixed
without (B and E) or with 24 h of IFNγ treatment (C and F). Samples were fixed, and cells incubated with an HLA-B specific antibody. FITC images identify HLA-B
(depicted in green) and DAPI (used for nuclear staining (depicted in blue)). n=3. Scale bar: 10 μm. (G and H) Quantification of HLA-B total fluorescence per cell in
presence or absence of IFNγ stimulation in (G) parental SiHa and (H) IFITM1/IFITM3 double null cells. For quantitation, three independent assays were performed,
and each assay had two independent biological replicates. For each assay, fluorescence was measured in at least 50 cells per condition. Fluorescence was measured
using ImageJ software. Statistical study was performed with 1-way Anova and Bonferroni correction (p-value < .0001). (I). FACS analysis was performed to measure
the relative amount of HLA-B expressed on the surface of non-permeabilized cells treated with carrier or IFNγ for 24 h. The parental SiHa cell was used as a positive
control and the two independently isolated IFITM1/IFITM3 double null cells were used as biological replicates. Samples were processed in two independent ex-
periments and HLA-B expression was normalized to 1.0 in the parental SiHa cell line. The data are plotted as relative arbitrary units (AU) as a function of the clone,
treated with carrier or with IFNγ. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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(data not shown) nor could we identify a protein-protein association
between IFITM1/3 proteins and ISG15 using proximity ligations (data
not shown). We thus used an independent assay for orthogonal vali-
dation of ISG15 induction. We developed a SBP-tagged IFITM1 ex-
pression construct in order to ectopically express the protein in the
parental SiHa cells and design methodologies for capturing IFITM1
associated proteins. The transfection of the SBP-IFITM1 expression
could be detected as migrating at a higher mass (due to the SBP tag)
than endogenous IFITM1/3 proteins in the parental SiHa cells (Fig. 8A,
lane 3 vs lane 1) and specifically captured after affinity purification
following expression in the IFITM1/IFITM3 double null cell (Fig. 8A,
lane 4 vs 2).
SWATH-MS analysis of the affinity purified material (SBP-IFITM1 vs
SBP-only; material Fig. 8A, lane 4 vs lane 2), from untreated vs inter-
feron treated, identified proteins that were enriched without or with
IFN-γ treatment of parental SiHa cells, respectively (Fig. 8B; Supple-
mentary Table 2). The data first highlight the detection of peptides
belonging to a homologous sequence for IFITM1/2/3 proteins (Fig. 8B,
Fig. 8C). Since IFITM1 was our bait protein we presume that it was the
detected isoform, serving as an internal positive control (Fig. 8A).
Nevertheless, IFITM1 may also be interacting with IFITM2 or IFITM3.
The previously identified IFITM1/2/3 interacting protein VAPA was
also detected (Fig. 8B and C), Supplementary Table 2. The proteins with
the most significant p-values were enriched in IFN-γ treated cells, re-
lative to non-treated cells (Fig. 8B and C, Supplementary Table 2).
These included several proteins involved in cell-cell or cell matrix in-
teractions including cornifin, galectin-7, desmocolin, JUP, hornerin,
and desmoglein (Fig. 8C; Supplementary Table 3). This is suggestive of
a pathway interaction of IFITM1 with membrane-dependent cell-cell
communications. The enrichment of higher confident targets in IFN-γ
treated cells also suggests that IFN-γ treatment may be required to fully
‘activate’ the IFITM1 protein interaction landscape. Interestingly, pro-
teins related to IFNγ signalling were also detected; ISG15 and HLA-B
(Fig. 8B and C). Immunoblotting also confirmed that ISG15ylation was
Fig. 7. Evaluation of the IFITM1/IFITM3:HLA-B protein-protein interaction in situ. Proximity ligation assays were used to study the endogenous interaction between
HLA-B and IFITM1/3 proteins in parental SiHa (A–D) and IFITM1/IFITM3 double null cells (E–H). Representative FITC images identify the protein-protein association
foci (depicted in green) and DAPI was used for nuclear staining (depicted in blue). (A–B and E–F). Cells were incubated as negative controls using IFITM1/3 or HLA-B
antibodies only. (C and G). Cells were incubated with both IFITM1/3 and HLA-B antibodies to define protein-protein foci in non-stimulated cells. (D and H) Cells were
incubated with both IFITM1/3 and HLA-B antibodies to define protein-protein foci in IFN-γ stimulated cells. n=3. Scale bar: 10 μm. (I and J) Quantification of HLA-
B and IFITM1/3 total fluorescence per cell in presence or absence of IFNγ stimulation in (I) parental SiHa and (J) IFITM1/IFITM3 double null cells. For quantitation,
three independent assays were performed, and each assay had two independent biological replicates. For each assay, fluorescence was measured in at least 50 cells
per condition. Fluorescence was measured using ImageJ software. Statistical study was performed with 1-way Anova and Bonferroni correction (p-value < .0001).
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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attenuated in IFITM1/IFITM3 double null cells after IFNγ stimulation
(Fig. 8D). By contrast free ISG15 protein remained equivalent in both
cells (Fig. 8D), suggesting that the ISG15 synthesis detected using pulse
SILAC is directly linked to IFN stimulated protein conjugation. The ratio
changes of conjugated to free ISG15 is summarized in Fig. 8E. Together,
the orthogonal validation of HLA-B and ISG15 is consistent with the
pulse SILAC data; IFITM1/3 proteins are required for maximal induc-
tion of HLA-B and ISG15ylation in IFNγ treated cells.
3.5. Orthogonal validation of the IFITM1 signalling protein landscape
We were unable to complement the IFITM1 and IFITM3 gene back
into the double-null SiHa cells to stimulate ISG15ylation and HLA-B
protein levels in IFN-γ treated cells (data not shown). As such, we took
an independent approach to define dominating IFITM1-dependent sig-
nalling pathways and whether these overlap with the signalling
proteins identified using the pulse-SILAC experimental methods.
Although the majority of analyses identified HLA-B and ISG15 protein
expression changes using IFITM1/IFITM3 double null cells, we did
create an IFITM1 single null cell that revealed similar reductions in
ISG15 and HLA-B after IFNγ treatment (Fig. 5D, G, and L). As such, we
examined IFITM1 dependence in the steady-state proteome levels using
IFITM1 targeted siRNA treatment of parental SiHa cells (Fig. 9A, lanes 4
and 2 vs 3 and 1) to determine if attenuation of IFITM1 by this method
gave rise to similar proteome changes. However, there is a caveat to this
method. Similar to plasmid transfection [46], double stranded RNA can
also induce an IRF-1 dependent transcriptional interferon response
[47]. Accordingly, we have also found that siRNA transfection meth-
odologies can induce an IRF1 transcriptional response (data not
shown). Nevertheless, siRNA is a powerful tool to determine gene de-
pendencies in cell models. When parental SiHa cells, treated from 48
and 72 h with control siRNA or IFITM1-targeted siRNA, there was
Fig. 8. Identification of IFITM1 interacting proteins in IFNγ treated cells. (A). SBP vector or SBP-tagged IFITM1 were transfected into parental SiHa cells and treated
with IFNγ. Cells were lysed (L) and subjected to immunoprecipitation (PD) and evaluated by immunoblotting with Mab-MHK that can detect untagged or SBP-tagged
IFITM1. (B). A 4-quadrant plot showing the relative quantification for binding proteins corresponding to fold change of cells transfected with SBP-IFITM1 versus SBP-
empty vector and affinity purified with IFN-γ for 24 h (X-axis) or without IFN-γ stimulation (Y-axis). (C). Table with selected binding proteins detected by mass
spectrometry for SBP-IFITM1 enrichment without or with IFN-γ stimulation (from Supplementary Table 3). (D). Cells (parental SiHa; lane 1; or IFITM1/IFITM3
double null (lane 2) were transfected with empty vector (as in 8A) and treated with IFNγ. Samples were processed by immunoblotting with antibodies to ISG15. Free,
monomeric ISG15 protein is highlighted, as well as conjugated ISG15. Free ISG15 protein is expressed at similar levels in both cells whilst conjugated ISG15 is
attenuated in the IFITM1/IFITM3 double null cell (lane 2 vs 1). This suggests that ISG15ylation protein synthesis is linked to covalent conjugation under these
conditions, under conditions where attenuated ISG15 protein synthesis was observed using pulse SILAC (Fig. 5). Antibodies to β-actin and IFITM1/3 proteins were
used as loading controls, as indicated. (E). Free and conjugated ISG15 were quantified using ImageJ software. The relative units (in A.U.) define expression as a
function of free or conjugated ISG15 in parental and IFITM1/IFITM3 double null cells. The relative change in ISG15 conjugation over free ISG15 was 5.58 A.U. in
parental cells. The relative change in ISG15 conjugation over free ISG15 was 3.63 A.U. in IFITM1/3 double null cells.
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striking and selective reduction in interferon-responsive proteins using
label free quantitative mass spectrometry at both time points (Fig. 9B
and Supplementary Table 3). Some of these proteins, including IFITM1
itself, are also components of the interferon-stimulated DNA damage
resistant signature of proteins [9,10]. Interestingly, ISG15 and HLA-B
are also lowered after the treatment of SiHa cells with IFITM1 targeted
siRNA. However, there is one notable difference in the pulse-SILAC
(Fig. 5) vs the siRNA methodology (Fig. 9B); STAT1 and B2M are
IFITM1/3-independent as defined using pulse SILAC (Fig. 5); whilst
STAT1 and B2M are IFITM1-dependent using the siRNA methodology
Fig. 9. The impact of IFITM1 targeted siRNA on the steady-state proteome. (A). Immunoblotting to demonstrate that IFITM1-targeted siRNA can attenuate IFITM1/3
protein levels. Cells were treated with the indicated control or targeted siRNA for two time points to capture the overlap in the transient dynamics of the interferon
signalling cascade. Lysates were immunoblotted with the Mab-MHK antibody (the MHK monoclonal antibody cross reacts to a common N-terminal epitope in IFITM1
and IFITM3, see Supplementary Fig. 1) to quantify IFITM1/3 protein and the loading control (GAPDH), as highlighted. (B). Evaluation of the total steady-state
proteome in response to siRNA targeting of IFITM1 in SiHa cells using SWATH-MS (data from Supplementary Table 3). The impact of IFITM1-targeted siRNA
treatment for 48 and 72 h. These time points were a point of focus since the siRNA treatment activates the IRF1 transcriptional response over these two-time frames
(data not shown). As such, the screen is conducted under experimental conditions in which we consider that the IRF1 response is activated by RNA treatment. The
data from these two biological states are plotted as log2 fold change in protein levels (using SWATH-MS) as a function of either the 48 or 72-hour time point. The key
proteins whose steady-state levels were suppressed after IFITM1-targeted siRNA treatment are highlighted in red, in the lower left quadrant. (C) The IFITM1
signalling model. Pulse labelling using SILAC methodologies identified STAT1 as a dominant protein synthesized after IFNγ treatment. This forms an internal positive
control and is consistent with the classic JAK-STAT response to IFNγ treatment. (I). STAT1 can produce mRNAs that are translated in response to IFNγ treatment
including IRF1 and other interferon effectors such as B2M. (II). By contrast to STAT1 and B2M, some of the IFNγ stimulated factors are IFITM1 dependent including
MHC Class I molecules and ISG15 (Fig. 5G and L). The siRNA-mediated depletion of IFITM1 represents an orthogonal assay that identified reductions in ISG15 and
MHC Class I molecules (Fig. 9A). STAT1 protein reflects a distinct mechanism of control by IFITM1/3. Although pulse SILAC revealed that STAT1 synthesis is
IFITM1/3-independent (Fig. 5), the steady state levels of STAT1 protein are reduced after targeted depletion of IFITM1 in SiHa cells (Fig. 9A). These data suggest that
turnover of STAT1 protein might be dependent on IFITM1/3, but its synthesis is independent of IFITM1/3. However, these methodologies are complicated to
compare directly, since the siRNA methodology uses an intrinsic RNA signal (double stranded RNA) that stimulates IRF1 but without exogenously added IFNγ, whilst
the pulse SILAC used IFNγ without RNA ligands. Altogether, these data place IFITM1/3 proteins as a coordinator of the synthesis and/or steady state levels of a sub-
set of key players in the IFNγ response. The notable induction of MHC Class I molecules and ISG15 in an IFITM1/3 dependent manner identifies a coordinated
signalling pathway with potential clinical relevance (Fig. 1). The recent observation that lowered HLA-A, HLA-B, and HLA-C alleles correlates with poor prognosis
and enhanced metastatic growth in cervical cancers [54] is further consistent with the existence of an IFITM1/3:HLA signalling pathway regulating cervical cancer
outcomes. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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(Fig. 9B, Supplementary Table 3). This might reflect that fact that the
RNA ligand (siRNA) induces additional RNA-activated pathways in the
targeted siRNA proteome screen than IFNγ alone.
In conclusion, the pulse SILAC methodology in the IFITM1 single
null (Fig. 5) and the siRNA treatment using IFITM1 targeted siRNA in
parental SiHa cells (Fig. 9) both gave rise to overlapping proteome
changes; mainly ISG15 and HLA-B. These data suggest that IFITM1
might alone function as an effector to these two proteins. However, we
cannot rule out a role for IFITM3 in the IFITM1 single null cell, since
IFITM3 is also reduced by IFITM1 targeted siRNA treatment of SiHa
cells (Fig. 9B). Thus, IFITM1 and IFITM3 might cooperate to mediate
these effects.
4. Discussion
The IFITM protein family was identified in whole genome siRNA
screens as RNA virus restriction factors [20]. The molecular functions of
the IFITM family in the anti-viral response are just beginning to be
defined. Yeast-two hybrid, with IFITM3 as a bait, was used as a meth-
odology to discover new protein-protein interactions within the IFITM
family that mediate viral restriction [21]; a protein-protein interaction
was identified for IFITM3 and the Vesicle-membrane-protein-associated
protein A (VAPA). The VAPA interaction occurred with IFITM1,
IFITM2, or IFITM3 and these three were not distinguished from each
other in this assay. Nevertheless, the study focused on defining how
VAPA interaction with IFITM3 results in reduction of VAPA binding to
oxysterol-binding protein (OSBP), disrupting cholesterol homeostasis,
and preventing viral maturation. As IFITM1 and IFITM2 are also re-
ported to bind to VAPA, it is not yet clear whether they play minor and/
or redundant roles in controlling cholesterol-mediated viral maturation
[21]. Interestingly, VAPA was also identified in our SWATH-IP using
SBP-tagged IFITM1 (Fig. 8), which is consistent with VAPA being a
dominant interactor for the IFITM family. In addition to VAPA, pal-
mitoylation of IFITM1/2/3 family members has been reported to be
required for some anti-viral functions [48]. Whether the anti-viral as-
sociations with VAPA or palmitoylation by the IFITM family impact on
cancer growth control is not yet known.
The IFITM family also have reported roles in oncogenic and/or pro-
metastatic cancer cell growth. It is not known if the anti-viral and pro-
oncogenic functions of the IFITM family overlap. Within the IFITM1
family, IFTM1 is the most well documented to have pro-metastatic roles
and it is the only IFITM family member with a partial residence in the
plasma membrane [19]. IFITM1 is also the only IFITM family member
that is a component of the Interferon-regulated DNA damage resistance
(IRDS) pathway [10]. The IRDS contains a subset of approximately 30
interferon responsive genes that are up-regulated late in the viral re-
sponse, upregulated during development of radiation resistance, and
upregulated as a result of chronic exposure to lower levels of type I or
type II interferons. IRDS pathway expression is mediated by ‘unpho-
sphorylated’ STAT1 [49] and can be stimulated by IRF9 [50]. Inter-
estingly, two IRDS genes (ISG15 and HLA-B) are induced after IFNγ
exposure in a ‘IFITM1-dependent’ manner (Fig. 9C). Our unpublished
data also indicate that IFITM1 single null cells are X-ray sensitive or
cisplatin-sensitive, consistent with the hypothesis that IFITM1 expres-
sion is linked to chemo or irradiation resistance. The mechanisms
whereby IFITM1 itself regulates such chemoresistant or pro-metastatic
cell signalling events have not been mechanistically defined.
In this report, we begin to set up biochemical assays that could shed
light on dominant cancer-associated functions of IFITM1. We first
aimed to identify a clinically relevant human cancer model to study
IFITM family of proteins. This required us to develop a pan-specific
antibody that binds to both IFITM1 and IFITM3 proteins
(Supplementary Fig. 1). This resulted in a focus on cervical cancer
(Fig. 1) that exhibited high, medium or no expression of IFITM1/3
proteins (Fig. 1F). Of particular interest was the inverse correlation
between IFITM1/3 protein expression and lymph node metastasis
(Fig. 1F) suggesting that loss of IFITM1/3 protein expression correlates
with evasion of the immune system. If IFITM1/3 are ‘pro-oncogenic’,
why would cervical cancer panels reveal an inverse correlation between
IFITM1/3 expression and cancer-positive lymph nodes in patients?
It is now becoming apparent that there are two distinct modes of
metastatic cell growth. The first is the more classically defined metas-
tasis due to enhanced ‘invasion and migration” to secondary tissue ni-
ches. The second represents metastasis due to cancer cell escape from
immune surveillance [51]. IFITM1/3-positive cancers might indeed be
pro-invasive, depending on the microenvironment and tissue type,
leading to poor clinical prognosis. The methodologies that highlighted
such classic pro-metastatic roles for IFITM1 include over-expression by
ectopic transfection of plasmid encoded genes or attenuation of gene
expression using targeted siRNA [14]. By such experimental ap-
proaches, IFITM1 does indeed promote cancer cell growth and/or ‘cell
invasion’ (i.e. a model of metastatic growth) [16]. Consistent with this,
using clinical material IFITM1 protein has often been shown in litera-
ture to be over-produced in cancers using immunohistochemistry and
this often correlates with poor prognosis [12,52].
However, our data reviewed using cervical cancer (Fig. 1) indicate
that there can be two distinct states of cervical cancer with respect to
IFITM1/3 expression. IFITM1/3 negative cervical cancers might also be
more pro-invasive due to immune escape. This is based on the data
indicating that the most dominant proteins whose synthesis depends on
IFITM1/3 using the pulse SILAC methodology are in fact HLA family
members (Figs. 4 and 5). HLA family members are components of the
IRDS, they play a role in anti-viral immunity through the presentation
of viral peptides through the MHC Class I system, and HLA expression is
linked to immune rejection of cancer cells [53]. This suggests that al-
though IFITM1/3 might be pro-oncogenic under some conditions,
IFITM1/3-HLA signalling would presumably function as a ‘tumor sup-
pressor’ signal via engagement of CD8+ T-cells. Such IFITM1/3 and
HLA positive cancers might not metastasize because they produce
neoantigen presenting MHC Class I molecules that keep the primary
tumor in a local chronic state of equilibrium with the immune system.
IFITM1/3-negative cancers by contrast might be expected to produce
lower amounts of MHC Class I molecules following IFNγ stimulation
(Fig. 9) resulting in lowered neoantigen expression, immune escape,
and metastasis. Such hypotheses are consistent with two clinical ob-
servations in cervical cancers. First, an inverse correlation exists be-
tween IFITM1/3 expression and lymph-node positive cancers (Fig. 1).
Second, a recent study has highlighted that lowered MHC Class I ex-
pression also predicts poor prognosis in cervical cancers [54]. This data
is also consistent with several studies that highlight elevated rates of
metastatic cancer cell growth in vivo are inversely correlated to MHC
Class I expression including deletion of the MHC Class I locus [53].
Although expression of IFITM1/3 was detected in cancer cells
(Fig. 1), it is interesting that IFITM1/3 protein expression was observed
and confined to the basal ‘stem cell’ layer in representative normal
tissue controls using immunohistochemistry (Fig. 1 E). Expression was
not observed even on one cell layer up from the basal layer. In squa-
mous human skin, this basal layer is reflective of p63 (a squamous stem
cell transcription factor) and phosphorylated p53 positive stem cell
populations after UV irradiation [55]. Thus, this expression might re-
flect a role for IFITM1 in squamous stem cell pluripotency. We do not
have very many samples reflecting a ‘normal’ human cervical epithe-
lium, but the few cases we have exhibit very strong staining in the basal
layer (data not shown). During the course of these studies the Human
Protein Atlas has also populated their immunohistochemical library
with expression patterns of IFITM1 protein in normal tissues. We can
see in this library that IFITM1 protein is also confined to the “basal stem
cell” layer in normal squamous oesophagus, cervix, and oral mucosa
(Supplementary Fig. 4). Together, these data would suggest that IFITM1
might play a role in squamous stem cell physiology as its expression
appears specifically confined to the basal layer and is not expressed in
suprabasal normal squamous cells. As the ‘normal’ squamous cervical
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epithelium we have used is from patients undergoing screening for
cervical cancer or dysplasia, we cannot rule out a role for HPV in this
expression in normal cervical cells. However, as the oesophagus squa-
mous epithelium also exhibits IFITM1 protein expression in the basal
cells of normal squamous epithelium (Protein Atlas, Supplementary
Fig. 4), and the normal oesophagus is not noted for HPV infection, we
would suggest that the expression of IFITM1 protein in basal cells is not
related to HPV status. The signalling pathways that might trigger basal
IFITM1 protein expression in squamous stem cell populations are not
precisely defined. However, at the mRNA level, differential expression
patterns of ifitm1 gene expression were identified in the uteri of mice
and there were correlations between the patterns of ifitm1 gene ex-
pression and Wnt/β-catenin expression [56]. These data might suggest
a role for Wnt signalling as an upstream regulator of IFITM1 in stem
cells.
Our focus on cervical cancer as a model to understand the cancer-
associated role of IFITM1/3 is interesting considering IFITM1/IFITM3
are themselves RNA viral restriction factors and HPV infection is a risk
factor in cervical cancer progression. There is evidence that IFITM1 and
IFITM3 might be a positive cofactor for a DNA virus; HPV16 viral
propagation [57]. We do not have any data that defines the HPV status
of the cervical cancers we have analyzed (Fig. 1), as the main clinically
approved assay for diagnostics is p16 positive cancer cells [58]. There is
a close relation between persistent viral infection, development of
cancer and failure in immune response. As an example, cervical as well
as vulvar intraepithelial neoplasia are pre-cancerous conditions char-
acterized by sustained HPV-16 infection. A clinical study shows favor-
able prognosis related to an increase in IFNγ-producing CD8+ cyto-
toxic T following to robust cell response induced by vaccination [59].
Vaccination delivers a high dose of specific antigen against HPV-16
oncoproteins E6 and E7 and mediates MHC-binding peptide complex
presentation [60]. A similar outcome was also observed after vaccina-
tion of a preclinical mouse model of HPV positive cervical cancer [61].
There is a significant correlation between MHC Class I (not found for
MHC Class II) expression on malignant cells and T-cell infiltration (TIL)
in human ovarian cancer [62], being a positive prognostic factor. Thus,
IFITM1 and IFITM3 might have dual roles in stimulating HPV propa-
gation, but also in suppressing cancer escape from immune surveil-
lance.
One of the key approaches we used to evaluate the role of IFITM1 in
IFNγ dependent protein production was the utilization of CRISPR-Cas9
guide RNAs to create isogenic knock-out cells. At the outset, we relied
less on the use of siRNA to deplete IFITM1 since this would only give a
transient reduction in a target protein but also siRNA itself can induce
an interferon response (data not shown; [46]). This would have com-
plicated our analysis of the interferon-responsive nature of any IFITM1
protein interactions we visualize and measure. Nevertheless, siRNA was
used as a final orthogonal approach to define IFITM1 signalling events
(Fig. 9A, B). By contrast, the limitation of using gene knockout tools to
reduce expression of a protein requires that loss of the protein is not a
lethal event. In the case of IFITM1 and IFITM3 knock-out mice are re-
ported as viable [41], thus it was not unexpected that we were able to
generate single IFITM1 null and double IFITM1/IFITM3 double null cell
panels (Figs. 2 and 3). However, we were unable to generate single
IFITM3 null cells under experiments carried out in parallel to those
reported in this manuscript (data not shown).
Using these isogenic cell panels, we were able to determine whether
there were defects in IFNγ dependent protein synthesis using pulse
SILAC methodologies. We chose to use a pulse-SILAC approach to
identify the isotopically labeled tryptic peptides with the most sig-
nificant fold change after IFNγ treatment and which are altered in the
double IFITM1/IFITM3 or IFITM1 single null cells. The most sig-
nificantly suppressed proteins in the double IFITM1/IFITM3 or IFITM1
single null cells after IFNγ treatment were MHC Class I orthologues
encoded by the HLA-A, HLA-B, and HLA-C genes (Fig. 5). As rationa-
lized above, the data suggested an inverse correlation between IFITM1/
3 protein and HLA expression with metastatic growth in cervical
cancer.
The interferon-responsive protein ISG15 was also attenuated in the
double IFITM1/IFITM3 null cells or single IFITM1 single null cells after
IFNγ treatment (Fig. 5G). The fact that ISG15 and HLA-B are enriched in
the SBP-IFITM1 protein affinity purification after IFNγ treatment
(Fig. 8) suggests a co-operative activity exists between the two proteins.
Indeed, as HLA-B can interact in situ with IFITM1/3 after IFNγ treat-
ment (Fig. 7), and as ISG15 is a high-confident IFITM1-associated
protein using SWATH-IP mass spectrometry (Fig. 8), these data suggest
that the two proteins are directly involved in the IFITM1/3 dependent
IFNγ response. ISG15 is also a component of an interferon and immune
responsive gene cluster that are suppressed by stem cell pluripotent
gene product expression [63], suggesting that, like HLA suppression,
ISG15 suppression might be co-incident with immune escape. In the
case of IFITM1/3 signalling, we do not see defects in ‘free’ monomeric
ISG15 in the double IFITM1/IFITM3 null cells, but reductions in the
conjugation of higher molecular mass ISG15ylated adducts (Fig. 8D).
These data suggest that conjugation of proteins to ISG15 during inter-
feron stimulation might play a coordinated role in the IFITM1/3 de-
pendent immune-tumor cell interactions. Overproduction of ISG15 has
been reported previously to stabilize IFITM3 [64], consistent with our
data that ISG15 is detected in the SBP-IFITM1 complex (Fig. 8). Ubi-
quitination of IFITM3 might counteract the stimulatory effect of ISG15
on the anti-viral functions of the protein [65]. How ubiquitination and
ISG15ylation regulate IFITM1 and/or IFITM3 in a coordinated fashion
is not defined.
These data together provide a novel biochemical pathway relevant
for cancer associated functions of IFITM1/3 that correlates with the
interferon-responsive nature of IFITM1/3 signalling; they can mediate
IFNγ dependent protein production of MHC Class I proteins and ISG15
(Fig. 5), whilst the maintenance of STAT1 protein in response to IFNγ
involves by a different signalling mechanism that is IFITM1/3-in-
dependent (Fig. 9B). Both antigen presentation and ISG15ylation sig-
nalling events are important for anti-viral signalling as well as immune
regulation of cancer cells at the immune-cancer synapse [66–71]. Fur-
ther research will shed light on how reductions in HLA and ISG15yla-
tion can impact on both oncogenic signalling and/or anti-viral activity
in response to IFITM1/3 expression.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.cellsig.2019.03.024.
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